

2024

# Prescription Drug Guide

## NC State Health Plan Formulary

List of covered drugs

PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION  
ABOUT THE DRUGS WE COVER IN THIS PLAN.

42

Formulary 24800 Version 1

This formulary was updated on 05/01/2024. For more recent information or other questions, please contact the NC State Health Plan Humana Customer Care Team with any questions at 1-888-700-2263 or for TTY users, 711, or visit [your.humana.com/ncshp](https://your.humana.com/ncshp). Monday through Friday, from 8 a.m. - 9 p.m., Eastern time. Our automated phone system is available after hours, weekends, and holidays. Our website is also available 24 hours a day, 7 days a week, by visiting [our.humana.com/ncshp](https://our.humana.com/ncshp).

**Humana**<sup>®</sup>



*Dale R. Folwell, CPA*  
STATE TREASURER OF NORTH CAROLINA  
DALE R. FOLWELL, CPA



# Welcome to Humana Group Medicare Plan!

**Note to existing members:** This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to "we," "us," or "our," it means Humana. When it refers to "plan" or "our plan," it means Humana Group Medicare Plan. This document includes a list of the drugs (formulary) for our plan which is current as of May 2024. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1 of each year, and from time to time during the year.

## What is the formulary?

A formulary is the entire list of covered drugs or medications selected by Humana Group Medicare Plan. The terms formulary and Drug List may be used interchangeably throughout communications regarding changes to your pharmacy benefits. Humana Group Medicare Plan worked with a team of doctors and pharmacists to make a formulary that represents the prescription drugs we think you need for a quality treatment program. The Humana Group Medicare Plan will generally cover the drugs listed in the formulary as long as the drug is medically necessary, the prescription is filled at a Humana Group Medicare Plan network pharmacy, and other plan rules are followed. For more information on how to fill your medications, please review your Evidence of Coverage.

## Can the formulary change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the Drug List during the year, move them to different cost sharing tiers, or add new restrictions. We must follow Medicare rules in making these changes.

**Changes that can affect you this year:** In the below cases, you will be affected by coverage changes during the year:

- **New generic drugs.** We may immediately remove a brand name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand name drug on our Drug List, but immediately move it to a different cost sharing tier or add new restrictions. If you are currently taking that brand name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
  - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below titled "How do I request an exception to the Humana formulary?"
- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug's manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to market to replace a brand name drug currently on the formulary or add new restrictions to the brand name drug or move it to a different cost sharing tier or both. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, or add prior authorization, quantity limits and/or step therapy restrictions on a drug or move a drug to a higher cost sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 30-day supply of the drug.

We will notify members who are affected by the following changes to the formulary:

- When a drug is removed from the formulary.
- When prior authorization, quantity limits, or step-therapy restrictions are added to a drug or made more restrictive.
- When a drug is moved to a higher cost sharing tier.

If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below titled "How do I request an exception to the Humana formulary?"

**Changes that will not affect you if you are currently taking the drug.** Generally, if you are taking a drug on our 2024 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2024 coverage year except as described above. This means these drugs will remain available at the same cost share and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs.

### **What if you are affected by a Drug List change?**

We will notify you by mail at least 30 days before one of these changes happens or we will provide a 30-day refill of the affected medicine with notice of the change.

The enclosed formulary is current as of May 2024. We will update the printed formularies each month and they will be available on [your.humana.com/ncshp](https://your.humana.com/ncshp).

### **How do I use the formulary?**

There are two ways to find your drug in the formulary:

#### **Medical condition**

The formulary starts on page 11. We have put the drugs into groups depending on the type of medical conditions that they are used to treat. For example, drugs that treat a heart condition are listed under the category "Cardiovascular Agents." If you know what medical condition your drug is used for, look for the category name in the list that begins on page 11. Then look under the category name for your drug. The formulary also lists the Tier and Utilization Management Requirements for each drug (see page 5 for more information on Utilization Management Requirements).

#### **Alphabetical listing**

If you are not sure about your drug's group, you should look for your drug in the Index that begins on page 200. The Index is an alphabetical list of all of the drugs included in this document. Both brand-name drugs and generic drugs are listed. Look in the Index to search for your drug. Next to each drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of the drug in the first column of the list.

Prescription drugs are grouped into one of four tiers.

Humana Group Medicare Plan covers both brand-name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand-name drug. Generally, generic drugs cost less than brand-name drugs.

- **Tier 1 - Generic or Preferred Generic:** Generic or brand drugs that are available at the lowest cost share for the plan
- **Tier 2 - Preferred Brand:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 1 Generic or Preferred Generic, and at a lower cost to you than Tier 3 Non-Preferred Drug
- **Tier 3 - Non-Preferred Drug:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 2 Preferred Brand drug
- **Tier 4 - Specialty Tier:** Some injectables and other high-cost drugs

### How much will I pay for covered drugs?

Humana Group Medicare Plan pays part of the costs for your covered drugs and you pay part of the costs, too.

### The amount of money you pay depends on:

- Which tier your drug is on
- Whether you fill your prescription at a network pharmacy
- Your current drug payment stage - please read your Evidence of Coverage (EOC) for more information

**If you qualified for extra help with your drug costs, your costs may be different from those described above. Please refer to your Evidence of Coverage (EOC) or call NC State Health Plan Humana Customer Care to find out what your costs are.**

### Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These are called Utilization Management Requirements. These requirements and limits may include:

- **Prior Authorization (PA):** Humana Group Medicare Plan requires you to get prior authorization for certain drugs to be covered under your plan. This means that you will need to get approval from Humana Group Medicare Plan before you fill your prescriptions. If you do not get approval, Humana Group Medicare Plan may not cover the drug.
- **Quantity Limits (QL):** For some drugs, Humana Group Medicare Plan limits the amount of the drug that is covered. Humana Group Medicare Plan might limit how many refills you can get or how much of a drug you can get each time you fill your prescription. For example, if it is normally considered safe to take only one pill per day for a certain drug, we may limit coverage for your prescription to no more than one pill per day. Some drugs are limited to a 30-day supply regardless of tier placement.
- **Step Therapy (ST):** In some cases, Humana Group Medicare Plan requires that you first try certain drugs to treat your medical condition before coverage is available for another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, Humana Group Medicare Plan may not cover Drug B unless you try Drug A first. If Drug A does not work for you, Humana Group Medicare Plan will then cover Drug B.
- **Part B versus Part D (B vs D):** Some drugs may be covered under Medicare Part B or Part D, depending upon the circumstances. Information may need to be submitted to the Humana Group Medicare Plan that describes the use and the place where you receive and take the drug so a determination can be made.

For drugs that need prior authorization or step therapy, or drugs that fall outside of quantity limits, your health care provider can fax information about your condition and need for those drugs to Humana Group Medicare Plan at **1-877-486-2621**. Representatives are available Monday - Friday, 8 a.m. - 8 p.m. (EST).

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 11.

You can also visit [your.humana.com/ncshp](https://your.humana.com/ncshp) to get more information about the restrictions applied to specific covered drugs.

You can ask Humana Group Medicare Plan to make an exception to these restrictions or limits. See the section "**How do I request an exception to the Humana formulary?**" on page 6 for information about how to request an exception.

### **What if my drug is not on the formulary?**

If your drug is not included in this list of covered drugs, visit [your.humana.com/ncshp](https://your.humana.com/ncshp) to see if your plan covers your drug. You can also call NC State Health Plan Humana Customer Care and ask if your drug is covered.

If Humana Group Medicare Plan does not cover your drug, you have two options:

- You can ask NC State Health Plan Humana Customer Care for a list of similar drugs that Humana Group Medicare Plan covers. Show the list to your doctor and ask them to prescribe a similar drug that is covered by Humana Group Medicare Plan.
- You can ask Humana Group Medicare Plan to make an exception and cover your drug. See below for information about how to request an exception.

Talk to your health care provider to decide if you should switch to another drug that is covered or if you should request a formulary exception so that it can be considered for coverage.

### **How do I request an exception to the Humana formulary?**

You can ask Humana Group Medicare Plan to make an exception to the coverage rules. There are several types of exceptions that you can ask to be made.

- **Formulary exception:** You can request that your drug be covered if it is not on the formulary. If approved, this drug will be covered at a pre-determined cost sharing level, and you would not be able to ask us to provide the drug at a lower cost sharing level.
- **Utilization restriction exception:** You can request coverage restrictions or limits not be applied to your drug. For example, if your drug has a quantity limit, you can ask for the limit not to be applied and to cover more doses of the drug.
- **Tier exception:** You can request a higher level of coverage for your drug. For example, if your drug is usually considered a non-preferred drug, you can request it to be covered as a preferred drug instead. This would lower how much money you must pay for your drug. Please remember a higher level of coverage cannot be requested for the drug if approval was granted to cover a drug that was not on the formulary. *You can ask us to cover a formulary drug at a lower cost-sharing level, unless the drug is on the specialty tier.*

Generally, Humana Group Medicare Plan will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost sharing drug, or other restrictions would not be as effective in treating your health condition and/or would cause adverse medical effects.

You should contact us to ask for an initial coverage decision for a formulary, tier, or utilization restriction exception. **When you ask for an exception, you should submit a statement from your health care provider that supports your request. This is called a supporting statement.**

Generally, we must make the decision within 72 hours of receiving your health care provider's supporting statement. You can request a fast, or expedited, exception if you or your health care provider thinks your health would seriously suffer if you wait as long as 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we receive your health care provider's supporting statement.

### **Will my plan cover my drugs if they are not on the formulary?**

You may take drugs that your plan does not cover, or you may talk to your provider about taking a different drug that your plan covers, but that drug might have a Utilization Management Requirement, such as a Prior Authorization or Step Therapy, that keeps you from getting the drug right away. In certain cases, we may cover as much as a 30-day supply of your drug during the first 90 days you are a member of the plan.

Here is what we will do for each of your current Part D drugs that are not on the formulary, or if you have limited ability to get your drugs:

- We will temporarily cover a 30-day supply of your drug unless you have a prescription written for fewer days (in which case we will allow multiple fills to provide up to a total of 30 days of a drug) when you go to a pharmacy.
- There will be no coverage for the drugs after your first 30-day supply, even if you have been a member of the plan for less than 90 days, unless a formulary exception has been approved.

If you are a resident of a long-term care facility and you take Part D drugs that are not on the formulary, we will cover a 31-day supply unless you have a prescription written for fewer days (in which case we will allow multiple fills to provide up to a total of 31 days of a drug) during the first 90 days you are a member of our plan. We will cover a 31-day emergency supply of your drug unless you have a prescription for fewer days (in which we will allow multiple fills to provide up to a total of 31 days of a drug) while you request a formulary exception if:

- You need a drug that is not on the formulary *or*
- You have limited ability to get your drugs *and*
- You are past the first 90 days of membership in the plan

Throughout the plan year, your treatment setting (the place where you receive and take your medicine) may change. These changes include:

- Members who are discharged from a hospital or skilled-nursing facility to a home setting
- Members who are admitted to a hospital or skilled-nursing facility from a home setting
- Members who transfer from one skilled-nursing facility to another and use a different pharmacy
- Members who end their skilled-nursing facility Medicare Part A stay (where payments include all pharmacy charges) and who now need to use their Part D plan benefit
- Members who give up Hospice Status and go back to standard Medicare Part A and B coverage
- Members discharged from chronic psychiatric hospitals with highly individualized drug regimens

For these changes in treatment settings, Humana Group Medicare Plan will cover as much as a 31-day temporary supply of a Part D-covered drug when you fill your prescription at a pharmacy. If you change treatment settings multiple times within the same month, you may have to request an exception or prior authorization and receive approval for continued coverage of your drug. Humana Group Medicare Plan will review requests for continuation of therapy on a case-by-case basis understanding when you are on a stabilized drug regimen that, if changed, is known to have risks.

## Transition extension

Humana Group Medicare Plan will consider on a case-by-case basis an extension of the transition period if your exception request or appeal has not been processed by the end of your initial transition period. We will continue to provide necessary drugs to you if your transition period is extended.

A Transition Policy is available on [your.humana.com/ncshp](https://your.humana.com/ncshp) in the same area where the Prescription Drug Guides are displayed.

## CenterWell Pharmacy™

You may fill your medications at any network pharmacy. CenterWell Pharmacy – Humana's mail-delivery pharmacy is one option. To get started or learn more, visit [CenterWellPharmacy.com](https://CenterWellPharmacy.com). You can also call CenterWell Pharmacy at **1-844-222-2151 (TTY: 711)** Monday – Friday, 8 a.m. to 11 p.m. (EST), and Saturday, 8 a.m. to 6:30 p.m. (EST).

Other pharmacies are available in our network.



## For More Information

For more detailed information about your Humana Group Medicare Plan prescription drug coverage, please read your Evidence of Coverage (EOC) and other plan materials.

If you have general questions about Medicare prescription drug coverage, please call Medicare at **1-800-MEDICARE (1-800-633-4227)** 24 hours a day, seven days a week. **TTY** users should call **1-877-486-2048**. You can also visit [www.medicare.gov](http://www.medicare.gov).

# Humana Group Medicare Plan Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by Humana Group Medicare Plan. If you have trouble finding your drug in the list, turn to the Index that begins on page 200.

Your plan has additional coverage of some drugs. These drugs are not normally covered under Medicare Part D and are not subject to the Medicare appeals process. These drugs are listed separately on page 196.

## How to read your formulary

The first column of the chart lists categories of medical conditions in alphabetical order. The drug names are then listed in alphabetical order within each category. Brand-name drugs are CAPITALIZED and generic drugs are listed in lower-case italics. Next to the drug name or Utilization Management column, you may see an indicator to tell you about additional coverage information for that drug. You might see the following indicators:

**\$0** - Paxlovid, most vaccines and diabetic supplies covered 100% with no member cost.

**DL** - Dispensing Limit; Drugs that may be limited to a 30 day supply, regardless of tier placement.

**MO** - Drugs that are typically available through mail-order. Please contact your mail-order pharmacy to make sure your drug is available.

**LA** - Limited Access; The health plan has authorized certain pharmacies to dispense this medicine, as it requires extra handling, doctor coordination or patient education. Please call the number on the back of your ID card for additional information.

**CI** - Covered insulin products; Part D insulin products covered by your plan. For more information on cost sharing for your covered insulin products, please refer to your Evidence of Coverage.

**PDS** - Preferred Diabetic Supplies; BD and HTL-Droplet are the preferred diabetic syringe and pen needle brands for the plan.

The second column lists the tier of the drug. See page 5 for more details on the drug tiers in your plan.

The third column shows the Utilization Management Requirements for the drug. Humana Group Medicare Plan may have special requirements for covering that drug. If the column is blank, then there are no utilization requirements for that drug. The supply for each drug is based on benefits and whether your health care provider prescribes a supply for 30, 60, or 90 days. The amount of any quantity limits will also be in this column (Example: "QL - 30 for 30 days" means you can only get 30 doses every 30 days). See page 5 for more information about these requirements.

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<b>ANALGESICS</b>		
acetaminophen-caff-dihydrocod 320.5-30-16 mg CAPSULE <b>DL</b>	1	QL(300 per 30 days)
acetaminophen-codeine 120 mg-12 mg /5 ml (5 ml), 120-12 mg/5 ml, 300 mg-30 mg /12.5 ml SOLUTION <b>DL</b>	1	QL(2700 per 30 days)
acetaminophen-codeine 300-15 mg TABLET <b>DL</b>	1	QL(390 per 30 days)
acetaminophen-codeine 300-30 mg TABLET <b>DL</b>	1	QL(360 per 30 days)
acetaminophen-codeine 300-60 mg TABLET <b>DL</b>	1	QL(180 per 30 days)
ACTIQ 1,200 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG LOZENGE <b>DL</b>	4	PA,QL(120 per 30 days)
ANAPROX DS 550 MG TABLET <b>MO</b>	3	
APADAZ 4.08-325 MG, 6.12-325 MG, 8.16-325 MG TABLET <b>DL</b>	3	
ARTHROTEC 50 50-200 MG-MCG TABLET, IR, DR, BIPHASIC <b>MO</b>	3	PA
ARTHROTEC 75 75-200 MG-MCG TABLET, IR, DR, BIPHASIC <b>MO</b>	3	PA
ascomp with codeine 30-50-325-40 mg CAPSULE <b>DL</b>	1	QL(360 per 30 days)
BELBUCA 150 MCG, 300 MCG, 450 MCG, 600 MCG, 75 MCG, 750 MCG, 900 MCG FILM <b>DL</b>	3	QL(60 per 30 days)
benzhydrocodone-acetaminophen 4.08-325 mg, 6.12-325 mg, 8.16-325 mg TABLET <b>DL</b>	3	
BUPRENEX 0.3 MG/ML SOLUTION <b>DL</b>	3	QL(240 per 30 days)
buprenorphine 10 mcg/hour, 15 mcg/hour, 20 mcg/hour, 5 mcg/hour, 7.5 mcg/hour PATCH, WEEKLY <b>DL</b>	1	PA,QL(4 per 28 days)
buprenorphine hcl 0.3 mg/ml SYRINGE <b>DL</b>	1	QL(240 per 30 days)
butalbital compound w/codeine 30-50-325-40 mg CAPSULE <b>DL</b>	1	QL(360 per 30 days)
butorphanol 1 mg/ml SOLUTION <b>DL</b>	1	QL(960 per 30 days)
butorphanol 10 mg/ml SPRAY, NON-AEROSOL <b>DL</b>	1	QL(5 per 28 days)
butorphanol 2 mg/ml SOLUTION <b>DL</b>	1	QL(480 per 30 days)
BUTRANS 10 MCG/HOUR, 15 MCG/HOUR, 20 MCG/HOUR, 5 MCG/HOUR, 7.5 MCG/HOUR PATCH, WEEKLY <b>DL</b>	3	PA,QL(4 per 28 days)
CALDOLOR 800 MG/200 ML (4 MG/ML) PIGGYBACK <b>MO</b>	3	
CALDOLOR 800 MG/8 ML (100 MG/ML) RECON SOLUTION <b>MO</b>	3	
CAMBIA 50 MG POWDER IN PACKET <b>DL</b>	4	ST,QL(9 per 30 days)
cataflam 50 mg TABLET <b>MO</b>	1	
CELEBREX 100 MG, 200 MG, 400 MG, 50 MG CAPSULE <b>MO</b>	3	PA,QL(60 per 30 days)
celecoxib 100 mg, 200 mg CAPSULE <b>MO</b>	1	QL(60 per 30 days)
celecoxib 400 mg, 50 mg CAPSULE <b>MO</b>	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
codeine sulfate 15 mg, 30 mg TABLET <b>DL</b>	1	QL(360 per 30 days)
codeine sulfate 60 mg TABLET <b>DL</b>	1	QL(180 per 30 days)
codeine-butalbital-asa-caff 30-50-325-40 mg CAPSULE <b>DL</b>	1	QL(360 per 30 days)
CONZIP 100 MG, 200 MG, 300 MG CAPSULE, ER, BIPHASIC <b>DL</b>	3	ST,QL(30 per 30 days)
DAYPRO 600 MG TABLET <b>MO</b>	3	
DEMEROL 50 MG/ML SOLUTION <b>DL</b>	3	QL(720 per 30 days)
DEMEROL (PF) 100 MG/2 ML SOLUTION <b>DL</b>	3	QL(360 per 30 days)
DEMEROL (PF) 100 MG/ML SYRINGE <b>DL</b>	3	QL(360 per 30 days)
DEMEROL (PF) 25 MG/ML SYRINGE <b>DL</b>	3	QL(1440 per 30 days)
DEMEROL (PF) 50 MG/ML SYRINGE <b>DL</b>	3	QL(720 per 30 days)
DEMEROL (PF) 75 MG/ML SYRINGE <b>DL</b>	3	QL(480 per 30 days)
diclofenac epolamine 1.3 % PATCH, 12 HR. <b>MO</b>	1	PA,QL(60 per 30 days)
diclofenac potassium 25 mg CAPSULE <b>MO</b>	3	ST,QL(120 per 30 days)
diclofenac potassium 25 mg TABLET <b>DL</b>	4	
diclofenac potassium 50 mg POWDER IN PACKET <b>MO</b>	3	ST,QL(9 per 30 days)
diclofenac potassium 50 mg TABLET <b>MO</b>	1	
diclofenac sodium 1 % GEL <b>MO</b>	1	QL(1000 per 30 days)
diclofenac sodium 1.5 % DROPS <b>MO</b>	1	PA,QL(300 per 30 days)
diclofenac sodium 100 mg TABLET, ER 24 HR. <b>MO</b>	1	
diclofenac sodium 20 mg/gram /actuation(2 %) SOLUTION IN METERED DOSE PUMP <b>DL</b>	4	PA,QL(224 per 28 days)
diclofenac sodium 25 mg, 50 mg TABLET, DR/EC <b>MO</b>	1	
diclofenac sodium 75 mg TABLET, DR/EC <b>MO</b>	1	
diclofenac-misoprostol 50-200 mg-mcg, 75-200 mg-mcg TABLET, IR, DR, BIPHASIC <b>MO</b>	1	
diflunisal 500 mg TABLET <b>MO</b>	1	
DILAUDID 1 MG/ML LIQUID <b>DL</b>	3	PA,QL(2400 per 30 days)
DILAUDID 2 MG, 4 MG TABLET <b>DL</b>	3	PA,QL(360 per 30 days)
DILAUDID 8 MG TABLET <b>DL</b>	3	PA,QL(240 per 30 days)
DUEXIS 800-26.6 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
DURAMORPH (PF) 0.5 MG/ML SOLUTION <b>DL</b>	3	BvsD,QL(7200 per 30 days)
DURAMORPH (PF) 1 MG/ML SOLUTION <b>DL</b>	3	BvsD,QL(3600 per 30 days)
EC-NAPROSYN 375 MG, 500 MG TABLET, DR/EC <b>MO</b>	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ec-naproxen 375 mg TABLET, DR/EC <b>MO</b>	3	PA
ec-naproxen 500 mg TABLET, DR/EC <b>MO</b>	1	
endocet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg TABLET <b>DL</b>	1	QL(360 per 30 days)
etodolac 200 mg, 300 mg CAPSULE <b>MO</b>	1	
etodolac 400 mg, 500 mg TABLET <b>MO</b>	1	
etodolac 400 mg, 500 mg, 600 mg TABLET, ER 24 HR. <b>MO</b>	1	
FELDENE 10 MG, 20 MG CAPSULE <b>MO</b>	3	
fenoprofen 200 mg, 400 mg CAPSULE <b>MO</b>	1	ST
fenoprofen 600 mg TABLET <b>MO</b>	1	ST
fentanyl 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75 mcg/hr, 87.5 mcg/hour PATCH. 72 HR. <b>DL</b>	1	QL(20 per 30 days)
fentanyl citrate 1,200 mcg, 1,600 mcg, 400 mcg, 600 mcg, 800 mcg LOZENGE <b>DL</b>	4	PA,QL(120 per 30 days)
fentanyl citrate 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg TABLET, EFFERVESCENT <b>DL</b>	4	PA,QL(120 per 30 days)
fentanyl citrate 200 mcg LOZENGE <b>DL</b>	1	PA,QL(120 per 30 days)
fentanyl citrate (pf) 50 mcg/ml SOLUTION <b>DL</b>	1	BvsD,QL(720 per 30 days)
FENTORA 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG TABLET, EFFERVESCENT <b>DL</b>	4	PA,QL(120 per 30 days)
FLECTOR 1.3 % PATCH, 12 HR. <b>MO</b>	3	PA,QL(60 per 30 days)
flurbiprofen 100 mg TABLET <b>MO</b>	1	
hydrocodone bitartrate 10 mg, 15 mg, 20 mg, 30 mg, 40 mg CAPSULE, ER 12 HR. <b>DL</b>	1	ST,QL(90 per 30 days)
hydrocodone bitartrate 100 mg, 120 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg TABLET, ER 24 HR. <b>DL</b>	1	ST,QL(30 per 30 days)
hydrocodone bitartrate 50 mg CAPSULE, ER 12 HR. <b>DL</b>	1	ST,QL(120 per 30 days)
hydrocodone-acetaminophen 10-300 mg, 5-300 mg, 7.5-300 mg TABLET <b>DL</b>	1	QL(390 per 30 days)
hydrocodone-acetaminophen 10-325 mg, 5-325 mg, 7.5-325 mg TABLET <b>DL</b>	1	QL(360 per 30 days)
hydrocodone-acetaminophen 10-325 mg/15 ml(15 ml) SOLUTION <b>DL</b>	1	QL(2700 per 30 days)
hydrocodone-acetaminophen 2.5-325 mg TABLET <b>DL</b>	1	QL(360 per 30 days)
hydrocodone-acetaminophen 7.5-325 mg/15 ml SOLUTION <b>DL</b>	1	QL(5520 per 30 days)
hydrocodone-ibuprofen 10-200 mg, 5-200 mg, 7.5-200 mg TABLET <b>DL</b>	1	QL(150 per 30 days)
HYDROMORPHONE 0.25 MG/0.5 ML SYRINGE <b>DL</b>	1	BvsD

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
hydromorphone 0.5 mg/0.5 ml, 1 mg/ml SYRINGE <b>DL</b>	1	BvsD,QL(720 per 30 days)
hydromorphone 1 mg/ml LIQUID <b>DL</b>	1	QL(2400 per 30 days)
hydromorphone 1 mg/ml SOLUTION <b>DL</b>	1	BvsD,QL(720 per 30 days)
hydromorphone 12 mg TABLET, ER 24 HR. <b>DL</b>	1	ST,QL(180 per 30 days)
hydromorphone 16 mg TABLET, ER 24 HR. <b>DL</b>	1	ST,QL(120 per 30 days)
hydromorphone 2 mg, 4 mg TABLET <b>DL</b>	1	QL(360 per 30 days)
hydromorphone 2 mg/ml SOLUTION <b>DL</b>	1	BvsD,QL(360 per 30 days)
hydromorphone 2 mg/ml SYRINGE <b>DL</b>	1	BvsD,QL(360 per 30 days)
hydromorphone 32 mg TABLET, ER 24 HR. <b>DL</b>	1	ST,QL(60 per 30 days)
hydromorphone 4 mg/ml SYRINGE <b>DL</b>	1	BvsD,QL(180 per 30 days)
hydromorphone 8 mg TABLET <b>DL</b>	1	QL(240 per 30 days)
hydromorphone 8 mg TABLET, ER 24 HR. <b>DL</b>	1	ST,QL(240 per 30 days)
hydromorphone (pf) 1 mg/ml SOLUTION <b>DL</b>	1	BvsD,QL(720 per 30 days)
hydromorphone (pf) 10 mg/ml SOLUTION <b>DL</b>	1	BvsD,QL(144 per 30 days)
hydromorphone (pf) 4 mg/ml SOLUTION <b>DL</b>	1	BvsD,QL(180 per 30 days)
HYSINGLA ER 100 MG, 120 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG TABLET, ER 24 HR. <b>DL</b>	3	ST,QL(30 per 30 days)
ibu 400 mg, 600 mg, 800 mg TABLET <b>MO</b>	1	
ibuprofen 100 mg/5 ml SUSPENSION <b>MO</b>	1	
ibuprofen 400 mg TABLET <b>MO</b>	1	
ibuprofen 600 mg, 800 mg TABLET <b>MO</b>	1	
ibuprofen-famotidine 800-26.6 mg TABLET <b>MO</b>	1	PA,QL(90 per 30 days)
INDOCIN 25 MG/5 ML SUSPENSION <b>DL</b>	4	
INDOCIN 50 MG SUPPOSITORY <b>MO</b>	3	
indomethacin 25 mg, 50 mg CAPSULE <b>MO</b>	1	
indomethacin 25 mg/5 ml SUSPENSION <b>DL</b>	4	
indomethacin 50 mg SUPPOSITORY <b>MO</b>	1	
indomethacin 75 mg CAPSULE, ER <b>MO</b>	1	
indomethacin sodium 1 mg RECON SOLUTION <b>MO</b>	1	
INFUMORPH P/F 10 MG/ML SOLUTION <b>DL</b>	3	BvsD,QL(360 per 30 days)
INFUMORPH P/F 25 MG/ML SOLUTION <b>DL</b>	3	BvsD,QL(150 per 30 days)
ketoprofen 200 mg CAPSULE ER PELLETS 24 HR. <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ketoprofen 25 mg CAPSULE <b>MO</b>	1	ST
ketoprofen 50 mg, 75 mg CAPSULE <b>MO</b>	1	ST
ketorolac 10 mg TABLET <b>MO</b>	1	QL(20 per 30 days)
ketorolac 15 mg/ml, 30 mg/ml, 30 mg/ml (1 ml), 60 mg/2 ml SOLUTION <b>MO</b>	1	
ketorolac 15 mg/ml, 30 mg/ml, 60 mg/2 ml SYRINGE <b>MO</b>	1	
ketorolac 15.75 mg/spray SPRAY, NON-AEROSOL <b>DL</b>	4	PA,QL(5 per 30 days)
kiprofen 25 mg CAPSULE <b>MO</b>	1	ST
LAZANDA 100 MCG/SPRAY, 400 MCG/SPRAY SPRAY, NON-AEROSOL <b>DL</b>	4	PA,QL(30 per 30 days)
levorphanol tartrate 2 mg TABLET <b>DL</b>	4	ST,QL(240 per 30 days)
levorphanol tartrate 3 mg TABLET <b>DL</b>	4	ST,QL(150 per 30 days)
LICART 1.3 % PATCH, 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
LODINE 400 MG TABLET <b>MO</b>	3	PA
lofena 25 mg TABLET <b>DL</b>	4	
lortab elixir 10-300 mg/15 ml SOLUTION <b>DL</b>	1	QL(6000 per 30 days)
meclofenamate 100 mg, 50 mg CAPSULE <b>MO</b>	1	
mefenamic acid 250 mg CAPSULE <b>MO</b>	1	
meloxicam 15 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
meloxicam 7.5 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
meloxicam submicronized 10 mg, 5 mg CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
meperidine 10 mg/ml CARTRIDGE <b>DL</b>	1	QL(3600 per 30 days)
meperidine 50 mg TABLET <b>DL</b>	1	QL(480 per 30 days)
meperidine 50 mg/5 ml SOLUTION <b>DL</b>	1	QL(720 per 30 days)
meperidine (pf) 100 mg/ml SOLUTION <b>DL</b>	1	QL(360 per 30 days)
meperidine (pf) 25 mg/ml SOLUTION <b>DL</b>	1	QL(1440 per 30 days)
meperidine (pf) 50 mg/ml SOLUTION <b>DL</b>	1	QL(720 per 30 days)
methadone 10 mg TABLET <b>DL</b>	1	QL(240 per 30 days)
methadone 10 mg/5 ml SOLUTION <b>DL</b>	1	QL(1800 per 30 days)
methadone 10 mg/ml CONCENTRATE <b>DL</b>	1	QL(360 per 30 days)
methadone 10 mg/ml SOLUTION <b>DL</b>	1	QL(360 per 30 days)
methadone 5 mg TABLET <b>DL</b>	1	QL(480 per 30 days)
methadone 5 mg/5 ml SOLUTION <b>DL</b>	1	QL(3600 per 30 days)
methadone intensol 10 mg/ml CONCENTRATE <b>DL</b>	1	QL(360 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
METHADOSE 10 MG/ML CONCENTRATE <b>DL</b>	3	QL(360 per 30 days)
mitigo (pf) 10 mg/ml SOLUTION <b>DL</b>	3	BvsD,QL(360 per 30 days)
mitigo (pf) 25 mg/ml SOLUTION <b>DL</b>	3	BvsD,QL(150 per 30 days)
morphine 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg CAPSULE ER PELLETS <b>DL</b>	1	ST,QL(60 per 30 days)
morphine 10 mg/5 ml SOLUTION <b>DL</b>	1	QL(2700 per 30 days)
morphine 10 mg/ml SOLUTION <b>DL</b>	1	BvsD,QL(360 per 30 days)
morphine 10 mg/ml SYRINGE <b>DL</b>	1	BvsD,QL(360 per 30 days)
morphine 100 mg TABLET ER <b>DL</b>	1	QL(180 per 30 days)
morphine 120 mg, 60 mg, 75 mg, 90 mg CAPSULE ER MULTIPHASE 24 HR. <b>DL</b>	1	ST,QL(60 per 30 days)
morphine 15 mg TABLET ER <b>DL</b>	1	QL(120 per 30 days)
morphine 15 mg, 30 mg TABLET <b>DL</b>	1	QL(180 per 30 days)
morphine 2 mg/ml SOLUTION <b>DL</b>	1	BvsD,QL(1800 per 30 days)
morphine 2 mg/ml SYRINGE <b>DL</b>	1	BvsD,QL(1800 per 30 days)
morphine 2 mg/ml, 4 mg/ml, 5 mg/ml SYRINGE <b>DL</b>	1	BvsD
morphine 20 mg/5 ml (4 mg/ml) SOLUTION <b>DL</b>	1	QL(1350 per 30 days)
morphine 200 mg TABLET ER <b>DL</b>	1	QL(90 per 30 days)
morphine 30 mg, 45 mg CAPSULE ER MULTIPHASE 24 HR. <b>DL</b>	1	ST,QL(30 per 30 days)
morphine 30 mg, 60 mg TABLET ER <b>DL</b>	1	QL(120 per 30 days)
morphine 4 mg/ml SOLUTION <b>DL</b>	1	BvsD,QL(900 per 30 days)
morphine 4 mg/ml SYRINGE <b>DL</b>	1	BvsD,QL(900 per 30 days)
morphine 5 mg/ml SOLUTION <b>DL</b>	1	BvsD,QL(720 per 30 days)
morphine 8 mg/ml SOLUTION <b>DL</b>	1	BvsD,QL(450 per 30 days)
morphine 8 mg/ml SYRINGE <b>DL</b>	1	BvsD,QL(450 per 30 days)
morphine (pf) 0.5 mg/ml SOLUTION <b>DL</b>	1	BvsD,QL(7200 per 30 days)
morphine (pf) 1 mg/ml SOLUTION <b>DL</b>	1	BvsD,QL(3600 per 30 days)
morphine (pf) 30 mg/30 ml (1 mg/ml) PATIENT CONTROL ANALGESIA SOLN <b>DL</b>	1	BvsD,QL(3600 per 30 days)
morphine concentrate 100 mg/5 ml (20 mg/ml) SOLUTION <b>DL</b>	1	QL(540 per 30 days)
MS CONTIN 100 MG TABLET ER <b>DL</b>	3	PA,QL(180 per 30 days)
MS CONTIN 15 MG, 30 MG, 60 MG TABLET ER <b>DL</b>	3	PA,QL(120 per 30 days)
MS CONTIN 200 MG TABLET ER <b>DL</b>	3	PA,QL(90 per 30 days)
nabumetone 500 mg, 750 mg TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>nalbuphine 10 mg/ml SOLUTION</i> <b>DL</b>	1	QL(240 per 30 days)
<i>nalbuphine 20 mg/ml SOLUTION</i> <b>DL</b>	1	QL(120 per 30 days)
NALFON 400 MG CAPSULE <b>MO</b>	3	ST
NALFON 600 MG TABLET <b>MO</b>	1	ST
<i>nalocet 2.5-300 mg TABLET</i> <b>DL</b>	4	PA,QL(360 per 30 days)
NAPRELAN CR 375 MG TABLET, ER 24 HR., MULTIPHASE <b>DL</b>	4	ST,QL(120 per 30 days)
NAPRELAN CR 500 MG TABLET, ER 24 HR., MULTIPHASE <b>DL</b>	4	ST,QL(90 per 30 days)
NAPRELAN CR 750 MG TABLET, ER 24 HR., MULTIPHASE <b>DL</b>	4	ST,QL(60 per 30 days)
NAPROSYN 125 MG/5 ML SUSPENSION <b>DL</b>	4	PA
NAPROSYN 500 MG TABLET <b>MO</b>	3	PA
<i>naproxen 125 mg/5 ml SUSPENSION</i> <b>MO</b>	1	
<i>naproxen 250 mg, 375 mg TABLET</i> <b>MO</b>	1	
<i>naproxen 375 mg, 500 mg TABLET, DR/EC</i> <b>MO</b>	1	
<i>naproxen 500 mg TABLET</i> <b>MO</b>	1	
<i>naproxen sodium 275 mg, 550 mg TABLET</i> <b>MO</b>	1	
<i>naproxen sodium 375 mg TABLET, ER 24 HR., MULTIPHASE</i> <b>MO</b>	1	ST,QL(120 per 30 days)
<i>naproxen sodium 500 mg TABLET, ER 24 HR., MULTIPHASE</i> <b>MO</b>	1	ST,QL(90 per 30 days)
<i>naproxen sodium 750 mg TABLET, ER 24 HR., MULTIPHASE</i> <b>MO</b>	1	ST,QL(60 per 30 days)
<i>naproxen-esomeprazole 375-20 mg, 500-20 mg TABLET, IR, DR, BIPHASIC</i> <b>DL</b>	4	PA,QL(60 per 30 days)
NUCYNTA 100 MG, 50 MG, 75 MG TABLET <b>DL</b>	4	ST,QL(180 per 30 days)
NUCYNTA ER 100 MG, 150 MG, 200 MG, 250 MG TABLET, ER 12 HR. <b>DL</b>	4	ST,QL(60 per 30 days)
NUCYNTA ER 50 MG TABLET, ER 12 HR. <b>DL</b>	3	ST,QL(60 per 30 days)
OLINVYK 1 MG/ML SOLUTION <b>DL</b>	4	PA
OLINVYK 30 MG/30 ML (1 MG/ML) PATIENT CONTROL ANALGESIA SOLN <b>DL</b>	4	PA
<i>oxaprozin 600 mg TABLET</i> <b>MO</b>	1	
OXAYDO 5 MG, 7.5 MG TABLET, ORAL ONLY <b>DL</b>	4	PA,QL(360 per 30 days)
<i>oxycodone 10 mg, 15 mg, 5 mg TABLET</i> <b>DL</b>	1	QL(360 per 30 days)
<i>oxycodone 10 mg, 20 mg, 40 mg TABLET, ER 12 HR.</i> <b>DL</b>	3	PA,QL(90 per 30 days)
<i>oxycodone 20 mg, 30 mg TABLET</i> <b>DL</b>	1	QL(360 per 30 days)
<i>oxycodone 20 mg/ml CONCENTRATE</i> <b>DL</b>	1	QL(270 per 30 days)
<i>oxycodone 5 mg CAPSULE</i> <b>DL</b>	1	QL(360 per 30 days)
<i>oxycodone 5 mg/5 ml SOLUTION</i> <b>DL</b>	1	QL(5400 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>oxycodone 80 mg TABLET, ER 12 HR. DL</i>	3	PA,QL(120 per 30 days)
<i>oxycodone-acetaminophen 10-300 mg, 5-300 mg, 7.5-300 mg TABLET DL</i>	4	PA,QL(390 per 30 days)
<i>oxycodone-acetaminophen 10-300 mg/5 ml SOLUTION DL</i>	4	PA,QL(900 per 30 days)
<i>oxycodone-acetaminophen 10-325 mg, 5-325 mg, 7.5-325 mg TABLET DL</i>	1	QL(360 per 30 days)
<i>oxycodone-acetaminophen 2.5-300 mg TABLET DL</i>	1	PA,QL(360 per 30 days)
<i>oxycodone-acetaminophen 2.5-325 mg TABLET DL</i>	1	QL(360 per 30 days)
<i>oxycodone-acetaminophen 5-325 mg/5 ml SOLUTION DL</i>	1	QL(1800 per 30 days)
<b>OXYCONTIN 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG TABLET, ER 12 HR. DL</b>	3	PA,QL(90 per 30 days)
<b>OXYCONTIN 80 MG TABLET, ER 12 HR. DL</b>	3	PA,QL(120 per 30 days)
<i>oxymorphone 10 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg TABLET, ER 12 HR. DL</i>	1	ST,QL(60 per 30 days)
<i>oxymorphone 10 mg, 5 mg TABLET DL</i>	1	QL(360 per 30 days)
<i>oxymorphone 40 mg TABLET, ER 12 HR. DL</i>	4	ST,QL(60 per 30 days)
<b>PENNSAID 2 % SOLUTION IN PACKET DL</b>	4	PA
<b>PENNSAID 20 MG/GRAM /ACTUATION(2 %) SOLUTION IN METERED DOSE PUMP DL</b>	4	PA,QL(224 per 28 days)
<i>pentazocine-naloxone 50-0.5 mg TABLET DL</i>	1	QL(360 per 30 days)
<b>PERCOCET 10-325 MG, 5-325 MG, 7.5-325 MG TABLET DL</b>	4	PA,QL(360 per 30 days)
<b>PERCOCET 2.5-325 MG TABLET DL</b>	1	PA,QL(360 per 30 days)
<i>piroxicam 10 mg, 20 mg CAPSULE MO</i>	1	
<i>primlev 10-300 mg, 5-300 mg, 7.5-300 mg TABLET DL</i>	4	PA,QL(390 per 30 days)
<i>prolate 10-300 mg, 5-300 mg, 7.5-300 mg TABLET DL</i>	4	PA,QL(390 per 30 days)
<b>PROLATE 10-300 MG/5 ML SOLUTION DL</b>	4	PA,QL(900 per 30 days)
<b>QDOLO 5 MG/ML SOLUTION DL</b>	4	QL(2400 per 30 days)
<b>RELAFEN 500 MG, 750 MG TABLET DL</b>	4	ST
<b>RELAFEN DS 1,000 MG TABLET DL</b>	4	ST,QL(60 per 30 days)
<b>ROXICODONE 15 MG TABLET DL</b>	3	PA,QL(360 per 30 days)
<b>ROXICODONE 30 MG TABLET DL</b>	4	PA,QL(360 per 30 days)
<b>ROXYBOND 15 MG, 30 MG TABLET, ORAL ONLY DL</b>	4	PA,QL(180 per 30 days)
<b>ROXYBOND 5 MG TABLET, ORAL ONLY DL</b>	4	PA,QL(360 per 30 days)
<b>SEGLENTIS 44-56 MG TABLET DL</b>	3	PA,QL(120 per 30 days)
<b>SPRIX 15.75 MG/SPRAY SPRAY, NON-AEROSOL DL</b>	4	PA,QL(5 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SUBSYS 1,200 MCG (600 MCG/SPRAY X 2), 1,600 MCG (800 MCG/SPRAY X 2), 100 MCG/SPRAY, 200 MCG/SPRAY, 400 MCG/SPRAY, 600 MCG/SPRAY, 800 MCG/SPRAY SPRAY, NON-AEROSOL <b>DL</b>	4	PA,QL(120 per 30 days)
<i>sulindac</i> 150 mg, 200 mg TABLET <b>MO</b>	1	
<i>tolmetin</i> 200 mg, 600 mg TABLET <b>MO</b>	1	
<i>tolmetin</i> 400 mg CAPSULE <b>MO</b>	1	
<i>tramadol</i> 100 mg TABLET <b>DL</b>	1	QL(120 per 30 days)
<i>tramadol</i> 100 mg, 200 mg, 300 mg CAPSULE, ER, BIPHASIC <b>DL</b>	1	ST,QL(30 per 30 days)
<i>tramadol</i> 100 mg, 200 mg, 300 mg TABLET, ER 24 HR. <b>DL</b>	1	ST,QL(30 per 30 days)
<i>tramadol</i> 100 mg, 200 mg, 300 mg TABLET, ER 24 HR., MULTIPHASE <b>DL</b>	1	ST,QL(30 per 30 days)
<i>tramadol</i> 25 mg TABLET <b>DL</b>	1	QL(180 per 30 days)
<i>tramadol</i> 5 mg/ml SOLUTION <b>DL</b>	4	QL(2400 per 30 days)
<i>tramadol</i> 50 mg TABLET <b>DL</b>	1	QL(240 per 30 days)
<i>tramadol-acetaminophen</i> 37.5-325 mg TABLET <b>DL</b>	1	QL(240 per 30 days)
TREZIX 320.5-30-16 MG CAPSULE <b>DL</b>	1	QL(300 per 30 days)
ULTRACET 37.5-325 MG TABLET <b>DL</b>	3	QL(240 per 30 days)
ULTRAM 50 MG TABLET <b>DL</b>	3	QL(240 per 30 days)
VIMOVO 375-20 MG, 500-20 MG TABLET, IR, DR, BIPHASIC <b>DL</b>	4	PA,QL(60 per 30 days)
VIVLODEX 10 MG, 5 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
XTAMPZA ER 13.5 MG, 18 MG, 27 MG, 36 MG, 9 MG CAPSULE ER SPRINKLE 12 HR. <b>DL</b>	2	QL(60 per 30 days)
ZIPSOR 25 MG CAPSULE <b>DL</b>	4	ST,QL(120 per 30 days)
ZORVOLEX 18 MG, 35 MG CAPSULE <b>MO</b>	3	ST,QL(90 per 30 days)
<b>ANESTHETICS</b>		
<i>bupivacaine</i> (pf) 0.25 % (2.5 mg/ml), 0.5 % (5 mg/ml), 0.75 % (7.5 mg/ml) SOLUTION <b>MO</b>	1	
<i>bupivacaine hcl</i> 0.25 % (2.5 mg/ml), 0.5 % (5 mg/ml) SOLUTION <b>MO</b>	1	
<i>bupivacaine-dextrose-water</i> (pf) 0.75 % (7.5 mg/ml) SOLUTION <b>MO</b>	1	
<i>bupivacaine-epinephrine</i> 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION <b>MO</b>	1	
<i>bupivacaine-epinephrine</i> (pf) 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION <b>MO</b>	1	
CARBOCAINE 1 % (10 MG/ML) SOLUTION <b>MO</b>	3	
CARBOCAINE (PF) 10 MG/ML (1 %), 15 MG/ML (1.5 %), 20 MG/ML (2 %) SOLUTION <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CARBOCAINE WITH NEO-COBEFRIN 2 % -1:20,000 CARTRIDGE <b>MO</b>	1	
chloroprocaine (pf) 20 mg/ml (2 %), 30 mg/ml (3 %) SOLUTION <b>MO</b>	1	
CLOROTEKAL 10 MG/ML (1 %) SOLUTION <b>MO</b>	3	
dermacinrx lidocan 5 % ADHESIVE PATCH, MEDICATED <b>DL</b>	4	PA,QL(90 per 30 days)
EXPAREL (PF) 1.3 % (13.3 MG/ML) SUSPENSION <b>MO</b>	3	
glydo 2 % JELLY IN APPLICATOR <b>MO</b>	1	
lidocaine 5 % ADHESIVE PATCH, MEDICATED <b>MO</b>	1	PA,QL(90 per 30 days)
lidocaine 5 % OINTMENT <b>MO</b>	1	PA
lidocaine (pf) in d7.5w 50 mg/ml (5 %) SOLUTION <b>MO</b>	1	
lidocaine (pf) 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %), 40 mg/ml (4 %), 5 mg/ml (0.5 %) SOLUTION <b>MO</b>	1	
lidocaine hcl 10 mg/ml (1 %), 2 %, 20 mg/ml (2 %), 4 %, 4 % (40 mg/ml), 5 mg/ml (0.5 %) SOLUTION <b>MO</b>	1	
lidocaine hcl 2 % JELLY <b>MO</b>	1	
lidocaine hcl 2 % JELLY IN APPLICATOR <b>MO</b>	1	
lidocaine viscous 2 % SOLUTION <b>MO</b>	1	
lidocaine-epinephrine 0.5 %-1:200,000, 1 %-1:100,000, 2 %-1:100,000 SOLUTION <b>MO</b>	1	
lidocaine-epinephrine bit 2 %-1:100,000, 2 %-1:50,000 CARTRIDGE <b>MO</b>	1	
lidocaine-prilocaine 2.5-2.5 % CREAM <b>MO</b>	1	
lidocan iii 5 % ADHESIVE PATCH, MEDICATED <b>DL</b>	4	PA,QL(90 per 30 days)
lidocan iv 5 % ADHESIVE PATCH, MEDICATED <b>DL</b>	4	PA,QL(90 per 30 days)
lidocan v 5 % ADHESIVE PATCH, MEDICATED <b>DL</b>	4	PA,QL(90 per 30 days)
LIDODERM 5 % ADHESIVE PATCH, MEDICATED <b>DL</b>	4	PA,QL(90 per 30 days)
lignospan standard 2 %-1:100,000 CARTRIDGE <b>MO</b>	1	
MARCAINE 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML) SOLUTION <b>MO</b>	3	
MARCAINE (PF) 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML), 0.75 % (7.5 MG/ML) SOLUTION <b>MO</b>	3	
MARCAINE SPINAL (PF) 0.75 % (7.5 MG/ML) SOLUTION <b>MO</b>	3	
MARCAINE-EPINEPHRINE 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION <b>MO</b>	3	
marcaine-epinephrine 0.5 %-1:200,000 CARTRIDGE <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MARCAINE-EPINEPHRINE (PF) 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION <b>MO</b>	3	
NAROPIN (PF) 10 MG/ML (1 %), 2 MG/ML (0.2 %), 5 MG/ML (0.5 %), 7.5 MG/ML (0.75 %) SOLUTION <b>MO</b>	3	
NESACAINE 10 MG/ML (1 %), 20 MG/ML (2 %) SOLUTION <b>MO</b>	3	
NESACAINE-MPF 20 MG/ML (2 %), 30 MG/ML (3 %) SOLUTION <b>MO</b>	3	
PLIAGLIS 7-7 % CREAM <b>MO</b>	3	
<i>polocaine 1 % (10 mg/ml), 2 % SOLUTION <b>MO</b></i>	1	
<i>polocaine-mpf 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %) SOLUTION <b>MO</b></i>	1	
<i>ropivacaine (pf) 10 mg/ml (1 %), 2 mg/ml (0.2 %), 5 mg/ml (0.5 %), 7.5 mg/ml (0.75 %) SOLUTION <b>MO</b></i>	1	
SENSORCAINE 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML) SOLUTION <b>MO</b>	1	
<i>sensorcaine-epinephrine 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION <b>MO</b></i>	1	
SENSORCAINE-MPF 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML), 0.75 % (7.5 MG/ML) SOLUTION <b>MO</b>	1	
<i>sensorcaine-mpf 0.25 % (2.5 mg/ml), 0.5 % (5 mg/ml), 0.75 % (7.5 mg/ml) SOLUTION <b>MO</b></i>	1	
<i>sensorcaine-mpf spinal 0.75 % (7.5 mg/ml) SOLUTION <b>MO</b></i>	1	
<i>sensorcaine-mpf/epinephrine 0.25 %-1:200,000 SOLUTION <b>MO</b></i>	1	
SENSORCAINE-MPF/EPINEPHRINE 0.5 %-1:200,000, 0.75 %-1:200,000 SOLUTION <b>MO</b>	1	
SYNERA 70-70 MG PATCH, MEDICATED SELF-HEATING <b>DL</b>	4	PA
<i>vivacaine 0.5 %-1:200,000 CARTRIDGE <b>MO</b></i>	1	
ZTLIDO 1.8 % ADHESIVE PATCH, MEDICATED <b>MO</b>	3	PA,QL(90 per 30 days)
<b>ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS</b>		
<i>acamprosate 333 mg TABLET, DR/EC <b>MO</b></i>	1	
<i>buprenorphine hcl 2 mg, 8 mg SUBLINGUAL TABLET <b>MO</b></i>	1	QL(90 per 30 days)
<i>buprenorphine-naloxone 12-3 mg FILM <b>MO</b></i>	1	QL(60 per 30 days)
<i>buprenorphine-naloxone 2-0.5 mg, 4-1 mg, 8-2 mg FILM <b>MO</b></i>	1	QL(90 per 30 days)
<i>buprenorphine-naloxone 2-0.5 mg, 8-2 mg SUBLINGUAL TABLET <b>MO</b></i>	3	PA,QL(90 per 30 days)
<i>bupropion hcl (smoking deter) 150 mg TABLET, ER 12 HR. <b>MO</b></i>	1	QL(90 per 30 days)
CHANTIX 1 MG TABLET <b>MO</b>	3	PA,QL(56 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CHANTIX CONTINUING MONTH BOX 1 MG TABLET <b>MO</b>	3	PA,QL(56 per 28 days)
CHANTIX STARTING MONTH BOX 0.5 MG (11)- 1 MG (42) TABLET, DOSE PACK <b>MO</b>	3	PA,QL(53 per 28 days)
<i>disulfiram 250 mg, 500 mg TABLET <b>MO</b></i>	1	
KLOXXADO 8 MG/ACTUATION SPRAY, NON-AEROSOL <b>MO</b>	3	PA,QL(2 per 30 days)
LUCEMYRA 0.18 MG TABLET <b>DL</b>	4	PA,QL(224 per 365 days)
<i>nalmefene 1 mg/ml SOLUTION <b>MO</b></i>	1	
<i>naloxone 0.4 mg/ml SOLUTION <b>MO</b></i>	1	
<i>naloxone 0.4 mg/ml, 1 mg/ml SYRINGE <b>MO</b></i>	1	
<i>naloxone 4 mg/actuation SPRAY, NON-AEROSOL <b>MO</b></i>	2	QL(2 per 30 days)
<i>naltrexone 50 mg TABLET <b>MO</b></i>	1	
NARCAN 4 MG/ACTUATION SPRAY, NON-AEROSOL <b>MO</b>	3	PA,QL(2 per 30 days)
NICOTROL 10 MG CARTRIDGE <b>MO</b>	3	
NICOTROL NS 10 MG/ML SPRAY, NON-AEROSOL <b>MO</b>	3	
OPVEE 2.7 MG/ACTUATION SPRAY, NON-AEROSOL <b>MO</b>	3	PA,QL(2 per 30 days)
SUBOXONE 12-3 MG FILM <b>MO</b>	3	PA,QL(60 per 30 days)
SUBOXONE 2-0.5 MG, 4-1 MG, 8-2 MG FILM <b>MO</b>	3	PA,QL(90 per 30 days)
<i>varenicline 0.5 mg (11)- 1 mg (42) TABLET, DOSE PACK <b>MO</b></i>	1	QL(53 per 28 days)
<i>varenicline 0.5 mg, 1 mg TABLET <b>MO</b></i>	1	QL(56 per 28 days)
VIVITROL 380 MG SUSPENSION, ER, RECON <b>DL</b>	4	QL(1 per 28 days)
ZIMHI 5 MG/0.5 ML SYRINGE <b>MO</b>	3	PA,QL(1 per 30 days)
ZUBSOLV 0.7-0.18 MG, 1.4-0.36 MG SUBLINGUAL TABLET <b>MO</b>	1	QL(90 per 30 days)
ZUBSOLV 11.4-2.9 MG SUBLINGUAL TABLET <b>MO</b>	1	QL(30 per 30 days)
ZUBSOLV 2.9-0.71 MG, 5.7-1.4 MG SUBLINGUAL TABLET <b>MO</b>	1	QL(90 per 30 days)
ZUBSOLV 8.6-2.1 MG SUBLINGUAL TABLET <b>MO</b>	1	QL(60 per 30 days)
<b>ANTIBACTERIALS</b>		
<i>acetic acid 2 % SOLUTION <b>MO</b></i>	1	
ACTICLATE 150 MG TABLET <b>DL</b>	4	ST,QL(30 per 30 days)
ACTICLATE 75 MG TABLET <b>DL</b>	4	ST,QL(60 per 30 days)
<i>amikacin 1,000 mg/4 ml, 500 mg/2 ml SOLUTION <b>MO</b></i>	1	
<i>amoxicillin 125 mg, 250 mg CHEWABLE TABLET <b>MO</b></i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
amoxicillin 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
amoxicillin 250 mg CAPSULE <b>MO</b>	1	
amoxicillin 500 mg CAPSULE <b>MO</b>	1	
amoxicillin 500 mg TABLET <b>MO</b>	1	
amoxicillin 875 mg TABLET <b>MO</b>	1	
amoxicillin-pot clavulanate 1,000-62.5 mg TABLET, ER 12 HR. <b>MO</b>	1	
amoxicillin-pot clavulanate 200-28.5 mg, 400-57 mg CHEWABLE TABLET <b>MO</b>	1	
amoxicillin-pot clavulanate 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
amoxicillin-pot clavulanate 250-125 mg, 500-125 mg TABLET <b>MO</b>	1	
amoxicillin-pot clavulanate 875-125 mg TABLET <b>MO</b>	1	
ampicillin 500 mg CAPSULE <b>MO</b>	1	
ampicillin sodium 1 gram, 10 gram, 125 mg, 2 gram, 250 mg, 500 mg RECON SOLUTION <b>MO</b>	1	
ampicillin-sulbactam 1.5 gram, 15 gram, 3 gram RECON SOLUTION <b>MO</b>	1	
ARIKAYCE 590 MG/8.4 ML SUSPENSION FOR NEBULIZATION <b>DL</b>	4	PA,QL(235.2 per 28 days)
AUGMENTIN 125-31.25 MG/5 ML, 250-62.5 MG/5 ML SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	
AUGMENTIN 500-125 MG TABLET <b>MO</b>	3	PA
AUGMENTIN ES-600 600-42.9 MG/5 ML SUSPENSION FOR RECONSTITUTION <b>MO</b>	3	
AUGMENTIN XR 1,000-62.5 MG TABLET, ER 12 HR. <b>MO</b>	3	
AVELOX IN NACL (ISO-OSMOTIC) 400 MG/250 ML PIGGYBACK <b>MO</b>	3	PA
avidoxy 100 mg TABLET <b>MO</b>	1	ST
AVYCAZ 2.5 GRAM RECON SOLUTION <b>DL</b>	4	
AZACTAM 1 GRAM, 2 GRAM RECON SOLUTION <b>MO</b>	3	PA
azithromycin 1 gram PACKET <b>MO</b>	1	
azithromycin 100 mg/5 ml, 200 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
azithromycin 250 mg TABLET <b>MO</b>	1	
azithromycin 500 mg RECON SOLUTION <b>MO</b>	1	
azithromycin 500 mg, 600 mg TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
aztreonam 1 gram, 2 gram RECON SOLUTION <b>MO</b>	1	
bacitracin 50,000 unit RECON SOLUTION <b>MO</b>	1	
BACTRIM 400-80 MG TABLET <b>MO</b>	3	
BACTRIM DS 800-160 MG TABLET <b>MO</b>	3	
BAXDELA 300 MG RECON SOLUTION <b>DL</b>	4	QL(28 per 14 days)
BAXDELA 450 MG TABLET <b>DL</b>	4	QL(28 per 14 days)
BETHKIS 300 MG/4 ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
BICILLIN C-R 1,200,000 UNIT/ 2 ML(600K/600K), 1,200,000 UNIT/ 2 ML(900K/300K) SYRINGE <b>MO</b>	3	
BICILLIN L-A 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML SYRINGE <b>MO</b>	3	
ceftazidime 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
ceftazidime 250 mg, 500 mg CAPSULE <b>MO</b>	1	
ceftazidime 500 mg TABLET, ER 12 HR. <b>MO</b>	1	
cefadroxil 1 gram TABLET <b>MO</b>	1	
cefadroxil 250 mg/5 ml, 500 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
cefadroxil 500 mg CAPSULE <b>MO</b>	1	
cefazolin 1 gram, 10 gram, 2 gram, 3 gram, 500 mg RECON SOLUTION <b>MO</b>	1	
CEFAZOLIN 2 GRAM, 3 GRAM RECON SOLUTION <b>MO</b>	1	
cefazolin in dextrose (iso-os) 1 gram/50 ml, 2 gram/100 ml, 2 gram/50 ml PIGGYBACK <b>MO</b>	1	
cefepime 125 mg/5 ml, 250 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
cefepime 300 mg CAPSULE <b>MO</b>	1	
cefepime 1 gram, 2 gram RECON SOLUTION <b>MO</b>	1	
cefepime in dextrose 5 % 1 gram/50 ml, 2 gram/50 ml PIGGYBACK <b>MO</b>	1	
cefepime in dextrose,iso-osm 1 gram/50 ml, 2 gram/100 ml PIGGYBACK <b>MO</b>	3	
cefixime 100 mg/5 ml, 200 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
cefixime 400 mg CAPSULE <b>MO</b>	1	
cefotaxime 1 gram RECON SOLUTION <b>MO</b>	1	
cefotetan 1 gram, 10 gram, 2 gram RECON SOLUTION <b>MO</b>	1	
cefoxitin 1 gram, 10 gram, 2 gram RECON SOLUTION <b>MO</b>	1	
cefoxitin in dextrose, iso-osm 1 gram/50 ml, 2 gram/50 ml PIGGYBACK <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
cefpodoxime 100 mg, 200 mg TABLET <b>MO</b>	1	
cefpodoxime 100 mg/5 ml, 50 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
cefprozil 125 mg/5 ml, 250 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
cefprozil 250 mg, 500 mg TABLET <b>MO</b>	1	
ceftazidime 1 gram, 2 gram, 6 gram RECON SOLUTION <b>MO</b>	1	
ceftazidime in d5w 1 gram/50 ml, 2 gram/50 ml PIGGYBACK <b>MO</b>	1	
ceftriaxone 1 gram, 10 gram, 100 gram, 2 gram, 250 mg, 500 mg RECON SOLUTION <b>MO</b>	1	
ceftriaxone in dextrose,iso-os 1 gram/50 ml, 2 gram/50 ml PIGGYBACK <b>MO</b>	1	
cefuroxime axetil 250 mg, 500 mg TABLET <b>MO</b>	1	
cefuroxime sodium 1.5 gram, 7.5 gram, 750 mg RECON SOLUTION <b>MO</b>	1	
cephalexin 125 mg/5 ml, 250 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
cephalexin 250 mg, 500 mg TABLET <b>MO</b>	1	
cephalexin 250 mg, 750 mg CAPSULE <b>MO</b>	1	
cephalexin 500 mg CAPSULE <b>MO</b>	1	
chloramphenicol sod succinate 1 gram RECON SOLUTION <b>MO</b>	1	
CIPRO 250 MG, 500 MG TABLET <b>MO</b>	3	
CIPRO 250 MG/5 ML, 500 MG/5 ML SUSPENSION, MICROCAPSULE RECON <b>MO</b>	3	
ciprofloxacin 250 mg/5 ml, 500 mg/5 ml SUSPENSION, MICROCAPSULE RECON <b>MO</b>	1	
ciprofloxacin hcl 100 mg, 250 mg, 750 mg TABLET <b>MO</b>	1	
ciprofloxacin hcl 500 mg TABLET <b>MO</b>	1	
ciprofloxacin in 5 % dextrose 200 mg/100 ml, 400 mg/200 ml PIGGYBACK <b>MO</b>	1	
CLAFORAN 1 GRAM, 10 GRAM, 2 GRAM RECON SOLUTION <b>MO</b>	3	
clarithromycin 125 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
clarithromycin 250 mg, 500 mg TABLET <b>MO</b>	1	
clarithromycin 250 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
clarithromycin 500 mg TABLET, ER 24 HR. <b>MO</b>	1	
CLEOCIN 100 MG SUPPOSITORY <b>MO</b>	3	
CLEOCIN 150 MG/ML SOLUTION <b>MO</b>	1	
CLEOCIN 2 % CREAM <b>MO</b>	3	PA
CLEOCIN HCL 150 MG, 300 MG, 75 MG CAPSULE <b>MO</b>	3	
CLEOCIN PEDIATRIC 75 MG/5 ML RECON SOLUTION <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
clindamycin hcl 150 mg, 75 mg CAPSULE <b>MO</b>	1	
clindamycin hcl 300 mg CAPSULE <b>MO</b>	1	
clindamycin in 0.9 % sod chlor 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml PIGGYBACK <b>MO</b>	1	
clindamycin in 5 % dextrose 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml PIGGYBACK <b>MO</b>	1	
clindamycin palmitate hcl 75 mg/5 ml RECON SOLUTION <b>MO</b>	1	
clindamycin pediatric 75 mg/5 ml RECON SOLUTION <b>MO</b>	1	
clindamycin phosphate 150 mg/ml SOLUTION <b>MO</b>	1	
clindamycin phosphate 2 % CREAM <b>MO</b>	1	
CLINDESSE 2 % CREAM, ER <b>MO</b>	3	
colistin (colistimethate na) 150 mg RECON SOLUTION <b>MO</b>	1	
COLY-MYCIN M PARENTERAL 150 MG RECON SOLUTION <b>DL</b>	4	
coremino 135 mg, 45 mg, 90 mg TABLET, ER 24 HR. <b>MO</b>	1	ST,QL(30 per 30 days)
CUBICIN 500 MG RECON SOLUTION <b>DL</b>	4	
CUBICIN RF 500 MG RECON SOLUTION <b>DL</b>	4	
DALVANCE 500 MG SOLUTION <b>DL</b>	4	QL(4 per 28 days)
daptomycin 350 mg RECON SOLUTION <b>MO</b>	1	
daptomycin 500 mg RECON SOLUTION <b>DL</b>	4	
daptomycin in 0.9 % sod chlor 1,000 mg/100 ml, 350 mg/50 ml, 500 mg/50 ml, 700 mg/100 ml PIGGYBACK <b>MO</b>	3	
demeclocycline 150 mg TABLET <b>MO</b>	1	QL(240 per 30 days)
demeclocycline 300 mg TABLET <b>MO</b>	1	QL(120 per 30 days)
dicloxacillin 250 mg, 500 mg CAPSULE <b>MO</b>	1	
DIFICID 200 MG TABLET <b>DL</b>	4	
DIFICID 40 MG/ML SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	
DORYX 200 MG TABLET, DR/EC <b>MO</b>	3	ST,QL(30 per 30 days)
DORYX 50 MG TABLET, DR/EC <b>MO</b>	3	ST,QL(60 per 30 days)
DORYX 80 MG TABLET, DR/EC <b>DL</b>	4	ST,QL(60 per 30 days)
DORYX MPC 120 MG TABLET, DR/EC <b>MO</b>	3	ST,QL(60 per 30 days)
DORYX MPC 60 MG TABLET, DR/EC <b>DL</b>	4	ST,QL(60 per 30 days)
doxy-100 100 mg RECON SOLUTION <b>MO</b>	1	
doxycycline hyclate 100 mg CAPSULE <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
doxycycline hyclate 100 mg RECON SOLUTION <b>MO</b>	1	
doxycycline hyclate 100 mg TABLET <b>MO</b>	1	
doxycycline hyclate 100 mg TABLET, DR/EC <b>MO</b>	1	ST,QL(90 per 30 days)
doxycycline hyclate 150 mg TABLET <b>MO</b>	1	ST,QL(30 per 30 days)
doxycycline hyclate 150 mg, 50 mg, 75 mg TABLET, DR/EC <b>MO</b>	1	ST,QL(60 per 30 days)
doxycycline hyclate 20 mg TABLET <b>MO</b>	1	
doxycycline hyclate 200 mg TABLET, DR/EC <b>MO</b>	1	ST,QL(30 per 30 days)
doxycycline hyclate 50 mg CAPSULE <b>MO</b>	1	
doxycycline hyclate 50 mg TABLET <b>MO</b>	1	ST,QL(180 per 30 days)
doxycycline hyclate 75 mg TABLET <b>MO</b>	1	ST,QL(60 per 30 days)
doxycycline hyclate 80 mg TABLET, DR/EC <b>DL</b>	4	ST,QL(60 per 30 days)
doxycycline monohydrate 100 mg, 150 mg, 50 mg, 75 mg TABLET <b>MO</b>	1	
doxycycline monohydrate 100 mg, 50 mg CAPSULE <b>MO</b>	1	
doxycycline monohydrate 150 mg CAPSULE <b>MO</b>	1	QL(30 per 30 days)
doxycycline monohydrate 25 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
doxycycline monohydrate 40 mg CAPSULE, IR/DR, BIPHASIC <b>MO</b>	1	ST,QL(30 per 30 days)
doxycycline monohydrate 75 mg CAPSULE <b>MO</b>	1	QL(60 per 30 days)
E.E.S. 400 400 MG TABLET <b>MO</b>	1	
E.E.S. GRANULES 200 MG/5 ML SUSPENSION FOR RECONSTITUTION <b>MO</b>	3	
ertapenem 1 gram RECON SOLUTION <b>MO</b>	1	
ERY-TAB 250 MG, 333 MG, 500 MG TABLET, DR/EC <b>MO</b>	1	
ERYPED 200 200 MG/5 ML SUSPENSION FOR RECONSTITUTION <b>MO</b>	3	
ERYPED 400 400 MG/5 ML SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	
ERYTHROCIN 500 MG RECON SOLUTION <b>MO</b>	1	
ERYTHROCIN (AS STEARATE) 250 MG TABLET <b>MO</b>	1	
erythromycin 250 mg CAPSULE, DR/EC <b>MO</b>	1	
erythromycin 250 mg, 333 mg, 500 mg TABLET, DR/EC <b>MO</b>	1	
erythromycin 250 mg, 500 mg TABLET <b>MO</b>	1	
erythromycin ethylsuccinate 200 mg/5 ml, 400 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
erythromycin ethylsuccinate 400 mg TABLET <b>MO</b>	1	
erythromycin lactobionate 500 mg RECON SOLUTION <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
FETROJA 1 GRAM RECON SOLUTION <b>DL</b>	4	QL(84 per 14 days)
FIRVANQ 25 MG/ML, 50 MG/ML RECON SOLUTION <b>MO</b>	3	
FLAGYL 375 MG CAPSULE <b>MO</b>	3	QL(320 per 30 days)
<i>fosfomycin tromethamine</i> 3 gram PACKET <b>MO</b>	1	
FURADANTIN 25 MG/5 ML SUSPENSION <b>MO</b>	3	
<i>gentamicin</i> 0.1 % CREAM <b>MO</b>	1	
<i>gentamicin</i> 0.1 % OINTMENT <b>MO</b>	1	
<i>gentamicin</i> 20 mg/2 ml, 40 mg/ml SOLUTION <b>MO</b>	1	
<i>gentamicin in nacl (iso-osm)</i> 100 mg/100 ml, 100 mg/50 ml, 120 mg/100 ml, 60 mg/50 ml, 70 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml, 90 mg/100 ml PIGGYBACK <b>MO</b>	1	
<i>gentamicin sulfate (ped) (pf)</i> 20 mg/2 ml SOLUTION <b>MO</b>	1	
<i>gentamicin sulfate (pf)</i> 100 mg/10 ml, 60 mg/6 ml SOLUTION <b>MO</b>	1	
HIPREX 1 GRAM TABLET <b>MO</b>	3	PA
HUMATIN 250 MG CAPSULE <b>DL</b>	4	
<i>imipenem-cilastatin</i> 250 mg, 500 mg RECON SOLUTION <b>MO</b>	1	
INVANZ 1 GRAM RECON SOLUTION <b>MO</b>	3	
KIMYRSA 1,200 MG RECON SOLUTION <b>DL</b>	4	QL(1 per 30 days)
KITABIS PAK 300 MG/5 ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
KLARON 10 % SUSPENSION <b>MO</b>	3	QL(118 per 30 days)
<i>levofloxacin</i> 25 mg/ml, 250 mg/10 ml SOLUTION <b>MO</b>	1	
<i>levofloxacin</i> 250 mg, 750 mg TABLET <b>MO</b>	1	
<i>levofloxacin</i> 500 mg TABLET <b>MO</b>	1	
<i>levofloxacin in d5w</i> 250 mg/50 ml, 500 mg/100 ml, 750 mg/150 ml PIGGYBACK <b>MO</b>	1	
LINCOCIN 300 MG/ML SOLUTION <b>MO</b>	3	
<i>lincomycin</i> 300 mg/ml SOLUTION <b>MO</b>	1	
<i>linezolid</i> 100 mg/5 ml SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	QL(1800 per 30 days)
<i>linezolid</i> 600 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
<i>linezolid in dextrose 5%</i> 600 mg/300 ml PIGGYBACK <b>MO</b>	1	
<i>linezolid-0.9% sodium chloride</i> 600 mg/300 ml PARENTERAL SOLUTION <b>MO</b>	1	
MACROBID 100 MG CAPSULE <b>MO</b>	3	
MACRODANTIN 100 MG, 25 MG, 50 MG CAPSULE <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
meropenem 1 gram, 500 mg RECON SOLUTION <b>MO</b>	1	
meropenem-0.9% sodium chloride 1 gram/50 ml, 500 mg/50 ml PIGGYBACK <b>MO</b>	1	
methenamine hippurate 1 gram TABLET <b>MO</b>	1	
METRO I.V. 500 MG/100 ML PIGGYBACK <b>MO</b>	3	
METROCREAM 0.75 % CREAM <b>MO</b>	3	PA
METROGEL 1 % GEL <b>MO</b>	3	ST
METROLOTION 0.75 % LOTION <b>MO</b>	3	PA
metronidazole 0.75 % CREAM <b>MO</b>	1	
metronidazole 0.75 % LOTION <b>MO</b>	1	
metronidazole 0.75 %, 0.75 % (37.5mg/5 gram), 1 % GEL <b>MO</b>	1	
metronidazole 1 % GEL WITH PUMP <b>MO</b>	1	
metronidazole 250 mg TABLET <b>MO</b>	1	
metronidazole 375 mg CAPSULE <b>MO</b>	1	QL(320 per 30 days)
metronidazole 500 mg TABLET <b>MO</b>	1	
metronidazole in nacl (iso-os) 500 mg/100 ml PIGGYBACK <b>MO</b>	1	
MINOCIN 100 MG RECON SOLUTION <b>DL</b>	4	PA
minocycline 100 mg, 50 mg, 75 mg CAPSULE <b>MO</b>	1	
minocycline 100 mg, 50 mg, 75 mg TABLET <b>MO</b>	1	
minocycline 105 mg, 115 mg, 135 mg, 45 mg, 55 mg, 65 mg, 80 mg, 90 mg TABLET, ER 24 HR. <b>MO</b>	1	ST,QL(30 per 30 days)
mondoxynol 100 mg CAPSULE <b>MO</b>	1	
mondoxynol 75 mg CAPSULE <b>MO</b>	1	ST,QL(60 per 30 days)
MONODOX 100 MG, 50 MG CAPSULE <b>MO</b>	3	ST
MONODOX 75 MG CAPSULE <b>MO</b>	3	ST,QL(60 per 30 days)
MONUROL 3 GRAM PACKET <b>MO</b>	3	
morgidox 100 mg, 50 mg CAPSULE <b>MO</b>	1	ST
moxifloxacin 400 mg TABLET <b>MO</b>	1	
moxifloxacin-sod.ace,sul-water 400 mg/250 ml PIGGYBACK <b>MO</b>	1	
moxifloxacin-sod.chloride(iso) 400 mg/250 ml PIGGYBACK <b>MO</b>	1	
nafcillin 1 gram, 10 gram, 2 gram RECON SOLUTION <b>MO</b>	1	
nafcillin in dextrose iso-osm 1 gram/50 ml, 2 gram/100 ml PIGGYBACK <b>DL</b>	4	
neomycin 500 mg TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
nitrofurantoin 25 mg/5 ml, 50 mg/5 ml SUSPENSION <b>DL</b>	4	
nitrofurantoin macrocrystal 100 mg, 25 mg, 50 mg CAPSULE <b>MO</b>	1	
nitrofurantoin monohyd/m-cryst 100 mg CAPSULE <b>MO</b>	1	
NORITATE 1 % CREAM <b>DL</b>	4	ST,QL(60 per 30 days)
NUVESSA 1.3 % (65 MG/5 GRAM) GEL <b>MO</b>	3	
NUZYRA 100 MG RECON SOLUTION <b>DL</b>	4	
NUZYRA 150 MG TABLET <b>DL</b>	4	QL(30 per 14 days)
ofloxacin 300 mg, 400 mg TABLET <b>MO</b>	1	
ORACEA 40 MG CAPSULE, IR/DR, BIPHASIC <b>MO</b>	3	ST,QL(30 per 30 days)
ORBACTIV 400 MG RECON SOLUTION <b>DL</b>	4	QL(3 per 28 days)
oxacillin 1 gram, 10 gram, 2 gram RECON SOLUTION <b>MO</b>	1	
oxacillin in dextrose(iso-osm) 1 gram/50 ml, 2 gram/50 ml PIGGYBACK <b>MO</b>	3	
paramomycin 250 mg CAPSULE <b>MO</b>	1	
penicillin g pot in dextrose 1 million unit/50 ml, 2 million unit/50 ml, 3 million unit/50 ml PIGGYBACK <b>MO</b>	3	
penicillin g potassium 20 million unit, 5 million unit RECON SOLUTION <b>MO</b>	1	
penicillin g procaine 1.2 million unit/2 ml, 600,000 unit/ml SYRINGE <b>MO</b>	1	
penicillin g sodium 5 million unit RECON SOLUTION <b>MO</b>	1	
penicillin v potassium 125 mg/5 ml, 250 mg/5 ml RECON SOLUTION <b>MO</b>	1	
penicillin v potassium 250 mg, 500 mg TABLET <b>MO</b>	1	
pfizerpen-g 20 million unit, 5 million unit RECON SOLUTION <b>MO</b>	1	
piperacillin-tazobactam 13.5 gram, 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram RECON SOLUTION <b>MO</b>	1	
polymyxin b sulfate 500,000 unit RECON SOLUTION <b>MO</b>	1	
PRIMAXIN IV 500 MG RECON SOLUTION <b>MO</b>	3	
PRIMSOL 50 MG/5 ML SOLUTION <b>MO</b>	3	
RECARBRIO 1.25 GRAM RECON SOLUTION <b>DL</b>	4	
rosadan 0.75 % CREAM <b>MO</b>	1	ST
rosadan 0.75 % GEL <b>MO</b>	1	ST
SEYSARA 100 MG, 150 MG, 60 MG TABLET <b>MO</b>	3	ST,QL(30 per 30 days)
SIVEXTRO 200 MG RECON SOLUTION <b>DL</b>	4	QL(6 per 28 days)
SIVEXTRO 200 MG TABLET <b>DL</b>	4	QL(6 per 28 days)
SOLODYN 105 MG, 115 MG, 55 MG, 65 MG, 80 MG TABLET, ER 24 HR. <b>DL</b>	4	ST,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SOLOSEC 2 GRAM DR GRANULES IN PACKET <b>MO</b>	3	PA
streptomycin 1 gram RECON SOLUTION <b>DL</b>	4	
sulfacetamide sodium 10 % OINTMENT <b>MO</b>	1	
sulfacetamide sodium (acne) 10 % SUSPENSION <b>MO</b>	1	QL(118 per 30 days)
sulfadiazine 500 mg TABLET <b>MO</b>	1	
sulfamethoxazole-trimethoprim 200-40 mg/5 ml SUSPENSION <b>MO</b>	1	
sulfamethoxazole-trimethoprim 400-80 mg TABLET <b>MO</b>	1	
sulfamethoxazole-trimethoprim 400-80 mg/5 ml SOLUTION <b>MO</b>	1	
sulfamethoxazole-trimethoprim 800-160 mg TABLET <b>MO</b>	1	
SULFATRIM 200-40 MG/5 ML SUSPENSION <b>MO</b>	3	
SUPRAX 100 MG/5 ML SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
SYNERCID 500 MG RECON SOLUTION <b>DL</b>	4	
TARGADOX 50 MG TABLET <b>MO</b>	1	ST,QL(180 per 30 days)
tazicef 1 gram, 2 gram, 6 gram RECON SOLUTION <b>MO</b>	1	
TEFLARO 400 MG, 600 MG RECON SOLUTION <b>DL</b>	4	
tetracycline 250 mg, 500 mg CAPSULE <b>MO</b>	1	
tetracycline 250 mg, 500 mg TABLET <b>DL</b>	4	
tigecycline 50 mg RECON SOLUTION <b>DL</b>	4	
tinidazole 250 mg, 500 mg TABLET <b>MO</b>	1	
TOBI 300 MG/5 ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
tobramycin 300 mg/4 ml SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
tobramycin in 0.225 % nacl 300 mg/5 ml SOLUTION FOR NEBULIZATION <b>MO</b>	1	PA
tobramycin sulfate 1.2 gram RECON SOLUTION <b>DL</b>	4	
tobramycin sulfate 10 mg/ml, 40 mg/ml SOLUTION <b>MO</b>	1	
tobramycin with nebulizer 300 mg/5 ml SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
trimethoprim 100 mg TABLET <b>MO</b>	1	
TYGACIL 50 MG RECON SOLUTION <b>DL</b>	4	
UNASYN 1.5 GRAM, 15 GRAM, 3 GRAM RECON SOLUTION <b>MO</b>	3	
VABOMERE 2 GRAM RECON SOLUTION <b>DL</b>	4	QL(84 per 14 days)
VANCOGIN 125 MG CAPSULE <b>MO</b>	3	PA,QL(120 per 30 days)
VANCOGIN 250 MG CAPSULE <b>DL</b>	4	PA,QL(240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
vancomycin 1,000 mg, 1.25 gram, 1.5 gram, 10 gram, 25 mg/ml, 5 gram, 50 mg/ml, 500 mg, 750 mg RECON SOLUTION <b>MO</b>	1	
vancomycin 125 mg CAPSULE <b>MO</b>	1	PA,QL(120 per 30 days)
vancomycin 250 mg CAPSULE <b>MO</b>	1	PA,QL(240 per 30 days)
vancomycin in 0.9 % sodium chl 1 gram/200 ml, 500 mg/100 ml, 750 mg/150 ml PIGGYBACK <b>MO</b>	3	
vancomycin in dextrose 5 % 1 gram/200 ml, 750 mg/150 ml PIGGYBACK <b>MO</b>	3	
VANCOMYCIN IN DEXTROSE 5 % 1.25 GRAM/250 ML, 1.5 GRAM/300 ML PIGGYBACK <b>MO</b>	3	
vancomycin in dextrose 5 % 500 mg/100 ml PIGGYBACK <b>DL</b>	3	
vancomycin-diluent combo no.1 1 gram/200 ml, 1.5 gram/300 ml, 500 mg/100 ml PIGGYBACK <b>DL</b>	3	
vancomycin-diluent combo no.1 1.25 gram/250 ml, 1.75 gram/350 ml, 2 gram/400 ml, 750 mg/150 ml PIGGYBACK <b>MO</b>	3	
VANDAZOLE 0.75 % (37.5MG/5 GRAM) GEL <b>MO</b>	3	
VIBATIV 750 MG RECON SOLUTION <b>DL</b>	4	
VIBRAMYCIN 100 MG CAPSULE <b>MO</b>	3	
VIBRAMYCIN (CALCIUM) 50 MG/5 ML SYRUP <b>MO</b>	3	ST
XACIATO 2 % GEL <b>MO</b>	3	
XENLETA 150 MG/15 ML SOLUTION <b>DL</b>	4	QL(210 per 7 days)
XENLETA 600 MG TABLET <b>DL</b>	4	
XERAVA 100 MG, 50 MG RECON SOLUTION <b>MO</b>	3	
XIMINO 135 MG, 90 MG CAPSULE, ER 24 HR. <b>DL</b>	4	ST,QL(30 per 30 days)
XIMINO 45 MG CAPSULE, ER 24 HR. <b>MO</b>	3	ST,QL(30 per 30 days)
ZEMDRI 50 MG/ML SOLUTION <b>DL</b>	4	
ZERBAXA 1.5 GRAM RECON SOLUTION <b>DL</b>	4	
ZITHROMAX 1 GRAM PACKET <b>MO</b>	3	
ZITHROMAX 100 MG/5 ML, 200 MG/5 ML SUSPENSION FOR RECONSTITUTION <b>MO</b>	3	
ZITHROMAX 250 MG, 500 MG TABLET <b>MO</b>	3	
ZITHROMAX 500 MG RECON SOLUTION <b>MO</b>	3	
ZITHROMAX TRI-PAK 500 MG TABLET <b>MO</b>	3	
ZITHROMAX Z-PAK 250 MG TABLET <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZOSYN IN DEXTROSE (ISO-OSM) 2.25 GRAM/50 ML, 3.375 GRAM/50 ML, 4.5 GRAM/100 ML PIGGYBACK <b>MO</b>	3	
ZYVOX 100 MG/5 ML SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	PA,QL(1800 per 30 days)
ZYVOX 200 MG/100 ML, 600 MG/300 ML PIGGYBACK <b>MO</b>	3	
ZYVOX 600 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
<b>ANTICONVULSANTS</b>		
APTIOM 200 MG, 400 MG TABLET	4	PA,QL(30 per 30 days)
APTIOM 600 MG, 800 MG TABLET	4	PA,QL(60 per 30 days)
BANZEL 200 MG TABLET <b>DL</b>	4	PA,QL(480 per 30 days)
BANZEL 40 MG/ML SUSPENSION <b>DL</b>	4	PA,QL(2760 per 30 days)
BANZEL 400 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
BRIVIACT 10 MG, 100 MG, 25 MG, 50 MG, 75 MG TABLET	4	PA,QL(60 per 30 days)
BRIVIACT 10 MG/ML SOLUTION	4	PA,QL(600 per 30 days)
BRIVIACT 50 MG/5 ML SOLUTION	4	PA
carbamazepine 100 mg CHEWABLE TABLET <b>MO</b>	1	
carbamazepine 100 mg, 200 mg TABLET, ER 12 HR. <b>MO</b>	1	QL(120 per 30 days)
carbamazepine 100 mg, 200 mg, 300 mg CAPSULE ER MULTIPHASE 12 HR. <b>MO</b>	1	
carbamazepine 100 mg/5 ml, 200 mg/10 ml SUSPENSION <b>MO</b>	1	
carbamazepine 200 mg TABLET <b>MO</b>	1	
carbamazepine 400 mg TABLET, ER 12 HR. <b>MO</b>	1	QL(225 per 30 days)
CARBATROL 100 MG, 200 MG, 300 MG CAPSULE ER MULTIPHASE 12 HR. <b>MO</b>	3	
CELONTIN 300 MG CAPSULE <b>MO</b>	3	
CEREBYX 100 MG PE/2 ML, 500 MG PE/10 ML SOLUTION <b>MO</b>	3	
clobazam 10 mg, 20 mg TABLET <b>DL</b>	1	PA
clobazam 2.5 mg/ml SUSPENSION <b>DL</b>	1	PA
DEPAKOTE 125 MG, 250 MG, 500 MG TABLET, DR/EC <b>MO</b>	3	
DEPAKOTE ER 250 MG, 500 MG TABLET, ER 24 HR. <b>MO</b>	3	
DEPAKOTE SPRINKLES 125 MG CAPSULE, DR SPRINKLE <b>MO</b>	3	
DIACOMIT 250 MG, 500 MG CAPSULE <b>DL</b>	4	PA,QL(180 per 30 days)
DIACOMIT 250 MG, 500 MG POWDER IN PACKET <b>DL</b>	4	PA,QL(180 per 30 days)
DIASTAT 2.5 MG KIT <b>DL</b>	3	PA
DIASTAT ACUDIAL 12.5-15-17.5-20 MG, 5-7.5-10 MG KIT <b>DL</b>	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
diazepam 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg KIT <b>DL</b>	1	
DILANTIN 30 MG CAPSULE <b>MO</b>	1	
DILANTIN EXTENDED 100 MG CAPSULE <b>MO</b>	1	
DILANTIN INFATABS 50 MG CHEWABLE TABLET <b>MO</b>	1	
DILANTIN-125 125 MG/5 ML SUSPENSION <b>MO</b>	3	
divalproex 125 mg CAPSULE, DR SPRINKLE <b>MO</b>	1	
divalproex 125 mg, 250 mg, 500 mg TABLET, DR/EC <b>MO</b>	1	
divalproex 250 mg, 500 mg TABLET, ER 24 HR. <b>MO</b>	1	
EPIDIOLEX 100 MG/ML SOLUTION <b>DL</b>	4	PA
epitol 200 mg TABLET <b>MO</b>	1	
EQUETRO 100 MG, 200 MG, 300 MG CAPSULE ER MULTIPHASE 12 HR. <b>MO</b>	3	PA
ethosuximide 250 mg CAPSULE <b>MO</b>	1	
ethosuximide 250 mg/5 ml SOLUTION <b>MO</b>	1	
felbamate 400 mg, 600 mg TABLET <b>MO</b>	1	
felbamate 600 mg/5 ml SUSPENSION <b>MO</b>	1	
FELBATOL 400 MG, 600 MG TABLET <b>DL</b>	4	PA
FELBATOL 600 MG/5 ML SUSPENSION <b>DL</b>	4	PA
FINTEPLA 2.2 MG/ML SOLUTION <b>DL,LA</b>	4	PA,QL(360 per 30 days)
fosphenytoin 100 mg pe/2 ml, 500 mg pe/10 ml SOLUTION <b>MO</b>	1	
FYCOMPA 0.5 MG/ML SUSPENSION	4	PA,QL(680 per 28 days)
FYCOMPA 10 MG, 12 MG, 4 MG, 6 MG, 8 MG TABLET	4	PA,QL(30 per 30 days)
FYCOMPA 2 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
gabapentin 100 mg, 300 mg, 400 mg CAPSULE <b>MO</b>	1	QL(270 per 30 days)
gabapentin 250 mg/5 ml, 250 mg/5 ml (5 ml), 300 mg/6 ml (6 ml) SOLUTION <b>MO</b>	1	QL(2250 per 30 days)
gabapentin 600 mg, 800 mg TABLET <b>MO</b>	1	QL(180 per 30 days)
GABITRIL 12 MG, 16 MG, 2 MG, 4 MG TABLET <b>DL</b>	4	PA
KEPPRA 1,000 MG, 500 MG, 750 MG TABLET	4	PA
KEPPRA 100 MG/ML, 500 MG/5 ML SOLUTION	4	PA
KEPPRA 250 MG TABLET <b>MO</b>	3	PA
KEPPRA XR 500 MG TABLET, ER 24 HR.	4	PA,QL(180 per 30 days)
KEPPRA XR 750 MG TABLET, ER 24 HR.	4	PA,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>lacosamide 10 mg/ml SOLUTION</i> <b>MO</b>	1	QL(1395 per 30 days)
<i>lacosamide 100 mg, 150 mg, 200 mg, 50 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
<i>lacosamide 200 mg/20 ml SOLUTION</i> <b>MO</b>	1	
LAMICTAL 100 MG, 150 MG, 200 MG, 25 MG TABLET	4	
LAMICTAL 25 MG, 5 MG TABLET, CHEWABLE DISPERSIBLE	4	
LAMICTAL ODT 100 MG, 200 MG, 25 MG, 50 MG TABLET, DISINTEGRATING	4	
LAMICTAL ODT STARTER (BLUE) 25 MG (21) -50 MG (7) TABLET, DISINTEGRATING,DOSE PK	4	
LAMICTAL ODT STARTER (GREEN) 50 MG (42) -100 MG (14) TABLET, DISINTEGRATING,DOSE PK	4	
LAMICTAL ODT STARTER (ORANGE) 25 MG(14)-50 MG (14)-100 MG (7) TABLET, DISINTEGRATING,DOSE PK	4	
LAMICTAL STARTER (BLUE) KIT 25 MG (35) TABLET, DOSE PACK <b>MO</b>	3	
LAMICTAL STARTER (GREEN) KIT 25 MG (84) -100 MG (14) TABLET, DOSE PACK <b>MO</b>	3	
LAMICTAL STARTER (ORANGE) KIT 25 MG (42) -100 MG (7) TABLET, DOSE PACK <b>MO</b>	3	
LAMICTAL XR 100 MG, 200 MG, 25 MG, 250 MG, 300 MG, 50 MG TABLET, ER 24 HR.	4	
LAMICTAL XR STARTER (BLUE) 25 MG (21) -50 MG (7) TABLET, ER, DOSE PACK <b>MO</b>	3	
LAMICTAL XR STARTER (GREEN) 50 MG(14)-100MG (14)-200 MG (7) TABLET, ER, DOSE PACK <b>MO</b>	3	
LAMICTAL XR STARTER (ORANGE) 25MG (14)-50 MG (14)-100MG (7) TABLET, ER, DOSE PACK <b>MO</b>	3	
<i>lamotrigine 100 mg, 200 mg TABLET</i> <b>MO</b>	1	
<i>lamotrigine 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	
<i>lamotrigine 100 mg, 200 mg, 25 mg, 50 mg TABLET, DISINTEGRATING</i> <b>MO</b>	1	
<i>lamotrigine 150 mg, 25 mg TABLET</i> <b>MO</b>	1	
<i>lamotrigine 25 mg (21) -50 mg (7), 25 mg(14)-50 mg (14)-100 mg (7), 50 mg (42) -100 mg (14) TABLET, DISINTEGRATING,DOSE PK</i> <b>MO</b>	1	
<i>lamotrigine 25 mg (35), 25 mg (42) -100 mg (7), 25 mg (84) -100 mg (14) TABLET, DOSE PACK</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
lamotrigine 25 mg, 5 mg TABLET, CHEWABLE DISPERSIBLE <b>MO</b>	1	
levetiracetam 1,000 mg, 250 mg, 750 mg TABLET <b>MO</b>	1	
levetiracetam 100 mg/ml, 500 mg/5 ml SOLUTION <b>MO</b>	1	
levetiracetam 500 mg TABLET <b>MO</b>	1	
levetiracetam 500 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(180 per 30 days)
levetiracetam 500 mg/5 ml (5 ml) SOLUTION <b>MO</b>	1	QL(900 per 30 days)
levetiracetam 750 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(120 per 30 days)
levetiracetam in nacl (iso-os) 1,000 mg/100 ml, 1,500 mg/100 ml, 500 mg/100 ml PIGGYBACK <b>MO</b>	1	
methsuximide 300 mg CAPSULE <b>MO</b>	1	
MOTPOLY XR 100 MG, 150 MG, 200 MG CAPSULE, ER 24 HR. <b>DL</b>	4	PA,QL(60 per 30 days)
MYSOLINE 250 MG, 50 MG TABLET <b>DL</b>	4	PA
NAYZILAM 5 MG/SPRAY (0.1 ML) SPRAY, NON-AEROSOL <b>DL</b>	3	QL(10 per 30 days)
NEMBUTAL SODIUM 50 MG/ML SOLUTION <b>MO</b>	1	
NEURONTIN 100 MG, 300 MG, 400 MG CAPSULE <b>MO</b>	3	PA,QL(270 per 30 days)
NEURONTIN 250 MG/5 ML SOLUTION <b>DL</b>	4	PA,QL(2250 per 30 days)
NEURONTIN 600 MG, 800 MG TABLET	4	PA,QL(180 per 30 days)
ONFI 10 MG, 20 MG TABLET <b>DL</b>	4	PA
ONFI 2.5 MG/ML SUSPENSION <b>DL</b>	4	PA
oxcarbazepine 150 mg, 300 mg, 600 mg TABLET <b>MO</b>	1	
oxcarbazepine 300 mg/5 ml (60 mg/ml) SUSPENSION <b>MO</b>	1	
OXTELLAR XR 150 MG, 300 MG, 600 MG TABLET, ER 24 HR.	4	ST
pentobarbital sodium 50 mg/ml SOLUTION <b>MO</b>	1	
phenobarbital 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg TABLET <b>MO</b>	1	QL(90 per 30 days)
phenobarbital 15 mg, 60 mg TABLET <b>MO</b>	1	QL(120 per 30 days)
phenobarbital 20 mg/5 ml (4 mg/ml) ELIXIR <b>MO</b>	1	QL(1500 per 30 days)
phenobarbital 30 mg TABLET <b>MO</b>	1	QL(300 per 30 days)
phenobarbital sodium 130 mg/ml, 65 mg/ml SOLUTION <b>DL</b>	4	
PHENYTEK 200 MG, 300 MG CAPSULE <b>MO</b>	1	
phenytoin 100 mg/4 ml, 125 mg/5 ml SUSPENSION <b>MO</b>	1	
phenytoin 50 mg CHEWABLE TABLET <b>MO</b>	1	
phenytoin sodium 50 mg/ml SOLUTION <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>phenytoin sodium 50 mg/ml SYRINGE</i> <b>MO</b>	1	
<i>phenytoin sodium extended 100 mg, 200 mg, 300 mg CAPSULE</i> <b>MO</b>	1	
<i>primidone 125 mg, 250 mg TABLET</i> <b>MO</b>	1	
<i>primidone 50 mg TABLET</i> <b>MO</b>	1	
<i>roweepra 1,000 mg, 500 mg, 750 mg TABLET</i> <b>MO</b>	1	
<i>roweepra xr 500 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(180 per 30 days)
<i>roweepra xr 750 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(120 per 30 days)
<i>rufinamide 200 mg TABLET</i> <b>MO</b>	1	PA,QL(480 per 30 days)
<i>rufinamide 40 mg/ml SUSPENSION</i> <b>MO</b>	1	PA,QL(2760 per 30 days)
<i>rufinamide 400 mg TABLET</i> <b>MO</b>	1	PA,QL(240 per 30 days)
SABRIL 500 MG POWDER IN PACKET <b>DL</b>	4	PA,QL(180 per 30 days)
SABRIL 500 MG TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
SEZABY 100 MG RECON SOLUTION <b>DL</b>	4	
SPRITAM 1,000 MG TABLET FOR SUSPENSION <b>MO</b>	3	ST,QL(90 per 30 days)
SPRITAM 250 MG TABLET FOR SUSPENSION <b>MO</b>	3	ST,QL(360 per 30 days)
SPRITAM 500 MG TABLET FOR SUSPENSION <b>MO</b>	3	ST,QL(180 per 30 days)
SPRITAM 750 MG TABLET FOR SUSPENSION <b>MO</b>	3	ST,QL(120 per 30 days)
<i>subvenite 100 mg, 150 mg, 200 mg, 25 mg TABLET</i> <b>MO</b>	1	
<i>subvenite starter (blue) kit 25 mg (35) TABLET, DOSE PACK</i> <b>MO</b>	1	
<i>subvenite starter (green) kit 25 mg (84) -100 mg (14) TABLET, DOSE PACK</i> <b>MO</b>	1	
<i>subvenite starter (orange) kit 25 mg (42) -100 mg (7) TABLET, DOSE PACK</i> <b>MO</b>	1	
SYMPAZAN 10 MG, 20 MG, 5 MG FILM <b>DL</b>	4	PA,QL(60 per 30 days)
TEGRETOL 100 MG/5 ML SUSPENSION <b>MO</b>	3	
TEGRETOL 200 MG TABLET <b>MO</b>	3	
TEGRETOL XR 100 MG, 200 MG TABLET, ER 12 HR. <b>MO</b>	3	QL(120 per 30 days)
TEGRETOL XR 400 MG TABLET, ER 12 HR. <b>MO</b>	3	QL(225 per 30 days)
<i>tiagabine 12 mg, 16 mg, 2 mg, 4 mg TABLET</i> <b>MO</b>	1	
TRILEPTAL 150 MG TABLET <b>MO</b>	3	PA
TRILEPTAL 300 MG, 600 MG TABLET	4	PA
TRILEPTAL 300 MG/5 ML (60 MG/ML) SUSPENSION	4	PA
<i>valproate sodium 500 mg/5 ml (100 mg/ml) SOLUTION</i> <b>MO</b>	1	
<i>valproic acid 250 mg CAPSULE</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
valproic acid (as sodium salt) 250 mg/5 ml, 250 mg/5 ml (5 ml), 500 mg/10 ml (10 ml) SOLUTION <b>MO</b>	1	
VALTOCO 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML) SPRAY, NON-AEROSOL <b>DL</b>	4	QL(10 per 30 days)
vigabatrin 500 mg POWDER IN PACKET <b>DL</b>	4	PA,QL(180 per 30 days)
vigabatrin 500 mg TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
vigadrone 500 mg POWDER IN PACKET <b>DL</b>	4	PA,QL(180 per 30 days)
vigadrone 500 mg TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
vigpoder 500 mg POWDER IN PACKET <b>DL</b>	4	PA,QL(180 per 30 days)
VIMPAT 10 MG/ML SOLUTION <b>DL</b>	4	PA,QL(1395 per 30 days)
VIMPAT 100 MG, 150 MG, 200 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
VIMPAT 200 MG/20 ML SOLUTION <b>DL</b>	4	PA
VIMPAT 50 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
XCOPRI 100 MG, 50 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
XCOPRI 150 MG, 200 MG TABLET <b>DL</b>	4	QL(60 per 30 days)
XCOPRI MAINTENANCE PACK 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) TABLET <b>DL</b>	4	QL(56 per 28 days)
XCOPRI TITRATION PACK 12.5 MG (14)- 25 MG (14) TABLET, DOSE PACK <b>MO</b>	3	QL(28 per 28 days)
XCOPRI TITRATION PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) TABLET, DOSE PACK <b>DL</b>	4	QL(28 per 28 days)
ZARONTIN 250 MG CAPSULE <b>MO</b>	3	
ZARONTIN 250 MG/5 ML SOLUTION <b>MO</b>	1	
ZONEGRAN 100 MG, 25 MG CAPSULE	4	PA
ZONISADE 100 MG/5 ML SUSPENSION <b>MO</b>	3	PA,QL(900 per 30 days)
zonisamide 100 mg, 25 mg, 50 mg CAPSULE <b>MO</b>	1	
ZTALMY 50 MG/ML SUSPENSION <b>DL</b>	4	PA,QL(1080 per 30 days)
<b>ANTIDEMENTIA AGENTS</b>		
ADLARITY 10 MG/24 HOUR, 5 MG/24 HOUR PATCH, WEEKLY <b>MO</b>	3	ST,QL(4 per 28 days)
ARICEPT 10 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
ARICEPT 23 MG, 5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
donepezil 10 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
donepezil 10 mg, 5 mg TABLET, DISINTEGRATING <b>MO</b>	1	QL(30 per 30 days)
donepezil 23 mg TABLET <b>MO</b>	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
donepezil 5 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
ergoloid 1 mg TABLET <b>MO</b>	1	
EXELON PATCH 13.3 MG/24 HOUR, 4.6 MG/24 HOUR, 9.5 MG/24 HOUR PATCH, 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
galantamine 12 mg, 4 mg, 8 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
galantamine 16 mg, 24 mg, 8 mg CAPSULE ER PELLETS 24 HR. <b>MO</b>	1	QL(30 per 30 days)
galantamine 4 mg/ml SOLUTION <b>MO</b>	1	QL(200 per 30 days)
memantine 10 mg, 5 mg TABLET <b>MO</b>	1	PA,QL(60 per 30 days)
memantine 14 mg, 21 mg, 28 mg, 7 mg CAPSULE ER SPRINKLE 24 HR. <b>MO</b>	1	PA,QL(30 per 30 days)
memantine 2 mg/ml SOLUTION <b>MO</b>	1	PA,QL(360 per 30 days)
memantine 5-10 mg TABLET, DOSE PACK <b>MO</b>	1	PA,QL(98 per 30 days)
NAMENDA 10 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
NAMENDA TITRATION PAK 5-10 MG TABLET, DOSE PACK <b>MO</b>	3	PA,QL(98 per 30 days)
NAMENDA XR 14 MG, 21 MG, 28 MG, 7 MG CAPSULE ER SPRINKLE 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
NAMENDA XR 7-14-21-28 MG CAPSULE ER SPRINKLE 24 HR. <b>MO</b>	3	PA,QL(28 per 28 days)
NAMZARIC 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG CAPSULE ER SPRINKLE 24 HR. <b>MO</b>	2	QL(30 per 30 days)
NAMZARIC 7/14/21/28 MG-10 MG CAPSULE ER SPRINKLE 24 HR. <b>MO</b>	2	QL(28 per 28 days)
RAZADYNE ER 16 MG, 24 MG, 8 MG CAPSULE ER PELLETS 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
rivastigmine 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour PATCH, 24 HR. <b>MO</b>	1	QL(30 per 30 days)
rivastigmine tartrate 1.5 mg, 3 mg CAPSULE <b>MO</b>	1	QL(90 per 30 days)
rivastigmine tartrate 4.5 mg, 6 mg CAPSULE <b>MO</b>	1	QL(60 per 30 days)
<b>ANTIDEPRESSANTS</b>		
amitriptyline 10 mg, 100 mg, 150 mg, 50 mg, 75 mg TABLET <b>MO</b>	1	
amitriptyline 25 mg TABLET <b>MO</b>	1	
amitriptyline-chlordiazepoxide 12.5-5 mg, 25-10 mg TABLET <b>DL</b>	1	
amoxapine 100 mg, 150 mg, 25 mg, 50 mg TABLET <b>MO</b>	1	
ANAFRANIL 25 MG, 50 MG, 75 MG CAPSULE <b>DL</b>	4	
APLENZIN 174 MG, 348 MG, 522 MG TABLET, ER 24 HR.	4	ST,QL(30 per 30 days)
AUVELITY 45-105 MG TABLET, IR/ER, BIPHASIC <b>MO</b>	3	PA,QL(60 per 30 days)
BRISDELLE 7.5 MG CAPSULE <b>MO</b>	3	QL(30 per 30 days)
bupropion hcl 100 mg TABLET, SR 12 HR. <b>MO</b>	1	QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
bupropion hcl 100 mg, 75 mg TABLET <b>MO</b>	1	QL(180 per 30 days)
bupropion hcl 150 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(90 per 30 days)
bupropion hcl 150 mg TABLET, SR 12 HR. <b>MO</b>	1	QL(90 per 30 days)
bupropion hcl 200 mg TABLET, SR 12 HR. <b>MO</b>	1	QL(60 per 30 days)
bupropion hcl 300 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
bupropion hcl 450 mg TABLET, ER 24 HR. <b>MO</b>	1	ST,QL(30 per 30 days)
CELEXA 10 MG, 40 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
CELEXA 20 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
citalopram 10 mg, 40 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
citalopram 10 mg/5 ml SOLUTION <b>MO</b>	1	
citalopram 20 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
CITALOPRAM 30 MG CAPSULE <b>MO</b>	3	QL(30 per 30 days)
clomipramine 25 mg, 50 mg, 75 mg CAPSULE <b>MO</b>	1	
CYMBALTA 20 MG CAPSULE, DR/EC <b>MO</b>	3	PA,QL(120 per 30 days)
CYMBALTA 30 MG CAPSULE, DR/EC <b>MO</b>	3	PA,QL(90 per 30 days)
CYMBALTA 60 MG CAPSULE, DR/EC <b>MO</b>	3	PA,QL(60 per 30 days)
desipramine 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg TABLET <b>MO</b>	1	
desvenlafaxine 100 mg, 50 mg TABLET, ER 24 HR. <b>MO</b>	3	ST,QL(30 per 30 days)
desvenlafaxine succinate 100 mg, 25 mg, 50 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
DRIZALMA SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG CAPSULE, DR SPRINKLE <b>MO</b>	3	PA,QL(60 per 30 days)
duloxetine 20 mg CAPSULE, DR/EC <b>MO</b>	1	QL(120 per 30 days)
duloxetine 30 mg CAPSULE, DR/EC <b>MO</b>	1	QL(90 per 30 days)
duloxetine 40 mg CAPSULE, DR/EC <b>MO</b>	1	QL(60 per 30 days)
duloxetine 60 mg CAPSULE, DR/EC <b>MO</b>	1	QL(60 per 30 days)
EFFEXOR XR 150 MG CAPSULE, ER 24 HR. <b>MO</b>	3	PA,QL(60 per 30 days)
EFFEXOR XR 37.5 MG, 75 MG CAPSULE, ER 24 HR. <b>MO</b>	3	PA,QL(90 per 30 days)
EMSAM 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR PATCH, 24 HR.	4	PA,QL(30 per 30 days)
escitalopram oxalate 10 mg TABLET <b>MO</b>	1	QL(45 per 30 days)
escitalopram oxalate 20 mg, 5 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
escitalopram oxalate 5 mg/5 ml SOLUTION <b>MO</b>	1	QL(600 per 30 days)
FETZIMA 120 MG, 20 MG, 40 MG, 80 MG CAPSULE, ER 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
FETZIMA 20 MG (2)- 40 MG (26) CAPSULE, ER 24 HR. <b>MO</b>	3	PA,QL(28 per 28 days)
fluoxetine 10 mg CAPSULE <b>MO</b>	1	QL(60 per 30 days)
fluoxetine 10 mg TABLET <b>MO</b>	1	QL(240 per 30 days)
fluoxetine 20 mg CAPSULE <b>MO</b>	1	QL(120 per 30 days)
fluoxetine 20 mg TABLET <b>MO</b>	1	QL(120 per 30 days)
fluoxetine 20 mg/5 ml (4 mg/ml) SOLUTION <b>MO</b>	1	
fluoxetine 40 mg CAPSULE <b>MO</b>	1	QL(60 per 30 days)
fluoxetine 60 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
fluoxetine 90 mg CAPSULE, DR/EC <b>MO</b>	1	QL(4 per 28 days)
fluvoxamine 100 mg, 150 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
fluvoxamine 100 mg, 25 mg, 50 mg TABLET <b>MO</b>	1	QL(90 per 30 days)
FORFIVO XL 450 MG TABLET, ER 24 HR. <b>MO</b>	3	ST,QL(30 per 30 days)
imipramine hcl 10 mg TABLET <b>MO</b>	1	
imipramine hcl 25 mg, 50 mg TABLET <b>MO</b>	1	
imipramine pamoate 100 mg, 125 mg, 150 mg, 75 mg CAPSULE <b>MO</b>	1	
LEXAPRO 10 MG TABLET <b>MO</b>	3	PA,QL(45 per 30 days)
LEXAPRO 20 MG, 5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
MARPLAN 10 MG TABLET <b>MO</b>	3	
mirtazapine 15 mg, 30 mg, 45 mg TABLET, DISINTEGRATING <b>MO</b>	1	QL(30 per 30 days)
mirtazapine 15 mg, 30 mg, 7.5 mg TABLET <b>MO</b>	1	
mirtazapine 45 mg TABLET <b>MO</b>	1	
NARDIL 15 MG TABLET <b>MO</b>	3	
nefazodone 100 mg, 150 mg, 200 mg, 250 mg, 50 mg TABLET <b>MO</b>	1	
NORPRAMIN 10 MG, 25 MG TABLET <b>MO</b>	3	
nortriptyline 10 mg, 25 mg, 50 mg, 75 mg CAPSULE <b>MO</b>	1	
nortriptyline 10 mg/5 ml SOLUTION <b>MO</b>	1	
olanzapine-fluoxetine 12-25 mg, 12-50 mg, 3-25 mg, 6-25 mg, 6-50 mg CAPSULE <b>MO</b>	1	QL(30 per 30 days)
PAMELOR 10 MG, 25 MG, 50 MG, 75 MG CAPSULE <b>DL</b>	4	
PARNATE 10 MG TABLET <b>DL</b>	4	
paroxetine hcl 10 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
paroxetine hcl 10 mg/5 ml SUSPENSION <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>paroxetine hcl 12.5 mg, 37.5 mg TABLET, ER 24 HR. MO</i>	1	QL(60 per 30 days)
<i>paroxetine hcl 20 mg TABLET MO</i>	1	QL(30 per 30 days)
<i>paroxetine hcl 25 mg TABLET, ER 24 HR. MO</i>	1	QL(90 per 30 days)
<i>paroxetine hcl 30 mg, 40 mg TABLET MO</i>	1	QL(60 per 30 days)
<i>paroxetine mesylate(menop.sym) 7.5 mg CAPSULE MO</i>	1	QL(30 per 30 days)
PAXIL 10 MG, 20 MG TABLET MO	3	QL(30 per 30 days)
PAXIL 10 MG/5 ML SUSPENSION MO	3	PA
PAXIL 30 MG, 40 MG TABLET MO	3	QL(60 per 30 days)
PAXIL CR 12.5 MG, 37.5 MG TABLET, ER 24 HR. MO	3	QL(60 per 30 days)
PAXIL CR 25 MG TABLET, ER 24 HR. MO	3	QL(90 per 30 days)
<i>perphenazine-amitriptyline 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg TABLET MO</i>	1	
PEXEVA 10 MG, 20 MG TABLET MO	3	QL(30 per 30 days)
PEXEVA 30 MG, 40 MG TABLET MO	3	QL(60 per 30 days)
<i>phenelzine 15 mg TABLET MO</i>	1	
PRISTIQ 100 MG, 25 MG, 50 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
<i>protriptyline 10 mg, 5 mg TABLET MO</i>	1	
PROZAC 10 MG, 40 MG CAPSULE	4	PA,QL(60 per 30 days)
PROZAC 20 MG CAPSULE	4	PA,QL(120 per 30 days)
REMERON 15 MG, 30 MG TABLET MO	3	
REMERON SOLTAB 15 MG, 30 MG, 45 MG TABLET, DISINTEGRATING MO	3	QL(30 per 30 days)
<i>sertraline 100 mg TABLET MO</i>	1	QL(60 per 30 days)
SERTRALINE 150 MG, 200 MG CAPSULE MO	3	QL(30 per 30 days)
<i>sertraline 20 mg/ml CONCENTRATE MO</i>	1	
<i>sertraline 25 mg, 50 mg TABLET MO</i>	1	QL(90 per 30 days)
SYMBYAX 12-50 MG, 3-25 MG, 6-25 MG, 6-50 MG CAPSULE MO	3	PA,QL(30 per 30 days)
<i>tranylcypromine 10 mg TABLET MO</i>	1	
<i>trazodone 100 mg, 150 mg, 50 mg TABLET MO</i>	1	
<i>trazodone 300 mg TABLET MO</i>	1	
<i>trimipramine 100 mg, 25 mg, 50 mg CAPSULE MO</i>	1	
TRINTELLIX 10 MG, 20 MG, 5 MG TABLET MO	3	ST,QL(30 per 30 days)
<i>venlafaxine 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg TABLET MO</i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
venlafaxine 150 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
venlafaxine 150 mg, 225 mg, 37.5 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
venlafaxine 37.5 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(90 per 30 days)
venlafaxine 75 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(90 per 30 days)
venlafaxine 75 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
VENLAFAXINE BESYLATE 112.5 MG TABLET, ER 24 HR. <b>MO</b>	3	QL(60 per 30 days)
VIIBRYD 10 MG (7)- 20 MG (23) TABLET, DOSE PACK <b>MO</b>	3	PA,QL(30 per 30 days)
VIIBRYD 10 MG, 20 MG, 40 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
vilazodone 10 mg, 20 mg, 40 mg TABLET <b>MO</b>	1	PA,QL(30 per 30 days)
WELLBUTRIN SR 100 MG TABLET, SR 12 HR. <b>MO</b>	3	PA,QL(120 per 30 days)
WELLBUTRIN SR 150 MG TABLET, SR 12 HR. <b>MO</b>	3	PA,QL(90 per 30 days)
WELLBUTRIN SR 200 MG TABLET, SR 12 HR. <b>MO</b>	3	PA,QL(60 per 30 days)
WELLBUTRIN XL 150 MG TABLET, ER 24 HR.	4	PA,QL(90 per 30 days)
WELLBUTRIN XL 300 MG TABLET, ER 24 HR.	4	PA,QL(60 per 30 days)
ZOLOFT 100 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
ZOLOFT 20 MG/ML CONCENTRATE <b>MO</b>	3	PA
ZOLOFT 25 MG, 50 MG TABLET <b>MO</b>	3	PA,QL(90 per 30 days)
ZULRESSO 5 MG/ML SOLUTION <b>DL</b>	4	PA,QL(100 per 365 days)
ZURZUVAE 20 MG, 25 MG CAPSULE <b>DL</b>	4	PA,QL(28 per 365 days)
ZURZUVAE 30 MG CAPSULE <b>DL</b>	4	PA,QL(14 per 365 days)
<b>ANTIEMETICS</b>		
AKYNZEO (FOSNETUPITANT) 235 MG-0.25 MG /20 ML SOLUTION <b>DL</b>	4	PA,QL(80 per 28 days)
AKYNZEO (FOSNETUPITANT) 235-0.25 MG RECON SOLUTION <b>DL</b>	4	PA,QL(4 per 28 days)
AKYNZEO (NETUPITANT) 300-0.5 MG CAPSULE <b>DL</b>	4	PA
ANTIVERT 25 MG CHEWABLE TABLET <b>MO</b>	3	
ANTIVERT 50 MG TABLET <b>MO</b>	3	
ANZEMET 50 MG TABLET <b>MO</b>	3	BvsD,QL(4 per 28 days)
APONVIE 7.2 MG/ML EMULSION <b>MO</b>	3	
aprepitant 125 mg (1)- 80 mg (2) CAPSULE, DOSE PACK <b>MO</b>	1	BvsD
aprepitant 125 mg, 40 mg CAPSULE <b>MO</b>	1	BvsD,QL(2 per 28 days)
aprepitant 80 mg CAPSULE <b>MO</b>	1	BvsD,QL(4 per 28 days)
BONJESTA 20-20 MG TABLET, IR, DR, BIPHASIC <b>MO</b>	3	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
COMPAZINE 10 MG, 5 MG TABLET <b>MO</b>	3	BvsD
COMPAZINE 25 MG SUPPOSITORY <b>MO</b>	1	
<i>compro 25 mg SUPPOSITORY</i> <b>MO</b>	1	
DICLEGIS 10-10 MG TABLET, DR/EC <b>MO</b>	3	QL(120 per 30 days)
<i>dimenhydrinate 50 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>doxylamine-pyridoxine (vit b6) 10-10 mg TABLET, DR/EC</i> <b>MO</b>	1	QL(120 per 30 days)
<i>dronabinol 10 mg, 2.5 mg, 5 mg CAPSULE</i> <b>MO</b>	1	BvsD,QL(120 per 30 days)
EMEND 125 MG (1)- 80 MG (2) CAPSULE, DOSE PACK <b>MO</b>	3	BvsD
EMEND 125 MG (25 MG/ ML FINAL CONC.) SUSPENSION FOR RECONSTITUTION <b>MO</b>	3	BvsD,QL(3 per 28 days)
EMEND 80 MG CAPSULE <b>MO</b>	3	BvsD,QL(4 per 28 days)
EMEND (FOSAPREPITANT) 150 MG RECON SOLUTION <b>MO</b>	3	PA
<i>fosaprepitant 150 mg RECON SOLUTION</i> <b>MO</b>	1	PA
GIMOTI 15 MG/SPRAY SPRAY WITH PUMP <b>DL</b>	4	PA,QL(9.8 per 28 days)
<i>granisetron (pf) 1 mg/ml (1 ml), 100 mcg/ml SOLUTION</i> <b>MO</b>	1	
<i>granisetron hcl 1 mg TABLET</i> <b>MO</b>	1	BvsD,QL(28 per 28 days)
<i>granisetron hcl 1 mg/ml, 1 mg/ml (1 ml) SOLUTION</i> <b>MO</b>	1	
MARINOL 10 MG, 2.5 MG, 5 MG CAPSULE <b>DL</b>	4	BvsD,QL(120 per 30 days)
<i>meclizine 12.5 mg TABLET</i> <b>MO</b>	1	
<i>meclizine 25 mg TABLET</i> <b>MO</b>	1	
<i>meclizine 50 mg TABLET</i> <b>MO</b>	3	
<i>metoclopramide hcl 10 mg, 5 mg TABLET</i> <b>MO</b>	1	
<i>metoclopramide hcl 5 mg/5 ml, 5 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>metoclopramide hcl 5 mg/ml SYRINGE</i> <b>MO</b>	1	
<i>ondansetron 4 mg TABLET, DISINTEGRATING</i> <b>MO</b>	1	BvsD
<i>ondansetron 8 mg TABLET, DISINTEGRATING</i> <b>MO</b>	1	BvsD
<i>ondansetron hcl 2 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>ondansetron hcl 4 mg TABLET</i> <b>MO</b>	1	BvsD
<i>ondansetron hcl 4 mg/5 ml SOLUTION</i> <b>MO</b>	1	BvsD,QL(450 per 30 days)
<i>ondansetron hcl 8 mg TABLET</i> <b>MO</b>	1	BvsD
<i>ondansetron hcl (pf) 4 mg/2 ml SOLUTION</i> <b>MO</b>	1	
<i>ondansetron hcl (pf) 4 mg/2 ml SYRINGE</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PHENERGAN 25 MG/ML, 50 MG/ML SOLUTION <b>MO</b>	1	
prochlorperazine 25 mg SUPPOSITORY <b>MO</b>	1	
prochlorperazine edisylate 10 mg/2 ml (5 mg/ml), 5 mg/ml SOLUTION <b>MO</b>	1	
prochlorperazine maleate 10 mg, 5 mg TABLET <b>MO</b>	1	BvsD
promethazine 12.5 mg, 25 mg, 50 mg SUPPOSITORY <b>MO</b>	1	
promethazine 12.5 mg, 50 mg TABLET <b>MO</b>	1	
promethazine 25 mg TABLET <b>MO</b>	1	
promethazine 25 mg/ml, 50 mg/ml SOLUTION <b>MO</b>	1	
promethazine 6.25 mg/5 ml SYRUP <b>MO</b>	1	
promethegan 12.5 mg, 25 mg, 50 mg SUPPOSITORY <b>MO</b>	1	
REGLAN 10 MG, 5 MG TABLET <b>MO</b>	3	
SANCUSO 3.1 MG/24 HOUR PATCH, WEEKLY <b>DL</b>	4	QL(4 per 30 days)
scopolamine base 1 mg over 3 days PATCH, 3 DAY <b>MO</b>	1	QL(10 per 30 days)
SYNDROS 5 MG/ML SOLUTION <b>DL</b>	4	PA
TIGAN 100 MG/ML SOLUTION <b>MO</b>	3	
TRANSDERM-SCOP 1 MG OVER 3 DAYS PATCH, 3 DAY <b>MO</b>	3	QL(10 per 30 days)
trimethobenzamide 300 mg CAPSULE <b>MO</b>	1	BvsD
VARUBI 90 MG TABLET <b>DL</b>	4	PA
<b>ANTIFUNGALS</b>		
ABELCET 5 MG/ML SUSPENSION <b>MO</b>	3	BvsD
AMBISOME 50 MG SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	BvsD
amphotericin b 50 mg RECON SOLUTION <b>MO</b>	1	BvsD
amphotericin b liposome 50 mg SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	BvsD
ANCOBON 250 MG, 500 MG CAPSULE <b>MO</b>	3	
CANCIDAS 50 MG, 70 MG RECON SOLUTION <b>DL</b>	4	PA
caspofungin 50 mg RECON SOLUTION <b>DL</b>	4	
caspofungin 70 mg RECON SOLUTION <b>MO</b>	1	
ciclodan 8 % SOLUTION <b>MO</b>	1	QL(13.2 per 30 days)
ciclopirox 0.77 % CREAM <b>MO</b>	1	QL(90 per 30 days)
ciclopirox 0.77 % GEL <b>MO</b>	1	QL(100 per 30 days)
ciclopirox 0.77 % SUSPENSION <b>MO</b>	1	QL(60 per 30 days)
ciclopirox 1 % SHAMPOO <b>MO</b>	1	QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ciclopirox 8 % SOLUTION</i> <b>MO</b>	1	QL(13.2 per 30 days)
<i>clotrimazole 1 % CREAM</i> <b>MO</b>	1	
<i>clotrimazole 1 % SOLUTION</i> <b>MO</b>	1	
<i>clotrimazole 10 mg TROCHE</i> <b>MO</b>	1	
<i>clotrimazole-betamethasone 1-0.05 % CREAM</i> <b>MO</b>	1	QL(180 per 30 days)
<i>clotrimazole-betamethasone 1-0.05 % LOTION</i> <b>MO</b>	1	QL(90 per 28 days)
CRESEMBA 186 MG, 74.5 MG CAPSULE <b>DL</b>	4	PA
CRESEMBA 372 MG RECON SOLUTION <b>DL</b>	4	PA
DIFLUCAN 10 MG/ML, 40 MG/ML SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	PA
DIFLUCAN 100 MG, 150 MG, 200 MG, 50 MG TABLET <b>MO</b>	3	PA
<i>econazole 1 % CREAM</i> <b>MO</b>	1	PA,QL(85 per 30 days)
ERAXIS(WATER DILUENT) 100 MG, 50 MG RECON SOLUTION <b>DL</b>	4	
ERTACZO 2 % CREAM <b>DL</b>	4	QL(60 per 30 days)
EXELDERM 1 % CREAM <b>MO</b>	3	
EXELDERM 1 % SOLUTION <b>MO</b>	3	QL(60 per 30 days)
EXTINA 2 % FOAM <b>MO</b>	3	QL(100 per 30 days)
<i>fluconazole 10 mg/ml, 40 mg/ml SUSPENSION FOR RECONSTITUTION</i> <b>MO</b>	1	
<i>fluconazole 100 mg, 200 mg, 50 mg TABLET</i> <b>MO</b>	1	
<i>fluconazole 150 mg TABLET</i> <b>MO</b>	1	
<i>fluconazole in nacl (iso-osm) 100 mg/50 ml, 200 mg/100 ml, 400 mg/200 ml PIGGYBACK</i> <b>MO</b>	1	
<i>flucytosine 250 mg, 500 mg CAPSULE</i> <b>DL</b>	4	
<i>griseofulvin microsize 125 mg/5 ml SUSPENSION</i> <b>MO</b>	1	
<i>griseofulvin microsize 500 mg TABLET</i> <b>MO</b>	1	
<i>griseofulvin ultramicrosize 125 mg, 250 mg TABLET</i> <b>MO</b>	1	
<i>gynazole-1 2 % CREAM</i> <b>MO</b>	1	
<i>itraconazole 10 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>itraconazole 100 mg CAPSULE</i> <b>MO</b>	1	QL(120 per 30 days)
JUBLIA 10 % SOLUTION W/APPLICATOR <b>DL</b>	4	PA,QL(4 per 28 days)
KERYDIN 5 % SOLUTION W/APPLICATOR <b>MO</b>	3	PA,QL(10 per 30 days)
<i>ketoconazole 2 % CREAM</i> <b>MO</b>	1	QL(60 per 30 days)
<i>ketoconazole 2 % FOAM</i> <b>MO</b>	1	QL(100 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ketoconazole 2 % SHAMPOO <b>MO</b>	1	QL(120 per 30 days)
ketoconazole 200 mg TABLET <b>MO</b>	1	PA
ketodan 2 % FOAM <b>MO</b>	1	QL(100 per 30 days)
klayesta 100,000 unit/gram POWDER <b>MO</b>	1	PA
LOPROX 1 % SHAMPOO <b>MO</b>	3	PA,QL(120 per 30 days)
LOPROX (AS OLAMINE) 0.77 % CREAM <b>MO</b>	3	PA,QL(90 per 30 days)
LOPROX (AS OLAMINE) 0.77 % SUSPENSION <b>MO</b>	3	PA,QL(60 per 30 days)
luliconazole 1 % CREAM <b>MO</b>	1	ST,QL(60 per 28 days)
LUZU 1 % CREAM <b>MO</b>	3	ST,QL(60 per 28 days)
MENTAX 1 % CREAM <b>MO</b>	3	QL(30 per 30 days)
micafungin 100 mg, 50 mg RECON SOLUTION <b>DL</b>	4	
miconazole nitrate-zinc ox-pet 0.25-15-81.35 % OINTMENT <b>MO</b>	1	
miconazole-3 200 mg SUPPOSITORY <b>MO</b>	1	
MYCAMINE 100 MG, 50 MG RECON SOLUTION <b>DL</b>	4	
naftifine 1 % CREAM <b>MO</b>	1	ST,QL(90 per 30 days)
naftifine 2 % CREAM <b>MO</b>	1	ST,QL(120 per 30 days)
naftifine 2 % GEL <b>MO</b>	1	ST,QL(120 per 30 days)
NAFTIN 1 % GEL <b>MO</b>	3	ST,QL(90 per 30 days)
NAFTIN 2 % GEL <b>MO</b>	3	ST,QL(120 per 30 days)
NOXAFIL 100 MG TABLET, DR/EC <b>DL</b>	4	PA
NOXAFIL 200 MG/5 ML (40 MG/ML) SUSPENSION <b>DL</b>	4	PA,QL(840 per 28 days)
NOXAFIL 300 MG SUSPENSION, DR FOR RECON <b>DL</b>	4	PA,QL(32 per 30 days)
NOXAFIL 300 MG/16.7 ML SOLUTION <b>DL</b>	4	PA
nyamyc 100,000 unit/gram POWDER <b>MO</b>	1	PA
nystatin 100,000 unit/gram CREAM <b>MO</b>	1	
nystatin 100,000 unit/gram OINTMENT <b>MO</b>	1	
nystatin 100,000 unit/gram POWDER <b>MO</b>	1	PA
nystatin 100,000 unit/ml SUSPENSION <b>MO</b>	1	
nystatin 500,000 unit TABLET <b>MO</b>	1	
nystatin-triamcinolone 100,000-0.1 unit/g-% CREAM <b>MO</b>	1	
nystatin-triamcinolone 100,000-0.1 unit/gram-% OINTMENT <b>MO</b>	1	
nystop 100,000 unit/gram POWDER <b>MO</b>	1	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>oxiconazole 1 % CREAM</i> <b>MO</b>	1	PA,QL(60 per 30 days)
OXISTAT 1 % CREAM <b>MO</b>	3	QL(60 per 30 days)
OXISTAT 1 % LOTION <b>MO</b>	3	PA
<i>posaconazole 100 mg TABLET, DR/EC</i> <b>DL</b>	4	PA
<i>posaconazole 200 mg/5 ml (40 mg/ml) SUSPENSION</i> <b>DL</b>	4	PA,QL(840 per 28 days)
<i>posaconazole 300 mg/16.7 ml SOLUTION</i> <b>DL</b>	4	PA
REZZAYO 200 MG RECON SOLUTION <b>DL</b>	4	PA
SPORANOX 10 MG/ML SOLUTION <b>DL</b>	4	
SPORANOX 100 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
SPORANOX PULSEPAK 100 MG CAPSULE <b>MO</b>	3	PA,QL(120 per 30 days)
<i>tavaborole 5 % SOLUTION W/APPLICATOR</i> <b>MO</b>	1	PA,QL(10 per 30 days)
<i>terbinafine hcl 250 mg TABLET</i> <b>MO</b>	1	
<i>terconazole 0.4 %, 0.8 % CREAM</i> <b>MO</b>	1	
<i>terconazole 80 mg SUPPOSITORY</i> <b>MO</b>	1	
TOLSURA 65 MG CAPSULE, SOLID DISPERSION <b>DL</b>	4	PA,QL(120 per 30 days)
VFEND 200 MG, 50 MG TABLET <b>MO</b>	3	PA,QL(120 per 30 days)
VFEND 200 MG/5 ML (40 MG/ML) SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	PA,QL(400 per 30 days)
VFEND IV 200 MG RECON SOLUTION <b>MO</b>	3	PA
VIVJOA 150 MG CAPSULE <b>MO</b>	3	PA
<i>voriconazole 200 mg RECON SOLUTION</i> <b>MO</b>	1	PA
<i>voriconazole 200 mg, 50 mg TABLET</i> <b>MO</b>	1	PA,QL(120 per 30 days)
<i>voriconazole 200 mg/5 ml (40 mg/ml) SUSPENSION FOR RECONSTITUTION</i> <b>DL</b>	4	PA,QL(400 per 30 days)
VUSION 0.25-15-81.35 % OINTMENT <b>MO</b>	3	
XOLEGEL 2 % GEL <b>MO</b>	3	
<b>ANTIGOUT AGENTS</b>		
<i>allopurinol 100 mg, 300 mg TABLET</i> <b>MO</b>	1	
<i>allopurinol 200 mg TABLET</i> <b>MO</b>	3	
<i>allopurinol sodium 500 mg RECON SOLUTION</i> <b>MO</b>	1	
ALOPRIM 500 MG RECON SOLUTION <b>MO</b>	3	
<i>colchicine 0.6 mg TABLET</i> <b>MO</b>	2	QL(120 per 30 days)
DUZALLO 200-200 MG, 200-300 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
<i>febuxostat 40 mg, 80 mg TABLET</i> <b>MO</b>	1	ST,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GLOPERBA 0.6 MG/5 ML SOLUTION <b>MO</b>	3	PA,QL(300 per 30 days)
MITIGARE 0.6 MG CAPSULE <b>MO</b>	2	
<i>probenecid 500 mg TABLET</i> <b>MO</b>	1	
<i>probenecid-colchicine 500-0.5 mg TABLET</i> <b>MO</b>	1	
ULORIC 40 MG, 80 MG TABLET <b>MO</b>	3	ST,QL(30 per 30 days)
ZYLOPRIM 100 MG TABLET <b>MO</b>	3	
<b>ANTIMIGRAINE AGENTS</b>		
AIMOVIG AUTOINJECTOR 140 MG/ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(1 per 28 days)
AIMOVIG AUTOINJECTOR 70 MG/ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(2 per 28 days)
AJOVY AUTOINJECTOR 225 MG/1.5 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(1.5 per 28 days)
AJOVY SYRINGE 225 MG/1.5 ML SYRINGE <b>MO</b>	3	PA,QL(1.5 per 28 days)
<i>almotriptan malate 12.5 mg, 6.25 mg TABLET</i> <b>MO</b>	1	ST,QL(9 per 30 days)
AMERGE 1 MG, 2.5 MG TABLET <b>MO</b>	3	PA,QL(9 per 30 days)
D.H.E.45 1 MG/ML SOLUTION <b>DL</b>	4	
<i>dihydroergotamine 0.5 mg/pump act. (4 mg/ml) SPRAY, NON-AEROSOL</i> <b>DL</b>	4	PA,QL(8 per 30 days)
<i>dihydroergotamine 1 mg/ml SOLUTION</i> <b>DL</b>	4	PA
<i>eletriptan 20 mg, 40 mg TABLET</i> <b>MO</b>	1	ST,QL(9 per 30 days)
EMGALITY PEN 120 MG/ML PEN INJECTOR <b>MO</b>	3	PA,QL(2 per 30 days)
EMGALITY SYRINGE 120 MG/ML SYRINGE <b>MO</b>	3	PA,QL(2 per 30 days)
EMGALITY SYRINGE 300 MG/3 ML (100 MG/ML X 3) SYRINGE <b>MO</b>	3	PA,QL(3 per 30 days)
EPRONTIA 25 MG/ML SOLUTION <b>MO</b>	3	PA,QL(480 per 30 days)
ERGOMAR 2 MG SUBLINGUAL TABLET <b>DL</b>	4	QL(20 per 28 days)
<i>ergotamine-caffeine 1-100 mg TABLET</i> <b>MO</b>	1	QL(40 per 30 days)
FROVA 2.5 MG TABLET <b>DL</b>	4	ST,QL(12 per 30 days)
<i>frovatriptan 2.5 mg TABLET</i> <b>MO</b>	1	ST,QL(12 per 30 days)
IMITREX 100 MG TABLET <b>DL</b>	4	PA,QL(9 per 30 days)
IMITREX 20 MG/ACTUATION, 5 MG/ACTUATION SPRAY, NON-AEROSOL <b>DL</b>	4	PA,QL(12 per 30 days)
IMITREX 25 MG, 50 MG TABLET <b>MO</b>	3	PA,QL(9 per 30 days)
IMITREX 6 MG/0.5 ML SOLUTION <b>DL</b>	4	PA,QL(6 per 30 days)
IMITREX STATDOSE PEN 4 MG/0.5 ML, 6 MG/0.5 ML PEN INJECTOR <b>MO</b>	3	PA,QL(6 per 30 days)
IMITREX STATDOSE REFILL 4 MG/0.5 ML, 6 MG/0.5 ML CARTRIDGE <b>DL</b>	4	PA,QL(6 per 30 days)
MAXALT 10 MG TABLET <b>MO</b>	3	PA,QL(12 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MAXALT-MLT 10 MG TABLET, DISINTEGRATING <b>MO</b>	3	PA,QL(12 per 30 days)
<i>migergot</i> 2-100 mg SUPPOSITORY <b>DL</b>	4	QL(20 per 28 days)
MIGRANAL 0.5 MG/PUMP ACT. (4 MG/ML) SPRAY, NON-AEROSOL <b>DL</b>	4	QL(8 per 30 days)
<i>naratriptan</i> 1 mg, 2.5 mg TABLET <b>MO</b>	1	QL(9 per 30 days)
ONZETRA XSAIL 11 MG AEROSOL POWDER BREATH ACTIV. <b>MO</b>	3	ST,QL(16 per 30 days)
QUDEXY XR 100 MG, 50 MG CAPSULE ER SPRINKLE 24 HR. <b>DL</b>	4	PA,QL(30 per 30 days)
QUDEXY XR 150 MG, 200 MG CAPSULE ER SPRINKLE 24 HR. <b>DL</b>	4	PA,QL(60 per 30 days)
QUDEXY XR 25 MG CAPSULE ER SPRINKLE 24 HR. <b>DL</b>	4	PA,QL(90 per 30 days)
QULIPTA 10 MG, 30 MG, 60 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
RELPAZ 20 MG, 40 MG TABLET <b>DL</b>	4	ST,QL(9 per 30 days)
REYVOW 100 MG TABLET <b>MO</b>	3	PA,QL(8 per 30 days)
REYVOW 50 MG TABLET <b>MO</b>	3	PA,QL(4 per 30 days)
<i>rizatriptan</i> 10 mg TABLET <b>MO</b>	1	QL(12 per 30 days)
<i>rizatriptan</i> 10 mg, 5 mg TABLET, DISINTEGRATING <b>MO</b>	1	QL(12 per 30 days)
<i>rizatriptan</i> 5 mg TABLET <b>MO</b>	1	QL(12 per 30 days)
<i>sumatriptan</i> 20 mg/actuation, 5 mg/actuation SPRAY, NON-AEROSOL <b>MO</b>	1	QL(12 per 30 days)
<i>sumatriptan succinate</i> 100 mg TABLET <b>MO</b>	1	QL(9 per 30 days)
<i>sumatriptan succinate</i> 25 mg, 50 mg TABLET <b>MO</b>	1	QL(9 per 30 days)
<i>sumatriptan succinate</i> 4 mg/0.5 ml, 6 mg/0.5 ml CARTRIDGE <b>MO</b>	3	QL(6 per 30 days)
<i>sumatriptan succinate</i> 4 mg/0.5 ml, 6 mg/0.5 ml PEN INJECTOR <b>MO</b>	1	QL(6 per 30 days)
<i>sumatriptan succinate</i> 6 mg/0.5 ml SOLUTION <b>MO</b>	1	QL(6 per 30 days)
<i>sumatriptan succinate</i> 6 mg/0.5 ml SYRINGE <b>MO</b>	1	QL(6 per 30 days)
<i>sumatriptan-naproxen</i> 85-500 mg TABLET <b>MO</b>	1	ST,QL(18 per 30 days)
TOPAMAX 100 MG, 200 MG, 50 MG TABLET	4	QL(120 per 30 days)
TOPAMAX 15 MG, 25 MG CAPSULE, SPRINKLE	4	
TOPAMAX 25 MG TABLET <b>MO</b>	3	QL(90 per 30 days)
<i>topiramate</i> 100 mg, 200 mg TABLET <b>MO</b>	1	QL(120 per 30 days)
<i>topiramate</i> 100 mg, 50 mg CAPSULE ER SPRINKLE 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
<i>topiramate</i> 100 mg, 50 mg CAPSULE, ER 24 HR. <b>MO</b>	1	PA,QL(30 per 30 days)
<i>topiramate</i> 15 mg, 25 mg CAPSULE, SPRINKLE <b>MO</b>	1	
<i>topiramate</i> 150 mg, 200 mg CAPSULE ER SPRINKLE 24 HR. <b>MO</b>	3	PA,QL(60 per 30 days)
<i>topiramate</i> 200 mg CAPSULE, ER 24 HR. <b>DL</b>	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
topiramate 25 mg CAPSULE ER SPRINKLE 24 HR. <b>MO</b>	3	PA,QL(90 per 30 days)
topiramate 25 mg CAPSULE, ER 24 HR. <b>MO</b>	1	PA,QL(90 per 30 days)
topiramate 25 mg TABLET <b>MO</b>	1	QL(90 per 30 days)
topiramate 50 mg TABLET <b>MO</b>	1	QL(120 per 30 days)
TOSYMRA 10 MG/ACTUATION SPRAY, NON-AEROSOL <b>MO</b>	3	ST,QL(12 per 30 days)
TREXIMET 85-500 MG TABLET <b>DL</b>	4	ST,QL(18 per 30 days)
TROKENDI XR 100 MG, 50 MG CAPSULE, ER 24 HR.	4	PA,QL(30 per 30 days)
TROKENDI XR 200 MG CAPSULE, ER 24 HR.	4	PA,QL(60 per 30 days)
TROKENDI XR 25 MG CAPSULE, ER 24 HR.	4	PA,QL(90 per 30 days)
TRUDHESA 0.725 MG/PUMP ACT. (4 MG/ML) SPRAY, NON-AEROSOL <b>DL</b>	4	PA,QL(8 per 30 days)
VYEPTI 100 MG/ML SOLUTION <b>MO</b>	3	PA,QL(3 per 90 days)
ZEMBRACE SYMTOUCH 3 MG/0.5 ML PEN INJECTOR <b>DL</b>	4	ST,QL(6 per 30 days)
zolmitriptan 2.5 mg TABLET <b>MO</b>	1	ST,QL(9 per 30 days)
zolmitriptan 2.5 mg TABLET, DISINTEGRATING <b>MO</b>	1	ST,QL(9 per 30 days)
zolmitriptan 2.5 mg, 5 mg SPRAY, NON-AEROSOL <b>MO</b>	1	ST,QL(12 per 30 days)
zolmitriptan 5 mg TABLET <b>MO</b>	1	ST,QL(6 per 30 days)
zolmitriptan 5 mg TABLET, DISINTEGRATING <b>MO</b>	1	ST,QL(6 per 30 days)
zomig 2.5 mg TABLET <b>DL</b>	4	ST,QL(9 per 30 days)
ZOMIG 2.5 MG TABLET <b>DL</b>	4	ST,QL(9 per 30 days)
ZOMIG 2.5 MG, 5 MG SPRAY, NON-AEROSOL <b>MO</b>	3	ST,QL(12 per 30 days)
zomig 5 mg TABLET <b>DL</b>	4	ST,QL(6 per 30 days)
ZOMIG 5 MG TABLET <b>DL</b>	4	ST,QL(6 per 30 days)
<b>ANTIMYASTHENIC AGENTS</b>		
MESTINON 60 MG TABLET	4	PA
MESTINON 60 MG/5 ML SYRUP	4	
MESTINON TIMESPAN 180 MG TABLET ER	4	PA
pyridostigmine bromide 180 mg TABLET ER <b>MO</b>	1	
pyridostigmine bromide 30 mg, 60 mg TABLET <b>MO</b>	1	
pyridostigmine bromide 60 mg/5 ml SYRUP <b>MO</b>	1	
REGONOL 5 MG/ML SOLUTION <b>MO</b>	3	
<b>ANTIMYCOBACTERIALS</b>		
cycloserine 250 mg CAPSULE <b>DL</b>	4	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>dapsone 100 mg, 25 mg TABLET</i> <b>MO</b>	1	
<i>ethambutol 100 mg, 400 mg TABLET</i> <b>MO</b>	1	
<i>isoniazid 100 mg, 300 mg TABLET</i> <b>MO</b>	1	
<i>isoniazid 100 mg/ml, 50 mg/5 ml SOLUTION</i> <b>MO</b>	1	
MYAMBUTOL 400 MG TABLET <b>MO</b>	3	
MYCOBUTIN 150 MG CAPSULE <b>MO</b>	3	
PASER 4 GRAM DR GRANULES IN PACKET <b>MO</b>	1	
PRETOMANID 200 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
PRIFTIN 150 MG TABLET <b>MO</b>	3	
<i>pyrazinamide 500 mg TABLET</i> <b>MO</b>	1	
<i>rifabutin 150 mg CAPSULE</i> <b>MO</b>	1	
RIFADIN 600 MG RECON SOLUTION <b>MO</b>	3	
<i>rifampin 150 mg, 300 mg CAPSULE</i> <b>MO</b>	1	
<i>rifampin 600 mg RECON SOLUTION</i> <b>MO</b>	1	
SIRTURO 100 MG, 20 MG TABLET <b>DL</b>	4	PA
TRECTOR 250 MG TABLET <b>MO</b>	3	
<b>ANTINEOPLASTICS</b>		
<i>abiraterone 250 mg TABLET</i> <b>DL</b>	4	PA,QL(120 per 30 days)
<i>abiraterone 500 mg TABLET</i> <b>DL</b>	4	PA,QL(60 per 30 days)
ABRAXANE 100 MG SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	PA
ADCETRIS 50 MG RECON SOLUTION <b>DL</b>	4	PA
ADRIAMYCIN 50 MG RECON SOLUTION <b>MO</b>	1	BvsD
<i>adrucil 2.5 gram/50 ml SOLUTION</i> <b>MO</b>	1	BvsD
AFINITOR 10 MG, 2.5 MG, 5 MG, 7.5 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
AFINITOR DISPERZ 2 MG, 3 MG, 5 MG TABLET FOR SUSPENSION <b>DL</b>	4	PA
AKEEGA 100-500 MG, 50-500 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
ALECENSA 150 MG CAPSULE <b>DL</b>	4	PA,QL(240 per 30 days)
ALIMTA 100 MG, 500 MG RECON SOLUTION <b>DL</b>	4	PA
ALIQOPA 60 MG RECON SOLUTION <b>DL</b>	4	PA,QL(3 per 28 days)
ALKERAN 2 MG TABLET <b>MO</b>	3	BvsD
ALKERAN (AS HCL) 50 MG RECON SOLUTION <b>MO</b>	3	
ALUNBRIG 180 MG, 90 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ALUNBRIG 30 MG TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
ALUNBRIG 90 MG (7)- 180 MG (23) TABLET, DOSE PACK <b>DL</b>	4	PA,QL(30 per 30 days)
ALYMSYS 25 MG/ML SOLUTION <b>DL</b>	4	PA
<i>anastrozole 1 mg TABLET <b>MO</b></i>	1	QL(30 per 30 days)
ARIMIDEX 1 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
AROMASIN 25 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
ARRANON 250 MG/50 ML SOLUTION <b>DL</b>	4	
<i>arsenic trioxide 1 mg/ml, 2 mg/ml SOLUTION <b>DL</b></i>	4	PA
ASPARLAS 750 UNIT/ML SOLUTION <b>DL</b>	4	PA
AUGTYRO 40 MG CAPSULE <b>DL</b>	4	PA,QL(240 per 30 days)
AVASTIN 25 MG/ML SOLUTION <b>DL</b>	4	PA
AYVAKIT 100 MG, 200 MG, 25 MG, 300 MG, 50 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
<i>azacitidine 100 mg RECON SOLUTION <b>DL</b></i>	4	PA
BALVERSA 3 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
BALVERSA 4 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
BALVERSA 5 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
BAVENCIO 20 MG/ML SOLUTION <b>DL</b>	4	PA
BELEODAQ 500 MG RECON SOLUTION <b>DL</b>	4	PA
BELRAPZO 25 MG/ML SOLUTION <b>DL</b>	4	PA
<i>bendamustine 100 mg, 25 mg RECON SOLUTION <b>DL</b></i>	4	PA
<i>bendamustine 25 mg/ml SOLUTION <b>DL</b></i>	4	PA
BENDEKA 25 MG/ML SOLUTION <b>DL</b>	4	PA
BESPONSA 0.9 MG (0.25 MG/ML INITIAL) RECON SOLUTION <b>DL</b>	4	PA
<i>bexarotene 1 % GEL <b>DL</b></i>	4	PA,QL(240 per 30 days)
<i>bexarotene 75 mg CAPSULE <b>DL</b></i>	4	PA,QL(300 per 30 days)
<i>bicalutamide 50 mg TABLET <b>MO</b></i>	1	QL(30 per 30 days)
BICNU 100 MG RECON SOLUTION <b>MO</b>	3	
<i>bleomycin 15 unit, 30 unit RECON SOLUTION <b>MO</b></i>	1	BvsD
BORTEZOMIB 1 MG, 2.5 MG RECON SOLUTION <b>DL</b>	4	PA
<i>bortezomib 3.5 mg RECON SOLUTION <b>DL</b></i>	4	PA
BOSULIF 100 MG CAPSULE <b>DL</b>	4	PA,QL(180 per 30 days)
BOSULIF 100 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BOSULIF 400 MG, 500 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
BOSULIF 50 MG CAPSULE <b>DL</b>	4	PA,QL(360 per 30 days)
BRAFTOVI 75 MG CAPSULE <b>DL</b>	4	PA,QL(180 per 30 days)
BRUKINSA 80 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
<i>busulfan 60 mg/10 ml SOLUTION</i> <b>MO</b>	1	
BUSULFEX 60 MG/10 ML SOLUTION <b>MO</b>	3	
CABOMETYX 20 MG, 40 MG, 60 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
CALQUENCE 100 MG CAPSULE <b>DL</b>	4	PA,QL(60 per 30 days)
CALQUENCE (ACALABRUTINIB MAL) 100 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
CAMPTOSAR 100 MG/5 ML, 300 MG/15 ML, 40 MG/2 ML SOLUTION <b>DL</b>	4	
CAPRELSA 100 MG TABLET <b>DL,LA</b>	4	PA,QL(60 per 30 days)
CAPRELSA 300 MG TABLET <b>DL,LA</b>	4	PA,QL(30 per 30 days)
<i>carboplatin 10 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>carmustine 100 mg RECON SOLUTION</i> <b>MO</b>	1	
CASODEX 50 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
<i>cisplatin 1 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>cladribine 10 mg/10 ml SOLUTION</i> <b>DL</b>	4	BvsD
<i>clofarabine 1 mg/ml SOLUTION</i> <b>DL</b>	4	
CLOLAR 1 MG/ML SOLUTION <b>DL</b>	4	
COLUMVI 1 MG/ML SOLUTION <b>DL</b>	4	PA
COMETRIQ 100 MG/DAY(80 MG X1-20 MG X1) CAPSULE <b>DL</b>	4	PA,QL(56 per 28 days)
COMETRIQ 140 MG/DAY(80 MG X1-20 MG X3) CAPSULE <b>DL</b>	4	PA,QL(112 per 28 days)
COMETRIQ 60 MG/DAY (20 MG X 3/DAY) CAPSULE <b>DL</b>	4	PA,QL(84 per 28 days)
COPIKTRA 15 MG, 25 MG CAPSULE <b>DL</b>	4	PA,QL(56 per 28 days)
COSMEGEN 0.5 MG RECON SOLUTION <b>DL</b>	4	
COTELLIC 20 MG TABLET <b>DL</b>	4	PA,QL(63 per 28 days)
<i>cyclophosphamide 1 gram, 2 gram, 500 mg RECON SOLUTION</i> <b>MO</b>	1	BvsD
CYCLOPHOSPHAMIDE 100 MG/ML, 200 MG/ML SOLUTION <b>MO</b>	1	BvsD
<i>cyclophosphamide 200 mg/ml, 500 mg/ml SOLUTION</i> <b>MO</b>	1	BvsD
<i>cyclophosphamide 25 mg, 50 mg CAPSULE</i> <b>MO</b>	1	BvsD
<i>cyclophosphamide 25 mg, 50 mg TABLET</i> <b>MO</b>	1	BvsD
CYRAMZA 10 MG/ML SOLUTION <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
cytarabine 20 mg/ml SOLUTION <b>MO</b>	1	BvsD
cytarabine (pf) 100 mg/5 ml (20 mg/ml), 2 gram/20 ml (100 mg/ml), 20 mg/ml SOLUTION <b>MO</b>	1	BvsD
dacarbazine 100 mg, 200 mg RECON SOLUTION <b>MO</b>	1	
DACOGEN 50 MG RECON SOLUTION <b>DL</b>	4	PA
dactinomycin 0.5 mg RECON SOLUTION <b>DL</b>	4	
DANYELZA 4 MG/ML SOLUTION <b>DL</b>	4	PA,QL(120 per 28 days)
DARZALEX 20 MG/ML SOLUTION <b>DL</b>	4	PA
DARZALEX FASPRO 1,800 MG-30,000 UNIT/15 ML SOLUTION <b>DL</b>	4	PA
daunorubicin 5 mg/ml SOLUTION <b>MO</b>	1	
DAURISMO 100 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
DAURISMO 25 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
decitabine 50 mg RECON SOLUTION <b>DL</b>	4	PA
dexrazoxane hcl 250 mg, 500 mg RECON SOLUTION <b>MO</b>	1	
DOCEFREZ 20 MG RECON SOLUTION <b>MO</b>	3	
DOCEFREZ 80 MG RECON SOLUTION <b>DL</b>	4	
docetaxel 160 mg/16 ml (10 mg/ml), 160 mg/8 ml (20 mg/ml), 20 mg/2 ml (10 mg/ml), 20 mg/ml (1 ml), 80 mg/4 ml (20 mg/ml), 80 mg/8 ml (10 mg/ml) SOLUTION <b>MO</b>	1	
DOXIL 2 MG/ML SUSPENSION <b>DL</b>	4	PA
doxorubicin 10 mg, 50 mg RECON SOLUTION <b>MO</b>	1	BvsD
doxorubicin 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml SOLUTION <b>MO</b>	1	BvsD
doxorubicin, peg-liposomal 2 mg/ml SUSPENSION <b>DL</b>	4	PA
ELITEK 1.5 MG, 7.5 MG RECON SOLUTION <b>DL</b>	4	PA
ELLENC 200 MG/100 ML, 50 MG/25 ML SOLUTION <b>DL</b>	4	
ELREXFIO 40 MG/ML SOLUTION <b>DL</b>	4	PA
ELZONRIS 1,000 MCG/ML SOLUTION <b>DL</b>	4	PA,QL(10 per 21 days)
EMCYT 140 MG CAPSULE <b>MO</b>	3	
EMPLICITI 300 MG, 400 MG RECON SOLUTION <b>DL</b>	4	PA
ENHERTU 100 MG RECON SOLUTION <b>DL</b>	4	PA
epirubicin 200 mg/100 ml, 50 mg/25 ml SOLUTION <b>MO</b>	1	
EPKINLY 4 MG/0.8 ML, 48 MG/0.8 ML SOLUTION <b>DL</b>	4	PA
ERBITUX 100 MG/50 ML, 200 MG/100 ML SOLUTION <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>eribulin</i> 1 mg/2 ml (0.5 mg/ml) SOLUTION <b>DL</b>	4	
ERIVEDGE 150 MG CAPSULE <b>DL</b>	4	PA,QL(28 per 28 days)
ERLEADA 240 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
ERLEADA 60 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
<i>erlotinib</i> 100 mg, 150 mg TABLET <b>MO</b>	1	PA,QL(30 per 30 days)
<i>erlotinib</i> 25 mg TABLET <b>MO</b>	1	PA,QL(90 per 30 days)
ETHYOL 500 MG RECON SOLUTION <b>DL</b>	4	
ETOPOPHOS 100 MG RECON SOLUTION <b>MO</b>	3	
<i>etoposide</i> 20 mg/ml SOLUTION <b>MO</b>	1	
EULEXIN 125 MG CAPSULE <b>DL</b>	4	PA
<i>everolimus (antineoplastic)</i> 10 mg, 2.5 mg, 5 mg, 7.5 mg TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
<i>everolimus (antineoplastic)</i> 2 mg, 3 mg, 5 mg TABLET FOR SUSPENSION <b>DL</b>	4	PA
EVOMELA 50 MG RECON SOLUTION <b>DL</b>	4	
<i>exemestane</i> 25 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
EXKIVITY 40 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
FARESTON 60 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
FASLODEX 250 MG/5 ML SYRINGE <b>DL</b>	4	PA,QL(30 per 30 days)
FEMARA 2.5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
<i>flouxuridine</i> 0.5 gram RECON SOLUTION <b>MO</b>	1	BvsD
<i>fludarabine</i> 50 mg RECON SOLUTION <b>MO</b>	1	
<i>fludarabine</i> 50 mg/2 ml SOLUTION <b>DL</b>	4	
<i>fluorouracil</i> 1 gram/20 ml, 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml SOLUTION <b>MO</b>	1	BvsD
<i>flutamide</i> 125 mg CAPSULE <b>MO</b>	1	
FOLOTYN 20 MG/ML (1 ML), 40 MG/2 ML (20 MG/ML) SOLUTION <b>DL</b>	4	PA
FOTIVDA 0.89 MG, 1.34 MG CAPSULE <b>DL</b>	4	PA,QL(21 per 28 days)
FRUZAQLA 1 MG CAPSULE <b>DL</b>	4	PA,QL(84 per 28 days)
FRUZAQLA 5 MG CAPSULE <b>DL</b>	4	PA,QL(21 per 28 days)
<i>fulvestrant</i> 250 mg/5 ml SYRINGE <b>MO</b>	1	PA,QL(30 per 30 days)
FUSILEV 50 MG RECON SOLUTION <b>DL</b>	4	PA
FYARRO 100 MG SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	PA
GAVRETO 100 MG CAPSULE <b>DL,LA</b>	4	PA,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GAZYVA 1,000 MG/40 ML SOLUTION <b>DL</b>	4	PA,QL(120 per 28 days)
<i>gefitinib</i> 250 mg TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
<i>gemcitabine</i> 1 gram, 2 gram, 200 mg RECON SOLUTION <b>MO</b>	1	
<i>gemcitabine</i> 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml) SOLUTION <b>MO</b>	1	
GILOTRIF 20 MG, 30 MG, 40 MG TABLET <b>DL,LA</b>	4	PA,QL(30 per 30 days)
GLEEVEC 100 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
GLEEVEC 400 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
GLEOSTINE 10 MG, 40 MG CAPSULE	4	PA
GLEOSTINE 100 MG CAPSULE <b>DL</b>	4	PA
HALAVEN 1 MG/2 ML (0.5 MG/ML) SOLUTION <b>DL</b>	4	
HERCEPTIN 150 MG RECON SOLUTION <b>DL</b>	4	PA
HERCEPTIN HYLECTA 600 MG-10,000 UNIT/5 ML SOLUTION <b>DL</b>	4	PA,QL(5 per 21 days)
HERZUMA 150 MG, 420 MG RECON SOLUTION <b>DL</b>	4	PA
HYCANTIN 4 MG RECON SOLUTION <b>DL</b>	4	
HYDREA 500 MG CAPSULE <b>MO</b>	3	
<i>hydroxyurea</i> 500 mg CAPSULE <b>MO</b>	1	
IBRANCE 100 MG, 125 MG, 75 MG CAPSULE <b>DL</b>	4	PA,QL(21 per 28 days)
IBRANCE 100 MG, 125 MG, 75 MG TABLET <b>DL</b>	4	PA,QL(21 per 28 days)
ICLUSIG 10 MG, 30 MG, 45 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
ICLUSIG 15 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
IDAMYCIN PFS 1 MG/ML SOLUTION <b>DL</b>	4	
<i>idarubicin</i> 1 mg/ml SOLUTION <b>DL</b>	4	
IDHIFA 100 MG, 50 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
IFEX 1 GRAM, 3 GRAM RECON SOLUTION <b>MO</b>	3	
<i>ifosfamide</i> 1 gram, 3 gram RECON SOLUTION <b>MO</b>	1	
<i>ifosfamide</i> 1 gram/20 ml, 3 gram/60 ml SOLUTION <b>MO</b>	1	
<i>imatinib</i> 100 mg TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
<i>imatinib</i> 400 mg TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
IMBRUVICA 140 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
IMBRUVICA 420 MG, 560 MG TABLET <b>DL</b>	4	PA,QL(28 per 28 days)
IMBRUVICA 70 MG CAPSULE <b>DL</b>	4	PA,QL(28 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
IMBRUVICA 70 MG/ML SUSPENSION <b>DL</b>	4	PA
IMFINZI 50 MG/ML SOLUTION <b>DL</b>	4	PA
IMJUDO 20 MG/ML SOLUTION <b>DL</b>	4	PA
IMLYGIC 10EXP6 (1 MILLION) PFU/ML SUSPENSION <b>DL</b>	4	PA,QL(4 per 365 days)
IMLYGIC 10EXP8 (100 MILLION) PFU/ML SUSPENSION <b>DL</b>	4	PA,QL(8 per 28 days)
INFUGEM 1,200 MG/120 ML (10 MG/ML), 1,300 MG/130 ML (10 MG/ML), 1,400 MG/140 ML (10 MG/ML), 1,500 MG/150 ML (10 MG/ML), 1,600 MG/160 ML (10 MG/ML), 1,700 MG/170 ML (10 MG/ML), 1,800 MG/180 ML (10 MG/ML), 1,900 MG/190 ML (10 MG/ML), 2,000 MG/200 ML (10 MG/ML), 2,200 MG/220 ML (10 MG/ML) PIGGYBACK <b>DL</b>	4	
INLYTA 1 MG TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
INLYTA 5 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
INQOVI 35-100 MG TABLET <b>DL</b>	4	PA,QL(5 per 28 days)
INREBIC 100 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
IRESSA 250 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
<i>irinotecan</i> 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml, 500 mg/25 ml SOLUTION <b>MO</b>	1	
ISTODAX 10 MG/2 ML RECON SOLUTION <b>DL</b>	4	PA
IWILFIN 192 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
IXEMPRA 15 MG, 45 MG RECON SOLUTION <b>DL</b>	4	PA
JAKAFI 10 MG, 15 MG, 20 MG, 25 MG, 5 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
JAYPIRCA 100 MG, 50 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
JEMPERLI 50 MG/ML SOLUTION	4	PA,QL(20 per 42 days)
JEVTANA 10 MG/ML (FIRST DILUTION) SOLUTION <b>DL</b>	4	PA
KADCYLA 100 MG, 160 MG RECON SOLUTION <b>DL</b>	4	PA
KANJINTI 150 MG, 420 MG RECON SOLUTION <b>DL</b>	4	PA
KEYTRUDA 25 MG/ML SOLUTION <b>DL</b>	4	PA
KHAPZORY 175 MG, 300 MG RECON SOLUTION <b>DL</b>	4	PA
KIMMTRAK 100 MCG/0.5 ML SOLUTION <b>DL</b>	4	PA
KISQALI 200 MG/DAY (200 MG X 1) TABLET <b>DL</b>	4	PA,QL(21 per 28 days)
KISQALI 400 MG/DAY (200 MG X 2) TABLET <b>DL</b>	4	PA,QL(42 per 28 days)
KISQALI 600 MG/DAY (200 MG X 3) TABLET <b>DL</b>	4	PA,QL(63 per 28 days)
KISQALI FEMARA CO-PACK 200 MG/DAY(200 MG X 1)-2.5 MG TABLET <b>DL</b>	4	PA,QL(49 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
KISQALI FEMARA CO-PACK 400 MG/DAY(200 MG X 2)-2.5 MG TABLET <b>DL</b>	4	PA,QL(70 per 28 days)
KISQALI FEMARA CO-PACK 600 MG/DAY(200 MG X 3)-2.5 MG TABLET <b>DL</b>	4	PA,QL(91 per 28 days)
KOSELUGO 10 MG CAPSULE <b>DL</b>	4	PA,QL(240 per 30 days)
KOSELUGO 25 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
KRAZATI 200 MG TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
KYPROLIS 10 MG RECON SOLUTION <b>DL</b>	4	PA,QL(6 per 28 days)
KYPROLIS 30 MG RECON SOLUTION <b>DL</b>	4	PA,QL(3 per 28 days)
KYPROLIS 60 MG RECON SOLUTION <b>DL</b>	4	PA,QL(12 per 28 days)
<i>lapatinib 250 mg TABLET <b>DL</b></i>	4	PA,QL(180 per 30 days)
<i>lenalidomide 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg CAPSULE <b>DL</b></i>	4	PA,QL(28 per 28 days)
LENVIMA 10 MG/DAY (10 MG X 1), 4 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
LENVIMA 12 MG/DAY (4 MG X 3), 18 MG/DAY (10 MG X 1-4 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1) CAPSULE <b>DL</b>	4	PA,QL(90 per 30 days)
LENVIMA 14 MG/DAY(10 MG X 1-4 MG X 1), 20 MG/DAY (10 MG X 2), 8 MG/DAY (4 MG X 2) CAPSULE <b>DL</b>	4	PA,QL(60 per 30 days)
<i>letrozole 2.5 mg TABLET <b>MO</b></i>	1	QL(30 per 30 days)
<i>leucovorin calcium 10 mg, 15 mg, 25 mg, 5 mg TABLET <b>MO</b></i>	1	
<i>leucovorin calcium 10 mg/ml SOLUTION <b>MO</b></i>	1	
<i>leucovorin calcium 100 mg, 200 mg, 350 mg, 50 mg, 500 mg RECON SOLUTION <b>MO</b></i>	1	
LEUKERAN 2 MG TABLET <b>DL</b>	4	
<i>levoleucovorin calcium 10 mg/ml SOLUTION <b>MO</b></i>	1	PA
<i>levoleucovorin calcium 50 mg RECON SOLUTION <b>MO</b></i>	1	PA
LEVULAN 20 % SOLUTION <b>MO</b>	3	
LIBTAYO 50 MG/ML SOLUTION <b>DL</b>	4	PA,QL(7 per 21 days)
LONSURF 15-6.14 MG TABLET <b>DL</b>	4	PA,QL(100 per 30 days)
LONSURF 20-8.19 MG TABLET <b>DL</b>	4	PA,QL(80 per 30 days)
LOQTORZI 240 MG/6 ML (40 MG/ML) SOLUTION <b>DL</b>	4	PA
LORBRENA 100 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
LORBRENA 25 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
LUMAKRAS 120 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
LUMAKRAS 320 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
LUNSUMIO 1 MG/ML SOLUTION <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LYNPARZA 100 MG, 150 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
LYTGOBI 4 MG TABLET <b>DL</b>	4	PA,QL(140 per 28 days)
MARGENZA 25 MG/ML SOLUTION <b>DL</b>	4	PA
MATULANE 50 MG CAPSULE <b>DL</b>	4	
MEKINIST 0.05 MG/ML RECON SOLUTION <b>DL</b>	4	PA,QL(1170 per 28 days)
MEKINIST 0.5 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
MEKINIST 2 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
MEKTOVI 15 MG TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
<i>melfhalan 2 mg TABLET <b>MO</b></i>	1	BvsD
<i>melfhalan hcl 50 mg RECON SOLUTION <b>MO</b></i>	1	
<i>mercaptopurine 50 mg TABLET <b>MO</b></i>	1	
<i>mesna 100 mg/ml SOLUTION <b>MO</b></i>	1	
MESNEX 100 MG/ML SOLUTION <b>DL</b>	4	
MESNEX 400 MG TABLET <b>MO</b>	3	
<i>mitomycin 20 mg, 40 mg, 5 mg RECON SOLUTION <b>DL</b></i>	4	
<i>mitoxantrone 2 mg/ml CONCENTRATE <b>MO</b></i>	1	
MUTAMYCIN 20 MG, 40 MG, 5 MG RECON SOLUTION <b>DL</b>	4	
MVASI 25 MG/ML SOLUTION <b>DL</b>	4	PA
MYLOTARG 4.5 MG (1 MG/ML INITIAL CONC) RECON SOLUTION <b>DL</b>	4	PA
<i>nelarabine 250 mg/50 ml SOLUTION <b>DL</b></i>	4	
NERLYNX 40 MG TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
NEXAVAR 200 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
NILANDRON 150 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
<i>nilutamide 150 mg TABLET <b>DL</b></i>	4	QL(60 per 30 days)
NINLARO 2.3 MG, 3 MG, 4 MG CAPSULE <b>DL</b>	4	PA,QL(3 per 28 days)
NIPENT 10 MG RECON SOLUTION <b>DL</b>	4	
NUBEQA 300 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
ODOMZO 200 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
OGIVRI 150 MG, 420 MG RECON SOLUTION <b>DL</b>	4	PA
OGSIVEO 100 MG, 150 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
OGSIVEO 50 MG TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
OJJAARA 100 MG, 150 MG, 200 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ONCASPAR 750 UNIT/ML SOLUTION <b>DL</b>	4	PA
ONIVYDE 4.3 MG/ML DISPERSION <b>DL</b>	4	PA
ONTRUZANT 150 MG, 420 MG RECON SOLUTION <b>DL</b>	4	PA
ONUREG 200 MG, 300 MG TABLET <b>DL</b>	4	PA,QL(14 per 28 days)
OPDIVO 100 MG/10 ML SOLUTION <b>DL</b>	4	PA,QL(40 per 28 days)
OPDIVO 120 MG/12 ML, 240 MG/24 ML SOLUTION <b>DL</b>	4	PA,QL(48 per 28 days)
OPDIVO 40 MG/4 ML SOLUTION <b>DL</b>	4	PA,QL(16 per 28 days)
OPDUALAG 240-80 MG/20 ML SOLUTION <b>DL</b>	4	PA,QL(40 per 28 days)
ORSERDU 345 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
ORSERDU 86 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
oxaliplatin 100 mg, 50 mg RECON SOLUTION <b>MO</b>	1	
oxaliplatin 100 mg/20 ml, 200 mg/40 ml, 50 mg/10 ml (5 mg/ml) SOLUTION <b>MO</b>	1	
paclitaxel 6 mg/ml CONCENTRATE <b>MO</b>	1	
paclitaxel protein-bound 100 mg SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	PA
PADCEV 20 MG RECON SOLUTION <b>DL</b>	4	PA,QL(21 per 28 days)
PADCEV 30 MG RECON SOLUTION <b>DL</b>	4	PA,QL(15 per 28 days)
PANRETIN 0.1 % GEL <b>DL</b>	4	PA
paraplatin 10 mg/ml SOLUTION <b>MO</b>	1	
pazopanib 200 mg TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
PEDMARK 12.5 GRAM/100ML (125 MG/ML) SOLUTION <b>DL</b>	4	PA
PEMAZYRE 13.5 MG, 4.5 MG, 9 MG TABLET <b>DL</b>	4	PA,QL(28 per 28 days)
pemetrexed 1 gram, 100 mg, 500 mg RECON SOLUTION <b>DL</b>	4	PA
pemetrexed 25 mg/ml SOLUTION <b>DL</b>	4	PA,QL(120 per 21 days)
pemetrexed disodium 1,000 mg, 100 mg, 500 mg, 750 mg RECON SOLUTION <b>DL</b>	4	PA
pemetrexed disodium 25 mg/ml SOLUTION <b>DL</b>	4	PA
PEMRYDI RTU 10 MG/ML SOLUTION <b>DL</b>	4	PA
PERJETA 420 MG/14 ML (30 MG/ML) SOLUTION <b>DL</b>	4	PA
PHESGO 1,200 MG-600MG- 30000 UNIT/15ML SOLUTION <b>DL</b>	4	PA,QL(15 per 21 days)
PHESGO 600 MG-600 MG- 20000 UNIT/10ML SOLUTION <b>DL</b>	4	PA,QL(10 per 21 days)
PIQRAY 200 MG/DAY (200 MG X 1) TABLET <b>DL</b>	4	PA,QL(28 per 28 days)
PIQRAY 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) TABLET <b>DL</b>	4	PA,QL(56 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
POLIVY 140 MG RECON SOLUTION <b>DL</b>	4	PA,QL(2 per 21 days)
POLIVY 30 MG RECON SOLUTION <b>DL</b>	4	PA,QL(8 per 21 days)
POMALYST 1 MG, 2 MG, 3 MG, 4 MG CAPSULE <b>DL</b>	4	PA,QL(21 per 28 days)
PORTRAZZA 800 MG/50 ML (16 MG/ML) SOLUTION <b>DL</b>	4	PA,QL(100 per 21 days)
POTELIGEO 4 MG/ML SOLUTION <b>DL</b>	4	PA
<i>pralatrexate 20 mg/ml (1 ml), 40 mg/2 ml (20 mg/ml) SOLUTION</i> <b>DL</b>	4	PA
PROLEUKIN 22 MILLION UNIT RECON SOLUTION <b>DL</b>	4	
PURIXAN 20 MG/ML SUSPENSION <b>DL</b>	4	QL(300 per 30 days)
QINLOCK 50 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
RETEVMO 40 MG CAPSULE <b>DL</b>	4	PA,QL(180 per 30 days)
RETEVMO 80 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
REZLIDHIA 150 MG CAPSULE <b>DL</b>	4	PA,QL(60 per 30 days)
RIABNI 10 MG/ML SOLUTION <b>DL</b>	4	PA
RITUXAN 10 MG/ML CONCENTRATE <b>DL</b>	4	PA
RITUXAN HYCELA 1400 MG/11.7 ML (120 MG/ML) SOLUTION <b>DL</b>	4	PA,QL(46.8 per 28 days)
RITUXAN HYCELA 1600 MG/13.4 ML (120 MG/ML) SOLUTION <b>DL</b>	4	PA,QL(13.4 per 28 days)
<i>romidepsin 10 mg/2 ml RECON SOLUTION</i> <b>DL</b>	4	PA
ROMIDEPSIN 5 MG/ML SOLUTION <b>DL</b>	4	PA
ROZLYTREK 100 MG CAPSULE <b>DL</b>	4	PA,QL(150 per 30 days)
ROZLYTREK 200 MG CAPSULE <b>DL</b>	4	PA,QL(90 per 30 days)
ROZLYTREK 50 MG PELLETS IN PACKET <b>DL</b>	4	PA,QL(360 per 30 days)
RUBRACA 200 MG, 250 MG, 300 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
RUXIENCE 10 MG/ML SOLUTION <b>DL</b>	4	PA
RYBREVANT 50 MG/ML SOLUTION <b>DL</b>	4	PA,QL(784 per 365 days)
RYDAPT 25 MG CAPSULE <b>DL</b>	4	PA,QL(224 per 28 days)
RYLAZE 10 MG/0.5 ML SOLUTION <b>DL</b>	4	PA
SARCLISA 20 MG/ML SOLUTION <b>DL</b>	4	PA
SCEMBLIX 20 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
SCEMBLIX 40 MG TABLET <b>DL</b>	4	PA,QL(300 per 30 days)
SOLTAMOX 20 MG/10 ML SOLUTION <b>DL</b>	4	
<i>sorafenib 200 mg TABLET</i> <b>DL</b>	4	PA,QL(120 per 30 days)
SPRYCEL 100 MG, 50 MG, 70 MG, 80 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SPRYCEL 140 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
SPRYCEL 20 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
STIVARGA 40 MG TABLET <b>DL</b>	4	PA,QL(84 per 28 days)
<i>sunitinib malate 12.5 mg, 25 mg, 37.5 mg, 50 mg CAPSULE</i> <b>DL</b>	4	PA,QL(28 per 28 days)
SUTENT 12.5 MG, 25 MG, 37.5 MG, 50 MG CAPSULE <b>DL</b>	4	PA,QL(28 per 28 days)
SYNRIBO 3.5 MG RECON SOLUTION <b>DL</b>	4	PA
TABLOID 40 MG TABLET <b>MO</b>	3	
TABRECTA 150 MG, 200 MG TABLET <b>DL</b>	4	PA,QL(112 per 28 days)
TAFINLAR 10 MG TABLET FOR SUSPENSION <b>DL</b>	4	PA,QL(840 per 28 days)
TAFINLAR 50 MG CAPSULE <b>DL</b>	4	PA,QL(180 per 30 days)
TAFINLAR 75 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
TAGRISSO 40 MG, 80 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
TALVEY 2 MG/ML, 40 MG/ML SOLUTION <b>DL</b>	4	PA
TALZENNA 0.1 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
TALZENNA 0.25 MG CAPSULE <b>DL</b>	4	PA,QL(90 per 30 days)
<i>tamoxifen 10 mg, 20 mg TABLET</i> <b>MO</b>	1	
TARCEVA 100 MG, 150 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
TARCEVA 25 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
TARGRETIN 1 % GEL <b>DL</b>	4	PA,QL(240 per 30 days)
TARGRETIN 75 MG CAPSULE <b>DL</b>	4	PA,QL(300 per 30 days)
TASIGNA 150 MG, 200 MG, 50 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
TAZVERIK 200 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
TECENTRIQ 1,200 MG/20 ML (60 MG/ML) SOLUTION <b>DL</b>	4	PA,QL(20 per 21 days)
TECENTRIQ 840 MG/14 ML (60 MG/ML) SOLUTION <b>DL</b>	4	PA,QL(28 per 28 days)
TECVAYLI 10 MG/ML, 90 MG/ML SOLUTION <b>DL</b>	4	PA
TEMODAR 100 MG RECON SOLUTION <b>DL</b>	4	PA,QL(27 per 30 days)
<i>temsirolimus 30 mg/3 ml (10 mg/ml) (first) RECON SOLUTION</i> <b>DL</b>	4	PA,QL(8 per 28 days)
<i>teniposide 50 mg/5 ml SOLUTION</i> <b>MO</b>	1	
TEPADINA 100 MG, 15 MG RECON SOLUTION <b>DL</b>	4	
TEPMETKO 225 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
THALOMID 100 MG, 200 MG, 50 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
THALOMID 150 MG CAPSULE <b>DL</b>	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>thiotepa</i> 100 mg RECON SOLUTION <b>DL</b>	4	
<i>thiotepa</i> 15 mg RECON SOLUTION <b>MO</b>	1	
TIBSOVO 250 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
TIVDAK 40 MG RECON SOLUTION <b>DL</b>	4	PA,QL(5 per 21 days)
<i>toposar</i> 20 mg/ml SOLUTION <b>MO</b>	1	
<i>topotecan</i> 4 mg RECON SOLUTION <b>MO</b>	1	
<i>topotecan</i> 4 mg/4 ml (1 mg/ml) SOLUTION <b>MO</b>	1	
<i>toremifene</i> 60 mg TABLET	4	QL(30 per 30 days)
TORISEL 30 MG/3 ML (10 MG/ML) (FIRST) RECON SOLUTION <b>DL</b>	4	PA,QL(8 per 28 days)
TOTECT 500 MG RECON SOLUTION <b>DL</b>	4	
TRAZIMERA 150 MG, 420 MG RECON SOLUTION <b>DL</b>	4	PA
TREANDA 100 MG, 25 MG RECON SOLUTION <b>DL</b>	4	PA
<i>tretinoin (antineoplastic)</i> 10 mg CAPSULE <b>DL</b>	4	
TRISENOX 2 MG/ML SOLUTION <b>DL</b>	4	PA
TRODELVY 180 MG RECON SOLUTION <b>DL</b>	4	PA
TRUQAP 160 MG, 200 MG TABLET <b>DL</b>	4	PA,QL(64 per 28 days)
TRUSELTIQ 100 MG/DAY (100 MG X 1) CAPSULE <b>DL</b>	4	PA,QL(21 per 28 days)
TRUSELTIQ 125 MG/DAY(100 MG X1-25MG X1), 50 MG/DAY (25 MG X 2) CAPSULE <b>DL</b>	4	PA,QL(42 per 28 days)
TRUSELTIQ 75 MG/DAY (25 MG X 3) CAPSULE <b>DL</b>	4	PA,QL(63 per 28 days)
TRUXIMA 10 MG/ML SOLUTION <b>DL</b>	4	PA
TUKYSA 150 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
TUKYSA 50 MG TABLET <b>DL</b>	4	PA,QL(300 per 30 days)
TURALIO 125 MG, 200 MG CAPSULE <b>DL,LA</b>	4	PA,QL(120 per 30 days)
TYKERB 250 MG TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
UNITUXIN 3.5 MG/ML SOLUTION <b>DL</b>	4	PA
VALCHLOR 0.016 % GEL <b>DL</b>	4	PA,QL(60 per 28 days)
<i>valrubicin</i> 40 mg/ml SOLUTION <b>DL</b>	4	PA,QL(80 per 28 days)
VALSTAR 40 MG/ML SOLUTION <b>DL</b>	4	PA,QL(80 per 28 days)
VANFLYTA 17.7 MG, 26.5 MG TABLET <b>DL</b>	4	PA,QL(56 per 28 days)
VECTIBIX 100 MG/5 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML) SOLUTION <b>DL</b>	4	PA
VEGZELMA 25 MG/ML SOLUTION <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VELCADE 3.5 MG RECON SOLUTION <b>DL</b>	4	PA
VENCLEXTA 10 MG TABLET <b>MO</b>	2	PA,QL(56 per 28 days)
VENCLEXTA 100 MG TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
VENCLEXTA 50 MG TABLET <b>MO</b>	2	PA,QL(28 per 28 days)
VENCLEXTA STARTING PACK 10 MG-50 MG- 100 MG TABLET, DOSE PACK <b>DL</b>	4	PA,QL(42 per 28 days)
VERZENIO 100 MG, 150 MG, 200 MG, 50 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
VIDAZA 100 MG RECON SOLUTION <b>DL</b>	4	PA
<i>vinblastine 1 mg/ml SOLUTION <b>MO</b></i>	1	BvsD
<i>vincasar pfs 1 mg/ml, 2 mg/2 ml SOLUTION <b>MO</b></i>	1	BvsD
<i>vincristine 1 mg/ml, 2 mg/2 ml SOLUTION <b>MO</b></i>	1	BvsD
<i>vinorelbine 10 mg/ml, 50 mg/5 ml SOLUTION <b>MO</b></i>	1	
VISTOGARD 10 GRAM GRANULES IN PACKET <b>DL</b>	4	QL(20 per 365 days)
VITRAKVI 100 MG CAPSULE <b>DL</b>	4	PA,QL(60 per 30 days)
VITRAKVI 20 MG/ML SOLUTION <b>DL</b>	4	PA,QL(300 per 30 days)
VITRAKVI 25 MG CAPSULE <b>DL</b>	4	PA,QL(180 per 30 days)
VIZIMPRO 15 MG, 30 MG, 45 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
VONJO 100 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
VOTRIENT 200 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
VYXEOS 44-100 MG RECON SOLUTION <b>DL</b>	4	PA
WELIREG 40 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
XALKORI 150 MG PELLETT <b>DL</b>	4	PA,QL(180 per 30 days)
XALKORI 20 MG PELLETT <b>DL</b>	4	PA,QL(120 per 30 days)
XALKORI 200 MG, 250 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
XALKORI 50 MG PELLETT <b>DL</b>	4	PA,QL(240 per 30 days)
XOSPATA 40 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
XPOVIO 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2) TABLET <b>DL</b>	4	PA,QL(8 per 28 days)
XPOVIO 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1) TABLET <b>DL</b>	4	PA,QL(4 per 28 days)
XPOVIO 60MG TWICE WEEK (120 MG/WEEK) TABLET <b>DL</b>	4	PA,QL(24 per 28 days)
XPOVIO 80MG TWICE WEEK (160 MG/WEEK) TABLET <b>DL</b>	4	PA,QL(32 per 28 days)
XTANDI 40 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
XTANDI 40 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
XTANDI 80 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
YERVOY 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML) SOLUTION <b>DL</b>	4	PA
YONDELIS 1 MG RECON SOLUTION <b>DL</b>	4	PA
YONSA 125 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
ZALTRAP 100 MG/4 ML (25 MG/ML), 200 MG/8 ML (25 MG/ML) SOLUTION <b>DL</b>	4	PA
ZANOSAR 1 GRAM RECON SOLUTION <b>MO</b>	3	
ZEJULA 100 MG CAPSULE <b>DL</b>	4	PA,QL(90 per 30 days)
ZEJULA 100 MG, 200 MG, 300 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
ZELBORAF 240 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
ZEPZELCA 4 MG RECON SOLUTION <b>DL</b>	4	PA
ZIRABEV 25 MG/ML SOLUTION <b>DL</b>	4	PA
ZOLINZA 100 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
ZYDELIG 100 MG, 150 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
ZYKADIA 150 MG TABLET <b>DL</b>	4	PA,QL(150 per 30 days)
ZYNLONTA 10 MG RECON SOLUTION <b>DL</b>	4	PA
ZYNYZ 500 MG/20 ML SOLUTION <b>DL</b>	4	PA,QL(20 per 28 days)
ZYTIGA 250 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
ZYTIGA 500 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
<b>ANTIPARASITICS</b>		
<i>albendazole 200 mg TABLET <b>MO</b></i>	1	
ALBENZA 200 MG TABLET <b>DL</b>	4	
<i>atovaquone 750 mg/5 ml SUSPENSION <b>MO</b></i>	1	
<i>atovaquone-proguanil 250-100 mg, 62.5-25 mg TABLET <b>MO</b></i>	1	
<i>benznidazole 100 mg, 12.5 mg TABLET <b>MO</b></i>	3	
BILTRICIDE 600 MG TABLET <b>DL</b>	4	PA
<i>chloroquine phosphate 250 mg, 500 mg TABLET <b>MO</b></i>	1	
COARTEM 20-120 MG TABLET <b>MO</b>	3	QL(24 per 30 days)
DARAPRIM 25 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
EGATEN 250 MG TABLET <b>MO</b>	3	
<i>emverm 100 mg CHEWABLE TABLET <b>DL</b></i>	4	
<i>hydroxychloroquine 100 mg, 300 mg, 400 mg TABLET <b>MO</b></i>	1	
<i>hydroxychloroquine 200 mg TABLET <b>MO</b></i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
IMPAVIDO 50 MG CAPSULE <b>DL</b>	4	QL(84 per 28 days)
<i>ivermectin 3 mg TABLET <b>MO</b></i>	1	
KRINTAFEL 150 MG TABLET <b>MO</b>	2	QL(4 per 180 days)
LAMPIT 120 MG, 30 MG TABLET <b>MO</b>	3	
MALARONE 250-100 MG TABLET <b>MO</b>	3	PA
MALARONE PEDIATRIC 62.5-25 MG TABLET <b>MO</b>	3	PA
<i>mefloquine 250 mg TABLET <b>MO</b></i>	1	
MEPRON 750 MG/5 ML SUSPENSION <b>DL</b>	4	
NEBUPENT 300 MG RECON SOLUTION <b>MO</b>	3	BvsD
<i>nitazoxanide 500 mg TABLET <b>DL</b></i>	4	
PENTAM 300 MG RECON SOLUTION <b>MO</b>	3	
<i>pentamidine 300 mg RECON SOLUTION <b>MO</b></i>	1	
<i>pentamidine 300 mg RECON SOLUTION <b>MO</b></i>	1	BvsD
PLAQUENIL 200 MG TABLET <b>MO</b>	3	PA
<i>praziquantel 600 mg TABLET <b>MO</b></i>	1	
<i>primaquine 26.3 mg TABLET <b>MO</b></i>	1	
<i>pyrimethamine 25 mg TABLET <b>DL</b></i>	4	QL(90 per 30 days)
QUALAQUIN 324 MG CAPSULE <b>MO</b>	3	PA,QL(42 per 7 days)
<i>quinine sulfate 324 mg CAPSULE <b>MO</b></i>	1	PA,QL(42 per 7 days)
SOVUNA 200 MG, 300 MG TABLET <b>MO</b>	3	
STROMECTOL 3 MG TABLET <b>MO</b>	3	PA
<b>ANTIPARKINSON AGENTS</b>		
<i>amantadine hcl 100 mg CAPSULE <b>MO</b></i>	1	
<i>amantadine hcl 100 mg TABLET <b>MO</b></i>	1	
<i>amantadine hcl 50 mg/5 ml SOLUTION <b>MO</b></i>	1	
APOKYN 10 MG/ML CARTRIDGE <b>DL</b>	4	PA,QL(84 per 28 days)
<i>apomorphine 10 mg/ml CARTRIDGE <b>DL</b></i>	4	PA,QL(84 per 28 days)
AZILECT 0.5 MG, 1 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
<i>benztropine 0.5 mg, 1 mg, 2 mg TABLET <b>MO</b></i>	1	
<i>benztropine 1 mg/ml SOLUTION <b>MO</b></i>	1	
<i>bromocriptine 2.5 mg TABLET <b>MO</b></i>	1	
<i>bromocriptine 5 mg CAPSULE <b>MO</b></i>	1	QL(600 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
carbidopa 25 mg TABLET <b>MO</b>	1	
carbidopa-levodopa 10-100 mg, 25-100 mg, 25-250 mg TABLET, DISINTEGRATING <b>MO</b>	1	
carbidopa-levodopa 10-100 mg, 25-250 mg TABLET <b>MO</b>	1	
carbidopa-levodopa 25-100 mg TABLET <b>MO</b>	1	
carbidopa-levodopa 25-100 mg, 50-200 mg TABLET ER <b>MO</b>	1	
carbidopa-levodopa-entacapone 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg TABLET <b>MO</b>	1	QL(240 per 30 days)
carbidopa-levodopa-entacapone 50-200-200 mg TABLET <b>MO</b>	1	
COMTAN 200 MG TABLET <b>MO</b>	3	PA,QL(300 per 30 days)
DHIVY 25-100 MG TABLET <b>MO</b>	3	
DUOPA 4.63-20 MG/ML INTESTINAL PUMP SUSPENSION <b>DL</b>	4	PA,QL(2800 per 28 days)
entacapone 200 mg TABLET <b>MO</b>	1	QL(300 per 30 days)
GOCOVRI 137 MG CAPSULE, ER 24 HR.	4	PA,QL(60 per 30 days)
GOCOVRI 68.5 MG CAPSULE, ER 24 HR.	4	PA,QL(30 per 30 days)
INBRIJA 42 MG CAPSULE <b>DL</b>	4	PA,QL(300 per 30 days)
INBRIJA 42 MG CAPSULE, W/INHALATION DEVICE <b>DL</b>	4	PA,QL(300 per 30 days)
LODOSYN 25 MG TABLET <b>DL</b>	4	PA
MIRAPEX ER 0.375 MG, 0.75 MG, 1.5 MG, 2.25 MG, 3 MG, 3.75 MG, 4.5 MG TABLET, ER 24 HR. <b>MO</b>	3	ST,QL(30 per 30 days)
NEUPRO 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR PATCH, 24 HR. <b>MO</b>	3	ST,QL(30 per 30 days)
NOURIANZ 20 MG, 40 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
ONGENTYS 25 MG, 50 MG CAPSULE <b>MO</b>	3	PA,QL(30 per 30 days)
OSMOLEX ER 129 MG, 193 MG, 258 MG TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	3	PA,QL(30 per 30 days)
OSMOLEX ER 322 MG/DAY(129 MG X1-193MG X1) TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	3	PA,QL(60 per 30 days)
PARLODEL 2.5 MG TABLET <b>MO</b>	3	PA
PARLODEL 5 MG CAPSULE <b>MO</b>	3	PA,QL(600 per 30 days)
pramipexole 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg TABLET <b>MO</b>	1	
pramipexole 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, 4.5 mg TABLET, ER 24 HR. <b>MO</b>	1	ST,QL(30 per 30 days)
rasagiline 0.5 mg, 1 mg TABLET <b>MO</b>	1	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ropinirole</i> 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg TABLET <b>MO</b>	1	
<i>ropinirole</i> 12 mg, 2 mg, 4 mg, 6 mg, 8 mg TABLET, ER 24 HR. <b>MO</b>	1	ST,QL(90 per 30 days)
RYTARY 23.75-95 MG CAPSULE, ER <b>MO</b>	3	ST,QL(360 per 30 days)
RYTARY 36.25-145 MG CAPSULE, ER <b>MO</b>	3	ST,QL(270 per 30 days)
RYTARY 48.75-195 MG CAPSULE, ER <b>MO</b>	3	ST,QL(360 per 30 days)
RYTARY 61.25-245 MG CAPSULE, ER <b>MO</b>	3	ST,QL(300 per 30 days)
<i>selegiline hcl</i> 5 mg CAPSULE <b>MO</b>	1	
<i>selegiline hcl</i> 5 mg TABLET <b>MO</b>	1	
SINEMET 10-100 MG, 25-100 MG TABLET <b>MO</b>	3	PA
STALEVO 100 25-100-200 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
STALEVO 125 31.25-125-200 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
STALEVO 150 37.5-150-200 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
STALEVO 200 50-200-200 MG TABLET <b>DL</b>	4	PA
STALEVO 50 12.5-50-200 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
STALEVO 75 18.75-75-200 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
TASMAR 100 MG TABLET <b>DL</b>	4	PA
<i>tolcapone</i> 100 mg TABLET <b>DL</b>	4	PA
<i>trihexyphenidyl</i> 0.4 mg/ml ELIXIR <b>MO</b>	1	
<i>trihexyphenidyl</i> 2 mg, 5 mg TABLET <b>MO</b>	1	
XADAGO 100 MG, 50 MG TABLET	4	PA,QL(30 per 30 days)
ZELAPAR 1.25 MG TABLET, DISINTEGRATING <b>DL</b>	4	
<b>ANTIPSYCHOTICS</b>		
ABILIFY 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG TABLET <b>MO</b>	3	PA
ABILIFY ASIMTUFII 720 MG/2.4 ML SUSPENSION, ER, SYRINGE	4	QL(2.4 per 56 days)
ABILIFY ASIMTUFII 960 MG/3.2 ML SUSPENSION, ER, SYRINGE	4	QL(3.2 per 56 days)
ABILIFY MAINTENA 300 MG, 400 MG SUSPENSION, ER, RECON <b>DL</b>	4	QL(1 per 28 days)
ABILIFY MAINTENA 300 MG, 400 MG SUSPENSION, ER, SYRINGE <b>DL</b>	4	QL(1 per 28 days)
ABILIFY MYCITE 10 MG, 15 MG, 2 MG, 20 MG, 5 MG TABLET WITH SENSOR AND PATCH <b>DL</b>	4	PA,QL(30 per 30 days)
ABILIFY MYCITE 30 MG TABLET WITH SENSOR AND PATCH <b>DL</b>	4	PA,QL(30 per 30 days)
ABILIFY MYCITE MAINTENANCE KIT 10 MG, 30 MG TABLET WITH SENSOR AND STRIP <b>DL</b>	4	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ABILIFY MYCITE MAINTENANCE KIT 15 MG, 2 MG, 20 MG, 5 MG TABLET WITH SENSOR AND STRIP <b>DL</b>	4	PA,QL(30 per 30 days)
ABILIFY MYCITE STARTER KIT 10 MG TABLET W/SENSOR AND STRIP, POD <b>DL</b>	4	PA,QL(30 per 30 days)
ABILIFY MYCITE STARTER KIT 15 MG, 2 MG, 20 MG, 30 MG, 5 MG TABLET W/SENSOR AND STRIP, POD <b>DL</b>	4	PA,QL(30 per 30 days)
<i>aripiprazole 1 mg/ml SOLUTION <b>MO</b></i>	1	QL(750 per 30 days)
<i>aripiprazole 10 mg, 15 mg TABLET, DISINTEGRATING <b>MO</b></i>	1	QL(60 per 30 days)
<i>aripiprazole 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg TABLET <b>MO</b></i>	1	
ARISTADA 1,064 MG/3.9 ML SUSPENSION, ER, SYRINGE	4	QL(3.9 per 56 days)
ARISTADA 441 MG/1.6 ML SUSPENSION, ER, SYRINGE	4	QL(1.6 per 28 days)
ARISTADA 662 MG/2.4 ML SUSPENSION, ER, SYRINGE	4	QL(2.4 per 28 days)
ARISTADA 882 MG/3.2 ML SUSPENSION, ER, SYRINGE	4	QL(3.2 per 28 days)
ARISTADA INITIO 675 MG/2.4 ML SUSPENSION, ER, SYRINGE	4	QL(2.4 per 42 days)
<i>asenapine maleate 10 mg, 2.5 mg, 5 mg SUBLINGUAL TABLET <b>MO</b></i>	1	PA,QL(60 per 30 days)
CAPLYTA 10.5 MG, 21 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
CAPLYTA 42 MG CAPSULE	4	PA,QL(30 per 30 days)
<i>chlorpromazine 10 mg, 25 mg TABLET <b>MO</b></i>	1	BvsD
<i>chlorpromazine 100 mg, 200 mg, 50 mg TABLET <b>MO</b></i>	1	
<i>chlorpromazine 100 mg/ml, 30 mg/ml CONCENTRATE <b>MO</b></i>	1	
<i>chlorpromazine 25 mg/ml SOLUTION <b>MO</b></i>	1	
<i>clozapine 100 mg TABLET <b>MO</b></i>	1	QL(270 per 30 days)
<i>clozapine 100 mg TABLET, DISINTEGRATING <b>MO</b></i>	1	PA,QL(270 per 30 days)
<i>clozapine 12.5 mg TABLET, DISINTEGRATING <b>MO</b></i>	1	PA
<i>clozapine 150 mg TABLET, DISINTEGRATING <b>MO</b></i>	1	PA,QL(180 per 30 days)
<i>clozapine 200 mg TABLET <b>MO</b></i>	1	QL(135 per 30 days)
<i>clozapine 200 mg TABLET, DISINTEGRATING <b>MO</b></i>	1	PA,QL(135 per 30 days)
<i>clozapine 25 mg TABLET <b>MO</b></i>	1	QL(1080 per 30 days)
<i>clozapine 25 mg TABLET, DISINTEGRATING <b>MO</b></i>	1	PA,QL(1080 per 30 days)
<i>clozapine 50 mg TABLET <b>MO</b></i>	1	
CLOZARIL 100 MG TABLET <b>DL</b>	4	QL(270 per 30 days)
CLOZARIL 200 MG TABLET <b>DL</b>	4	QL(135 per 30 days)
CLOZARIL 25 MG TABLET <b>DL</b>	4	QL(1080 per 30 days)
CLOZARIL 50 MG TABLET <b>DL</b>	4	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>droperidol 2.5 mg/ml SOLUTION</i> <b>MO</b>	1	
FANAPT 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
FANAPT 1MG(2)-2MG(2)- 4MG(2)-6MG(2) TABLET, DOSE PACK <b>MO</b>	3	PA,QL(56 per 28 days)
<i>fluphenazine decanoate 25 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>fluphenazine hcl 1 mg, 10 mg, 2.5 mg, 5 mg TABLET</i> <b>MO</b>	1	
<i>fluphenazine hcl 2.5 mg/5 ml ELIXIR</i> <b>MO</b>	1	
<i>fluphenazine hcl 2.5 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>fluphenazine hcl 5 mg/ml CONCENTRATE</i> <b>MO</b>	1	
GEODON 20 MG, 40 MG, 60 MG, 80 MG CAPSULE <b>DL</b>	4	PA
GEODON 20 MG/ML (FINAL CONC.) RECON SOLUTION <b>MO</b>	3	PA
HALDOL DECANOATE 100 MG/ML, 50 MG/ML SOLUTION <b>MO</b>	3	PA
<i>haloperidol 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg TABLET</i> <b>MO</b>	1	
<i>haloperidol decanoate 100 mg/ml, 50 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>haloperidol lactate 2 mg/ml CONCENTRATE</i> <b>MO</b>	1	
<i>haloperidol lactate 5 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>haloperidol lactate 5 mg/ml SYRINGE</i> <b>MO</b>	1	
INVEGA 1.5 MG, 3 MG, 9 MG TABLET, ER 24 HR. <b>DL</b>	4	PA,QL(30 per 30 days)
INVEGA 6 MG TABLET, ER 24 HR. <b>DL</b>	4	PA,QL(60 per 30 days)
INVEGA HAFYERA 1,092 MG/3.5 ML SYRINGE	4	QL(3.5 per 180 days)
INVEGA HAFYERA 1,560 MG/5 ML SYRINGE	4	QL(5 per 180 days)
INVEGA SUSTENNA 117 MG/0.75 ML, 234 MG/1.5 ML, 78 MG/0.5 ML SYRINGE <b>DL</b>	4	QL(1.5 per 28 days)
INVEGA SUSTENNA 156 MG/ML SYRINGE <b>DL</b>	4	QL(1 per 28 days)
INVEGA SUSTENNA 39 MG/0.25 ML SYRINGE <b>MO</b>	3	QL(1.5 per 28 days)
INVEGA TRINZA 273 MG/0.88 ML SYRINGE	4	QL(0.88 per 90 days)
INVEGA TRINZA 410 MG/1.32 ML SYRINGE	4	QL(1.32 per 90 days)
INVEGA TRINZA 546 MG/1.75 ML SYRINGE	4	QL(1.75 per 90 days)
INVEGA TRINZA 819 MG/2.63 ML SYRINGE	4	QL(2.63 per 90 days)
LATUDA 120 MG, 20 MG, 40 MG, 60 MG TABLET	4	PA,QL(30 per 30 days)
LATUDA 80 MG TABLET	4	PA,QL(60 per 30 days)
<i>loxapine succinate 10 mg, 25 mg, 5 mg, 50 mg CAPSULE</i> <b>MO</b>	1	
<i>lurasidone 120 mg, 20 mg, 40 mg, 60 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>lurasidone 80 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
LYBALVI 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
<i>molindone 10 mg TABLET</i> <b>MO</b>	1	PA,QL(240 per 30 days)
<i>molindone 25 mg TABLET</i> <b>MO</b>	1	PA,QL(270 per 30 days)
<i>molindone 5 mg TABLET</i> <b>MO</b>	1	PA,QL(360 per 30 days)
NUPLAZID 10 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
NUPLAZID 34 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
<i>olanzapine 10 mg RECON SOLUTION</i> <b>MO</b>	1	
<i>olanzapine 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg TABLET</i> <b>MO</b>	1	
<i>olanzapine 10 mg, 5 mg TABLET, DISINTEGRATING</i> <b>MO</b>	1	QL(30 per 30 days)
<i>olanzapine 15 mg, 20 mg TABLET, DISINTEGRATING</i> <b>MO</b>	1	QL(60 per 30 days)
<i>paliperidone 1.5 mg, 3 mg, 9 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(30 per 30 days)
<i>paliperidone 6 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(60 per 30 days)
<i>perphenazine 16 mg, 2 mg, 4 mg, 8 mg TABLET</i> <b>MO</b>	1	
PERSERIS 120 MG, 90 MG SUSPENSION, ER, SYRINGE <b>DL</b>	4	QL(1 per 28 days)
<i>pimozide 1 mg, 2 mg TABLET</i> <b>MO</b>	1	
<i>quetiapine 100 mg TABLET</i> <b>MO</b>	1	QL(90 per 30 days)
<i>quetiapine 150 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>quetiapine 150 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(90 per 30 days)
<i>quetiapine 200 mg TABLET</i> <b>MO</b>	1	QL(120 per 30 days)
<i>quetiapine 200 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(30 per 30 days)
<i>quetiapine 25 mg, 50 mg TABLET</i> <b>MO</b>	1	QL(120 per 30 days)
<i>quetiapine 300 mg, 400 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
<i>quetiapine 300 mg, 400 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(60 per 30 days)
<i>quetiapine 50 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(120 per 30 days)
REXULTI 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
RISPERDAL 0.5 MG TABLET <b>MO</b>	3	QL(120 per 30 days)
RISPERDAL 1 MG, 2 MG TABLET <b>MO</b>	3	QL(60 per 30 days)
RISPERDAL 1 MG/ML SOLUTION <b>DL</b>	4	
RISPERDAL 3 MG, 4 MG TABLET <b>DL</b>	4	QL(60 per 30 days)
RISPERDAL CONSTA 12.5 MG/2 ML, 25 MG/2 ML SUSPENSION, ER, RECON <b>MO</b>	3	QL(2 per 28 days)
RISPERDAL CONSTA 37.5 MG/2 ML, 50 MG/2 ML SUSPENSION, ER, RECON <b>DL</b>	4	QL(2 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
<i>risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg TABLET, DISINTEGRATING</i> <b>MO</b>	1	ST,QL(60 per 30 days)
<i>risperidone 0.5 mg TABLET</i> <b>MO</b>	1	QL(120 per 30 days)
<i>risperidone 0.5 mg TABLET, DISINTEGRATING</i> <b>MO</b>	1	ST,QL(120 per 30 days)
<i>risperidone 1 mg/ml SOLUTION</i> <b>MO</b>	1	
SAPHRIS 10 MG, 2.5 MG, 5 MG SUBLINGUAL TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
SECUADO 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR PATCH, 24 HR. <b>DL</b>	4	PA,QL(30 per 30 days)
SEROQUEL 100 MG TABLET <b>MO</b>	3	QL(90 per 30 days)
SEROQUEL 200 MG, 25 MG, 50 MG TABLET <b>MO</b>	3	QL(120 per 30 days)
SEROQUEL 300 MG, 400 MG TABLET <b>MO</b>	3	QL(60 per 30 days)
SEROQUEL XR 150 MG TABLET, ER 24 HR. <b>MO</b>	3	PA,QL(90 per 30 days)
SEROQUEL XR 200 MG TABLET, ER 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
SEROQUEL XR 300 MG, 400 MG TABLET, ER 24 HR. <b>MO</b>	3	PA,QL(60 per 30 days)
SEROQUEL XR 50 MG TABLET, ER 24 HR. <b>MO</b>	3	PA,QL(120 per 30 days)
SEROQUEL XR 50 MG(3)-200 MG (1)-300 MG(11) TABLET, ER 24 HR., DOSE PACK <b>MO</b>	3	PA,QL(15 per 30 days)
<i>thioridazine 10 mg, 100 mg, 25 mg, 50 mg TABLET</i> <b>MO</b>	1	
<i>thiothixene 1 mg, 10 mg, 2 mg, 5 mg CAPSULE</i> <b>MO</b>	1	
<i>trifluoperazine 1 mg, 10 mg, 2 mg, 5 mg TABLET</i> <b>MO</b>	1	
UZEDY 100 MG/0.28 ML SUSPENSION, ER, SYRINGE <b>DL</b>	4	QL(0.28 per 28 days)
UZEDY 125 MG/0.35 ML SUSPENSION, ER, SYRINGE <b>DL</b>	4	QL(0.35 per 28 days)
UZEDY 150 MG/0.42 ML SUSPENSION, ER, SYRINGE	4	QL(0.42 per 56 days)
UZEDY 200 MG/0.56 ML SUSPENSION, ER, SYRINGE	4	QL(0.56 per 56 days)
UZEDY 250 MG/0.7 ML SUSPENSION, ER, SYRINGE	4	QL(0.7 per 56 days)
UZEDY 50 MG/0.14 ML SUSPENSION, ER, SYRINGE <b>DL</b>	4	QL(0.14 per 28 days)
UZEDY 75 MG/0.21 ML SUSPENSION, ER, SYRINGE <b>DL</b>	4	QL(0.21 per 28 days)
VERSACLOZ 50 MG/ML SUSPENSION <b>DL</b>	4	PA,QL(540 per 30 days)
VRAYLAR 1.5 MG (1)- 3 MG (6) CAPSULE, DOSE PACK <b>MO</b>	3	PA
VRAYLAR 1.5 MG, 3 MG, 4.5 MG, 6 MG CAPSULE	4	PA,QL(30 per 30 days)
<i>ziprasidone hcl 20 mg, 40 mg, 60 mg, 80 mg CAPSULE</i> <b>MO</b>	1	
<i>ziprasidone mesylate 20 mg/ml (final conc.) RECON SOLUTION</i> <b>MO</b>	1	
ZYPREXA 10 MG RECON SOLUTION <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZYPREXA 10 MG, 15 MG, 2.5 MG, 20 MG, 5 MG, 7.5 MG TABLET	4	
ZYPREXA RELPREVV 210 MG SUSPENSION FOR RECONSTITUTION <b>MO</b>	3	QL(4 per 28 days)
ZYPREXA RELPREVV 300 MG SUSPENSION FOR RECONSTITUTION	4	QL(2 per 28 days)
ZYPREXA RELPREVV 405 MG SUSPENSION FOR RECONSTITUTION	4	QL(1 per 28 days)
ZYPREXA ZYDIS 10 MG TABLET, DISINTEGRATING	4	QL(30 per 30 days)
ZYPREXA ZYDIS 15 MG, 20 MG TABLET, DISINTEGRATING	4	QL(60 per 30 days)
ZYPREXA ZYDIS 5 MG TABLET, DISINTEGRATING <b>MO</b>	3	QL(30 per 30 days)
<b>ANTISPASTICITY AGENTS</b>		
<i>baclofen 10 mg TABLET <b>MO</b></i>	1	
<i>baclofen 10 mg/5 ml (2 mg/ml), 5 mg/5 ml SOLUTION <b>DL</b></i>	4	
<i>baclofen 15 mg, 20 mg TABLET <b>MO</b></i>	1	
<i>baclofen 25 mg/5 ml (5 mg/ml) SUSPENSION <b>DL</b></i>	4	QL(480 per 30 days)
<i>baclofen 5 mg TABLET <b>MO</b></i>	1	QL(90 per 30 days)
DANTRIUM 20 MG RECON SOLUTION <b>MO</b>	3	
DANTRIUM 25 MG CAPSULE <b>MO</b>	3	
<i>dantrolene 100 mg, 25 mg, 50 mg CAPSULE <b>MO</b></i>	1	
<i>dantrolene 20 mg RECON SOLUTION <b>MO</b></i>	1	
FLEQSUVY 25 MG/5 ML (5 MG/ML) SUSPENSION <b>DL</b>	4	QL(480 per 30 days)
LYVISPAH 10 MG, 20 MG GRANULES IN PACKET <b>DL</b>	4	ST,QL(120 per 30 days)
LYVISPAH 5 MG GRANULES IN PACKET <b>MO</b>	3	ST,QL(270 per 30 days)
OZOBAX 5 MG/5 ML SOLUTION <b>DL</b>	4	
OZOBAX DS 10 MG/5 ML (2 MG/ML) SOLUTION <b>DL</b>	4	
<i>revonto 20 mg RECON SOLUTION <b>MO</b></i>	1	
<i>tizanidine 2 mg, 4 mg TABLET <b>MO</b></i>	1	
<i>tizanidine 2 mg, 4 mg, 6 mg CAPSULE <b>MO</b></i>	1	ST
ZANAFLEX 2 MG, 4 MG, 6 MG CAPSULE <b>MO</b>	3	ST
ZANAFLEX 4 MG TABLET <b>MO</b>	3	ST
<b>ANTIVIRALS</b>		
<i>abacavir 20 mg/ml SOLUTION <b>MO</b></i>	1	QL(960 per 30 days)
<i>abacavir 300 mg TABLET <b>MO</b></i>	1	QL(60 per 30 days)
<i>abacavir-lamivudine 600-300 mg TABLET <b>MO</b></i>	1	QL(30 per 30 days)
<i>acyclovir 200 mg CAPSULE <b>MO</b></i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>acyclovir 200 mg/5 ml SUSPENSION</i> <b>MO</b>	1	
<i>acyclovir 400 mg TABLET</i> <b>MO</b>	1	
<i>acyclovir 5 % CREAM</i> <b>MO</b>	3	PA,QL(5 per 30 days)
<i>acyclovir 5 % OINTMENT</i> <b>MO</b>	1	PA,QL(30 per 30 days)
<i>acyclovir 800 mg TABLET</i> <b>MO</b>	1	
<i>acyclovir sodium 1,000 mg, 500 mg RECON SOLUTION</i> <b>MO</b>	1	BvsD
<i>acyclovir sodium 50 mg/ml SOLUTION</i> <b>MO</b>	1	BvsD
<i>adefovir 10 mg TABLET</i> <b>MO</b>	1	
APRETUDE 600 MG/3 ML (200 MG/ML) SUSPENSION, ER <b>DL</b>	4	QL(21 per 365 days)
APTIVUS 250 MG CAPSULE <b>DL</b>	4	QL(120 per 30 days)
<i>atazanavir 150 mg, 200 mg CAPSULE</i> <b>MO</b>	1	QL(60 per 30 days)
<i>atazanavir 300 mg CAPSULE</i> <b>MO</b>	1	QL(30 per 30 days)
ATRIPLA 600-200-300 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
BARACLUDE 0.05 MG/ML SOLUTION <b>MO</b>	3	QL(630 per 30 days)
BARACLUDE 0.5 MG, 1 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
BIKTARVY 30-120-15 MG, 50-200-25 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
CABENUVA 400 MG/2 ML- 600 MG/2 ML, 600 MG/3 ML- 900 MG/3 ML SUSPENSION, ER <b>DL</b>	4	QL(50 per 365 days)
<i>cidofovir 75 mg/ml SOLUTION</i> <b>DL</b>	4	
CIMDUO 300-300 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
COMBIVIR 150-300 MG TABLET <b>DL</b>	4	QL(60 per 30 days)
COMPLERA 200-25-300 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
<i>darunavir 600 mg TABLET</i> <b>DL</b>	4	QL(60 per 30 days)
<i>darunavir 800 mg TABLET</i> <b>DL</b>	4	QL(30 per 30 days)
DELSTRIGO 100-300-300 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
DENAVIR 1 % CREAM <b>MO</b>	3	PA
DESCOVY 120-15 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
DESCOVY 200-25 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
<i>didanosine 250 mg, 400 mg CAPSULE, DR/EC</i> <b>MO</b>	1	QL(30 per 30 days)
DOVATO 50-300 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
EDURANT 25 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
<i>efavirenz 200 mg CAPSULE</i> <b>MO</b>	1	QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
efavirenz 50 mg CAPSULE <b>MO</b>	1	QL(480 per 30 days)
efavirenz 600 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
efavirenz-emtricitabin-tenofov 600-200-300 mg TABLET <b>DL</b>	1	QL(30 per 30 days)
efavirenz-lamivu-tenofov disop 400-300-300 mg, 600-300-300 mg TABLET <b>DL</b>	4	QL(30 per 30 days)
emtricitabine 200 mg CAPSULE <b>MO</b>	1	QL(30 per 30 days)
emtricitabine-tenofovir (tdf) 100-150 mg, 133-200 mg, 167-250 mg, 200-300 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
EMTRIVA 10 MG/ML SOLUTION <b>MO</b>	3	QL(680 per 28 days)
EMTRIVA 200 MG CAPSULE <b>MO</b>	3	QL(30 per 30 days)
entecavir 0.5 mg, 1 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
EPCLUSA 150-37.5 MG PELLETS IN PACKET <b>DL</b>	4	PA,QL(28 per 28 days)
EPCLUSA 200-50 MG PELLETS IN PACKET <b>DL</b>	4	PA,QL(56 per 28 days)
EPCLUSA 200-50 MG, 400-100 MG TABLET <b>DL</b>	4	PA,QL(28 per 28 days)
EPIVIR 10 MG/ML SOLUTION <b>MO</b>	3	QL(900 per 30 days)
EPIVIR 150 MG TABLET <b>MO</b>	3	QL(60 per 30 days)
EPIVIR 300 MG TABLET <b>MO</b>	3	QL(30 per 30 days)
EPIVIR HBV 100 MG TABLET <b>MO</b>	3	QL(90 per 30 days)
EPIVIR HBV 25 MG/5 ML (5 MG/ML) SOLUTION <b>MO</b>	3	
EPZICOM 600-300 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
etravirine 100 mg TABLET <b>DL</b>	4	QL(120 per 30 days)
etravirine 200 mg TABLET <b>DL</b>	4	QL(60 per 30 days)
EVOTAZ 300-150 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
famciclovir 125 mg, 250 mg, 500 mg TABLET <b>MO</b>	1	QL(90 per 30 days)
FLUMADINE 100 MG TABLET <b>MO</b>	3	
fosamprenavir 700 mg TABLET <b>DL</b>	4	QL(120 per 30 days)
foscarnet 24 mg/ml SOLUTION <b>MO</b>	1	BvsD
FOSCAVIR 24 MG/ML SOLUTION <b>MO</b>	3	BvsD
FUZEON 90 MG RECON SOLUTION <b>DL</b>	4	QL(60 per 30 days)
ganciclovir sodium 50 mg/ml SOLUTION <b>MO</b>	1	BvsD
ganciclovir sodium 500 mg RECON SOLUTION <b>MO</b>	1	BvsD
GENVOYA 150-150-200-10 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
HARVONI 33.75-150 MG PELLETS IN PACKET <b>DL</b>	4	PA,QL(28 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HARVONI 45-200 MG PELLETS IN PACKET <b>DL</b>	4	PA,QL(56 per 28 days)
HARVONI 45-200 MG TABLET <b>DL</b>	4	PA,QL(28 per 28 days)
HARVONI 90-400 MG TABLET <b>DL</b>	4	PA,QL(28 per 28 days)
HEPSERA 10 MG TABLET <b>DL</b>	4	
INTELENCE 100 MG TABLET <b>DL</b>	4	QL(120 per 30 days)
INTELENCE 200 MG TABLET <b>DL</b>	4	QL(60 per 30 days)
INTELENCE 25 MG TABLET <b>MO</b>	3	QL(120 per 30 days)
ISENTRESS 100 MG CHEWABLE TABLET <b>DL</b>	4	QL(180 per 30 days)
ISENTRESS 100 MG POWDER IN PACKET <b>MO</b>	2	QL(300 per 30 days)
ISENTRESS 25 MG CHEWABLE TABLET <b>MO</b>	3	QL(180 per 30 days)
ISENTRESS 400 MG TABLET <b>DL</b>	4	QL(120 per 30 days)
ISENTRESS HD 600 MG TABLET <b>DL</b>	4	QL(60 per 30 days)
JULUCA 50-25 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
KALETRA 100-25 MG TABLET <b>MO</b>	3	QL(300 per 30 days)
KALETRA 200-50 MG TABLET <b>MO</b>	3	QL(150 per 30 days)
KALETRA 400-100 MG/5 ML SOLUTION <b>DL</b>	4	
<i>lamivudine 10 mg/ml SOLUTION</i> <b>MO</b>	1	QL(900 per 30 days)
<i>lamivudine 100 mg TABLET</i> <b>MO</b>	1	QL(90 per 30 days)
<i>lamivudine 150 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
<i>lamivudine 300 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>lamivudine-zidovudine 150-300 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
LEXIVA 50 MG/ML SUSPENSION <b>MO</b>	3	QL(1575 per 28 days)
LEXIVA 700 MG TABLET <b>DL</b>	4	QL(120 per 30 days)
LIVTENCITY 200 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
<i>lopinavir-ritonavir 100-25 mg TABLET</i> <b>MO</b>	1	QL(300 per 30 days)
<i>lopinavir-ritonavir 200-50 mg TABLET</i> <b>MO</b>	1	QL(150 per 30 days)
<i>lopinavir-ritonavir 400-100 mg/5 ml SOLUTION</i> <b>MO</b>	1	
<i>maraviroc 150 mg TABLET</i> <b>DL</b>	4	QL(240 per 30 days)
<i>maraviroc 300 mg TABLET</i> <b>DL</b>	4	QL(120 per 30 days)
MAVYRET 100-40 MG TABLET <b>DL</b>	4	PA,QL(84 per 28 days)
MAVYRET 50-20 MG PELLETS IN PACKET <b>DL</b>	4	PA,QL(150 per 30 days)
<i>nevirapine 100 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
nevirapine 200 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
nevirapine 400 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
nevirapine 50 mg/5 ml SUSPENSION <b>MO</b>	1	QL(1200 per 30 days)
NORVIR 100 MG POWDER IN PACKET <b>MO</b>	3	QL(360 per 30 days)
NORVIR 100 MG TABLET <b>MO</b>	3	QL(360 per 30 days)
NORVIR 80 MG/ML SOLUTION <b>MO</b>	3	QL(480 per 30 days)
ODEFSEY 200-25-25 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
oseltamivir 30 mg CAPSULE <b>MO</b>	1	QL(224 per 365 days)
oseltamivir 45 mg, 75 mg CAPSULE <b>MO</b>	1	QL(112 per 365 days)
oseltamivir 6 mg/ml SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	QL(1440 per 365 days)
penciclovir 1 % CREAM <b>MO</b>	1	PA
PIFELTRO 100 MG TABLET <b>DL</b>	4	QL(60 per 30 days)
PREVYMIS 240 MG TABLET <b>DL</b>	4	PA,QL(28 per 28 days)
PREVYMIS 240 MG/12 ML SOLUTION <b>DL</b>	4	PA,QL(336 per 28 days)
PREVYMIS 480 MG TABLET <b>DL</b>	4	PA
PREVYMIS 480 MG/24 ML SOLUTION <b>DL</b>	4	PA,QL(672 per 28 days)
PREZCOBIX 800-150 MG-MG TABLET <b>DL</b>	4	QL(30 per 30 days)
PREZISTA 100 MG/ML SUSPENSION <b>DL</b>	4	QL(360 per 30 days)
PREZISTA 150 MG TABLET <b>DL</b>	4	QL(240 per 30 days)
PREZISTA 600 MG TABLET <b>DL</b>	4	QL(60 per 30 days)
PREZISTA 75 MG TABLET <b>MO</b>	3	QL(480 per 30 days)
PREZISTA 800 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
RELENZA DISKHALER 5 MG/ACTUATION BLISTER WITH DEVICE <b>MO</b>	3	QL(60 per 180 days)
RETROVIR 10 MG/ML SOLUTION <b>MO</b>	3	
RETROVIR 10 MG/ML SYRUP <b>MO</b>	3	QL(1680 per 28 days)
RETROVIR 100 MG CAPSULE <b>MO</b>	3	QL(180 per 30 days)
REYATAZ 200 MG CAPSULE <b>DL</b>	4	QL(60 per 30 days)
REYATAZ 300 MG CAPSULE <b>DL</b>	4	QL(30 per 30 days)
REYATAZ 50 MG POWDER IN PACKET <b>MO</b>	3	
ribavirin 200 mg CAPSULE <b>MO</b>	1	QL(168 per 28 days)
ribavirin 200 mg TABLET <b>MO</b>	1	QL(168 per 28 days)
rimantadine 100 mg TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ritonavir 100 mg TABLET</i> <b>MO</b>	1	QL(360 per 30 days)
RUKOBIA 600 MG TABLET, ER 12 HR. <b>DL</b>	4	QL(60 per 30 days)
SELZENTRY 150 MG TABLET <b>DL</b>	4	QL(240 per 30 days)
SELZENTRY 20 MG/ML SOLUTION <b>DL</b>	4	QL(1800 per 30 days)
SELZENTRY 25 MG TABLET <b>MO</b>	3	QL(240 per 30 days)
SELZENTRY 300 MG, 75 MG TABLET <b>DL</b>	4	QL(120 per 30 days)
SOVALDI 150 MG PELLETS IN PACKET <b>DL</b>	4	PA,QL(28 per 28 days)
SOVALDI 200 MG PELLETS IN PACKET <b>DL</b>	4	PA,QL(56 per 28 days)
SOVALDI 200 MG, 400 MG TABLET <b>DL</b>	4	PA,QL(28 per 28 days)
<i>stavudine 15 mg, 20 mg CAPSULE</i> <b>MO</b>	1	QL(120 per 30 days)
<i>stavudine 30 mg, 40 mg CAPSULE</i> <b>MO</b>	1	QL(60 per 30 days)
STRIBILD 150-150-200-300 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
SUNLENCA 300 MG TABLET <b>DL</b>	4	QL(10 per 365 days)
SUNLENCA 309 MG/ML SOLUTION	4	QL(9 per 365 days)
SUSTIVA 200 MG CAPSULE <b>DL</b>	4	QL(120 per 30 days)
SUSTIVA 50 MG CAPSULE <b>DL</b>	4	QL(480 per 30 days)
SUSTIVA 600 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
SYMFI 600-300-300 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
SYMFI LO 400-300-300 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
SYMTUZA 800-150-200-10 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
TAMIFLU 30 MG CAPSULE <b>MO</b>	3	PA,QL(224 per 365 days)
TAMIFLU 45 MG, 75 MG CAPSULE <b>MO</b>	3	PA,QL(112 per 365 days)
TAMIFLU 6 MG/ML SUSPENSION FOR RECONSTITUTION <b>MO</b>	3	PA,QL(1440 per 365 days)
TEMIXYS 300-300 MG TABLET <b>MO</b>	3	QL(30 per 30 days)
<i>tenofovir disoproxil fumarate 300 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
TIVICAY 10 MG TABLET <b>MO</b>	3	QL(60 per 30 days)
TIVICAY 25 MG, 50 MG TABLET <b>DL</b>	4	QL(60 per 30 days)
TIVICAY PD 5 MG TABLET FOR SUSPENSION <b>DL</b>	4	QL(180 per 30 days)
TRIUMEQ 600-50-300 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
TRIUMEQ PD 60-5-30 MG TABLET FOR SUSPENSION <b>DL</b>	4	QL(180 per 30 days)
TRIZIVIR 300-150-300 MG TABLET <b>DL</b>	4	QL(60 per 30 days)
TROGARZO 200 MG/1.33 ML (150 MG/ML) SOLUTION <b>DL</b>	4	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TRUVADA 100-150 MG, 133-200 MG, 167-250 MG, 200-300 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
TYBOST 150 MG TABLET <b>MO</b>	2	QL(30 per 30 days)
<i>valacyclovir 1 gram, 500 mg TABLET <b>MO</b></i>	1	
VALCYTE 450 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
VALCYTE 50 MG/ML RECON SOLUTION <b>DL</b>	4	PA,QL(1056 per 30 days)
<i>valganciclovir 450 mg TABLET <b>MO</b></i>	1	QL(120 per 30 days)
<i>valganciclovir 50 mg/ml RECON SOLUTION <b>DL</b></i>	4	QL(1056 per 30 days)
VALTREX 1 GRAM, 500 MG TABLET <b>MO</b>	3	PA
VEMLIDY 25 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
VIRACEPT 250 MG TABLET <b>DL</b>	4	QL(300 per 30 days)
VIRACEPT 625 MG TABLET <b>DL</b>	4	QL(120 per 30 days)
VIREAD 150 MG, 200 MG, 250 MG, 300 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
VIREAD 40 MG/SCOOP (40 MG/GRAM) POWDER <b>DL</b>	4	QL(240 per 30 days)
VOCABRIA 30 MG TABLET <b>DL</b>	4	QL(30 per 30 days)
VOSEVI 400-100-100 MG TABLET <b>DL</b>	4	PA,QL(28 per 28 days)
XERESE 5-1 % CREAM <b>DL</b>	4	QL(5 per 30 days)
XOFLUZA 20 MG, 40 MG, 80 MG TABLET <b>MO</b>	3	
ZEPATIER 50-100 MG TABLET <b>DL</b>	4	PA,QL(28 per 28 days)
ZIAGEN 20 MG/ML SOLUTION <b>MO</b>	3	QL(960 per 30 days)
ZIAGEN 300 MG TABLET <b>MO</b>	3	QL(60 per 30 days)
<i>zidovudine 10 mg/ml SYRUP <b>MO</b></i>	1	QL(1680 per 28 days)
<i>zidovudine 100 mg CAPSULE <b>MO</b></i>	1	QL(180 per 30 days)
<i>zidovudine 300 mg TABLET <b>MO</b></i>	1	QL(60 per 30 days)
ZIRGAN 0.15 % GEL <b>MO</b>	3	QL(5 per 30 days)
ZOVIRAX 200 MG/5 ML SUSPENSION <b>MO</b>	3	PA
ZOVIRAX 5 % CREAM <b>MO</b>	3	PA,QL(5 per 30 days)
ZOVIRAX 5 % OINTMENT <b>DL</b>	4	PA,QL(30 per 30 days)
<b>ANXIOLYTICS</b>		
<i>alprazolam 0.25 mg, 0.5 mg, 1 mg TABLET <b>DL</b></i>	1	QL(120 per 30 days)
<i>alprazolam 0.25 mg, 0.5 mg, 1 mg, 2 mg TABLET, DISINTEGRATING <b>DL</b></i>	1	
<i>alprazolam 0.5 mg, 1 mg, 2 mg, 3 mg TABLET, ER 24 HR. <b>DL</b></i>	1	QL(60 per 30 days)
<i>alprazolam 2 mg TABLET <b>DL</b></i>	1	QL(150 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>alprazolam intensol 1 mg/ml CONCENTRATE</i> <b>DL</b>	1	
ATIVAN 0.5 MG, 1 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
ATIVAN 2 MG TABLET <b>DL</b>	4	PA,QL(150 per 30 days)
ATIVAN 2 MG/ML, 4 MG/ML SOLUTION <b>DL</b>	3	PA
<i>bupirone 10 mg, 15 mg, 5 mg TABLET</i> <b>MO</b>	1	
<i>bupirone 30 mg, 7.5 mg TABLET</i> <b>MO</b>	1	
<i>chlordiazepoxide hcl 10 mg, 25 mg, 5 mg CAPSULE</i> <b>DL</b>	1	QL(120 per 30 days)
<i>clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg TABLET, DISINTEGRATING</i> <b>DL</b>	1	
<i>clonazepam 0.5 mg, 1 mg TABLET</i> <b>DL</b>	1	
<i>clonazepam 2 mg TABLET</i> <b>DL</b>	1	
<i>clorazepate dipotassium 15 mg, 3.75 mg, 7.5 mg TABLET</i> <b>DL</b>	1	
<i>diazepam 10 mg TABLET</i> <b>DL</b>	1	QL(120 per 30 days)
<i>diazepam 2 mg TABLET</i> <b>DL</b>	1	QL(90 per 30 days)
<i>diazepam 5 mg TABLET</i> <b>DL</b>	1	QL(90 per 30 days)
<i>diazepam 5 mg/5 ml (1 mg/ml), 5 mg/5 ml (1 mg/ml, 5 ml) SOLUTION</i> <b>DL</b>	1	QL(1200 per 30 days)
<i>diazepam 5 mg/ml CONCENTRATE</i> <b>DL</b>	1	QL(240 per 30 days)
<i>diazepam 5 mg/ml SOLUTION</i> <b>DL</b>	1	
<i>diazepam 5 mg/ml SYRINGE</i> <b>DL</b>	1	
<i>diazepam intensol 5 mg/ml CONCENTRATE</i> <b>DL</b>	1	QL(240 per 30 days)
<i>doxepin 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg CAPSULE</i> <b>MO</b>	1	
<i>doxepin 10 mg/ml CONCENTRATE</i> <b>MO</b>	1	
<i>hydroxyzine hcl 10 mg, 50 mg TABLET</i> <b>MO</b>	1	
<i>hydroxyzine hcl 10 mg/5 ml, 25 mg/ml, 50 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>hydroxyzine hcl 25 mg TABLET</i> <b>MO</b>	1	
KLONOPIN 0.5 MG, 1 MG, 2 MG TABLET <b>DL</b>	3	PA
<i>lorazepam 0.5 mg, 1 mg TABLET</i> <b>DL</b>	1	QL(90 per 30 days)
<i>lorazepam 2 mg TABLET</i> <b>DL</b>	1	QL(150 per 30 days)
<i>lorazepam 2 mg/ml CONCENTRATE</i> <b>DL</b>	1	QL(150 per 30 days)
<i>lorazepam 2 mg/ml SYRINGE</i> <b>DL</b>	1	
<i>lorazepam 2 mg/ml, 4 mg/ml SOLUTION</i> <b>DL</b>	1	
<i>lorazepam intensol 2 mg/ml CONCENTRATE</i> <b>DL</b>	1	QL(150 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LOREEV XR 1 MG CAPSULE, ER 24 HR. <b>DL</b>	4	PA,QL(210 per 30 days)
LOREEV XR 1.5 MG, 2 MG CAPSULE, ER 24 HR. <b>DL</b>	4	PA,QL(150 per 30 days)
LOREEV XR 3 MG CAPSULE, ER 24 HR. <b>DL</b>	4	PA,QL(90 per 30 days)
<i>meprobamate</i> 200 mg, 400 mg TABLET <b>MO</b>	1	
<i>oxazepam</i> 10 mg, 15 mg, 30 mg CAPSULE <b>DL</b>	1	
TRANXENE T-TAB 7.5 MG TABLET <b>DL</b>	3	PA
VALIUM 10 MG TABLET <b>DL</b>	3	PA,QL(120 per 30 days)
VALIUM 2 MG, 5 MG TABLET <b>DL</b>	3	PA,QL(90 per 30 days)
XANAX 0.25 MG, 0.5 MG, 1 MG TABLET <b>DL</b>	3	PA,QL(120 per 30 days)
XANAX 2 MG TABLET <b>DL</b>	3	PA,QL(150 per 30 days)
XANAX XR 0.5 MG, 1 MG, 2 MG, 3 MG TABLET, ER 24 HR. <b>DL</b>	3	PA,QL(60 per 30 days)
<b>BIPOLAR AGENTS</b>		
<i>lithium carbonate</i> 150 mg, 300 mg, 600 mg CAPSULE <b>MO</b>	1	
<i>lithium carbonate</i> 300 mg TABLET <b>MO</b>	1	
<i>lithium carbonate</i> 300 mg, 450 mg TABLET ER <b>MO</b>	1	
<i>lithium citrate</i> 8 meq/5 ml SOLUTION <b>MO</b>	1	
LITHOBID 300 MG TABLET ER <b>MO</b>	3	
<b>BLOOD GLUCOSE REGULATORS</b>		
<i>acarbose</i> 100 mg, 25 mg, 50 mg TABLET <b>MO</b>	1	
ACTOPLUS MET 15-850 MG TABLET <b>MO</b>	3	PA,QL(90 per 30 days)
ACTOS 15 MG, 30 MG, 45 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
ADLYXIN 10 MCG/0.2 ML- 20 MCG/0.2 ML, 20 MCG/0.2 ML PEN INJECTOR <b>MO</b>	3	ST,QL(6 per 28 days)
ADMELOG SOLOSTAR U-100 INSULIN 100 UNIT/ML INSULIN PEN <b>CI,MO</b>	3	ST
ADMELOG U-100 INSULIN LISPRO 100 UNIT/ML SOLUTION <b>CI,MO</b>	3	ST
AFREZZA 12 UNIT CARTRIDGE WITH INHALER <b>CI</b>	4	PA,QL(90 per 30 days)
AFREZZA 4 UNIT (90)/ 8 UNIT (90), 4 UNIT/8 UNIT/ 12 UNIT (60), 8 UNIT (90)/ 12 UNIT (90) CARTRIDGE WITH INHALER <b>CI</b>	4	PA,QL(180 per 30 days)
AFREZZA 4 UNIT, 8 UNIT CARTRIDGE WITH INHALER <b>CI,MO</b>	3	PA,QL(90 per 30 days)
AMARYL 1 MG, 2 MG, 4 MG TABLET <b>MO</b>	3	PA
APIDRA SOLOSTAR U-100 INSULIN 100 UNIT/ML INSULIN PEN <b>CI,MO</b>	3	ST
APIDRA U-100 INSULIN 100 UNIT/ML SOLUTION <b>CI,MO</b>	3	ST
BAQSIMI 3 MG/ACTION SPRAY, NON-AEROSOL <b>MO</b>	2	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BASAGLAR KWIKPEN U-100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	3	PA
BASAGLAR TEMPO PEN(U-100)INSLN 100 UNIT/ML (3 ML) INSULIN PEN, SENSOR <b>CI,MO</b>	3	PA
BYDUREON BCISE 2 MG/0.85 ML AUTO-INJECTOR <b>MO</b>	3	QL(3.4 per 28 days)
BYETTA 10 MCG/DOSE(250 MCG/ML) 2.4 ML, 5 MCG/DOSE (250 MCG/ML) 1.2 ML PEN INJECTOR <b>MO</b>	3	ST,QL(2.4 per 30 days)
CYCLOSET 0.8 MG TABLET <b>MO</b>	3	ST,QL(180 per 30 days)
<i>diazoxide 50 mg/ml SUSPENSION</i> <b>MO</b>	1	
DUETACT 30-2 MG, 30-4 MG TABLET <b>MO</b>	3	QL(30 per 30 days)
FARXIGA 10 MG TABLET <b>MO</b>	3	QL(30 per 30 days)
FARXIGA 5 MG TABLET <b>MO</b>	3	QL(30 per 30 days)
FIASP FLEXTOUCH U-100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	
FIASP PENFILL U-100 INSULIN 100 UNIT/ML (3 ML) CARTRIDGE <b>CI,MO</b>	2	
FIASP U-100 INSULIN 100 UNIT/ML SOLUTION <b>CI,MO</b>	2	
<i>glimepiride 1 mg TABLET</i> <b>MO</b>	1	
<i>glimepiride 2 mg, 4 mg TABLET</i> <b>MO</b>	1	
<i>glipizide 10 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	
<i>glipizide 10 mg, 5 mg TABLET</i> <b>MO</b>	1	
<i>glipizide 2.5 mg TABLET</i> <b>MO</b>	1	
<i>glipizide 2.5 mg, 5 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	
<i>glipizide-metformin 2.5-250 mg, 2.5-500 mg, 5-500 mg TABLET</i> <b>MO</b>	1	
GLUCAGEN HYPOKIT 1 MG RECON SOLUTION <b>MO</b>	2	
GLUCAGON (HCL) EMERGENCY KIT 1 MG RECON SOLUTION <b>MO</b>	3	ST
GLUCAGON EMERGENCY KIT (HUMAN) 1 MG RECON SOLUTION <b>MO</b>	3	ST
<i>glucagon emergency kit (human) 1 mg RECON SOLUTION</i> <b>MO</b>	3	ST
GLUCOTROL XL 10 MG, 2.5 MG, 5 MG TABLET, ER 24 HR. <b>MO</b>	3	
GLUMETZA 1,000 MG TABLET, GAST. RETENTION 24 HR. <b>DL</b>	4	ST,QL(60 per 30 days)
GLUMETZA 500 MG TABLET, GAST. RETENTION 24 HR. <b>DL</b>	4	ST,QL(120 per 30 days)
<i>glyburide 1.25 mg, 2.5 mg, 5 mg TABLET</i> <b>MO</b>	1	
<i>glyburide micronized 1.5 mg, 3 mg, 6 mg TABLET</i> <b>MO</b>	1	
<i>glyburide-metformin 1.25-250 mg, 2.5-500 mg, 5-500 mg TABLET</i> <b>MO</b>	1	
GLYNASE 1.5 MG, 3 MG, 6 MG TABLET <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GLYXAMBI 10-5 MG, 25-5 MG TABLET <b>MO</b>	2	QL(30 per 30 days)
GVOKE 1 MG/0.2 ML SOLUTION <b>MO</b>	2	
GVOKE HYPOPEN 1-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML AUTO-INJECTOR <b>MO</b>	2	
GVOKE HYPOPEN 2-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML AUTO-INJECTOR <b>MO</b>	2	
GVOKE PFS 1-PACK SYRINGE 0.5 MG/0.1 ML, 1 MG/0.2 ML SYRINGE <b>MO</b>	2	
GVOKE PFS 2-PACK SYRINGE 0.5 MG/0.1 ML, 1 MG/0.2 ML SYRINGE <b>MO</b>	2	
HUMALOG JUNIOR KWIKPEN U-100 100 UNIT/ML INSULIN PEN, HALF-UNIT <b>CI,MO</b>	2	
HUMALOG KWIKPEN INSULIN 100 UNIT/ML, 200 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	
HUMALOG MIX 50-50 INSULN U-100 100 UNIT/ML (50-50) SUSPENSION <b>CI,MO</b>	2	
HUMALOG MIX 50-50 KWIKPEN 100 UNIT/ML (50-50) INSULIN PEN <b>CI,MO</b>	2	
HUMALOG MIX 75-25 KWIKPEN 100 UNIT/ML (75-25) INSULIN PEN <b>CI,MO</b>	2	
HUMALOG MIX 75-25(U-100)INSULN 100 UNIT/ML (75-25) SUSPENSION <b>CI,MO</b>	2	
HUMALOG TEMPO PEN(U-100)INSULN 100 UNIT/ML INSULIN PEN, SENSOR <b>CI,MO</b>	2	
HUMALOG U-100 INSULIN 100 UNIT/ML CARTRIDGE <b>CI,MO</b>	2	
HUMALOG U-100 INSULIN 100 UNIT/ML SOLUTION <b>CI,MO</b>	2	
HUMULIN 70/30 U-100 INSULIN 100 UNIT/ML (70-30) SUSPENSION <b>CI,MO</b>	2	
HUMULIN 70/30 U-100 KWIKPEN 100 UNIT/ML (70-30) INSULIN PEN <b>CI,MO</b>	2	
HUMULIN N NPH INSULIN KWIKPEN 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	
HUMULIN N NPH U-100 INSULIN 100 UNIT/ML SUSPENSION <b>CI,MO</b>	2	
HUMULIN R REGULAR U-100 INSULN 100 UNIT/ML SOLUTION <b>CI,MO</b>	2	
HUMULIN R U-500 (CONC) INSULIN 500 UNIT/ML SOLUTION <b>CI</b>	4	
HUMULIN R U-500 (CONC) KWIKPEN 500 UNIT/ML (3 ML) INSULIN PEN <b>CI</b>	4	
INPEFA 200 MG, 400 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
INSULIN ASP PRT-INSULIN ASPART 100 UNIT/ML (70-30) INSULIN PEN <b>CI,MO</b>	2	
INSULIN ASP PRT-INSULIN ASPART 100 UNIT/ML (70-30) SOLUTION <b>CI,MO</b>	2	
INSULIN ASPART U-100 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	
INSULIN ASPART U-100 100 UNIT/ML CARTRIDGE <b>CI,MO</b>	2	
INSULIN ASPART U-100 100 UNIT/ML SOLUTION <b>CI,MO</b>	2	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
INSULIN DEGLUDEC 100 UNIT/ML (3 ML), 200 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	3	PA
INSULIN DEGLUDEC 100 UNIT/ML SOLUTION <b>CI,MO</b>	3	PA
INSULIN GLARGINE 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	3	PA
INSULIN GLARGINE 100 UNIT/ML SOLUTION <b>CI,MO</b>	3	PA
INSULIN GLARGINE U-300 CONC 300 UNIT/ML (1.5 ML), 300 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	3	PA
INSULIN GLARGINE-YFGN 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	3	PA
INSULIN GLARGINE-YFGN 100 UNIT/ML SOLUTION <b>CI,MO</b>	3	PA
INSULIN LISPRO 100 UNIT/ML INSULIN PEN <b>CI,MO</b>	2	
INSULIN LISPRO 100 UNIT/ML INSULIN PEN, HALF-UNIT <b>CI,MO</b>	2	
INSULIN LISPRO 100 UNIT/ML SOLUTION <b>CI,MO</b>	2	
INSULIN LISPRO PROTAMIN-LISPRO 100 UNIT/ML (75-25) INSULIN PEN <b>CI,MO</b>	2	
INVOKAMET 150-1,000 MG, 150-500 MG, 50-1,000 MG, 50-500 MG TABLET <b>MO</b>	2	QL(60 per 30 days)
INVOKAMET XR 150-1,000 MG, 150-500 MG, 50-1,000 MG, 50-500 MG TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	2	QL(60 per 30 days)
INVOKANA 100 MG, 300 MG TABLET <b>MO</b>	2	QL(30 per 30 days)
JANUMET 50-1,000 MG TABLET <b>MO</b>	2	QL(60 per 30 days)
JANUMET 50-500 MG TABLET <b>MO</b>	2	QL(60 per 30 days)
JANUMET XR 100-1,000 MG TABLET, ER 24 HR., MULTIPHASE <b>MO</b>	2	QL(30 per 30 days)
JANUMET XR 50-1,000 MG TABLET, ER 24 HR., MULTIPHASE <b>MO</b>	2	QL(60 per 30 days)
JANUMET XR 50-500 MG TABLET, ER 24 HR., MULTIPHASE <b>MO</b>	2	QL(60 per 30 days)
JANUVIA 100 MG, 25 MG, 50 MG TABLET <b>MO</b>	2	QL(30 per 30 days)
JARDIANCE 10 MG, 25 MG TABLET <b>MO</b>	2	QL(30 per 30 days)
JENTADUETO 2.5-1,000 MG, 2.5-500 MG, 2.5-850 MG TABLET <b>MO</b>	2	QL(60 per 30 days)
JENTADUETO XR 2.5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	2	QL(60 per 30 days)
JENTADUETO XR 5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	2	QL(30 per 30 days)
KAZANO 12.5-1,000 MG, 12.5-500 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
LANTUS SOLOSTAR U-100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	
LANTUS U-100 INSULIN 100 UNIT/ML SOLUTION <b>CI,MO</b>	2	
LEVEMIR FLEXPEN 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LEVEMIR FLEXTOUCH U100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	3	PA
LEVEMIR U-100 INSULIN 100 UNIT/ML SOLUTION <b>CI,MO</b>	3	PA
LYUMJEV KWIKPEN U-100 INSULIN 100 UNIT/ML INSULIN PEN <b>CI,MO</b>	2	
LYUMJEV KWIKPEN U-200 INSULIN 200 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	
LYUMJEV TEMPO PEN(U-100)INSULN 100 UNIT/ML INSULIN PEN, SENSOR <b>CI,MO</b>	2	
LYUMJEV U-100 INSULIN 100 UNIT/ML SOLUTION <b>CI,MO</b>	2	
metformin 1,000 mg TABLET, ER 24 HR. <b>MO</b>	3	ST,QL(60 per 30 days)
metformin 1,000 mg TABLET, GAST. RETENTION 24 HR.	4	ST,QL(60 per 30 days)
metformin 1,000 mg, 500 mg TABLET <b>MO</b>	1	
metformin 500 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(120 per 30 days)
metformin 500 mg TABLET, ER 24 HR. <b>MO</b>	3	ST,QL(150 per 30 days)
metformin 500 mg TABLET, GAST. RETENTION 24 HR.	4	ST,QL(120 per 30 days)
metformin 500 mg/5 ml SOLUTION <b>MO</b>	1	QL(750 per 30 days)
metformin 625 mg TABLET <b>DL</b>	4	ST,QL(120 per 30 days)
metformin 750 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
metformin 850 mg TABLET <b>MO</b>	1	
miglitol 100 mg, 25 mg, 50 mg TABLET <b>MO</b>	1	
MOUNJARO 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML PEN INJECTOR <b>MO</b>	2	QL(2 per 28 days)
nateglinide 120 mg, 60 mg TABLET <b>MO</b>	1	
NESINA 12.5 MG, 25 MG, 6.25 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
NOVOLIN 70-30 FLEXPEN U-100 100 UNIT/ML (70-30) INSULIN PEN <b>CI,MO</b>	2	
NOVOLIN 70/30 U-100 INSULIN 100 UNIT/ML (70-30) SUSPENSION <b>CI,MO</b>	2	
NOVOLIN N FLEXPEN 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	
NOVOLIN N NPH U-100 INSULIN 100 UNIT/ML SUSPENSION <b>CI,MO</b>	2	
NOVOLIN R FLEXPEN 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	
NOVOLIN R REGULAR U100 INSULIN 100 UNIT/ML SOLUTION <b>CI,MO</b>	2	
NOVOLOG FLEXPEN U-100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	
NOVOLOG MIX 70-30 U-100 INSULN 100 UNIT/ML (70-30) SOLUTION <b>CI,MO</b>	2	
NOVOLOG MIX 70-30FLEXPEN U-100 100 UNIT/ML (70-30) INSULIN PEN <b>CI,MO</b>	2	
NOVOLOG PENFILL U-100 INSULIN 100 UNIT/ML CARTRIDGE <b>CI,MO</b>	2	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NOVOLOG U-100 INSULIN ASPART 100 UNIT/ML SOLUTION <b>CI,MO</b>	2	
OSENI 12.5-15 MG, 12.5-30 MG, 12.5-45 MG, 25-15 MG, 25-30 MG, 25-45 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
OZEMPIC 0.25 MG OR 0.5 MG (2 MG/3 ML) PEN INJECTOR <b>MO</b>	2	QL(3 per 28 days)
OZEMPIC 0.25 MG OR 0.5 MG(2 MG/1.5 ML) PEN INJECTOR <b>MO</b>	2	QL(1.5 per 28 days)
OZEMPIC 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) PEN INJECTOR <b>MO</b>	2	QL(3 per 28 days)
pioglitazone 15 mg, 30 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
pioglitazone 45 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
pioglitazone-glimepiride 30-2 mg, 30-4 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
pioglitazone-metformin 15-500 mg, 15-850 mg TABLET <b>MO</b>	1	QL(90 per 30 days)
PRECOSE 100 MG, 25 MG, 50 MG TABLET <b>MO</b>	3	
PROGLYCEM 50 MG/ML SUSPENSION <b>DL</b>	4	PA
QTERN 10-5 MG, 5-5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
repaglinide 0.5 mg, 1 mg, 2 mg TABLET <b>MO</b>	1	
REZVOGLAR KWIKPEN 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	3	PA
RIOMET 500 MG/5 ML SOLUTION <b>MO</b>	3	QL(750 per 30 days)
RIOMET ER 500 MG/5 ML SUSPENSION, ER, RECON <b>MO</b>	3	QL(750 per 30 days)
RYBELSUS 14 MG, 3 MG, 7 MG TABLET <b>MO</b>	2	QL(30 per 30 days)
saxagliptin 2.5 mg, 5 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
saxagliptin-metformin 2.5-1,000 mg TABLET, ER 24 HR., MULTIPHASE <b>MO</b>	1	QL(60 per 30 days)
saxagliptin-metformin 5-1,000 mg, 5-500 mg TABLET, ER 24 HR., MULTIPHASE <b>MO</b>	1	QL(30 per 30 days)
SEGLUROMET 2.5-1,000 MG, 2.5-500 MG, 7.5-1,000 MG, 7.5-500 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
SEMGLEE(INSULIN GLARG-YFGN)PEN 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	3	PA
SEMGLEE(INSULIN GLARGINE-YFGN) 100 UNIT/ML SOLUTION <b>CI,MO</b>	3	PA
sitagliptin 100 mg, 25 mg, 50 mg TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
SOLIQUA 100/33 100 UNIT-33 MCG/ML INSULIN PEN <b>CI,MO</b>	2	QL(15 per 24 days)
STEGLATRO 15 MG, 5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
STEGLUJAN 15-100 MG, 5-100 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
SYMLINPEN 120 2,700 MCG/2.7 ML PEN INJECTOR	4	QL(10.8 per 30 days)
SYMLINPEN 60 1,500 MCG/1.5 ML PEN INJECTOR	4	QL(10.5 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SYNJARDY 12.5-1,000 MG, 12.5-500 MG, 5-1,000 MG, 5-500 MG TABLET <b>MO</b>	2	QL(60 per 30 days)
SYNJARDY XR 10-1,000 MG, 25-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	2	QL(30 per 30 days)
SYNJARDY XR 12.5-1,000 MG, 5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	2	QL(60 per 30 days)
TOUJEO MAX U-300 SOLOSTAR 300 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	
TOUJEO SOLOSTAR U-300 INSULIN 300 UNIT/ML (1.5 ML) INSULIN PEN <b>CI,MO</b>	2	
TRADJENTA 5 MG TABLET <b>MO</b>	2	QL(30 per 30 days)
TRESIBA FLEXTOUCH U-100 100 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	
TRESIBA FLEXTOUCH U-200 200 UNIT/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	
TRESIBA U-100 INSULIN 100 UNIT/ML SOLUTION <b>CI,MO</b>	2	
TRIJARDY XR 10-5-1,000 MG, 25-5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	2	QL(30 per 30 days)
TRIJARDY XR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	2	QL(60 per 30 days)
TRULICITY 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML PEN INJECTOR <b>MO</b>	2	QL(2 per 28 days)
VICTOZA 2-PAK 0.6 MG/0.1 ML (18 MG/3 ML) PEN INJECTOR <b>MO</b>	2	QL(9 per 30 days)
VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) PEN INJECTOR <b>MO</b>	2	QL(9 per 30 days)
XIGDUO XR 10-1,000 MG, 10-500 MG TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	3	QL(30 per 30 days)
XIGDUO XR 2.5-1,000 MG, 5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	3	QL(60 per 30 days)
XIGDUO XR 5-500 MG TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	3	QL(30 per 30 days)
XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) INSULIN PEN <b>CI,MO</b>	2	QL(15 per 30 days)
ZEGALOGUE AUTOINJECTOR 0.6 MG/0.6 ML AUTO-INJECTOR <b>MO</b>	2	
ZEGALOGUE SYRINGE 0.6 MG/0.6 ML SYRINGE <b>MO</b>	2	
ZITUVIO 100 MG, 25 MG, 50 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
<b>BLOOD PRODUCTS AND MODIFIERS</b>		
ADZYNMA 1,500 UNIT, 500 UNIT KIT <b>DL</b>	4	PA
AGGRASTAT CONCENTRATE 250 MCG/ML CONCENTRATE <b>MO</b>	3	
AGGRASTAT IN SODIUM CHLORIDE 12.5 MG/250 ML (50 MCG/ML), 5 MG/100 ML (50 MCG/ML) SOLUTION <b>MO</b>	3	
AGRYLIN 0.5 MG CAPSULE <b>MO</b>	3	PA
ALVAIZ 18 MG, 9 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ALVAIZ 36 MG, 54 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
aminocaproic acid 1,000 mg TABLET <b>DL</b>	4	
aminocaproic acid 250 mg/ml, 250 mg/ml (25 %) SOLUTION <b>MO</b>	1	
aminocaproic acid 500 mg TABLET <b>MO</b>	1	
anagrelide 0.5 mg, 1 mg CAPSULE <b>MO</b>	1	
ARANESP (IN POLYSORBATE) 10 MCG/0.4 ML, 40 MCG/0.4 ML SYRINGE <b>MO</b>	3	PA,QL(1.6 per 30 days)
ARANESP (IN POLYSORBATE) 100 MCG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(2 per 30 days)
ARANESP (IN POLYSORBATE) 100 MCG/ML, 200 MCG/ML, 60 MCG/ML SOLUTION <b>DL</b>	4	PA,QL(4 per 30 days)
ARANESP (IN POLYSORBATE) 150 MCG/0.3 ML SYRINGE <b>DL</b>	4	PA,QL(1.2 per 30 days)
ARANESP (IN POLYSORBATE) 200 MCG/0.4 ML SYRINGE <b>DL</b>	4	PA,QL(1.6 per 30 days)
ARANESP (IN POLYSORBATE) 25 MCG/0.42 ML SYRINGE <b>MO</b>	3	PA,QL(1.68 per 30 days)
ARANESP (IN POLYSORBATE) 25 MCG/ML, 40 MCG/ML SOLUTION <b>MO</b>	3	PA,QL(4 per 30 days)
ARANESP (IN POLYSORBATE) 300 MCG/0.6 ML SYRINGE <b>DL</b>	4	PA,QL(2.4 per 30 days)
ARANESP (IN POLYSORBATE) 500 MCG/ML SYRINGE <b>DL</b>	4	PA,QL(4 per 30 days)
ARANESP (IN POLYSORBATE) 60 MCG/0.3 ML SYRINGE <b>MO</b>	3	PA,QL(1.2 per 30 days)
ARIXTRA 10 MG/0.8 ML SYRINGE <b>DL</b>	4	PA,QL(24 per 30 days)
ARIXTRA 2.5 MG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(15 per 30 days)
ARIXTRA 5 MG/0.4 ML SYRINGE <b>DL</b>	4	PA,QL(12 per 30 days)
ARIXTRA 7.5 MG/0.6 ML SYRINGE <b>DL</b>	4	PA,QL(18 per 30 days)
aspirin-dipyridamole 25-200 mg CAPSULE ER MULTIPHASE 12 HR. <b>MO</b>	1	ST,QL(60 per 30 days)
BRILINTA 60 MG, 90 MG TABLET <b>MO</b>	2	QL(60 per 30 days)
CABLIVI 11 MG KIT <b>DL</b>	4	PA,QL(30 per 30 days)
cilostazol 100 mg, 50 mg TABLET <b>MO</b>	1	
clopidogrel 300 mg TABLET <b>MO</b>	1	
clopidogrel 75 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
CYKLOKAPRON 1,000 MG/10 ML (100 MG/ML) SOLUTION <b>DL</b>	4	PA
dabigatran etexilate 110 mg, 150 mg, 75 mg CAPSULE <b>MO</b>	1	QL(60 per 30 days)
dipyridamole 25 mg, 50 mg, 75 mg TABLET <b>MO</b>	1	
DOPTELET (10 TAB PACK) 20 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
DOPTELET (15 TAB PACK) 20 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
DOPTELET (30 TAB PACK) 20 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EFFIENT 10 MG, 5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
ELIQUIS 2.5 MG TABLET <b>MO</b>	2	QL(60 per 30 days)
ELIQUIS 5 MG TABLET <b>MO</b>	2	QL(74 per 30 days)
ELIQUIS DVT-PE TREAT 30D START 5 MG (74 TABS) TABLET, DOSE PACK <b>MO</b>	2	QL(74 per 30 days)
enoxaparin 100 mg/ml, 120 mg/0.8 ml, 150 mg/ml, 30 mg/0.3 ml, 40 mg/0.4 ml, 60 mg/0.6 ml, 80 mg/0.8 ml SYRINGE <b>MO</b>	1	
enoxaparin 300 mg/3 ml SOLUTION <b>MO</b>	1	
EPOGEN 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML SOLUTION <b>MO</b>	3	PA,QL(14 per 30 days)
EPOGEN 20,000 UNIT/2 ML SOLUTION <b>MO</b>	3	PA,QL(28 per 30 days)
eptifibatide 0.75 mg/ml, 2 mg/ml SOLUTION <b>MO</b>	1	
fondaparinux 10 mg/0.8 ml SYRINGE <b>DL</b>	4	QL(24 per 30 days)
fondaparinux 2.5 mg/0.5 ml SYRINGE <b>DL</b>	4	QL(15 per 30 days)
fondaparinux 5 mg/0.4 ml SYRINGE <b>DL</b>	4	QL(12 per 30 days)
fondaparinux 7.5 mg/0.6 ml SYRINGE <b>DL</b>	4	QL(18 per 30 days)
FRAGMIN 10,000 ANTI-XA UNIT/ML SYRINGE <b>DL</b>	4	QL(30 per 30 days)
FRAGMIN 12,500 ANTI-XA UNIT/0.5 ML SYRINGE <b>DL</b>	4	QL(15 per 30 days)
FRAGMIN 15,000 ANTI-XA UNIT/0.6 ML SYRINGE <b>DL</b>	4	QL(18 per 30 days)
FRAGMIN 18,000 ANTI-XA UNIT/0.72 ML SYRINGE <b>DL</b>	4	QL(21.6 per 30 days)
FRAGMIN 2,500 ANTI-XA UNIT/0.2 ML, 5,000 ANTI-XA UNIT/0.2 ML SYRINGE <b>DL</b>	4	QL(6 per 30 days)
FRAGMIN 2,500 ANTI-XA UNIT/ML SOLUTION <b>DL</b>	4	QL(120 per 30 days)
FRAGMIN 25,000 ANTI-XA UNIT/ML SOLUTION <b>DL</b>	4	QL(22.8 per 30 days)
FRAGMIN 7,500 ANTI-XA UNIT/0.3 ML SYRINGE <b>DL</b>	4	QL(9 per 30 days)
FULPHILA 6 MG/0.6 ML SYRINGE <b>DL</b>	4	PA,QL(1.2 per 28 days)
FYLNETRA 6 MG/0.6 ML SYRINGE <b>DL</b>	4	PA,QL(1.2 per 28 days)
GRANIX 300 MCG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(7 per 28 days)
GRANIX 300 MCG/ML SOLUTION <b>DL</b>	4	PA,QL(14 per 28 days)
GRANIX 480 MCG/0.8 ML SYRINGE <b>DL</b>	4	PA,QL(11.2 per 28 days)
GRANIX 480 MCG/1.6 ML SOLUTION <b>DL</b>	4	PA,QL(22.4 per 28 days)
heparin (porcine) 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml SOLUTION <b>MO</b>	1	
heparin (porcine) 5,000 unit/ml (1 ml) CARTRIDGE <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
heparin (porcine) 5,000 unit/ml SYRINGE <b>MO</b>	1	
heparin, porcine (pf) 1,000 unit/ml, 5,000 unit/0.5 ml SOLUTION <b>MO</b>	1	
heparin, porcine (pf) 5,000 unit/0.5 ml, 5,000 unit/ml SYRINGE <b>MO</b>	1	
jantoven 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg TABLET <b>MO</b>	1	
KENREAL 50 MG RECON SOLUTION <b>DL</b>	4	
LEUKINE 250 MCG RECON SOLUTION <b>DL</b>	4	PA
LOVENOX 100 MG/ML, 120 MG/0.8 ML, 150 MG/ML, 30 MG/0.3 ML, 40 MG/0.4 ML, 60 MG/0.6 ML, 80 MG/0.8 ML SYRINGE <b>DL</b>	4	PA
LOVENOX 300 MG/3 ML SOLUTION <b>DL</b>	4	PA
LYSTEDA 650 MG TABLET <b>MO</b>	3	QL(30 per 5 days)
MOZOBIL 24 MG/1.2 ML (20 MG/ML) SOLUTION <b>DL</b>	4	PA,QL(9.6 per 30 days)
MULPLETA 3 MG TABLET <b>DL</b>	4	PA
NEULASTA 6 MG/0.6 ML SYRINGE <b>DL</b>	4	PA,QL(1.2 per 28 days)
NEULASTA ONPRO 6 MG/0.6 ML SYRINGE W/WEARABLE INJECTOR <b>DL</b>	4	PA,QL(1.2 per 28 days)
NEUPOGEN 300 MCG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(7 per 30 days)
NEUPOGEN 300 MCG/ML SOLUTION <b>DL</b>	4	PA,QL(14 per 30 days)
NEUPOGEN 480 MCG/0.8 ML SYRINGE <b>DL</b>	4	PA,QL(11.2 per 30 days)
NEUPOGEN 480 MCG/1.6 ML SOLUTION <b>DL</b>	4	PA,QL(22.4 per 30 days)
NIVESTYM 300 MCG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(7 per 30 days)
NIVESTYM 300 MCG/ML SOLUTION <b>DL</b>	4	PA,QL(14 per 30 days)
NIVESTYM 480 MCG/0.8 ML SYRINGE <b>DL</b>	4	PA,QL(11.2 per 30 days)
NIVESTYM 480 MCG/1.6 ML SOLUTION <b>DL</b>	4	PA,QL(22.4 per 30 days)
NYVEPRIA 6 MG/0.6 ML SYRINGE <b>DL</b>	4	PA,QL(1.2 per 28 days)
PLAVIX 75 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
plerixafor 24 mg/1.2 ml (20 mg/ml) SOLUTION <b>DL</b>	4	PA,QL(9.6 per 30 days)
PRADAXA 110 MG, 150 MG, 75 MG CAPSULE <b>MO</b>	3	QL(60 per 30 days)
PRADAXA 110 MG, 30 MG, 40 MG, 50 MG PELLETS IN PACKET <b>DL</b>	4	PA,QL(120 per 30 days)
PRADAXA 150 MG, 20 MG PELLETS IN PACKET <b>DL</b>	4	PA,QL(60 per 30 days)
prasugrel 10 mg, 5 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
PROCRIT 10,000 UNIT/ML SOLUTION <b>MO</b>	3	PA,QL(14 per 30 days)
PROCRIT 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML SOLUTION <b>MO</b>	3	PA,QL(14 per 30 days)
PROCRIT 20,000 UNIT/2 ML SOLUTION <b>DL</b>	3	PA,QL(28 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROCRIT 20,000 UNIT/ML, 40,000 UNIT/ML SOLUTION <b>DL</b>	3	PA,QL(14 per 30 days)
PROMACTA 12.5 MG POWDER IN PACKET <b>DL,LA</b>	4	PA,QL(360 per 30 days)
PROMACTA 12.5 MG, 75 MG TABLET <b>DL,LA</b>	4	PA,QL(60 per 30 days)
PROMACTA 25 MG POWDER IN PACKET <b>DL,LA</b>	4	PA,QL(180 per 30 days)
PROMACTA 25 MG TABLET <b>DL,LA</b>	4	PA,QL(30 per 30 days)
PROMACTA 50 MG TABLET <b>DL,LA</b>	4	PA,QL(90 per 30 days)
PYRUKYND 20 MG (7)- 5 MG (7), 50 MG (7)- 20 MG (7) TABLET, DOSE PACK <b>DL</b>	4	PA,QL(14 per 14 days)
PYRUKYND 20 MG, 5 MG, 50 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
REBLOZYL 25 MG, 75 MG RECON SOLUTION <b>DL</b>	4	PA
RELEUKO 300 MCG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(7 per 30 days)
RELEUKO 300 MCG/ML SOLUTION <b>DL</b>	4	PA,QL(14 per 30 days)
RELEUKO 480 MCG/0.8 ML SYRINGE <b>DL</b>	4	PA,QL(11.2 per 30 days)
RELEUKO 480 MCG/1.6 ML SOLUTION <b>DL</b>	4	PA,QL(22.4 per 30 days)
RETACRIT 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML SOLUTION <b>MO</b>	3	PA,QL(14 per 30 days)
RIASTAP 1 GRAM (900MG-1,300MG) RECON SOLUTION <b>MO</b>	3	
ROLVEDON 13.2 MG/0.6 ML SYRINGE <b>DL</b>	4	PA,QL(1.2 per 28 days)
SAVAYSA 15 MG, 30 MG, 60 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
STIMUFEND 6 MG/0.6 ML SYRINGE <b>DL</b>	4	PA,QL(1.2 per 28 days)
TAVALISSE 100 MG, 150 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
<i>tirofiban-0.9% sodium chloride 12.5 mg/250 ml (50 mcg/ml), 5 mg/100 ml (50 mcg/ml) SOLUTION <b>MO</b></i>	1	
<i>tranexamic acid 1,000 mg/10 ml (100 mg/ml) SOLUTION <b>MO</b></i>	1	PA
<i>tranexamic acid 650 mg TABLET <b>MO</b></i>	1	QL(30 per 5 days)
UDENYCA 6 MG/0.6 ML SYRINGE <b>DL</b>	4	PA,QL(1.2 per 28 days)
UDENYCA AUTOINJECTOR 6 MG/0.6 ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(1.2 per 28 days)
UDENYCA ONBODY 6 MG/0.6 ML SYRINGE W/WEARABLE INJECTOR <b>DL</b>	4	PA,QL(1.2 per 28 days)
<i>warfarin 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 6 mg, 7.5 mg TABLET <b>MO</b></i>	1	
<i>warfarin 5 mg TABLET <b>MO</b></i>	1	
XARELTO 1 MG/ML SUSPENSION FOR RECONSTITUTION <b>MO</b>	2	ST,QL(600 per 30 days)
XARELTO 10 MG, 20 MG TABLET <b>MO</b>	2	QL(30 per 30 days)
XARELTO 15 MG, 2.5 MG TABLET <b>MO</b>	2	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
XARELTO DVT-PE TREAT 30D START 15 MG (42)- 20 MG (9) TABLET, DOSE PACK <b>MO</b>	2	QL(51 per 30 days)
YOSPRALA 325-40 MG, 81-40 MG TABLET, IR, DR, BIPHASIC <b>MO</b>	3	PA,QL(30 per 30 days)
ZARXIO 300 MCG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(7 per 30 days)
ZARXIO 480 MCG/0.8 ML SYRINGE <b>DL</b>	4	PA,QL(11.2 per 30 days)
ZIEXTENZO 6 MG/0.6 ML SYRINGE <b>DL</b>	4	PA,QL(1.2 per 28 days)
ZONTIVITY 2.08 MG TABLET <b>MO</b>	3	QL(30 per 30 days)
<b>CARDIOVASCULAR AGENTS</b>		
ACCUPRIL 10 MG, 20 MG, 40 MG, 5 MG TABLET <b>MO</b>	3	
ACCURETIC 10-12.5 MG, 20-12.5 MG, 20-25 MG TABLET <b>MO</b>	3	
acebutolol 200 mg, 400 mg CAPSULE <b>MO</b>	1	
acetazolamide 125 mg, 250 mg TABLET <b>MO</b>	1	
acetazolamide 500 mg CAPSULE, ER <b>MO</b>	1	
acetazolamide sodium 500 mg RECON SOLUTION <b>MO</b>	1	
adenosine 3 mg/ml SOLUTION <b>MO</b>	1	
adenosine 3 mg/ml SYRINGE <b>MO</b>	1	
ALDACTAZIDE 25-25 MG, 50-50 MG TABLET <b>MO</b>	3	
ALDACTONE 100 MG, 25 MG, 50 MG TABLET <b>MO</b>	3	
aliskiren 150 mg, 300 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
ALTACE 1.25 MG, 10 MG, 2.5 MG, 5 MG CAPSULE <b>MO</b>	3	PA
ALTOPREV 20 MG, 40 MG, 60 MG TABLET, ER 24 HR. <b>DL</b>	4	ST,QL(30 per 30 days)
amiloride 5 mg TABLET <b>MO</b>	1	
amiloride-hydrochlorothiazide 5-50 mg TABLET <b>MO</b>	1	
amiodarone 100 mg TABLET <b>MO</b>	1	
amiodarone 150 mg/3 ml SYRINGE <b>MO</b>	1	
amiodarone 200 mg TABLET <b>MO</b>	1	
amiodarone 400 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
amiodarone 50 mg/ml SOLUTION <b>MO</b>	1	
amlodipine 10 mg, 2.5 mg, 5 mg TABLET <b>MO</b>	1	
amlodipine-atorvastatin 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
amlodipine-benazepril 10-20 mg, 2.5-10 mg, 5-10 mg, 5-20 mg CAPSULE <b>MO</b>	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
amlodipine-benazepril 10-40 mg, 5-40 mg CAPSULE <b>MO</b>	1	QL(30 per 30 days)
amlodipine-olmesartan 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
amlodipine-valsartan 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
amlodipine-valsartan-hcthiamid 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
ASPRUZYO SPRINKLE 1,000 MG, 500 MG ER GRANULES, PACKET <b>MO</b>	3	QL(60 per 30 days)
ATACAND 16 MG, 4 MG, 8 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
ATACAND 32 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
ATACAND HCT 16-12.5 MG, 32-12.5 MG, 32-25 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
atenolol 100 mg TABLET <b>MO</b>	1	
atenolol 25 mg, 50 mg TABLET <b>MO</b>	1	
atenolol-chlorthalidone 100-25 mg, 50-25 mg TABLET <b>MO</b>	1	
ATORVALIQ 20 MG/5 ML (4 MG/ML) SUSPENSION <b>MO</b>	3	ST,QL(600 per 30 days)
atorvastatin 10 mg, 20 mg, 40 mg, 80 mg TABLET <b>MO</b>	1	
AVALIDE 150-12.5 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
AVALIDE 300-12.5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
AVAPRO 150 MG, 300 MG, 75 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
AZOR 10-20 MG, 10-40 MG, 5-20 MG, 5-40 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
benazepril 10 mg, 20 mg, 40 mg, 5 mg TABLET <b>MO</b>	1	
benazepril-hydrochlorothiazide 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg TABLET <b>MO</b>	1	
BENICAR 20 MG, 40 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
BENICAR 5 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
BENICAR HCT 20-12.5 MG, 40-12.5 MG, 40-25 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
BETAPACE 120 MG, 160 MG, 240 MG, 80 MG TABLET <b>DL</b>	4	PA
BETAPACE AF 120 MG, 160 MG, 80 MG TABLET <b>DL</b>	4	PA
betaxolol 10 mg, 20 mg TABLET <b>MO</b>	1	
BIDIL 20-37.5 MG TABLET <b>MO</b>	3	PA,QL(180 per 30 days)
BIORPHEN 0.1 MG/ML SOLUTION <b>MO</b>	3	
bisoprolol fumarate 10 mg, 5 mg TABLET <b>MO</b>	1	
bisoprolol-hydrochlorothiazide 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg TABLET <b>MO</b>	1	
bretylum tosylate 50 mg/ml SOLUTION <b>MO</b>	1	
BREVIBLOC 100 MG/10 ML (10 MG/ML) SOLUTION <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BREVIBLOC IN NACL (ISO-OSM) 2,000 MG/100 ML, 2,500 MG/250 ML (10 MG/ML) PARENTERAL SOLUTION <b>MO</b>	3	
<i>bumetanide 0.25 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>bumetanide 0.5 mg, 2 mg TABLET</i> <b>MO</b>	1	
<i>bumetanide 1 mg TABLET</i> <b>MO</b>	1	
BYSTOLIC 10 MG TABLET <b>MO</b>	3	PA,QL(120 per 30 days)
BYSTOLIC 2.5 MG, 5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
BYSTOLIC 20 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
CADUET 10-10 MG, 10-20 MG, 10-40 MG, 10-80 MG, 5-10 MG, 5-20 MG, 5-40 MG, 5-80 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
CALAN SR 120 MG, 240 MG TABLET ER <b>MO</b>	3	
CAMZYOS 10 MG, 15 MG, 2.5 MG, 5 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
<i>candesartan 16 mg, 4 mg, 8 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
<i>candesartan 32 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>candesartan-hydrochlorothiazid 16-12.5 mg, 32-12.5 mg, 32-25 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>captopril 100 mg, 12.5 mg, 25 mg, 50 mg TABLET</i> <b>MO</b>	1	
<i>captopril-hydrochlorothiazide 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg TABLET</i> <b>MO</b>	1	
CARDIZEM 120 MG, 30 MG, 60 MG TABLET <b>MO</b>	3	
CARDIZEM CD 120 MG, 180 MG, 240 MG CAPSULE, ER 24 HR. <b>DL</b>	4	PA,QL(60 per 30 days)
CARDIZEM CD 300 MG, 360 MG CAPSULE, ER 24 HR. <b>DL</b>	4	PA,QL(30 per 30 days)
CARDIZEM LA 120 MG, 300 MG, 360 MG, 420 MG TABLET, ER 24 HR. <b>MO</b>	3	QL(30 per 30 days)
CARDIZEM LA 180 MG, 240 MG TABLET, ER 24 HR. <b>MO</b>	3	QL(60 per 30 days)
CARDURA 1 MG, 2 MG, 4 MG, 8 MG TABLET <b>MO</b>	3	
CARDURA XL 4 MG, 8 MG TABLET, ER 24 HR. <b>MO</b>	3	QL(30 per 30 days)
CAROSPIR 25 MG/5 ML SUSPENSION <b>MO</b>	3	PA,QL(450 per 30 days)
<i>cartia xt 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR.</i> <b>MO</b>	1	QL(60 per 30 days)
<i>cartia xt 300 mg CAPSULE, ER 24 HR.</i> <b>MO</b>	1	QL(30 per 30 days)
<i>carvedilol 12.5 mg, 25 mg, 3.125 mg, 6.25 mg TABLET</i> <b>MO</b>	1	
<i>carvedilol phosphate 10 mg, 20 mg, 40 mg, 80 mg CAPSULE ER MULTIPHASE 24 HR.</i> <b>MO</b>	1	QL(30 per 30 days)
CATAPRES-TTS-1 0.1 MG/24 HR PATCH, WEEKLY <b>MO</b>	3	PA,QL(4 per 28 days)
CATAPRES-TTS-2 0.2 MG/24 HR PATCH, WEEKLY <b>MO</b>	3	PA,QL(4 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CATAPRES-TTS-3 0.3 MG/24 HR PATCH, WEEKLY <b>MO</b>	3	PA,QL(4 per 28 days)
chlorothiazide sodium 500 mg RECON SOLUTION <b>MO</b>	1	
chlorthalidone 25 mg TABLET <b>MO</b>	1	
chlorthalidone 50 mg TABLET <b>MO</b>	1	
cholestyramine (with sugar) 4 gram POWDER <b>MO</b>	1	
cholestyramine (with sugar) 4 gram POWDER IN PACKET <b>MO</b>	1	
cholestyramine light 4 gram POWDER <b>MO</b>	1	
cholestyramine light 4 gram POWDER IN PACKET <b>MO</b>	1	
cholestyramine-aspartame 4 gram POWDER IN PACKET <b>MO</b>	1	
CLEVIPREX 25 MG/50 ML, 50 MG/100 ML EMULSION <b>MO</b>	3	
clonidine 0.1 mg/24 hr, 0.2 mg/24 hr, 0.3 mg/24 hr PATCH, WEEKLY <b>MO</b>	1	QL(4 per 28 days)
clonidine hcl 0.1 mg TABLET <b>MO</b>	1	
clonidine hcl 0.17 mg TABLET, ER 24 HR. <b>DL</b>	4	PA,QL(90 per 30 days)
clonidine hcl 0.2 mg, 0.3 mg TABLET <b>MO</b>	1	
colesevelam 3.75 gram POWDER IN PACKET <b>MO</b>	1	QL(30 per 30 days)
colesevelam 625 mg TABLET <b>MO</b>	1	QL(180 per 30 days)
COLESTID 1 GRAM TABLET <b>MO</b>	3	
COLESTID 5 GRAM GRANULES <b>MO</b>	3	QL(1000 per 30 days)
COLESTID 5 GRAM PACKET <b>MO</b>	3	
COLESTID FLAVORED 5 GRAM GRANULES <b>MO</b>	3	QL(1000 per 30 days)
COLESTID FLAVORED 7.5 GRAM PACKET <b>MO</b>	3	
colestipol 1 gram TABLET <b>MO</b>	1	
colestipol 5 gram GRANULES <b>MO</b>	1	QL(1000 per 30 days)
colestipol 5 gram PACKET <b>MO</b>	1	
CONJUPRI 2.5 MG, 5 MG TABLET <b>MO</b>	3	QL(30 per 30 days)
COREG 12.5 MG, 25 MG, 3.125 MG, 6.25 MG TABLET <b>MO</b>	3	PA
COREG CR 10 MG, 20 MG, 40 MG, 80 MG CAPSULE ER MULTIPHASE 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
CORGARD 20 MG, 40 MG, 80 MG TABLET <b>MO</b>	3	PA
CORLANOR 5 MG, 7.5 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
CORLANOR 5 MG/5 ML SOLUTION <b>MO</b>	3	PA,QL(560 per 28 days)
CORLOPAM 10 MG/ML SOLUTION <b>MO</b>	3	
CORVERT 0.1 MG/ML SOLUTION <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
COZAAR 100 MG, 25 MG, 50 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
CRESTOR 10 MG, 20 MG, 40 MG, 5 MG TABLET <b>MO</b>	3	PA
DEMSER 250 MG CAPSULE <b>DL</b>	4	
DIBENZYLIN 10 MG CAPSULE <b>DL</b>	4	
digitek 125 mcg (0.125 mg), 250 mcg (0.25 mg) TABLET <b>MO</b>	1	QL(30 per 30 days)
digox 125 mcg (0.125 mg), 250 mcg (0.25 mg) TABLET <b>MO</b>	1	QL(30 per 30 days)
digoxin 125 mcg (0.125 mg) TABLET <b>MO</b>	1	QL(30 per 30 days)
digoxin 250 mcg (0.25 mg), 62.5 mcg (0.0625 mg) TABLET <b>MO</b>	1	QL(30 per 30 days)
digoxin 250 mcg/ml (0.25 mg/ml), 50 mcg/ml (0.05 mg/ml) SOLUTION <b>MO</b>	1	
dilt-xr 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
diltiazem hcl 100 mg RECON SOLUTION <b>MO</b>	1	
diltiazem hcl 120 mg CAPSULE, ER 12 HR. <b>MO</b>	1	QL(90 per 30 days)
diltiazem hcl 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
diltiazem hcl 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
diltiazem hcl 120 mg, 30 mg, 60 mg, 90 mg TABLET <b>MO</b>	1	
diltiazem hcl 120 mg, 300 mg, 360 mg, 420 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
diltiazem hcl 180 mg, 240 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
diltiazem hcl 300 mg, 360 mg, 420 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
diltiazem hcl 5 mg/ml SOLUTION <b>MO</b>	1	
diltiazem hcl 60 mg, 90 mg CAPSULE, ER 12 HR. <b>MO</b>	1	QL(180 per 30 days)
DIOVAN 160 MG, 320 MG, 40 MG, 80 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
DIOVAN HCT 160-12.5 MG, 160-25 MG, 320-12.5 MG, 320-25 MG, 80-12.5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
disopyramide phosphate 100 mg, 150 mg CAPSULE <b>MO</b>	1	
DIURIL 250 MG/5 ML SUSPENSION <b>MO</b>	3	
dobutamine 250 mg/20 ml (12.5 mg/ml) SOLUTION <b>MO</b>	1	BvsD
dobutamine in d5w 1,000 mg/250 ml (4,000 mcg/ml), 250 mg/250 ml (1 mg/ml), 500 mg/250 ml (2,000 mcg/ml) PARENTERAL SOLUTION <b>MO</b>	1	BvsD
dofetilide 125 mcg, 250 mcg, 500 mcg CAPSULE <b>MO</b>	1	
dopamine 200 mg/5 ml (40 mg/ml), 400 mg/10 ml (40 mg/ml), 400 mg/5 ml (80 mg/ml), 800 mg/10 ml (80 mg/ml), 800 mg/5 ml (160 mg/ml) SOLUTION <b>MO</b>	1	BvsD

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
dopamine in 5 % dextrose 200 mg/250 ml (800 mcg/ml), 400 mg/250 ml (1,600 mcg/ml), 400 mg/500 ml (800 mcg/ml), 800 mg/250 ml (3,200 mcg/ml), 800 mg/500 ml (1,600 mcg/ml) SOLUTION <b>MO</b>	1	BvsD
doxazosin 1 mg, 2 mg, 4 mg, 8 mg TABLET <b>MO</b>	1	
droxidopa 100 mg, 200 mg CAPSULE <b>MO</b>	1	PA,QL(90 per 30 days)
droxidopa 300 mg CAPSULE <b>MO</b>	1	PA,QL(180 per 30 days)
DYRENIUM 100 MG, 50 MG CAPSULE <b>MO</b>	3	
EDARBI 40 MG, 80 MG TABLET <b>MO</b>	3	ST,QL(30 per 30 days)
EDARBYCLOR 40-12.5 MG, 40-25 MG TABLET <b>MO</b>	3	ST,QL(30 per 30 days)
EDECIN 25 MG TABLET <b>DL</b>	4	QL(480 per 30 days)
enalapril maleate 1 mg/ml SOLUTION <b>MO</b>	1	
enalapril maleate 10 mg, 2.5 mg, 20 mg, 5 mg TABLET <b>MO</b>	1	
enalapril-hydrochlorothiazide 10-25 mg, 5-12.5 mg TABLET <b>MO</b>	1	
enalaprilat 1.25 mg/ml SOLUTION <b>MO</b>	1	
ENTRESTO 24-26 MG, 49-51 MG, 97-103 MG TABLET <b>MO</b>	2	QL(60 per 30 days)
EPANED 1 MG/ML SOLUTION <b>DL</b>	4	
eplerenone 25 mg, 50 mg TABLET <b>MO</b>	1	PA
eprosartan 600 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
esmolol 100 mg/10 ml (10 mg/ml) SOLUTION <b>MO</b>	1	
esmolol in nacl (iso-osm) 2,000 mg/100 ml, 2,500 mg/250 ml (10 mg/ml) PARENTERAL SOLUTION <b>MO</b>	1	
ethacrynate sodium 50 mg RECON SOLUTION <b>MO</b>	1	
ethacrynic acid 25 mg TABLET <b>MO</b>	1	QL(480 per 30 days)
EVKEEZA 150 MG/ML SOLUTION <b>DL</b>	4	PA
EXFORGE 10-160 MG, 10-320 MG, 5-160 MG, 5-320 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
EXFORGE HCT 10-160-12.5 MG, 10-160-25 MG, 10-320-25 MG, 5-160-12.5 MG, 5-160-25 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
EZALLOR SPRINKLE 10 MG, 20 MG, 40 MG, 5 MG CAPSULE, SPRINKLE <b>MO</b>	3	ST,QL(30 per 30 days)
ezetimibe 10 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
ezetimibe-atorvastatin 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg TABLET <b>MO</b>	1	ST,QL(30 per 30 days)
ezetimibe-rosuvastatin 10-10 mg, 10-20 mg, 10-40 mg, 10-5 mg TABLET <b>MO</b>	3	ST,QL(30 per 30 days)
ezetimibe-simvastatin 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
felodipine 10 mg, 2.5 mg, 5 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>fenofibrate 120 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>fenofibrate 150 mg CAPSULE</i> <b>MO</b>	1	QL(30 per 30 days)
<i>fenofibrate 160 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>fenofibrate 40 mg, 54 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
<i>fenofibrate 50 mg CAPSULE</i> <b>MO</b>	1	QL(60 per 30 days)
<i>fenofibrate micronized 130 mg, 43 mg CAPSULE</i> <b>MO</b>	1	ST,QL(30 per 30 days)
<i>fenofibrate micronized 134 mg, 200 mg CAPSULE</i> <b>MO</b>	1	QL(30 per 30 days)
<i>fenofibrate micronized 30 mg, 90 mg CAPSULE</i> <b>MO</b>	3	QL(30 per 30 days)
<i>fenofibrate micronized 67 mg CAPSULE</i> <b>MO</b>	1	QL(60 per 30 days)
<i>fenofibrate nanocrystallized 145 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>fenofibrate nanocrystallized 48 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
<i>fenofibric acid 105 mg, 35 mg TABLET</i> <b>MO</b>	2	QL(30 per 30 days)
<i>fenofibric acid (choline) 135 mg, 45 mg CAPSULE, DR/EC</i> <b>MO</b>	1	QL(30 per 30 days)
FENOGLIDE 120 MG TABLET <b>MO</b>	3	QL(30 per 30 days)
FENOGLIDE 40 MG TABLET <b>MO</b>	3	QL(60 per 30 days)
FIBRICOR 105 MG, 35 MG TABLET <b>MO</b>	3	QL(30 per 30 days)
<i>flecainide 100 mg, 150 mg, 50 mg TABLET</i> <b>MO</b>	1	
FLOLIPID 20 MG/5 ML (4 MG/ML), 40 MG/5 ML (8 MG/ML) SUSPENSION <b>MO</b>	3	ST,QL(150 per 30 days)
<i>fluvastatin 20 mg, 40 mg CAPSULE</i> <b>MO</b>	1	ST,QL(60 per 30 days)
<i>fluvastatin 80 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	ST,QL(30 per 30 days)
<i>fosinopril 10 mg, 20 mg, 40 mg TABLET</i> <b>MO</b>	1	
<i>fosinopril-hydrochlorothiazide 10-12.5 mg, 20-12.5 mg TABLET</i> <b>MO</b>	1	
FUROSCIX 80 MG/10 ML KIT <b>MO</b>	3	PA
<i>furosemide 10 mg/ml SYRINGE</i> <b>MO</b>	1	
<i>furosemide 10 mg/ml, 40 mg/5 ml (8 mg/ml) SOLUTION</i> <b>MO</b>	1	
<i>furosemide 20 mg, 40 mg TABLET</i> <b>MO</b>	1	
<i>furosemide 80 mg TABLET</i> <b>MO</b>	1	
<i>gemfibrozil 600 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
GONITRO 400 MCG POWDER IN PACKET <b>MO</b>	3	
<i>guanfacine 1 mg TABLET</i> <b>MO</b>	1	
<i>guanfacine 2 mg TABLET</i> <b>MO</b>	1	
HEMANGEOL 4.28 MG/ML SOLUTION <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
hydralazine 10 mg, 100 mg TABLET <b>MO</b>	1	
hydralazine 20 mg/ml SOLUTION <b>MO</b>	1	
hydralazine 25 mg, 50 mg TABLET <b>MO</b>	1	
hydrochlorothiazide 12.5 mg CAPSULE <b>MO</b>	1	
hydrochlorothiazide 12.5 mg, 25 mg TABLET <b>MO</b>	1	
hydrochlorothiazide 50 mg TABLET <b>MO</b>	1	
HYZAAR 100-12.5 MG, 100-25 MG, 50-12.5 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
ibutilide fumarate 0.1 mg/ml SOLUTION <b>MO</b>	1	
IMMPHENTIV 0.1 MG/ML SOLUTION <b>MO</b>	3	
indapamide 1.25 mg, 2.5 mg TABLET <b>MO</b>	1	
INDERAL LA 120 MG, 160 MG, 60 MG, 80 MG CAPSULE, ER 24 HR. <b>DL</b>	4	PA
INNOPRAN XL 120 MG, 80 MG CAPSULE, ER 24 HR.	4	
INSPRA 25 MG, 50 MG TABLET <b>MO</b>	3	PA
irbesartan 150 mg, 75 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
irbesartan 300 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
irbesartan-hydrochlorothiazide 150-12.5 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
irbesartan-hydrochlorothiazide 300-12.5 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
ISORDIL 40 MG TABLET <b>DL</b>	4	
ISORDIL TITRADOSE 5 MG TABLET <b>DL</b>	4	PA
isosorbide dinitrate 10 mg, 20 mg, 30 mg, 40 mg, 5 mg TABLET <b>MO</b>	1	
isosorbide mononitrate 10 mg, 20 mg TABLET <b>MO</b>	1	
isosorbide mononitrate 120 mg TABLET, ER 24 HR. <b>MO</b>	1	
isosorbide mononitrate 30 mg, 60 mg TABLET, ER 24 HR. <b>MO</b>	1	
isosorbide-hydralazine 20-37.5 mg TABLET <b>MO</b>	1	QL(180 per 30 days)
isradipine 2.5 mg, 5 mg CAPSULE <b>MO</b>	1	
ISUPREL 0.2 MG/ML SOLUTION <b>MO</b>	3	
JUXTAPID 10 MG, 30 MG, 5 MG CAPSULE <b>DL</b>	4	PA,QL(28 per 28 days)
JUXTAPID 20 MG CAPSULE <b>DL</b>	4	PA,QL(84 per 28 days)
KAPSPARGO SPRINKLE 100 MG, 25 MG, 50 MG CAPSULE ER SPRINKLE 24 HR. <b>MO</b>	3	ST,QL(30 per 30 days)
KAPSPARGO SPRINKLE 200 MG CAPSULE ER SPRINKLE 24 HR. <b>MO</b>	3	ST,QL(60 per 30 days)
KATERZIA 1 MG/ML SUSPENSION <b>MO</b>	3	ST,QL(300 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
KERENDIA 10 MG, 20 MG TABLET <b>MO</b>	2	PA,QL(30 per 30 days)
<i>labetalol 100 mg, 200 mg, 300 mg TABLET <b>MO</b></i>	1	
<i>labetalol 5 mg/ml SOLUTION <b>MO</b></i>	1	
LABELALOL IN DEXTROSE,ISO-OSM 1 MG/ML SOLUTION <b>MO</b>	1	
LABELALOL IN NACL (ISO-OSMOT) 1 MG/ ML SOLUTION <b>MO</b>	1	
LANOXIN 125 MCG (0.125 MG), 250 MCG (0.25 MG), 62.5 MCG (0.0625 MG) TABLET <b>MO</b>	3	QL(30 per 30 days)
LANOXIN 250 MCG/ML (0.25 MG/ML), 500 MCG/2 ML (0.5 MG/2 ML) SOLUTION <b>MO</b>	3	
LANOXIN PEDIATRIC 100 MCG/ML (0.1 MG/ML) SOLUTION <b>MO</b>	3	
LASIX 20 MG, 40 MG, 80 MG TABLET <b>MO</b>	3	
LEQVIO 284 MG/1.5 ML SYRINGE	4	PA,QL(4.5 per 365 days)
LESCOL XL 80 MG TABLET, ER 24 HR. <b>MO</b>	3	ST,QL(30 per 30 days)
<i>levamlodipine 2.5 mg, 5 mg TABLET <b>MO</b></i>	3	QL(30 per 30 days)
LEVOPHED (BITARTRATE) 1 MG/ML SOLUTION <b>MO</b>	3	
<i>lidocaine (pf) 20 mg/ml (2 %) SOLUTION <b>MO</b></i>	1	
<i>lidocaine in 5 % dextrose (pf) 4 mg/ml (0.4 %), 8 mg/ml (0.8 %) PARENTERAL SOLUTION <b>MO</b></i>	1	
LIPITOR 10 MG, 20 MG, 40 MG, 80 MG TABLET <b>MO</b>	3	PA
LIPOFEN 150 MG CAPSULE <b>MO</b>	3	QL(30 per 30 days)
LIPOFEN 50 MG CAPSULE <b>MO</b>	3	QL(60 per 30 days)
<i>lisinopril 10 mg, 2.5 mg, 20 mg, 40 mg, 5 mg TABLET <b>MO</b></i>	1	
<i>lisinopril 30 mg TABLET <b>MO</b></i>	1	
<i>lisinopril-hydrochlorothiazide 10-12.5 mg, 20-12.5 mg, 20-25 mg TABLET <b>MO</b></i>	1	
LIVALO 1 MG, 2 MG, 4 MG TABLET <b>MO</b>	3	ST,QL(30 per 30 days)
LODOCO 0.5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
LOPID 600 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
LOPRESSOR 100 MG, 50 MG TABLET <b>MO</b>	3	
<i>losartan 100 mg, 25 mg, 50 mg TABLET <b>MO</b></i>	1	QL(60 per 30 days)
<i>losartan-hydrochlorothiazide 100-12.5 mg, 100-25 mg, 50-12.5 mg TABLET <b>MO</b></i>	1	QL(60 per 30 days)
LOTENSIN 10 MG, 20 MG, 40 MG TABLET <b>MO</b>	3	
LOTENSIN HCT 10-12.5 MG, 20-12.5 MG, 20-25 MG TABLET <b>MO</b>	3	
LOTREL 10-20 MG, 5-10 MG, 5-20 MG CAPSULE <b>MO</b>	3	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LOTREL 10-40 MG CAPSULE <b>MO</b>	3	PA,QL(30 per 30 days)
lovastatin 10 mg TABLET <b>MO</b>	1	
lovastatin 20 mg, 40 mg TABLET <b>MO</b>	1	
LOVAZA 1 GRAM CAPSULE <b>MO</b>	3	PA,QL(120 per 30 days)
mannitol 10 % 10 % PARENTERAL SOLUTION <b>MO</b>	1	
mannitol 20 % 20 % PARENTERAL SOLUTION <b>MO</b>	1	
mannitol 25 % 25 % SOLUTION <b>MO</b>	1	
mannitol 5 % 5 % PARENTERAL SOLUTION <b>MO</b>	1	
matzim la 180 mg, 240 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
matzim la 300 mg, 360 mg, 420 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
MAXZIDE 75-50 MG TABLET <b>MO</b>	3	PA
MAXZIDE-25MG 37.5-25 MG TABLET <b>MO</b>	3	PA
methazolamide 25 mg, 50 mg TABLET <b>MO</b>	1	
methyl dopa 250 mg, 500 mg TABLET <b>MO</b>	1	
methyl dopa-hydrochlorothiazide 250-15 mg, 250-25 mg TABLET <b>MO</b>	1	
methyl dopate 250 mg/5 ml SOLUTION <b>MO</b>	1	
metolazone 10 mg, 2.5 mg, 5 mg TABLET <b>MO</b>	1	
metoprolol succinate 100 mg, 25 mg, 50 mg TABLET, ER 24 HR. <b>MO</b>	1	
metoprolol succinate 200 mg TABLET, ER 24 HR. <b>MO</b>	1	
metoprolol ta-hydrochlorothiaz 100-25 mg, 100-50 mg, 50-25 mg TABLET <b>MO</b>	1	
metoprolol tartrate 100 mg, 25 mg, 50 mg TABLET <b>MO</b>	1	
metoprolol tartrate 37.5 mg, 75 mg TABLET <b>MO</b>	1	
metoprolol tartrate 5 mg/5 ml SOLUTION <b>MO</b>	1	
metyrosine 250 mg CAPSULE <b>DL</b>	4	
mexiletine 150 mg, 200 mg, 250 mg CAPSULE <b>MO</b>	1	
MICARDIS 20 MG, 40 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
MICARDIS 80 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
MICARDIS HCT 40-12.5 MG, 80-25 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
MICARDIS HCT 80-12.5 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
midodrine 10 mg, 2.5 mg, 5 mg TABLET <b>MO</b>	1	
milrinone 1 mg/ml SOLUTION <b>MO</b>	1	BvsD

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>milrinone in 5 % dextrose 20 mg/100 ml (200 mcg/ml), 40 mg/200 ml (200 mcg/ml) PIGGYBACK</i> <b>MO</b>	1	BvsD
MINIPRESS 1 MG, 2 MG, 5 MG CAPSULE <b>MO</b>	3	
<i>minoxidil 10 mg, 2.5 mg TABLET</i> <b>MO</b>	1	
<i>moexipril 15 mg, 7.5 mg TABLET</i> <b>MO</b>	1	
MULTAQ 400 MG TABLET <b>MO</b>	2	QL(60 per 30 days)
<i>nadolol 20 mg, 40 mg, 80 mg TABLET</i> <b>MO</b>	1	
<i>nebivolol 10 mg TABLET</i> <b>MO</b>	1	QL(120 per 30 days)
<i>nebivolol 2.5 mg, 5 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>nebivolol 20 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
NEXICLON XR 0.17 MG TABLET, ER 24 HR. <b>DL</b>	4	PA,QL(90 per 30 days)
NEXLETOL 180 MG TABLET <b>MO</b>	2	PA,QL(30 per 30 days)
NEXLIZET 180-10 MG TABLET <b>MO</b>	2	PA,QL(30 per 30 days)
NEXTERONE 150 MG/100 ML (1.5 MG/ML), 360 MG/200 ML (1.8 MG/ML) SOLUTION <b>MO</b>	3	
<i>niacin 1,000 mg, 500 mg, 750 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	
<i>niacin 500 mg TABLET</i> <b>MO</b>	1	
<i>niacor 500 mg TABLET</i> <b>MO</b>	1	
<i>nicardipine 20 mg, 30 mg CAPSULE</i> <b>MO</b>	1	
<i>nicardipine 25 mg/10 ml SOLUTION</i> <b>MO</b>	1	
<i>nifedipine 10 mg, 20 mg CAPSULE</i> <b>MO</b>	1	
<i>nifedipine 30 mg, 60 mg, 90 mg TABLET ER</i> <b>MO</b>	1	QL(60 per 30 days)
<i>nifedipine 30 mg, 60 mg, 90 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(60 per 30 days)
<i>nimodipine 30 mg CAPSULE</i> <b>MO</b>	1	
<i>nisoldipine 17 mg, 20 mg, 34 mg, 40 mg, 8.5 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(30 per 30 days)
<i>nisoldipine 25.5 mg, 30 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(60 per 30 days)
NITRO-BID 2 % OINTMENT <b>MO</b>	1	
NITRO-DUR 0.1 MG/HR, 0.4 MG/HR PATCH, 24 HR. <b>MO</b>	3	
NITRO-DUR 0.2 MG/HR, 0.3 MG/HR, 0.6 MG/HR, 0.8 MG/HR PATCH, 24 HR.	4	
<i>nitroglycerin 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr PATCH, 24 HR.</i> <b>MO</b>	1	
<i>nitroglycerin 0.3 mg, 0.6 mg SUBLINGUAL TABLET</i> <b>MO</b>	1	
<i>nitroglycerin 0.4 mg SUBLINGUAL TABLET</i> <b>MO</b>	1	
<i>nitroglycerin 400 mcg/spray SPRAY, NON-AEROSOL</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>nitroglycerin 50 mg/10 ml (5 mg/ml) SOLUTION</i> <b>MO</b>	1	
<i>nitroglycerin in 5 % dextrose 100 mg/250 ml (400 mcg/ml), 25 mg/250 ml (100 mcg/ml), 50 mg/250 ml (200 mcg/ml) SOLUTION</i> <b>MO</b>	1	
NITROLINGUAL 400 MCG/SPRAY SPRAY, NON-AEROSOL <b>MO</b>	3	
NITROSTAT 0.3 MG, 0.4 MG, 0.6 MG SUBLINGUAL TABLET <b>MO</b>	2	
<i>norepinephrine bitartrate 1 mg/ml SOLUTION</i> <b>MO</b>	1	
NORLIQVA 1 MG/ML SOLUTION <b>DL</b>	4	ST,QL(300 per 30 days)
NORPACE 100 MG, 150 MG CAPSULE <b>MO</b>	3	
NORPACE CR 100 MG, 150 MG CAPSULE, ER <b>MO</b>	3	
NORTHERA 100 MG, 200 MG CAPSULE <b>DL</b>	4	PA,QL(90 per 30 days)
NORTHERA 300 MG CAPSULE <b>DL</b>	4	PA,QL(180 per 30 days)
NORVASC 10 MG, 2.5 MG, 5 MG TABLET <b>MO</b>	3	PA
NYMALIZE 30 MG/5 ML SYRINGE <b>DL</b>	4	QL(630 per 28 days)
NYMALIZE 60 MG/10 ML SOLUTION <b>DL</b>	4	QL(1260 per 28 days)
NYMALIZE 60 MG/10 ML SYRINGE <b>DL</b>	4	QL(1260 per 28 days)
<i>olmesartan 20 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>olmesartan 40 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>olmesartan 5 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
<i>olmesartan-amlodipin-hcthiazyd 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>olmesartan-hydrochlorothiazide 20-12.5 mg, 40-12.5 mg, 40-25 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>omega-3 acid ethyl esters 1 gram CAPSULE</i> <b>MO</b>	1	QL(120 per 30 days)
OSMITROL 10 % 10 % PARENTERAL SOLUTION <b>MO</b>	3	
OSMITROL 15 % 15 % PARENTERAL SOLUTION <b>MO</b>	3	
OSMITROL 20 % 20 % PARENTERAL SOLUTION <b>MO</b>	3	
OSMITROL 5 % 5 % PARENTERAL SOLUTION <b>MO</b>	3	
PACERONE 100 MG TABLET <b>MO</b>	1	
<i>pacerone 200 mg TABLET</i> <b>MO</b>	1	
PACERONE 400 MG TABLET <b>MO</b>	1	QL(60 per 30 days)
<i>pentoxifylline 400 mg TABLET ER</i> <b>MO</b>	1	
<i>perindopril erbumine 2 mg, 4 mg, 8 mg TABLET</i> <b>MO</b>	1	
<i>phenoxybenzamine 10 mg CAPSULE</i> <b>DL</b>	4	
<i>phenylephrine hcl 10 mg/ml SOLUTION</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>pindolol 10 mg, 5 mg TABLET</i> <b>MO</b>	1	
<i>pitavastatin calcium 1 mg, 2 mg, 4 mg TABLET</i> <b>MO</b>	1	ST,QL(30 per 30 days)
PRALUENT PEN 150 MG/ML, 75 MG/ML PEN INJECTOR <b>MO</b>	3	PA,QL(2 per 28 days)
<i>pravastatin 10 mg, 20 mg, 40 mg, 80 mg TABLET</i> <b>MO</b>	1	
<i>prazosin 1 mg, 2 mg, 5 mg CAPSULE</i> <b>MO</b>	1	
PRESTALIA 14-10 MG, 3.5-2.5 MG, 7-5 MG TABLET <b>MO</b>	3	QL(30 per 30 days)
<i>prevalite 4 gram POWDER</i> <b>MO</b>	1	
<i>prevalite 4 gram POWDER IN PACKET</i> <b>MO</b>	1	
<i>procainamide 100 mg/ml, 500 mg/ml SOLUTION</i> <b>MO</b>	1	
PROCARDIA XL 30 MG, 60 MG, 90 MG TABLET, ER 24 HR. <b>MO</b>	3	PA,QL(60 per 30 days)
<i>propafenone 150 mg, 225 mg, 300 mg TABLET</i> <b>MO</b>	1	
<i>propafenone 225 mg, 325 mg CAPSULE, ER 12 HR.</i> <b>MO</b>	1	QL(60 per 30 days)
<i>propafenone 425 mg CAPSULE, ER 12 HR.</i> <b>MO</b>	1	
<i>propranolol 1 mg/ml, 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml) SOLUTION</i> <b>MO</b>	1	
<i>propranolol 10 mg, 20 mg, 40 mg, 60 mg, 80 mg TABLET</i> <b>MO</b>	1	
<i>propranolol 120 mg, 160 mg, 60 mg, 80 mg CAPSULE, ER 24 HR.</i> <b>MO</b>	1	
<i>propranolol-hydrochlorothiazid 40-25 mg, 80-25 mg TABLET</i> <b>MO</b>	1	
QBRELIS 1 MG/ML SOLUTION <b>DL</b>	4	QL(1200 per 30 days)
QUESTRAN 4 GRAM POWDER <b>MO</b>	1	
QUESTRAN 4 GRAM POWDER IN PACKET <b>MO</b>	1	
QUESTRAN LIGHT 4 GRAM POWDER <b>MO</b>	1	
<i>quinapril 10 mg, 20 mg, 40 mg, 5 mg TABLET</i> <b>MO</b>	1	
<i>quinapril-hydrochlorothiazide 10-12.5 mg, 20-12.5 mg, 20-25 mg TABLET</i> <b>MO</b>	1	
<i>quinidine gluconate 324 mg TABLET ER</i> <b>MO</b>	1	
<i>quinidine sulfate 200 mg, 300 mg TABLET</i> <b>MO</b>	1	
<i>ramipril 1.25 mg, 10 mg, 2.5 mg, 5 mg CAPSULE</i> <b>MO</b>	1	
RANEXA 1,000 MG, 500 MG TABLET, ER 12 HR. <b>MO</b>	3	PA,QL(120 per 30 days)
<i>ranolazine 1,000 mg, 500 mg TABLET, ER 12 HR.</i> <b>MO</b>	1	QL(120 per 30 days)
REPATHA PUSHTRONEX 420 MG/3.5 ML WEARABLE INJECTOR <b>MO</b>	2	PA,QL(3.5 per 28 days)
REPATHA SURECLICK 140 MG/ML PEN INJECTOR <b>MO</b>	2	PA,QL(3 per 28 days)
REPATHA SYRINGE 140 MG/ML SYRINGE <b>MO</b>	2	PA,QL(3 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>rosuvastatin 10 mg, 20 mg, 40 mg, 5 mg TABLET</i> <b>MO</b>	1	
ROSZET 10-10 MG, 10-20 MG, 10-40 MG, 10-5 MG TABLET <b>MO</b>	3	ST,QL(30 per 30 days)
RYTHMOL SR 225 MG, 325 MG CAPSULE, ER 12 HR. <b>MO</b>	3	PA,QL(60 per 30 days)
RYTHMOL SR 425 MG CAPSULE, ER 12 HR. <b>MO</b>	3	PA
<i>simvastatin 10 mg, 20 mg, 40 mg TABLET</i> <b>MO</b>	1	
<i>simvastatin 5 mg, 80 mg TABLET</i> <b>MO</b>	1	
SOAANZ 20 MG, 40 MG, 60 MG TABLET <b>MO</b>	3	ST
SODIUM EDECRIN 50 MG RECON SOLUTION <b>MO</b>	3	
<i>sorine 120 mg, 160 mg, 240 mg, 80 mg TABLET</i> <b>MO</b>	1	
<i>sotalol 120 mg, 160 mg, 240 mg, 80 mg TABLET</i> <b>MO</b>	1	
<i>sotalol 150 mg/10 ml (15 mg/ml) SOLUTION</i> <b>MO</b>	1	
<i>sotalol af 120 mg, 160 mg, 80 mg TABLET</i> <b>MO</b>	1	
SOTYLIZE 5 MG/ML SOLUTION <b>MO</b>	3	
<i>spironolacton-hydrochlorothiaz 25-25 mg TABLET</i> <b>MO</b>	1	
<i>spironolactone 100 mg TABLET</i> <b>MO</b>	1	
<i>spironolactone 25 mg, 50 mg TABLET</i> <b>MO</b>	1	
<i>spironolactone 25 mg/5 ml SUSPENSION</i> <b>MO</b>	3	PA,QL(450 per 30 days)
SULAR 17 MG, 34 MG, 8.5 MG TABLET, ER 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
<i>taztia xt 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR.</i> <b>MO</b>	1	QL(60 per 30 days)
<i>taztia xt 300 mg, 360 mg CAPSULE, ER 24 HR.</i> <b>MO</b>	1	QL(30 per 30 days)
TEKURNA 150 MG, 300 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
TEKURNA HCT 150-12.5 MG, 150-25 MG, 300-12.5 MG, 300-25 MG TABLET <b>MO</b>	3	ST,QL(30 per 30 days)
<i>telmisartan 20 mg, 40 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>telmisartan 80 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
<i>telmisartan-amlodipine 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>telmisartan-hydrochlorothiazid 40-12.5 mg, 80-25 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>telmisartan-hydrochlorothiazid 80-12.5 mg TABLET</i> <b>MO</b>	1	QL(60 per 30 days)
TENORETIC 100 100-25 MG TABLET <b>MO</b>	3	
TENORETIC 50 50-25 MG TABLET <b>MO</b>	3	PA
TENORMIN 100 MG, 25 MG, 50 MG TABLET <b>MO</b>	3	PA
<i>terazosin 1 mg, 10 mg, 2 mg, 5 mg CAPSULE</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
THALITONE 15 MG TABLET <b>MO</b>	3	
tiadylt er 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
tiadylt er 300 mg, 360 mg, 420 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
TIAZAC 120 MG, 180 MG, 240 MG CAPSULE, ER 24 HR. <b>MO</b>	3	QL(60 per 30 days)
TIAZAC 300 MG, 360 MG, 420 MG CAPSULE, ER 24 HR. <b>MO</b>	3	QL(30 per 30 days)
TIKOSYN 125 MCG, 250 MCG, 500 MCG CAPSULE <b>MO</b>	3	PA
timolol maleate 10 mg, 20 mg, 5 mg TABLET <b>MO</b>	1	
TOPROL XL 100 MG, 200 MG, 25 MG, 50 MG TABLET, ER 24 HR. <b>MO</b>	3	
torse mide 10 mg, 100 mg, 5 mg TABLET <b>MO</b>	1	
torse mide 20 mg TABLET <b>MO</b>	1	
trandolapril 1 mg, 2 mg, 4 mg TABLET <b>MO</b>	1	
trandolapril-verapamil 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	1	
triamterene 100 mg, 50 mg CAPSULE <b>MO</b>	1	
triamterene-hydrochlorothiazid 37.5-25 mg CAPSULE <b>MO</b>	1	
triamterene-hydrochlorothiazid 37.5-25 mg TABLET <b>MO</b>	1	
triamterene-hydrochlorothiazid 75-50 mg TABLET <b>MO</b>	1	
TRIBENZOR 20-5-12.5 MG, 40-10-12.5 MG, 40-10-25 MG, 40-5-12.5 MG, 40-5-25 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
TRICOR 145 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
TRICOR 48 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
TRILIPIX 135 MG, 45 MG CAPSULE, DR/EC <b>MO</b>	3	PA,QL(30 per 30 days)
valsartan 160 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
valsartan 320 mg, 40 mg, 80 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
VALSARTAN 4 MG/ML SOLUTION <b>DL</b>	4	ST,QL(2400 per 30 days)
valsartan 4 mg/ml SOLUTION <b>DL</b>	4	ST,QL(2400 per 30 days)
valsartan-hydrochlorothiazide 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
VASCEPA 0.5 GRAM CAPSULE <b>MO</b>	2	QL(240 per 30 days)
VASCEPA 1 GRAM CAPSULE <b>MO</b>	2	QL(120 per 30 days)
VASERETIC 10-25 MG TABLET <b>MO</b>	3	
VASOTEC 10 MG, 2.5 MG, 20 MG, 5 MG TABLET <b>DL</b>	4	PA
VAZCULEP 10 MG/ML SOLUTION <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
vecamyl 2.5 mg TABLET <b>DL</b>	4	QL(300 per 30 days)
verapamil 100 mg, 120 mg, 180 mg, 200 mg, 240 mg, 300 mg CAPSULE ER PELLETS 24 HR. <b>MO</b>	1	
verapamil 120 mg, 180 mg, 240 mg TABLET ER <b>MO</b>	1	
verapamil 120 mg, 40 mg, 80 mg TABLET <b>MO</b>	1	QL(120 per 30 days)
verapamil 2.5 mg/ml SOLUTION <b>MO</b>	1	
verapamil 2.5 mg/ml SYRINGE <b>MO</b>	1	
verapamil 360 mg CAPSULE ER PELLETS 24 HR. <b>MO</b>	1	QL(60 per 30 days)
VERELAN 120 MG, 180 MG, 240 MG CAPSULE ER PELLETS 24 HR. <b>MO</b>	3	
VERELAN 360 MG CAPSULE ER PELLETS 24 HR. <b>MO</b>	3	QL(60 per 30 days)
VERELAN PM 100 MG, 200 MG, 300 MG CAPSULE ER PELLETS 24 HR. <b>MO</b>	3	PA
VERQUVO 10 MG, 2.5 MG, 5 MG TABLET <b>MO</b>	2	PA,QL(30 per 30 days)
VYTORIN 10-10 10-10 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
VYTORIN 10-20 10-20 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
VYTORIN 10-40 10-40 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
VYTORIN 10-80 10-80 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
WELCHOL 3.75 GRAM POWDER IN PACKET <b>MO</b>	3	QL(30 per 30 days)
WELCHOL 625 MG TABLET <b>MO</b>	3	QL(180 per 30 days)
ZESTORETIC 10-12.5 MG, 20-12.5 MG, 20-25 MG TABLET <b>MO</b>	3	
ZESTRIL 10 MG, 2.5 MG, 20 MG, 30 MG, 40 MG, 5 MG TABLET <b>MO</b>	3	PA
ZETIA 10 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
ZIAC 10-6.25 MG, 2.5-6.25 MG, 5-6.25 MG TABLET <b>MO</b>	3	PA
ZOCOR 10 MG, 20 MG, 40 MG, 80 MG TABLET <b>MO</b>	3	PA
ZYPITAMAG 2 MG, 4 MG TABLET <b>MO</b>	2	ST,QL(30 per 30 days)
<b>CENTRAL NERVOUS SYSTEM AGENTS</b>		
ADDERALL 10 MG, 12.5 MG, 15 MG, 20 MG, 5 MG, 7.5 MG TABLET <b>MO</b>	1	PA,QL(90 per 30 days)
ADDERALL 30 MG TABLET <b>MO</b>	1	PA,QL(60 per 30 days)
ADDERALL XR 10 MG, 15 MG, 5 MG CAPSULE, ER 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
ADDERALL XR 20 MG, 25 MG, 30 MG CAPSULE, ER 24 HR. <b>MO</b>	3	PA,QL(60 per 30 days)
ADZENYS XR-ODT 12.5 MG, 15.7 MG, 18.8 MG, 3.1 MG, 6.3 MG, 9.4 MG TABLET, DISINTEGRATING ER BIPH <b>MO</b>	3	QL(30 per 30 days)
amphetamine 1.25 mg/ml SUSPENSION, IR/ER BIPHASIC <b>MO</b>	3	QL(450 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>amphetamine sulfate 10 mg, 5 mg TABLET</i> <b>MO</b>	1	QL(90 per 30 days)
AMPYRA 10 MG TABLET, ER 12 HR. <b>DL</b>	4	PA,QL(60 per 30 days)
APTENSIO XR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG CAPSULE, ER SPRINKLE, BIPHASIC <b>MO</b>	3	QL(30 per 30 days)
<i>atomoxetine 10 mg, 18 mg, 25 mg, 40 mg CAPSULE</i> <b>MO</b>	1	QL(60 per 30 days)
<i>atomoxetine 100 mg, 60 mg, 80 mg CAPSULE</i> <b>MO</b>	1	QL(30 per 30 days)
AUBAGIO 14 MG, 7 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
AUSTEDO 12 MG, 9 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
AUSTEDO 6 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
AUSTEDO XR 12 MG, 6 MG TABLET, ER 24 HR. <b>DL</b>	4	PA,QL(90 per 30 days)
AUSTEDO XR 24 MG TABLET, ER 24 HR. <b>DL</b>	4	PA,QL(60 per 30 days)
AUSTEDO XR TITRATION KT(WK1-4) 6 MG (14)-12 MG (14)-24 MG (14) TABLET, ER 24 HR., DOSE PACK <b>DL</b>	4	PA,QL(42 per 28 days)
AVONEX 30 MCG/0.5 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(1 per 28 days)
AVONEX 30 MCG/0.5 ML SYRINGE KIT <b>DL</b>	4	PA,QL(1 per 28 days)
AZSTARYS 26.1 MG- 5.2 MG, 39.2 MG- 7.8 MG, 52.3 MG- 10.4 MG CAPSULE <b>MO</b>	3	QL(30 per 30 days)
BAFIERTAM 95 MG CAPSULE, DR/EC <b>DL</b>	4	PA,QL(120 per 30 days)
BETASERON 0.3 MG KIT <b>DL</b>	4	PA,QL(15 per 30 days)
BRIUMVI 25 MG/ML SOLUTION	4	PA
<i>clonidine hcl 0.1 mg TABLET, ER 12 HR.</i> <b>MO</b>	1	QL(120 per 30 days)
CONCERTA 18 MG, 27 MG, 54 MG TABLET, ER 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
CONCERTA 36 MG TABLET, ER 24 HR. <b>MO</b>	3	PA,QL(60 per 30 days)
COPAXONE 20 MG/ML SYRINGE <b>DL</b>	4	PA,QL(30 per 30 days)
COPAXONE 40 MG/ML SYRINGE <b>DL</b>	4	PA,QL(12 per 28 days)
COTEMPLA XR-ODT 17.3 MG, 8.6 MG TABLET, DISINTEGRATING ER BIPH <b>MO</b>	3	QL(30 per 30 days)
COTEMPLA XR-ODT 25.9 MG TABLET, DISINTEGRATING ER BIPH <b>MO</b>	3	QL(60 per 30 days)
<i>dalfampridine 10 mg TABLET, ER 12 HR.</i> <b>MO</b>	1	PA,QL(60 per 30 days)
DAYBUE 200 MG/ML SOLUTION <b>DL</b>	4	PA,QL(3600 per 30 days)
DAYTRANA 10 MG/9 HR, 15 MG/9 HR, 20 MG/9 HR, 30 MG/9 HR PATCH, 24 HR. <b>MO</b>	3	QL(30 per 30 days)
DESOXYN 5 MG TABLET <b>DL</b>	4	PA,QL(150 per 30 days)
DEXEDRINE SPANSULE 10 MG CAPSULE, ER <b>DL</b>	4	PA,QL(180 per 30 days)
DEXEDRINE SPANSULE 15 MG CAPSULE, ER <b>DL</b>	4	PA,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DEXEDRINE SPANSULE 5 MG CAPSULE, ER <b>DL</b>	4	PA,QL(60 per 30 days)
dexmethylphenidate 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 5 mg CAPSULE, ER, BIPHASIC <b>MO</b>	1	QL(30 per 30 days)
dexmethylphenidate 10 mg, 2.5 mg, 5 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
dextroamphetamine sulfate 10 mg CAPSULE, ER <b>MO</b>	1	QL(180 per 30 days)
dextroamphetamine sulfate 10 mg TABLET <b>MO</b>	1	QL(180 per 30 days)
dextroamphetamine sulfate 15 mg CAPSULE, ER <b>MO</b>	1	QL(120 per 30 days)
dextroamphetamine sulfate 15 mg TABLET <b>MO</b>	1	QL(120 per 30 days)
dextroamphetamine sulfate 2.5 mg, 20 mg, 7.5 mg TABLET <b>MO</b>	1	QL(90 per 30 days)
dextroamphetamine sulfate 30 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
dextroamphetamine sulfate 5 mg CAPSULE, ER <b>MO</b>	1	QL(60 per 30 days)
dextroamphetamine sulfate 5 mg TABLET <b>MO</b>	1	QL(150 per 30 days)
dextroamphetamine sulfate 5 mg/5 ml SOLUTION <b>MO</b>	1	QL(1800 per 30 days)
dextroamphetamine-amphetamine 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg TABLET <b>MO</b>	1	QL(90 per 30 days)
dextroamphetamine-amphetamine 10 mg, 15 mg, 5 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
dextroamphetamine-amphetamine 12.5 mg, 25 mg, 37.5 mg, 50 mg CAPSULE ER TRIPHASIC 24 HR. <b>MO</b>	1	QL(30 per 30 days)
dextroamphetamine-amphetamine 20 mg, 25 mg, 30 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
dextroamphetamine-amphetamine 30 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
dimethyl fumarate 120 mg (14)- 240 mg (46), 240 mg CAPSULE, DR/EC <b>MO</b>	1	PA,QL(60 per 30 days)
dimethyl fumarate 120 mg CAPSULE, DR/EC <b>MO</b>	1	PA,QL(14 per 30 days)
DYANAVEL XR 10 MG, 15 MG, 20 MG, 5 MG TABLET, IR/ER 24 HR., BIPHASIC <b>MO</b>	3	QL(30 per 30 days)
DYANAVEL XR 2.5 MG/ML SUSPENSION, IR/ER BIPHASIC <b>MO</b>	3	QL(240 per 30 days)
EVEKEO 10 MG, 5 MG TABLET <b>MO</b>	1	QL(90 per 30 days)
EVEKEO ODT 10 MG, 5 MG TABLET, DISINTEGRATING <b>MO</b>	3	QL(90 per 30 days)
EVEKEO ODT 15 MG, 20 MG TABLET, DISINTEGRATING <b>MO</b>	3	QL(60 per 30 days)
EXSERVAN 50 MG FILM <b>DL</b>	4	PA,QL(60 per 30 days)
EXTAVIA 0.3 MG KIT <b>DL</b>	4	PA,QL(15 per 30 days)
EXTAVIA 0.3 MG RECON SOLUTION <b>DL</b>	4	PA,QL(15 per 30 days)
fingolimod 0.5 mg CAPSULE <b>MO</b>	1	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
FIRDAPSE 10 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
FOCALIN 10 MG, 2.5 MG, 5 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
FOCALIN XR 10 MG, 15 MG, 20 MG, 25 MG, 30 MG, 35 MG, 40 MG, 5 MG CAPSULE, ER, BIPHASIC <b>MO</b>	3	QL(30 per 30 days)
<i>gabapentin</i> 300 mg TABLET, ER 24 HR. <b>MO</b>	1	ST,QL(30 per 30 days)
<i>gabapentin</i> 600 mg TABLET, ER 24 HR. <b>MO</b>	1	ST,QL(90 per 30 days)
GILENYA 0.25 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
GILENYA 0.5 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
<i>glatiramer</i> 20 mg/ml SYRINGE <b>DL</b>	4	PA,QL(30 per 30 days)
<i>glatiramer</i> 40 mg/ml SYRINGE <b>DL</b>	4	PA,QL(12 per 28 days)
<i>glatopa</i> 20 mg/ml SYRINGE <b>DL</b>	4	PA,QL(30 per 30 days)
<i>glatopa</i> 40 mg/ml SYRINGE <b>DL</b>	4	PA,QL(12 per 28 days)
GRALISE 300 MG TABLET, ER 24 HR. <b>MO</b>	3	ST,QL(30 per 30 days)
GRALISE 450 MG, 600 MG TABLET, ER 24 HR. <b>MO</b>	3	ST,QL(90 per 30 days)
GRALISE 750 MG, 900 MG TABLET, ER 24 HR. <b>MO</b>	3	ST,QL(60 per 30 days)
<i>guanfacine</i> 1 mg, 2 mg, 3 mg, 4 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
HORIZANT 300 MG, 600 MG TABLET ER <b>MO</b>	3	PA,QL(60 per 30 days)
INGREZZA 40 MG, 60 MG, 80 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
INGREZZA INITIATION PACK 40 MG (7)- 80 MG (21) CAPSULE, DOSE PACK <b>DL</b>	4	PA,QL(28 per 28 days)
INTUNIV ER 1 MG, 2 MG, 3 MG, 4 MG TABLET, ER 24 HR. <b>MO</b>	3	QL(30 per 30 days)
JORNAY PM 100 MG, 20 MG, 40 MG, 60 MG, 80 MG CAPSULE, DR, ER SPRINKLE <b>MO</b>	3	QL(30 per 30 days)
KAPVAY 0.1 MG TABLET, ER 12 HR. <b>MO</b>	3	QL(120 per 30 days)
KESIMPTA PEN 20 MG/0.4 ML PEN INJECTOR <b>DL</b>	4	PA,QL(1.2 per 28 days)
LEMRADA 12 MG/1.2 ML SOLUTION <b>DL</b>	4	PA,QL(6 per 365 days)
<i>lisdexamfetamine</i> 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg CHEWABLE TABLET <b>MO</b>	1	PA,QL(30 per 30 days)
<i>lisdexamfetamine</i> 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg CAPSULE <b>MO</b>	1	PA,QL(30 per 30 days)
LYRICA 100 MG, 150 MG, 200 MG, 25 MG, 50 MG, 75 MG CAPSULE <b>MO</b>	3	PA,QL(90 per 30 days)
LYRICA 20 MG/ML SOLUTION <b>MO</b>	3	PA,QL(900 per 30 days)
LYRICA 225 MG, 300 MG CAPSULE <b>MO</b>	3	PA,QL(60 per 30 days)
LYRICA CR 165 MG, 82.5 MG TABLET, ER 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LYRICA CR 330 MG TABLET, ER 24 HR. <b>MO</b>	3	PA,QL(60 per 30 days)
MAVENCLAD (10 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA
MAVENCLAD (4 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA
MAVENCLAD (5 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA
MAVENCLAD (6 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA
MAVENCLAD (7 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA
MAVENCLAD (8 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA
MAVENCLAD (9 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA
MAYZENT 0.25 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
MAYZENT 1 MG, 2 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
MAYZENT STARTER(FOR 1MG MAINT) 0.25 MG (7 TABS) TABLET, DOSE PACK <b>DL</b>	4	PA,QL(7 per 30 days)
MAYZENT STARTER(FOR 2MG MAINT) 0.25 MG (12 TABS) TABLET, DOSE PACK <b>DL</b>	4	PA,QL(12 per 30 days)
METADATE CD 10 MG, 40 MG, 50 MG, 60 MG CAPSULE, ER, BIPHASIC <b>MO</b>	3	QL(30 per 30 days)
METADATE CD 20 MG, 30 MG CAPSULE, ER, BIPHASIC <b>MO</b>	3	QL(60 per 30 days)
<i>metadate er 20 mg TABLET ER</i> <b>MO</b>	1	QL(90 per 30 days)
<i>methamphetamine 5 mg TABLET</i> <b>DL</b>	4	QL(150 per 30 days)
METHYLIN 10 MG/5 ML SOLUTION <b>MO</b>	3	PA,QL(900 per 30 days)
METHYLIN 5 MG/5 ML SOLUTION <b>MO</b>	3	PA,QL(1800 per 30 days)
<i>methylphenidate 10 mg/9 hr, 15 mg/9 hr, 20 mg/9 hr, 30 mg/9 hr PATCH, 24 HR.</i> <b>MO</b>	1	QL(30 per 30 days)
<i>methylphenidate hcl 10 mg CHEWABLE TABLET</i> <b>MO</b>	1	QL(180 per 30 days)
<i>methylphenidate hcl 10 mg TABLET ER</i> <b>MO</b>	1	QL(180 per 30 days)
<i>methylphenidate hcl 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg CAPSULE, ER SPRINKLE, BIPHASIC</i> <b>MO</b>	3	QL(30 per 30 days)
<i>methylphenidate hcl 10 mg, 20 mg, 40 mg, 50 mg, 60 mg CAPSULE, ER, BIPHASIC</i> <b>MO</b>	1	QL(30 per 30 days)
<i>methylphenidate hcl 10 mg, 20 mg, 5 mg TABLET</i> <b>MO</b>	1	QL(90 per 30 days)
<i>methylphenidate hcl 10 mg/5 ml SOLUTION</i> <b>MO</b>	1	QL(900 per 30 days)
<i>methylphenidate hcl 18 mg, 27 mg, 54 mg, 72 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(30 per 30 days)
<i>methylphenidate hcl 2.5 mg, 5 mg CHEWABLE TABLET</i> <b>MO</b>	1	QL(150 per 30 days)
<i>methylphenidate hcl 20 mg TABLET ER</i> <b>MO</b>	1	QL(90 per 30 days)
<i>methylphenidate hcl 20 mg, 30 mg CAPSULE, ER, BIPHASIC</i> <b>MO</b>	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>methylphenidate hcl 36 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	QL(60 per 30 days)
<i>methylphenidate hcl 45 mg, 63 mg TABLET, ER 24 HR.</i> <b>MO</b>	3	QL(30 per 30 days)
<i>methylphenidate hcl 5 mg/5 ml SOLUTION</i> <b>MO</b>	1	QL(1800 per 30 days)
MYDAYIS 12.5 MG, 25 MG, 37.5 MG, 50 MG CAPSULE ER TRIPHASIC 24 HR. <b>MO</b>	3	QL(30 per 30 days)
NUEDEXTA 20-10 MG CAPSULE	4	PA,QL(60 per 30 days)
OCREVUS 30 MG/ML SOLUTION	4	PA,QL(40 per 365 days)
PLEGRIDY 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML PEN INJECTOR <b>DL</b>	4	PA,QL(1 per 28 days)
PLEGRIDY 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(1 per 28 days)
PONVORY 20 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
PONVORY 14-DAY STARTER PACK 2 MG (2) - 10 MG (3) TABLET, DOSE PACK <b>DL</b>	4	PA,QL(14 per 30 days)
<i>pregabalin 100 mg, 150 mg, 50 mg, 75 mg CAPSULE</i> <b>MO</b>	1	QL(90 per 30 days)
<i>pregabalin 165 mg, 82.5 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	PA,QL(30 per 30 days)
<i>pregabalin 20 mg/ml SOLUTION</i> <b>MO</b>	1	QL(900 per 30 days)
<i>pregabalin 200 mg, 25 mg CAPSULE</i> <b>MO</b>	1	QL(90 per 30 days)
<i>pregabalin 225 mg, 300 mg CAPSULE</i> <b>MO</b>	1	QL(60 per 30 days)
<i>pregabalin 330 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	PA,QL(60 per 30 days)
<i>procentra 5 mg/5 ml SOLUTION</i> <b>DL</b>	4	QL(1800 per 30 days)
QALSODY 100 MG/15 ML (6.7 MG/ML) SOLUTION <b>DL</b>	4	PA
QELBREE 100 MG CAPSULE, ER 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
QELBREE 150 MG, 200 MG CAPSULE, ER 24 HR. <b>MO</b>	3	PA,QL(60 per 30 days)
QUILLICHEW ER 20 MG, 40 MG CHEWABLE TABLET, IR/ER BIPHASE <b>MO</b>	3	QL(30 per 30 days)
QUILLICHEW ER 30 MG CHEWABLE TABLET, IR/ER BIPHASE <b>MO</b>	3	QL(60 per 30 days)
QUILLIVANT XR 5 MG/ML (25 MG/5 ML) SUSPENSION, ER, RECON <b>MO</b>	3	QL(360 per 30 days)
RADICAVA 30 MG/100 ML SOLUTION <b>DL</b>	4	PA
RADICAVA ORS 105 MG/5 ML SUSPENSION <b>DL</b>	4	PA,QL(70 per 28 days)
RADICAVA ORS STARTER KIT SUSP 105 MG/5 ML SUSPENSION <b>DL</b>	4	PA,QL(70 per 28 days)
REBIF (WITH ALBUMIN) 22 MCG/0.5 ML, 44 MCG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(6 per 28 days)
REBIF REBIDOSE 22 MCG/0.5 ML, 44 MCG/0.5 ML PEN INJECTOR <b>DL</b>	4	PA,QL(6 per 28 days)
REBIF REBIDOSE 8.8MCG/0.2ML-22 MCG/0.5ML (6) PEN INJECTOR <b>DL</b>	4	PA,QL(4.2 per 28 days)
REBIF TITRATION PACK 8.8MCG/0.2ML-22 MCG/0.5ML (6) SYRINGE <b>DL</b>	4	PA,QL(4.2 per 28 days)
RELEXXII 18 MG, 27 MG, 45 MG, 54 MG, 63 MG TABLET, ER 24 HR. <b>MO</b>	3	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RELEXXII 36 MG TABLET, ER 24 HR. <b>MO</b>	3	QL(60 per 30 days)
RELEXXII 72 MG TABLET, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
RILUTEK 50 MG TABLET <b>DL</b>	4	
<i>riluzole 50 mg TABLET</i> <b>MO</b>	1	
RITALIN 10 MG, 20 MG, 5 MG TABLET <b>MO</b>	3	PA,QL(90 per 30 days)
RITALIN LA 10 MG, 20 MG, 40 MG CAPSULE, ER, BIPHASIC <b>MO</b>	3	PA,QL(30 per 30 days)
RITALIN LA 30 MG CAPSULE, ER, BIPHASIC <b>MO</b>	3	PA,QL(60 per 30 days)
SAVELLA 100 MG, 12.5 MG, 25 MG, 50 MG TABLET <b>MO</b>	2	QL(60 per 30 days)
SAVELLA 12.5 MG (5)-25 MG(8)-50 MG(42) TABLET, DOSE PACK <b>MO</b>	2	QL(55 per 28 days)
SKYCLARYS 50 MG CAPSULE <b>DL</b>	4	PA,QL(90 per 30 days)
STRATTERA 10 MG, 18 MG, 25 MG, 40 MG CAPSULE <b>MO</b>	3	PA,QL(60 per 30 days)
STRATTERA 100 MG, 60 MG, 80 MG CAPSULE <b>MO</b>	3	PA,QL(30 per 30 days)
TASCENSO ODT 0.25 MG, 0.5 MG TABLET, DISINTEGRATING <b>DL</b>	4	PA,QL(30 per 30 days)
TECFIDERA 120 MG (14)- 240 MG (46), 240 MG CAPSULE, DR/EC <b>DL</b>	4	PA,QL(60 per 30 days)
TECFIDERA 120 MG CAPSULE, DR/EC <b>DL</b>	4	PA,QL(14 per 30 days)
TEGLUTIK 50 MG/10 ML SUSPENSION <b>DL</b>	4	PA,QL(600 per 30 days)
<i>teriflunomide 14 mg, 7 mg TABLET</i> <b>MO</b>	1	PA,QL(30 per 30 days)
<i>tetrabenazine 12.5 mg TABLET</i> <b>MO</b>	1	PA,QL(240 per 30 days)
<i>tetrabenazine 25 mg TABLET</i> <b>MO</b>	1	PA,QL(120 per 30 days)
TIGLUTIK 50 MG/10 ML SUSPENSION <b>DL</b>	4	PA,QL(600 per 30 days)
TYSABRI 300 MG/15 ML SOLUTION <b>DL</b>	4	PA,QL(15 per 28 days)
VUMERITY 231 MG CAPSULE, DR/EC <b>DL</b>	4	PA,QL(120 per 30 days)
VYVANSE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG CHEWABLE TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
VYVANSE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG, 70 MG CAPSULE <b>MO</b>	3	PA,QL(30 per 30 days)
XELSTRYM 13.5 MG/9 HOUR, 18 MG/9 HOUR, 4.5 MG/9 HOUR, 9 MG/9 HOUR PATCH, 24 HR. <b>MO</b>	3	QL(30 per 30 days)
XENAZINE 12.5 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
XENAZINE 25 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
<i>zenzedi 10 mg TABLET</i> <b>MO</b>	1	QL(180 per 30 days)
ZENZEDI 15 MG TABLET <b>MO</b>	1	QL(120 per 30 days)
ZENZEDI 2.5 MG, 20 MG, 7.5 MG TABLET <b>MO</b>	1	QL(90 per 30 days)
ZENZEDI 30 MG TABLET <b>MO</b>	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
zenzedi 5 mg TABLET <b>MO</b>	1	QL(150 per 30 days)
ZEPOSIA 0.92 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
ZEPOSIA STARTER KIT (28-DAY) 0.23 MG-0.46 MG -0.92 MG (21) CAPSULE, DOSE PACK <b>DL</b>	4	PA,QL(28 per 28 days)
ZEPOSIA STARTER KIT (37-DAY) 0.23 MG-0.46 MG -0.92 MG (30) CAPSULE, DOSE PACK	4	PA,QL(37 per 37 days)
ZEPOSIA STARTER PACK (7-DAY) 0.23 MG (4)- 0.46 MG (3) CAPSULE, DOSE PACK <b>DL</b>	4	PA,QL(7 per 7 days)
<b>DENTAL &amp; ORAL AGENTS</b>		
cevimeline 30 mg CAPSULE <b>MO</b>	1	
chlorhexidine gluconate 0.12 % MOUTHWASH <b>MO</b>	1	
EVOXAC 30 MG CAPSULE <b>MO</b>	3	PA
KEPIVANCE 5.16 MG, 6.25 MG RECON SOLUTION <b>DL</b>	4	
kourzeq 0.1 % PASTE <b>MO</b>	1	
oralone 0.1 % PASTE <b>MO</b>	1	
paroex oral rinse 0.12 % MOUTHWASH <b>MO</b>	1	
periogard 0.12 % MOUTHWASH <b>MO</b>	1	
pilocarpine hcl 5 mg, 7.5 mg TABLET <b>MO</b>	1	
SALAGEN (PILOCARPINE) 5 MG, 7.5 MG TABLET <b>MO</b>	3	
triamcinolone acetonide 0.1 % PASTE <b>MO</b>	1	
<b>DERMATOLOGICAL AGENTS</b>		
ABSORICA 10 MG, 20 MG, 25 MG, 30 MG, 35 MG CAPSULE <b>DL</b>	4	ST,QL(60 per 30 days)
ABSORICA 40 MG CAPSULE <b>DL</b>	4	ST,QL(120 per 30 days)
ABSORICA LD 16 MG, 24 MG, 8 MG CAPSULE <b>DL</b>	4	ST,QL(60 per 30 days)
ABSORICA LD 32 MG CAPSULE <b>DL</b>	4	ST,QL(120 per 30 days)
ACANYA 1.2-2.5 % GEL WITH PUMP <b>MO</b>	3	QL(50 per 30 days)
accutane 10 mg, 20 mg, 30 mg CAPSULE <b>MO</b>	1	QL(60 per 30 days)
accutane 40 mg CAPSULE <b>MO</b>	1	QL(120 per 30 days)
acitretin 10 mg CAPSULE <b>MO</b>	1	PA,QL(90 per 30 days)
acitretin 17.5 mg CAPSULE <b>MO</b>	1	PA,QL(60 per 30 days)
acitretin 25 mg CAPSULE <b>MO</b>	1	PA
ACZONE 5 % GEL <b>MO</b>	3	QL(90 per 30 days)
ACZONE 7.5 % GEL WITH PUMP <b>MO</b>	3	QL(90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>adapalene 0.1 % CREAM</i> <b>MO</b>	1	QL(45 per 30 days)
<i>adapalene 0.1 % SOLUTION</i> <b>DL</b>	4	QL(60 per 30 days)
<i>adapalene 0.1 % SWAB</i> <b>MO</b>	1	QL(30 per 30 days)
<i>adapalene 0.3 % GEL</i> <b>MO</b>	1	QL(45 per 30 days)
<i>adapalene 0.3 % GEL WITH PUMP</i> <b>MO</b>	1	QL(45 per 30 days)
<i>adapalene-benzoyl peroxide 0.1-2.5 % GEL WITH PUMP</i> <b>MO</b>	1	QL(45 per 30 days)
<i>adapalene-benzoyl peroxide 0.3-2.5 % GEL WITH PUMP</i> <b>MO</b>	1	QL(60 per 30 days)
<i>AKLIEF 0.005 % CREAM</i> <b>MO</b>	3	PA,QL(90 per 30 days)
<i>ALA-CORT 1 % CREAM</i> <b>MO</b>	1	QL(240 per 30 days)
<i>ALA-SCALP 2 % LOTION</i> <b>MO</b>	1	QL(236.8 per 30 days)
<i>alclometasone 0.05 % CREAM</i> <b>MO</b>	1	QL(240 per 30 days)
<i>alclometasone 0.05 % OINTMENT</i> <b>MO</b>	1	QL(240 per 30 days)
<i>ALTABAX 1 % OINTMENT</i> <b>MO</b>	3	
<i>ALTRENO 0.05 % LOTION</i> <b>MO</b>	3	PA,QL(90 per 30 days)
<i>amcinonide 0.1 % CREAM</i> <b>MO</b>	1	QL(120 per 30 days)
<i>amcinonide 0.1 % OINTMENT</i> <b>DL</b>	4	ST,QL(120 per 30 days)
<i>ammonium lactate 12 % CREAM</i> <b>MO</b>	1	
<i>ammonium lactate 12 % LOTION</i> <b>MO</b>	1	
<i>amnesteem 10 mg, 20 mg CAPSULE</i> <b>MO</b>	1	QL(60 per 30 days)
<i>amnesteem 40 mg CAPSULE</i> <b>MO</b>	1	QL(120 per 30 days)
<i>AMZEEQ 4 % FOAM</i> <b>MO</b>	3	PA,QL(30 per 30 days)
<i>anusol-hc 2.5 % CREAM W/PERINEAL APPLICATOR</i> <b>MO</b>	1	QL(60 per 30 days)
<i>apexicon e 0.05 % CREAM</i> <b>MO</b>	1	QL(60 per 30 days)
<i>ARAZLO 0.045 % LOTION</i> <b>MO</b>	3	PA
<i>ATRALIN 0.05 % GEL</i> <b>MO</b>	3	PA,QL(45 per 30 days)
<i>AVITA 0.025 % CREAM</i> <b>MO</b>	3	PA,QL(45 per 30 days)
<i>AVITA 0.025 % GEL</i> <b>MO</b>	3	PA,QL(45 per 30 days)
<i>azelaic acid 15 % GEL</i> <b>MO</b>	1	ST,QL(50 per 30 days)
<i>AZELEX 20 % CREAM</i> <b>MO</b>	3	QL(50 per 30 days)
<i>BENZAMYCIN 3-5 % GEL</i> <b>MO</b>	3	QL(46.6 per 30 days)
<i>beser 0.05 % LOTION</i> <b>MO</b>	1	QL(240 per 30 days)
<i>betamethasone dipropionate 0.05 % CREAM</i> <b>MO</b>	1	QL(90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>betamethasone dipropionate 0.05 % LOTION</i> <b>MO</b>	1	QL(120 per 30 days)
<i>betamethasone dipropionate 0.05 % OINTMENT</i> <b>MO</b>	1	QL(90 per 30 days)
<i>betamethasone valerate 0.1 % CREAM</i> <b>MO</b>	1	QL(180 per 30 days)
<i>betamethasone valerate 0.1 % LOTION</i> <b>MO</b>	1	QL(120 per 30 days)
<i>betamethasone valerate 0.1 % OINTMENT</i> <b>MO</b>	1	QL(180 per 30 days)
<i>betamethasone valerate 0.12 % FOAM</i> <b>MO</b>	1	QL(200 per 30 days)
<i>betamethasone, augmented 0.05 % CREAM</i> <b>MO</b>	1	QL(100 per 30 days)
<i>betamethasone, augmented 0.05 % GEL</i> <b>MO</b>	1	QL(100 per 30 days)
<i>betamethasone, augmented 0.05 % LOTION</i> <b>MO</b>	1	QL(120 per 30 days)
<i>betamethasone, augmented 0.05 % OINTMENT</i> <b>MO</b>	1	QL(100 per 30 days)
<i>brimonidine 0.33 % GEL WITH PUMP</i> <b>MO</b>	1	ST,QL(30 per 30 days)
BRYHALI 0.01 % LOTION <b>MO</b>	3	ST,QL(200 per 30 days)
CABTREO 0.15-3.1-1.2 % GEL <b>MO</b>	3	QL(50 per 30 days)
<i>calcipotriene 0.005 % CREAM</i> <b>MO</b>	1	PA,QL(120 per 30 days)
<i>calcipotriene 0.005 % FOAM</i> <b>MO</b>	1	ST,QL(120 per 28 days)
<i>calcipotriene 0.005 % OINTMENT</i> <b>MO</b>	1	QL(240 per 30 days)
<i>calcipotriene 0.005 % SOLUTION</i> <b>MO</b>	1	QL(60 per 30 days)
<i>calcipotriene-betamethasone 0.005-0.064 % OINTMENT</i> <b>MO</b>	1	PA,QL(60 per 30 days)
<i>calcipotriene-betamethasone 0.005-0.064 % SUSPENSION</i> <b>MO</b>	1	PA,QL(420 per 30 days)
<i>calcitriol 3 mcg/gram OINTMENT</i> <b>MO</b>	1	ST,QL(800 per 28 days)
CAPEX 0.01 % SHAMPOO <b>MO</b>	3	QL(840 per 30 days)
CARAC 0.5 % CREAM <b>DL</b>	4	PA,QL(60 per 30 days)
CENTANY 2 % OINTMENT <b>MO</b>	3	
<i>claravis 10 mg, 20 mg, 30 mg CAPSULE</i> <b>MO</b>	1	QL(60 per 30 days)
<i>claravis 40 mg CAPSULE</i> <b>MO</b>	1	QL(120 per 30 days)
CLEOCIN T 1 % LOTION <b>MO</b>	3	QL(60 per 30 days)
<i>clindacin 1 % FOAM</i> <b>MO</b>	1	QL(100 per 30 days)
<i>clindacin etz 1 % SWAB</i> <b>MO</b>	1	
<i>clindacin p 1 % SWAB</i> <b>MO</b>	1	
CLINDAGEL 1 % GEL, ONCE DAILY <b>DL</b>	4	PA,QL(75 per 30 days)
<i>clindamycin phosphate 1 % FOAM</i> <b>MO</b>	1	QL(100 per 30 days)
<i>clindamycin phosphate 1 % GEL</i> <b>MO</b>	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
clindamycin phosphate 1 % GEL, ONCE DAILY <b>MO</b>	1	PA,QL(75 per 30 days)
clindamycin phosphate 1 % LOTION <b>MO</b>	1	QL(60 per 30 days)
clindamycin phosphate 1 % SOLUTION <b>MO</b>	1	QL(60 per 30 days)
clindamycin phosphate 1 % SWAB <b>MO</b>	1	
clindamycin-benzoyl peroxide 1-5 % GEL <b>MO</b>	1	QL(50 per 30 days)
clindamycin-benzoyl peroxide 1-5 %, 1.2 %(1 % base) -3.75 %, 1.2-2.5 % GEL WITH PUMP <b>MO</b>	1	QL(50 per 30 days)
clindamycin-benzoyl peroxide 1.2 %(1 % base) -5 % GEL <b>MO</b>	1	QL(45 per 30 days)
clindamycin-tretinoin 1.2-0.025 % GEL <b>MO</b>	1	QL(60 per 30 days)
clobetasol 0.05 % CREAM <b>MO</b>	1	QL(120 per 30 days)
clobetasol 0.05 % FOAM <b>MO</b>	1	QL(100 per 28 days)
clobetasol 0.05 % GEL <b>MO</b>	1	QL(120 per 28 days)
clobetasol 0.05 % LOTION <b>MO</b>	1	QL(240 per 28 days)
clobetasol 0.05 % OINTMENT <b>MO</b>	1	QL(120 per 28 days)
clobetasol 0.05 % SHAMPOO <b>MO</b>	1	QL(240 per 30 days)
clobetasol 0.05 % SOLUTION <b>MO</b>	1	QL(100 per 30 days)
clobetasol 0.05 % SPRAY, NON-AEROSOL <b>MO</b>	1	QL(240 per 30 days)
clobetasol-emollient 0.05 % CREAM <b>MO</b>	1	QL(120 per 30 days)
clobetasol-emollient 0.05 % FOAM <b>MO</b>	1	QL(100 per 30 days)
CLOBEX 0.05 % LOTION <b>MO</b>	3	ST,QL(240 per 28 days)
CLOBEX 0.05 % SHAMPOO <b>MO</b>	3	ST,QL(240 per 30 days)
CLOBEX 0.05 % SPRAY, NON-AEROSOL <b>MO</b>	3	ST,QL(240 per 30 days)
clocortolone pivalate 0.1 % CREAM <b>MO</b>	1	QL(180 per 30 days)
clodan 0.05 % SHAMPOO <b>MO</b>	1	QL(240 per 30 days)
CONDYLOX 0.5 % GEL <b>MO</b>	3	
CORDRAN 0.025 % CREAM <b>MO</b>	3	ST,QL(240 per 30 days)
CORDRAN 0.05 % CREAM <b>DL</b>	4	ST,QL(240 per 30 days)
CORDRAN 0.05 % LOTION <b>DL</b>	4	ST,QL(240 per 30 days)
CORDRAN 0.05 % OINTMENT <b>MO</b>	3	ST,QL(240 per 30 days)
CORDRAN TAPE LARGE ROLL 4 MCG/CM2 TAPE <b>MO</b>	3	QL(2 per 30 days)
CORTEF 10 MG, 20 MG, 5 MG TABLET <b>MO</b>	3	
crotan 10 % LOTION <b>DL</b>	4	PA,QL(454 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
dapsone 5 % GEL <b>MO</b>	1	QL(90 per 30 days)
dapsone 7.5 % GEL WITH PUMP <b>MO</b>	1	QL(90 per 30 days)
DERMA-SMOOTHIE/FS BODY OIL 0.01 % OIL <b>MO</b>	3	QL(118.28 per 30 days)
DERMA-SMOOTHIE/FS SCALP OIL 0.01 % OIL <b>MO</b>	3	QL(118.28 per 30 days)
desonide 0.05 % CREAM <b>MO</b>	1	QL(240 per 30 days)
desonide 0.05 % GEL <b>MO</b>	1	QL(240 per 30 days)
desonide 0.05 % LOTION <b>MO</b>	1	QL(240 per 30 days)
desonide 0.05 % OINTMENT <b>MO</b>	1	QL(240 per 30 days)
DESOWEN 0.05 % CREAM <b>MO</b>	3	QL(240 per 30 days)
desoximetasone 0.05 % CREAM <b>MO</b>	1	QL(240 per 30 days)
desoximetasone 0.05 % GEL <b>MO</b>	1	QL(240 per 30 days)
desoximetasone 0.05 % OINTMENT <b>MO</b>	1	QL(240 per 30 days)
desoximetasone 0.25 % CREAM <b>MO</b>	1	QL(120 per 30 days)
desoximetasone 0.25 % OINTMENT <b>MO</b>	1	QL(120 per 30 days)
desoximetasone 0.25 % SPRAY, NON-AEROSOL <b>MO</b>	1	QL(100 per 30 days)
desrx 0.05 % GEL <b>MO</b>	1	QL(240 per 30 days)
diclofenac sodium 3 % GEL <b>MO</b>	1	PA
DIFFERIN 0.1 % CREAM <b>MO</b>	3	PA,QL(45 per 30 days)
DIFFERIN 0.1 % LOTION <b>MO</b>	3	QL(59 per 30 days)
DIFFERIN 0.3 % GEL WITH PUMP <b>MO</b>	3	QL(45 per 30 days)
diflorasone 0.05 % CREAM <b>DL</b>	4	QL(120 per 30 days)
diflorasone 0.05 % OINTMENT <b>MO</b>	3	QL(120 per 30 days)
DIPROLENE (AUGMENTED) 0.05 % OINTMENT <b>MO</b>	3	QL(100 per 30 days)
DOVONEX 0.005 % CREAM <b>MO</b>	3	PA,QL(120 per 30 days)
doxepin 5 % CREAM <b>DL</b>	4	PA,QL(45 per 30 days)
DUOBRII 0.01-0.045 % LOTION <b>MO</b>	3	PA,QL(200 per 28 days)
EFUDEX 5 % CREAM <b>MO</b>	3	PA
ELIDEL 1 % CREAM <b>MO</b>	3	PA,QL(100 per 30 days)
ELIMITE 5 % CREAM <b>MO</b>	3	
ENSTILAR 0.005-0.064 % FOAM <b>MO</b>	3	QL(120 per 30 days)
EPIDUO 0.1-2.5 % GEL WITH PUMP <b>MO</b>	3	QL(45 per 30 days)
EPIDUO FORTE 0.3-2.5 % GEL WITH PUMP <b>MO</b>	3	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EPIFOAM 1-1 % FOAM <b>MO</b>	1	
EPSOLAY 5 % CREAM <b>MO</b>	3	ST,QL(30 per 30 days)
ery pads 2 % SWAB <b>MO</b>	1	QL(60 per 30 days)
ERYGEL 2 % GEL <b>MO</b>	1	QL(60 per 30 days)
erythromycin with ethanol 2 % GEL <b>MO</b>	1	QL(60 per 30 days)
erythromycin with ethanol 2 % SOLUTION <b>MO</b>	1	QL(120 per 30 days)
erythromycin-benzoyl peroxide 3-5 % GEL <b>MO</b>	1	QL(46.6 per 30 days)
EUCRISA 2 % OINTMENT <b>MO</b>	3	PA,QL(100 per 30 days)
EURAX 10 % CREAM <b>MO</b>	3	PA
EURAX 10 % LOTION <b>MO</b>	3	PA,QL(454 per 30 days)
EVOCLIN 1 % FOAM <b>MO</b>	3	PA,QL(100 per 30 days)
FABIOR 0.1 % FOAM <b>MO</b>	3	PA,QL(100 per 30 days)
FINACEA 15 % FOAM <b>MO</b>	3	ST,QL(50 per 30 days)
FINACEA 15 % GEL <b>MO</b>	3	ST,QL(50 per 30 days)
fluocinolone 0.01 % OIL <b>MO</b>	1	QL(118.28 per 30 days)
fluocinolone 0.01 % SOLUTION <b>MO</b>	1	QL(180 per 30 days)
fluocinolone 0.01 %, 0.025 % CREAM <b>MO</b>	1	QL(120 per 30 days)
fluocinolone 0.025 % OINTMENT <b>MO</b>	1	QL(120 per 30 days)
fluocinolone and shower cap 0.01 % OIL <b>MO</b>	1	QL(118.28 per 30 days)
fluocinonide 0.05 % CREAM <b>MO</b>	1	QL(120 per 30 days)
fluocinonide 0.05 % GEL <b>MO</b>	1	QL(120 per 30 days)
fluocinonide 0.05 % OINTMENT <b>MO</b>	1	QL(120 per 30 days)
fluocinonide 0.05 % SOLUTION <b>MO</b>	1	QL(120 per 30 days)
fluocinonide 0.1 % CREAM <b>MO</b>	1	QL(120 per 28 days)
fluocinonide-e 0.05 % CREAM <b>MO</b>	1	QL(120 per 30 days)
fluocinonide-emollient 0.05 % CREAM <b>MO</b>	1	QL(120 per 30 days)
FLUOROPLEX 1 % CREAM <b>DL</b>	4	
fluorouracil 0.5 % CREAM <b>DL</b>	4	QL(60 per 30 days)
fluorouracil 2 % SOLUTION <b>MO</b>	1	QL(30 per 30 days)
fluorouracil 5 % CREAM <b>MO</b>	1	
fluorouracil 5 % SOLUTION <b>MO</b>	1	QL(60 per 30 days)
flurandrenolide 0.05 % CREAM <b>MO</b>	1	QL(240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
flurandrenolide 0.05 % LOTION <b>MO</b>	3	QL(240 per 30 days)
flurandrenolide 0.05 % OINTMENT <b>MO</b>	1	QL(240 per 30 days)
fluticasone propionate 0.005 % OINTMENT <b>MO</b>	1	QL(240 per 30 days)
fluticasone propionate 0.05 % CREAM <b>MO</b>	1	QL(240 per 30 days)
fluticasone propionate 0.05 % LOTION <b>MO</b>	1	QL(240 per 30 days)
halcinonide 0.1 % CREAM <b>MO</b>	1	QL(120 per 30 days)
halobetasol propionate 0.05 % CREAM <b>MO</b>	1	QL(100 per 30 days)
halobetasol propionate 0.05 % FOAM <b>MO</b>	3	PA,QL(100 per 30 days)
halobetasol propionate 0.05 % OINTMENT <b>MO</b>	1	QL(100 per 30 days)
HALOG 0.1 % CREAM <b>DL</b>	4	QL(120 per 30 days)
HALOG 0.1 % OINTMENT <b>MO</b>	3	QL(120 per 30 days)
HALOG 0.1 % SOLUTION <b>MO</b>	3	QL(120 per 30 days)
hydrocortisone 1 % CREAM W/PERINEAL APPLICATOR <b>MO</b>	1	QL(28.4 per 30 days)
hydrocortisone 1 %, 2.5 % CREAM <b>MO</b>	1	QL(240 per 30 days)
hydrocortisone 1 %, 2.5 % OINTMENT <b>MO</b>	1	QL(240 per 30 days)
hydrocortisone 10 mg, 20 mg, 5 mg TABLET <b>MO</b>	1	
hydrocortisone 2.5 % CREAM W/PERINEAL APPLICATOR <b>MO</b>	1	QL(60 per 30 days)
hydrocortisone 2.5 % LOTION <b>MO</b>	1	QL(236 per 30 days)
hydrocortisone butyr-emollient 0.1 % CREAM <b>MO</b>	1	QL(240 per 30 days)
hydrocortisone butyrate 0.1 % CREAM <b>MO</b>	1	QL(240 per 30 days)
hydrocortisone butyrate 0.1 % LOTION <b>MO</b>	1	QL(236 per 30 days)
hydrocortisone butyrate 0.1 % OINTMENT <b>MO</b>	1	QL(180 per 30 days)
hydrocortisone butyrate 0.1 % SOLUTION <b>MO</b>	1	QL(240 per 30 days)
hydrocortisone valerate 0.2 % CREAM <b>MO</b>	1	QL(240 per 30 days)
hydrocortisone valerate 0.2 % OINTMENT <b>MO</b>	1	QL(240 per 30 days)
HYFTOR 0.2 % GEL <b>DL</b>	4	PA
imiquimod 3.75 % CREAM IN PACKET <b>MO</b>	3	ST,QL(28 per 28 days)
imiquimod 3.75 % CREAM, METERED DOSE PUMP <b>DL</b>	4	ST,QL(15 per 30 days)
imiquimod 5 % CREAM IN PACKET <b>MO</b>	1	QL(12 per 30 days)
IMPEKLO 0.05 % LOTION IN METERED DOSE PUMP <b>DL</b>	4	ST,QL(136 per 28 days)
isotretinoin 10 mg, 20 mg, 30 mg CAPSULE <b>MO</b>	1	QL(60 per 30 days)
isotretinoin 25 mg, 35 mg CAPSULE <b>DL</b>	4	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
isotretinoin 40 mg CAPSULE <b>MO</b>	1	QL(120 per 30 days)
ivermectin 1 % CREAM <b>MO</b>	1	ST,QL(45 per 30 days)
KLISYRI 1 % OINTMENT IN PACKET <b>DL</b>	4	PA,QL(5 per 30 days)
LEXETTE 0.05 % FOAM <b>MO</b>	3	PA,QL(100 per 30 days)
lindane 1 % SHAMPOO <b>MO</b>	1	QL(60 per 30 days)
LOCOID 0.1 % LOTION <b>MO</b>	3	QL(236 per 30 days)
LOCOID LIPOCREAM 0.1 % CREAM <b>MO</b>	3	QL(240 per 30 days)
LUXIQ 0.12 % FOAM <b>MO</b>	3	ST,QL(200 per 30 days)
mafenide acetate 50 gram PACKET <b>MO</b>	1	
malathion 0.5 % LOTION <b>MO</b>	1	
methoxsalen 10 mg CAPSULE, LIQ FILLED, RAPID REL <b>MO</b>	1	
MIRVASO 0.33 % GEL WITH PUMP <b>MO</b>	3	ST,QL(30 per 30 days)
mometasone 0.1 % CREAM <b>MO</b>	1	QL(180 per 30 days)
mometasone 0.1 % OINTMENT <b>MO</b>	1	QL(180 per 30 days)
mometasone 0.1 % SOLUTION <b>MO</b>	1	QL(180 per 30 days)
mupirocin 2 % OINTMENT <b>MO</b>	1	
mupirocin calcium 2 % CREAM <b>MO</b>	1	ST
myorisan 10 mg, 20 mg, 30 mg CAPSULE <b>MO</b>	1	QL(60 per 30 days)
myorisan 40 mg CAPSULE <b>MO</b>	1	QL(120 per 30 days)
NATROBA 0.9 % SUSPENSION <b>MO</b>	3	QL(240 per 30 days)
NEO-SYNALAR 0.5 % (0.35 % BASE)-0.025 % CREAM <b>MO</b>	3	
neuac 1.2 %(1 % base) -5 % GEL <b>MO</b>	1	QL(45 per 30 days)
nolix 0.05 % LOTION <b>MO</b>	1	QL(240 per 30 days)
OLUX 0.05 % FOAM <b>MO</b>	3	PA,QL(100 per 28 days)
OLUX-E 0.05 % FOAM <b>MO</b>	3	PA,QL(100 per 30 days)
ONEXTON 1.2 %(1 % BASE) -3.75 % GEL <b>MO</b>	3	
ONEXTON 1.2 %(1 % BASE) -3.75 % GEL WITH PUMP <b>MO</b>	3	QL(50 per 30 days)
OPZELURA 1.5 % CREAM <b>DL</b>	4	PA,QL(240 per 28 days)
OTEZLA 30 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
OTEZLA STARTER 10 MG (4)-20 MG (4)-30 MG (47) TABLET, DOSE PACK <b>DL</b>	4	PA,QL(55 per 28 days)
OTEZLA STARTER 10 MG (4)-20 MG (4)-30 MG(19) TABLET, DOSE PACK <b>DL</b>	4	PA,QL(27 per 30 days)
OVIDE 0.5 % LOTION <b>MO</b>	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PANDEL 0.1 % CREAM <b>DL</b>	4	QL(160 per 30 days)
permethrin 5 % CREAM <b>MO</b>	1	
pimecrolimus 1 % CREAM <b>MO</b>	1	PA,QL(100 per 30 days)
podofilox 0.5 % GEL <b>MO</b>	1	
podofilox 0.5 % SOLUTION <b>MO</b>	1	QL(7 per 30 days)
prednicarbate 0.1 % CREAM <b>MO</b>	1	QL(240 per 30 days)
prednicarbate 0.1 % OINTMENT <b>MO</b>	1	QL(240 per 30 days)
procto-med hc 2.5 % CREAM W/PERINEAL APPLICATOR <b>MO</b>	1	QL(60 per 30 days)
proctosol hc 2.5 % CREAM W/PERINEAL APPLICATOR <b>MO</b>	1	QL(60 per 30 days)
proctozone-hc 2.5 % CREAM W/PERINEAL APPLICATOR <b>MO</b>	1	QL(60 per 30 days)
PROTOPIC 0.03 %, 0.1 % OINTMENT <b>MO</b>	3	QL(200 per 30 days)
PRUDOXIN 5 % CREAM <b>DL</b>	4	PA,QL(45 per 30 days)
QBREXZA 2.4 % TOWELETTE <b>MO</b>	3	PA,QL(30 per 30 days)
REGGRANEX 0.01 % GEL	4	PA
RETIN-A 0.01 %, 0.025 % GEL <b>MO</b>	3	PA,QL(45 per 30 days)
RETIN-A 0.025 %, 0.05 %, 0.1 % CREAM <b>MO</b>	3	PA,QL(45 per 30 days)
RETIN-A MICRO 0.04 % GEL <b>DL</b>	4	PA,QL(45 per 30 days)
RETIN-A MICRO 0.1 % GEL <b>MO</b>	3	PA,QL(45 per 30 days)
RETIN-A MICRO PUMP 0.04 %, 0.1 % GEL WITH PUMP <b>DL</b>	4	PA,QL(50 per 30 days)
RETIN-A MICRO PUMP 0.06 %, 0.08 % GEL WITH PUMP <b>MO</b>	3	PA,QL(50 per 30 days)
SANTYL 250 UNIT/GRAM OINTMENT <b>MO</b>	3	QL(180 per 30 days)
selenium sulfide 2.5 % LOTION <b>MO</b>	1	QL(120 per 30 days)
SILVADENE 1 % CREAM <b>MO</b>	2	
silver sulfadiazine 1 % CREAM <b>MO</b>	1	
SOOLANTRA 1 % CREAM <b>MO</b>	3	ST,QL(45 per 30 days)
SORILUX 0.005 % FOAM <b>DL</b>	4	ST,QL(120 per 28 days)
spinosad 0.9 % SUSPENSION <b>MO</b>	3	QL(240 per 30 days)
SSD 1 % CREAM <b>MO</b>	1	
SULFAMYLON 50 GRAM PACKET <b>MO</b>	3	
SULFAMYLON 85 MG/G CREAM <b>MO</b>	3	
SYNALAR 0.01 % SOLUTION <b>MO</b>	3	QL(180 per 30 days)
TACLONEX 0.005-0.064 % OINTMENT <b>DL</b>	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TACLONEX 0.005-0.064 % SUSPENSION <b>DL</b>	4	PA,QL(420 per 30 days)
<i>tacrolimus</i> 0.03 %, 0.1 % OINTMENT <b>MO</b>	1	QL(200 per 30 days)
<i>tazarotene</i> 0.05 %, 0.1 % GEL <b>MO</b>	1	PA,QL(200 per 30 days)
<i>tazarotene</i> 0.1 % CREAM <b>MO</b>	1	PA,QL(120 per 30 days)
<i>tazarotene</i> 0.1 % FOAM <b>DL</b>	4	PA,QL(100 per 30 days)
TAZORAC 0.05 %, 0.1 % CREAM <b>MO</b>	3	PA,QL(120 per 30 days)
TAZORAC 0.05 %, 0.1 % GEL <b>MO</b>	3	PA,QL(200 per 30 days)
TEMOVATE 0.05 % OINTMENT <b>MO</b>	3	PA,QL(120 per 28 days)
TEXACORT 2.5 % SOLUTION <b>MO</b>	1	QL(240 per 30 days)
TOLAK 4 % CREAM <b>MO</b>	3	PA
TOPICORT 0.05 % CREAM <b>MO</b>	1	QL(240 per 30 days)
TOPICORT 0.05 % GEL <b>MO</b>	1	QL(240 per 30 days)
TOPICORT 0.05 % OINTMENT <b>MO</b>	3	QL(240 per 30 days)
TOPICORT 0.25 % CREAM <b>MO</b>	1	QL(120 per 30 days)
TOPICORT 0.25 % OINTMENT <b>MO</b>	1	QL(120 per 30 days)
TOPICORT 0.25 % SPRAY, NON-AEROSOL <b>MO</b>	3	QL(100 per 30 days)
<i>tovet emollient</i> 0.05 % FOAM <b>MO</b>	1	QL(100 per 30 days)
<i>tretinoin</i> 0.01 %, 0.025 %, 0.05 % GEL <b>MO</b>	1	PA,QL(45 per 30 days)
<i>tretinoin</i> 0.025 %, 0.05 %, 0.1 % CREAM <b>MO</b>	1	PA,QL(45 per 30 days)
<i>tretinoin microspheres</i> 0.04 %, 0.08 %, 0.1 % GEL WITH PUMP <b>MO</b>	1	PA,QL(50 per 30 days)
<i>tretinoin microspheres</i> 0.04 %, 0.1 % GEL <b>MO</b>	1	PA,QL(45 per 30 days)
TWYNEO 0.1-3 % CREAM <b>MO</b>	3	QL(30 per 30 days)
ULTRAVATE 0.05 % LOTION <b>MO</b>	3	QL(120 per 30 days)
UVADEX 20 MCG/ML SOLUTION <b>MO</b>	3	
VANOS 0.1 % CREAM <b>MO</b>	3	QL(120 per 28 days)
VECTICAL 3 MCG/GRAM OINTMENT <b>DL</b>	4	ST,QL(800 per 28 days)
VELTIN 1.2-0.025 % GEL <b>MO</b>	3	PA,QL(60 per 30 days)
VERDESO 0.05 % FOAM <b>DL</b>	4	QL(200 per 30 days)
VEREGEN 15 % OINTMENT <b>DL</b>	4	QL(30 per 30 days)
VTAMA 1 % CREAM <b>DL</b>	4	PA,QL(60 per 30 days)
WINLEVI 1 % CREAM <b>MO</b>	3	PA
XEPI 1 % CREAM <b>MO</b>	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
zenatane 10 mg, 20 mg, 30 mg CAPSULE <b>MO</b>	1	QL(60 per 30 days)
zenatane 40 mg CAPSULE <b>MO</b>	1	QL(120 per 30 days)
ZIANA 1.2-0.025 % GEL <b>MO</b>	3	PA,QL(60 per 30 days)
ZILXI 1.5 % FOAM <b>MO</b>	3	PA,QL(30 per 30 days)
ZONALON 5 % CREAM <b>MO</b>	3	PA,QL(45 per 30 days)
ZORYVE 0.3 % CREAM <b>DL</b>	4	PA,QL(120 per 30 days)
ZORYVE 0.3 % FOAM <b>DL</b>	4	PA,QL(120 per 30 days)
ZYCLARA 2.5 %, 3.75 % CREAM, METERED DOSE PUMP <b>DL</b>	4	ST,QL(15 per 30 days)
ZYCLARA 3.75 % CREAM IN PACKET <b>MO</b>	3	ST,QL(28 per 28 days)
<b>ELECTROLYTES/MINERALS/METALS/VITAMINS</b>		
AMINOSYN 10 % 10 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AMINOSYN 7 % WITH ELECTROLYTES 7 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AMINOSYN 8.5 % 8.5 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AMINOSYN 8.5 %-ELECTROLYTES 8.5 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AMINOSYN II 10 % 10 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AMINOSYN II 15 % 15 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AMINOSYN II 7 % 7 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AMINOSYN II 8.5 % 8.5 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AMINOSYN II 8.5 %-ELECTROLYTES 8.5 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AMINOSYN M 3.5 % 3.5 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AMINOSYN-PF 10 % 10 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AMINOSYN-PF 7 % (SULFITE-FREE) 7 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AMINOSYN-RF 5.2 % 5.2 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
AURYXIA 210 MG IRON TABLET <b>MO</b>	3	PA,QL(360 per 30 days)
bal-care dha 27-1-430 mg COMBO PACK, DR TAB/DR CAP <b>MO</b>	1	
c-nate dha 28 mg iron-1 mg -200 mg CAPSULE <b>MO</b>	1	
calcium acetate(phosphat bind) 667 mg CAPSULE <b>MO</b>	1	
calcium acetate(phosphat bind) 667 mg TABLET <b>MO</b>	1	
calcium chloride 100 mg/ml (10 %) SOLUTION <b>MO</b>	1	
calcium chloride 100 mg/ml (10 %) SYRINGE <b>MO</b>	1	
calcium gluconate 100 mg/ml (10%) SOLUTION <b>MO</b>	1	
CARBAGLU 200 MG TABLET, DISPERSIBLE <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>carglumic acid 200 mg TABLET, DISPERSIBLE</i> <b>DL</b>	4	PA
CARNITOR 100 MG/ML, 200 MG/ML SOLUTION <b>MO</b>	3	
CARNITOR 330 MG TABLET <b>MO</b>	3	
CARNITOR (SUGAR-FREE) 100 MG/ML SOLUTION <b>MO</b>	3	
CHEMET 100 MG CAPSULE <b>DL</b>	4	
CITRANATAL B-CALM (FE GLUC) 20 MG IRON-1 MG -25 MG/25 MG TABLET, SEQUENTIAL <b>MO</b>	3	
CLINIMIX 5%/D15W SULFITE FREE 5 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX 4.25%/D10W SULF FREE 4.25 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX 4.25%/D5W SULFIT FREE 4.25 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX 5%-D20W(SULFITE-FREE) 5 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX 6%-D5W (SULFITE-FREE) 6-5 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX 8%-D10W(SULFITE-FREE) 8-10 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX 8%-D14W(SULFITE-FREE) 8-14 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX E 2.75%/D5W SULF FREE 2.75 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX E 4.25%/D10W SUL FREE 4.25 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX E 4.25%/D5W SULF FREE 4.25 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX E 5%/D15W SULFIT FREE 5 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX E 5%/D20W SULFIT FREE 5 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX E 8%-D10W SULFITEFREE 8-10 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINIMIX E 8%-D14W SULFITEFREE 8-14 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
CLINISOL SF 15 % 15 % PARENTERAL SOLUTION <b>MO</b>	1	BvsD
CLINOLIPID 20 % EMULSION <b>MO</b>	3	BvsD
<i>complete natal dha 29 mg iron- 1 mg-200 mg COMBO PACK</i> <b>MO</b>	1	
CUPRIMINE 250 MG CAPSULE <b>DL</b>	4	PA,QL(600 per 30 days)
CUVRIOR 300 MG TABLET <b>DL</b>	4	PA,QL(300 per 30 days)
<i>d10 %-0.45 % sodium chloride PARENTERAL SOLUTION</i> <b>MO</b>	1	
<i>d2.5 %-0.45 % sodium chloride PARENTERAL SOLUTION</i> <b>MO</b>	1	
<i>d5 % and 0.9 % sodium chloride PARENTERAL SOLUTION</i> <b>MO</b>	1	
<i>d5 %-0.45 % sodium chloride PARENTERAL SOLUTION</i> <b>MO</b>	1	
deferasirox 125 mg, 250 mg, 500 mg TABLET, DISPERSIBLE <b>DL</b>	4	PA
deferasirox 180 mg, 360 mg, 90 mg GRANULES IN PACKET <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
deferasirox 180 mg, 360 mg, 90 mg TABLET <b>MO</b>	1	PA
deferiprone 1,000 mg TABLET <b>DL</b>	4	PA,QL(300 per 30 days)
deferiprone 500 mg TABLET <b>DL</b>	4	PA,QL(720 per 30 days)
deferoxamine 2 gram, 500 mg RECON SOLUTION <b>MO</b>	1	BvsD
DEPEN TITRATABS 250 MG TABLET <b>DL</b>	4	PA
DESFERAL 500 MG RECON SOLUTION <b>MO</b>	3	BvsD
dextrose 10 % and 0.2 % nacl PARENTERAL SOLUTION <b>MO</b>	1	
dextrose 10 % in water (d10w) 10 % PARENTERAL SOLUTION <b>MO</b>	1	
dextrose 20 % in water (d20w) 20 % PARENTERAL SOLUTION <b>MO</b>	1	
dextrose 25 % in water (d25w) SYRINGE <b>MO</b>	1	
dextrose 30 % in water (d30w) PARENTERAL SOLUTION <b>MO</b>	1	
dextrose 40 % in water (d40w) 40 % PARENTERAL SOLUTION <b>MO</b>	1	
dextrose 5 % in water (d5w) PARENTERAL SOLUTION <b>MO</b>	1	
dextrose 5 % in water (d5w) 5 % PIGGYBACK <b>MO</b>	1	
dextrose 5 %-lactated ringers PARENTERAL SOLUTION <b>MO</b>	1	
dextrose 5%-0.2 % sod chloride PARENTERAL SOLUTION <b>MO</b>	1	
dextrose 5%-0.3 % sod.chloride PARENTERAL SOLUTION <b>MO</b>	1	
dextrose 50 % in water (d50w) PARENTERAL SOLUTION <b>MO</b>	1	
dextrose 50 % in water (d50w) SYRINGE <b>MO</b>	1	
dextrose 70 % in water (d70w) PARENTERAL SOLUTION <b>MO</b>	1	
DUET DHA WITH OMEGA-3 25 MG IRON-1 MG -400 MG COMBO PACK <b>MO</b>	3	
electrolyte-148 PARENTERAL SOLUTION <b>MO</b>	1	
electrolyte-48 in d5w PARENTERAL SOLUTION <b>MO</b>	1	
electrolyte-a PARENTERAL SOLUTION <b>MO</b>	1	
EXJADE 125 MG, 250 MG, 500 MG TABLET, DISPERSIBLE <b>DL</b>	4	PA
FERRIPROX 1,000 MG TABLET <b>DL</b>	4	PA,QL(300 per 30 days)
FERRIPROX 100 MG/ML SOLUTION <b>DL</b>	4	PA,QL(3600 per 30 days)
FERRIPROX 500 MG TABLET <b>DL</b>	4	PA,QL(720 per 30 days)
FERRIPROX (2 TIMES A DAY) 1,000 MG TABLET, MODIFIED RELEASE <b>DL</b>	4	PA,QL(300 per 30 days)
FOSRENOL 1,000 MG, 500 MG, 750 MG CHEWABLE TABLET <b>DL</b>	4	ST
FOSRENOL 1,000 MG, 750 MG POWDER IN PACKET <b>DL</b>	4	ST
GLYCOPHOS 1 MMOL/ML SOLUTION <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
INTRALIPID 20 %, 30 % EMULSION <b>MO</b>	3	BvsD
IONOSOL-B IN D5W 5 % PARENTERAL SOLUTION <b>MO</b>	3	
IONOSOL-MB IN D5W 5 % PARENTERAL SOLUTION <b>MO</b>	3	
ISOLYTE S PH 7.4 PARENTERAL SOLUTION <b>MO</b>	3	
ISOLYTE-P IN 5 % DEXTROSE 5 % PARENTERAL SOLUTION <b>MO</b>	3	
ISOLYTE-S PARENTERAL SOLUTION <b>MO</b>	3	
JADENU 180 MG, 360 MG, 90 MG TABLET <b>DL</b>	4	PA
JADENU SPRINKLE 180 MG, 360 MG, 90 MG GRANULES IN PACKET <b>DL</b>	4	PA
JYNARQUE 15 MG (AM)/ 15 MG (PM), 30 MG (AM)/ 15 MG (PM), 45 MG (AM)/ 15 MG (PM), 60 MG (AM)/ 30 MG (PM), 90 MG (AM)/ 30 MG (PM) TABLET, SEQUENTIAL <b>DL</b>	4	PA,QL(56 per 28 days)
JYNARQUE 15 MG, 30 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
K-TAB 10 MEQ, 20 MEQ TABLET ER <b>MO</b>	3	
KABIVEN 3.31-9.8-3.9 % EMULSION <b>MO</b>	3	BvsD
<i>klor-con</i> 20 meq PACKET <b>MO</b>	1	QL(240 per 30 days)
KLOR-CON 10 10 MEQ TABLET ER <b>MO</b>	1	
KLOR-CON 8 8 MEQ TABLET ER <b>MO</b>	1	
<i>klor-con m10</i> 10 meq TABLET, ER PARTICLES/CRYSTALS <b>MO</b>	1	
KLOR-CON M15 15 MEQ TABLET, ER PARTICLES/CRYSTALS <b>MO</b>	1	
<i>klor-con m20</i> 20 meq TABLET, ER PARTICLES/CRYSTALS <b>MO</b>	1	
KOSHER PRENATAL PLUS IRON 30 MG IRON- 1 MG TABLET <b>MO</b>	3	
<i>lactated ringers</i> PARENTERAL SOLUTION <b>MO</b>	1	
lanthanum 1,000 mg, 500 mg, 750 mg CHEWABLE TABLET <b>DL</b>	4	ST
levocarnitine 100 mg/ml, 200 mg/ml SOLUTION <b>MO</b>	1	
levocarnitine 330 mg TABLET <b>MO</b>	1	
levocarnitine (with sugar) 100 mg/ml SOLUTION <b>MO</b>	1	
LOKELMA 10 GRAM, 5 GRAM POWDER IN PACKET <b>MO</b>	3	PA,QL(30 per 30 days)
<i>m-natal plus</i> 27 mg iron- 1 mg TABLET <b>MO</b>	1	
magnesium sulfate 500 mg/ml (50 %) SOLUTION <b>MO</b>	1	
magnesium sulfate 500 mg/ml (50 %) SYRINGE <b>MO</b>	1	
magnesium sulfate in d5w 1 gram/100 ml PIGGYBACK <b>MO</b>	1	
magnesium sulfate in water 2 gram/50 ml (4 %), 4 gram/100 ml (4 %), 4 gram/50 ml (8 %) PIGGYBACK <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>magnesium sulfate in water 20 gram/500 ml (4 %), 40 gram/1,000 ml (4 %)</i> <i>PARENTERAL SOLUTION</i> <b>MO</b>	1	
NATACHEW (FE BIS-GLYCINATE) 28 MG IRON -1 MG CHEWABLE TABLET <b>MO</b>	3	
NEONATAL COMPLETE 29-1 MG TABLET <b>MO</b>	1	
NEONATAL PLUS VITAMIN 27 MG IRON- 1 MG TABLET <b>MO</b>	1	
NEONATAL-DHA 29-1-200-500 MG COMBO PACK <b>MO</b>	1	
NORMOSOL-M IN 5 % DEXTROSE PARENTERAL SOLUTION <b>MO</b>	3	
NORMOSOL-R PARENTERAL SOLUTION <b>MO</b>	3	
NORMOSOL-R IN 5 % DEXTROSE 5 % PARENTERAL SOLUTION <b>MO</b>	3	
NORMOSOL-R PH 7.4 PARENTERAL SOLUTION <b>MO</b>	3	
NUTRILIPID 20 % EMULSION <b>MO</b>	3	BvsD
OB COMPLETE ONE 40-10-1-300 MG CAPSULE <b>MO</b>	3	
OB COMPLETE PETITE 35 MG IRON-5 MG IRON-1 MG CAPSULE <b>MO</b>	3	
OB COMPLETE PREMIER 30-20-1 MG TABLET <b>MO</b>	3	
OMEGAVEN 10 % EMULSION <b>DL</b>	4	BvsD
<i>penicillamine 250 mg CAPSULE</i> <b>DL</b>	4	PA,QL(600 per 30 days)
<i>penicillamine 250 mg TABLET</i> <b>DL</b>	4	
PERIKABIVEN 2.36-7.5-3.5 % EMULSION <b>MO</b>	3	BvsD
PHOSLYRA 667 MG (169 MG CALCIUM)/5 ML SOLUTION <b>MO</b>	3	ST
PLASMA-LYTE 148 PARENTERAL SOLUTION <b>MO</b>	3	
PLASMA-LYTE A PARENTERAL SOLUTION <b>MO</b>	3	
PLENAMINE 15 % PARENTERAL SOLUTION <b>MO</b>	1	BvsD
<i>prv-dha 27 mg iron-1 mg -300 mg CAPSULE</i> <b>MO</b>	1	
<i>prv-omega 28-1-300 mg CAPSULE</i> <b>MO</b>	1	
<i>potassium acetate 2 meq/ml SOLUTION</i> <b>MO</b>	1	
<i>potassium chlorid-d5-0.45%nacl 10 meq/l, 20 meq/l, 30 meq/l, 40 meq/l</i> <i>PARENTERAL SOLUTION</i> <b>MO</b>	1	
<i>potassium chloride 10 meq CAPSULE, ER</i> <b>MO</b>	1	
<i>potassium chloride 10 meq, 20 meq TABLET ER</i> <b>MO</b>	1	
<i>potassium chloride 10 meq, 20 meq TABLET, ER PARTICLES/CRYSTALS</i> <b>MO</b>	1	
<i>potassium chloride 15 meq TABLET, ER PARTICLES/CRYSTALS</i> <b>MO</b>	1	
<i>potassium chloride 2 meq/ml SOLUTION</i> <b>MO</b>	1	
<i>potassium chloride 20 meq PACKET</i> <b>MO</b>	1	QL(240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
potassium chloride 20 meq/15 ml LIQUID <b>MO</b>	1	QL(1125 per 30 days)
potassium chloride 40 meq/15 ml LIQUID <b>MO</b>	1	
potassium chloride 8 meq CAPSULE, ER <b>MO</b>	1	
potassium chloride 8 meq TABLET ER <b>MO</b>	1	
potassium chloride in 0.9%nacl 20 meq/l, 40 meq/l PARENTERAL SOLUTION <b>MO</b>	1	
potassium chloride in 5 % dex 10 meq/l, 20 meq/l, 30 meq/l PARENTERAL SOLUTION <b>MO</b>	1	
potassium chloride in lr-d5 20 meq/l, 40 meq/l PARENTERAL SOLUTION <b>MO</b>	1	
potassium chloride in water 10 meq/100 ml, 10 meq/50 ml, 20 meq/100 ml, 20 meq/50 ml, 30 meq/100 ml, 40 meq/100 ml PIGGYBACK <b>MO</b>	1	
potassium chloride-0.45 % nacl 20 meq/l PARENTERAL SOLUTION <b>MO</b>	1	
potassium chloride-d5-0.2%nacl 20 meq/l, 40 meq/l PARENTERAL SOLUTION <b>MO</b>	1	
potassium chloride-d5-0.3%nacl 20 meq/l PARENTERAL SOLUTION <b>MO</b>	1	
potassium chloride-d5-0.9%nacl 20 meq/l, 40 meq/l PARENTERAL SOLUTION <b>MO</b>	1	
potassium citrate 10 meq (1,080 mg), 15 meq, 5 meq (540 mg) TABLET ER <b>MO</b>	1	
pr natal 400 29-1-400 mg COMBO PACK <b>MO</b>	1	
pr natal 400 ec 29-1-400 mg COMBO PACK, DR TAB/DR CAP <b>MO</b>	1	
pr natal 430 29 mg iron-1 mg -430 mg COMBO PACK <b>MO</b>	1	
pr natal 430 ec 29-1-430 mg COMBO PACK, DR TAB/DR CAP <b>MO</b>	1	
PREMASOL 10 % 10 % PARENTERAL SOLUTION <b>MO</b>	1	BvsD
PRENATA 29 MG IRON- 1 MG CHEWABLE TABLET <b>MO</b>	1	
PRENATABS FA 29-1 MG TABLET <b>MO</b>	1	
prenatal plus (calcium carb) 27 mg iron- 1 mg TABLET <b>MO</b>	1	
prenatal plus dha 27 mg iron-1 mg -312 mg-250 mg COMBO PACK <b>MO</b>	3	
prenatal plus vitamin-mineral 27 mg iron- 1 mg TABLET <b>MO</b>	1	
prenatal vitamin plus low iron 27 mg iron- 1 mg TABLET <b>MO</b>	1	
prenatal-u 106.5-1 mg CAPSULE <b>MO</b>	1	
PRENATE ELITE 26 MG IRON- 1 MG TABLET <b>MO</b>	1	
preplus 27 mg iron- 1 mg TABLET <b>MO</b>	1	
PROCALAMINE 3% 3 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
PROSOL 20 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
RENAGEL 800 MG TABLET <b>DL</b>	4	ST
REVELA 0.8 GRAM POWDER IN PACKET <b>DL</b>	4	PA,QL(540 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
REVELA 2.4 GRAM POWDER IN PACKET <b>DL</b>	4	PA,QL(180 per 30 days)
REVELA 800 MG TABLET <b>DL</b>	4	PA,QL(540 per 30 days)
ringer's PARENTERAL SOLUTION <b>MO</b>	1	
SAMSCA 15 MG, 30 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
se-natal 19 chewable 29 mg iron- 1 mg CHEWABLE TABLET <b>MO</b>	1	
SELECT-OB 29 MG IRON- 1 MG CHEWABLE TABLET <b>MO</b>	3	
SELECT-OB (FOLIC ACID) 29 MG IRON- 1 MG CHEWABLE TABLET <b>MO</b>	3	
SELECT-OB + DHA 29 MG IRON-1 MG -250 MG COMBO PACK <b>MO</b>	3	
sevelamer carbonate 0.8 gram POWDER IN PACKET <b>MO</b>	1	QL(540 per 30 days)
sevelamer carbonate 2.4 gram POWDER IN PACKET <b>MO</b>	1	QL(180 per 30 days)
sevelamer carbonate 800 mg TABLET <b>MO</b>	1	QL(540 per 30 days)
sevelamer hcl 400 mg, 800 mg TABLET <b>MO</b>	1	ST
SMOFLIPID 20 % EMULSION <b>MO</b>	3	BvsD
sodium bicarbonate 8.4 % (1 meq/ml) SYRINGE <b>MO</b>	1	
sodium chloride 2.5 meq/ml SOLUTION <b>MO</b>	1	
sodium chloride 0.45 % 0.45 % PARENTERAL SOLUTION <b>MO</b>	1	
sodium chloride 0.9 % PARENTERAL SOLUTION <b>MO</b>	1	
sodium chloride 0.9 % PIGGYBACK <b>MO</b>	1	
sodium chloride 0.9 % SOLUTION <b>MO</b>	1	
sodium chloride 3 % hypertonic 3 % PARENTERAL SOLUTION <b>MO</b>	1	
sodium chloride 5 % hypertonic 5 % PARENTERAL SOLUTION <b>MO</b>	1	
sodium phosphate 3 mmol/ml SOLUTION <b>MO</b>	1	
sodium polystyrene sulfonate POWDER <b>MO</b>	1	
SPS (WITH SORBITOL) 15-20 GRAM/60 ML SUSPENSION <b>MO</b>	1	
SPS (WITH SORBITOL) 30-40 GRAM/120 ML ENEMA <b>MO</b>	1	
SYPRINE 250 MG CAPSULE <b>DL</b>	4	PA,QL(240 per 30 days)
THAM 36 MG/ML (0.3 M) SOLUTION <b>MO</b>	3	
tolvaptan 15 mg, 30 mg TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
TPN ELECTROLYTES 35-20-5 MEQ/20 ML SOLUTION <b>MO</b>	3	
TRAVASOL 10 % 10 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
TRICARE 27 MG IRON- 1 MG TABLET <b>MO</b>	1	
trientine 250 mg CAPSULE <b>DL</b>	4	QL(240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>trientine 500 mg CAPSULE</i> <b>DL</b>	4	QL(120 per 30 days)
<i>trinatal rx 1 60 mg iron-1 mg TABLET</i> <b>MO</b>	1	
TRISTART DHA 31 MG IRON- 1 MG-200 MG CAPSULE <b>MO</b>	3	
TROPHAMINE 10 % 10 % PARENTERAL SOLUTION <b>MO</b>	3	BvsD
UROKIT-K 10 10 MEQ (1,080 MG) TABLET ER <b>MO</b>	3	
UROKIT-K 15 15 MEQ TABLET ER <b>MO</b>	3	
UROKIT-K 5 5 MEQ (540 MG) TABLET ER <b>MO</b>	3	
VAPRISOL IN 5 % DEXTROSE 20 MG/100 ML SOLUTION <b>MO</b>	3	
VELPHORO 500 MG CHEWABLE TABLET	4	ST
VELTASSA 16.8 GRAM, 25.2 GRAM, 8.4 GRAM POWDER IN PACKET <b>MO</b>	2	QL(30 per 30 days)
<i>virt-c dha 35-1-200 mg CAPSULE</i> <b>MO</b>	1	
<i>virt-nate dha 28 mg iron-1 mg -200 mg CAPSULE</i> <b>MO</b>	1	
<i>virt-pn dha 27 mg iron-1 mg -300 mg CAPSULE</i> <b>MO</b>	1	
VITAFOL FE PLUS 90 MG IRON- 1 MG-200 MG CAPSULE <b>MO</b>	3	
VITAFOL GUMMIES 3.33 MG IRON- 0.33 MG CHEWABLE TABLET <b>MO</b>	3	
VITAFOL NANO 18 MG IRON- 1 MG TABLET <b>MO</b>	3	
VITAFOL ULTRA 29 MG IRON- 1 MG-200 MG CAPSULE <b>MO</b>	3	
VITAFOL-OB 65-1 MG TABLET <b>MO</b>	3	
VITAFOL-OB+DHA 65-1-250 MG COMBO PACK <b>MO</b>	3	
VITAFOL-ONE 29 MG IRON- 1 MG-200 MG CAPSULE <b>MO</b>	3	
VITAMEDMD ONE RX 30 MG IRON-1MG -200 MG CAPSULE <b>MO</b>	3	
VP-PNV-DHA 28 MG IRON- 1 MG-200 MG CAPSULE <b>MO</b>	3	
<i>wescap-pn dha 27 mg iron-1 mg -300 mg CAPSULE</i> <b>MO</b>	1	
<i>wesnatal dha complete 29 mg iron- 1 mg-200 mg COMBO PACK</i> <b>MO</b>	1	
<i>wesnate dha 28 mg iron-1 mg -200 mg CAPSULE</i> <b>MO</b>	1	
<i>westab plus 27 mg iron- 1 mg TABLET</i> <b>MO</b>	1	
<i>westgel dha 31 mg iron- 1 mg-200 mg CAPSULE</i> <b>MO</b>	1	
XPHOZAH 20 MG, 30 MG TABLET <b>DL</b>	4	ST,QL(60 per 30 days)
<i>zatean-pn dha 27 mg iron-1 mg -300 mg CAPSULE</i> <b>MO</b>	1	
<i>zatean-pn plus 28-1-300 mg CAPSULE</i> <b>MO</b>	1	
<b>GASTROINTESTINAL AGENTS</b>		
ACIPHEX 20 MG TABLET, DR/EC <b>MO</b>	3	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ACIPHEX SPRINKLE 10 MG CAPSULE, DR SPRINKLE <b>DL</b>	4	QL(60 per 30 days)
ACIPHEX SPRINKLE 5 MG CAPSULE, DR SPRINKLE <b>DL</b>	4	QL(30 per 30 days)
AEMCOLO 194 MG TABLET, DR/EC <b>MO</b>	3	PA,QL(12 per 30 days)
<i>alose tron</i> 0.5 mg, 1 mg TABLET <b>MO</b>	1	PA,QL(60 per 30 days)
AMITIZA 24 MCG, 8 MCG CAPSULE <b>MO</b>	3	PA,QL(60 per 30 days)
<i>amoxicil-clarithromy-lansopraz</i> 500-500-30 mg COMBO PACK <b>MO</b>	1	ST
<i>atropine</i> 0.1 mg/ml, 0.25 mg/5 ml (0.05 mg/ml) SYRINGE <b>MO</b>	1	
BENTYL 10 MG/ML SOLUTION <b>MO</b>	3	
<i>bismuth subcit k-metronidz-tcn</i> 140-125-125 mg CAPSULE <b>MO</b>	1	QL(120 per 30 days)
CARAFATE 1 GRAM TABLET <b>MO</b>	3	
CARAFATE 100 MG/ML SUSPENSION <b>MO</b>	3	
CHENODAL 250 MG TABLET <b>DL</b>	4	PA
<i>cimetidine</i> 200 mg, 300 mg, 400 mg, 800 mg TABLET <b>MO</b>	1	
<i>cimetidine hcl</i> 300 mg/5 ml SOLUTION <b>MO</b>	1	
CLENPIQ 10 MG-3.5 GRAM- 12 GRAM/160 ML SOLUTION <b>MO</b>	2	
CLENPIQ 10 MG-3.5 GRAM- 12 GRAM/175 ML SOLUTION <b>MO</b>	2	
<i>constulose</i> 10 gram/15 ml SOLUTION <b>MO</b>	1	
CUVPOSA 1 MG/5 ML (0.2 MG/ML) SOLUTION <b>MO</b>	3	
CYTOTEC 100 MCG, 200 MCG TABLET <b>DL</b>	4	
DARTISLA 1.7 MG TABLET, DISINTEGRATING <b>MO</b>	3	ST,QL(120 per 30 days)
DEXILANT 30 MG, 60 MG CAPSULE, DR, BIPHASIC <b>MO</b>	3	ST,QL(30 per 30 days)
<i>dexlansoprazole</i> 30 mg, 60 mg CAPSULE, DR, BIPHASIC <b>MO</b>	3	ST,QL(30 per 30 days)
<i>dicyclomine</i> 10 mg CAPSULE <b>MO</b>	1	
<i>dicyclomine</i> 10 mg/5 ml, 10 mg/ml SOLUTION <b>MO</b>	1	
<i>dicyclomine</i> 20 mg TABLET <b>MO</b>	1	
<i>diphenoxylate-atropine</i> 2.5-0.025 mg TABLET <b>MO</b>	1	
<i>diphenoxylate-atropine</i> 2.5-0.025 mg/5 ml LIQUID <b>MO</b>	1	
ENDARI 5 GRAM POWDER IN PACKET <b>DL</b>	4	PA,QL(180 per 30 days)
<i>enulose</i> 10 gram/15 ml SOLUTION <b>MO</b>	1	
<i>esomeprazole magnesium</i> 10 mg, 20 mg, 40 mg DR GRANULES IN PACKET <b>MO</b>	1	QL(30 per 30 days)
<i>esomeprazole magnesium</i> 20 mg CAPSULE, DR/EC <b>MO</b>	1	QL(60 per 30 days)
<i>esomeprazole magnesium</i> 40 mg CAPSULE, DR/EC <b>MO</b>	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
esomeprazole sodium 20 mg, 40 mg RECON SOLUTION <b>MO</b>	1	
ESOMEPRAZOLE STRONTIUM 49.3 MG CAPSULE, DR/EC <b>MO</b>	3	QL(30 per 30 days)
famotidine 10 mg/ml SOLUTION <b>MO</b>	1	
famotidine 20 mg, 40 mg TABLET <b>MO</b>	1	
famotidine 40 mg/5 ml (8 mg/ml) SUSPENSION FOR RECONSTITUTION <b>MO</b>	1	
famotidine (pf) 20 mg/2 ml SOLUTION <b>MO</b>	1	
famotidine (pf)-nacl (iso-os) 20 mg/50 ml PIGGYBACK <b>MO</b>	1	
GATTEX 30-VIAL 5 MG KIT <b>DL,LA</b>	4	PA
GATTEX ONE-VIAL 5 MG KIT <b>DL,LA</b>	4	PA
gavilyte-c 240-22.72-6.72 -5.84 gram RECON SOLUTION <b>MO</b>	1	
gavilyte-g 236-22.74-6.74 -5.86 gram RECON SOLUTION <b>MO</b>	1	
generlac 10 gram/15 ml SOLUTION <b>MO</b>	1	
GLYCATE 1.5 MG TABLET <b>MO</b>	1	
glycopyrrolate 0.2 mg/ml, 1 mg/5 ml (0.2 mg/ml) SOLUTION <b>MO</b>	1	
glycopyrrolate 1 mg, 1.5 mg, 2 mg TABLET <b>MO</b>	1	
glycopyrrolate (pf) 0.6 mg/3 ml (0.2 mg/ml) SYRINGE <b>MO</b>	3	
glycopyrrolate (pf) in water 0.2 mg/ml SYRINGE <b>MO</b>	1	
GOLYTELY 236-22.74-6.74 -5.86 GRAM RECON SOLUTION <b>MO</b>	3	ST
IBSRELA 50 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
KONVOMEK 2-84 MG/ML SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	ST,QL(600 per 30 days)
KRISTALOSE 10 GRAM, 20 GRAM PACKET <b>MO</b>	1	
lactulose 10 gram PACKET <b>DL</b>	4	
lactulose 10 gram/15 ml (15 ml), 20 gram/30 ml SOLUTION <b>MO</b>	1	
lactulose 10 gram/15 ml SOLUTION <b>MO</b>	1	
lansoprazole 15 mg, 30 mg CAPSULE, DR/EC <b>MO</b>	1	QL(60 per 30 days)
lansoprazole 15 mg, 30 mg TABLET, DISINTEGRATING DR <b>MO</b>	1	QL(30 per 30 days)
LINZESS 145 MCG, 290 MCG, 72 MCG CAPSULE <b>MO</b>	2	QL(30 per 30 days)
LOMOTIL 2.5-0.025 MG TABLET <b>MO</b>	3	
loperamide 2 mg CAPSULE <b>MO</b>	1	
LOTROXEX 0.5 MG, 1 MG TABLET	4	PA,QL(60 per 30 days)
lubiprostone 24 mcg, 8 mcg CAPSULE <b>MO</b>	1	QL(60 per 30 days)
methscopolamine 2.5 mg, 5 mg TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>misoprostol 100 mcg TABLET</i> <b>MO</b>	1	
<i>misoprostol 200 mcg TABLET</i> <b>MO</b>	1	
MOTEGRITY 1 MG, 2 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
MOTOFEN 1-0.025 MG TABLET <b>MO</b>	3	
MOVANTIK 12.5 MG, 25 MG TABLET <b>MO</b>	2	QL(30 per 30 days)
MOVIPREP 100-7.5-2.691 GRAM POWDER IN PACKET <b>MO</b>	3	ST
MYALEPT 5 MG/ML (FINAL CONC.) RECON SOLUTION <b>DL</b>	4	PA,QL(30 per 30 days)
MYTESI 125 MG TABLET, DR/EC <b>DL</b>	4	PA,QL(60 per 30 days)
NEXIUM 20 MG, 40 MG CAPSULE, DR/EC <b>MO</b>	3	PA,QL(60 per 30 days)
NEXIUM IV 40 MG RECON SOLUTION <b>MO</b>	3	PA
NEXIUM PACKET 10 MG, 2.5 MG, 20 MG, 40 MG, 5 MG DR GRANULES IN PACKET <b>MO</b>	3	QL(30 per 30 days)
<i>nizatidine 150 mg, 300 mg CAPSULE</i> <b>MO</b>	1	
<i>nizatidine 150 mg/10 ml SOLUTION</i> <b>MO</b>	1	
NULYTELY LEMON-LIME 420 GRAM RECON SOLUTION <b>MO</b>	3	ST
OICALIVA 10 MG, 5 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
OMECLAMOX-PAK 20 MG-500 MG- 500 MG (40) COMBO PACK <b>MO</b>	3	ST
<i>omeprazole 10 mg CAPSULE, DR/EC</i> <b>MO</b>	1	QL(60 per 30 days)
<i>omeprazole 20 mg, 40 mg CAPSULE, DR/EC</i> <b>MO</b>	1	QL(60 per 30 days)
<i>omeprazole-sodium bicarbonate 20-1,680 mg, 40-1,680 mg PACKET</i> <b>DL</b>	4	ST,QL(30 per 30 days)
<i>omeprazole-sodium bicarbonate 20-1.1 mg-gram, 40-1.1 mg-gram CAPSULE</i> <b>MO</b>	1	ST,QL(30 per 30 days)
<i>opium tincture 10 mg/ml (morphine) TINCTURE</i> <b>MO</b>	3	QL(180 per 30 days)
OSMOPREP 1.5 GRAM TABLET <b>MO</b>	3	ST
<i>pantoprazole 20 mg, 40 mg TABLET, DR/EC</i> <b>MO</b>	1	QL(60 per 30 days)
<i>pantoprazole 40 mg DR GRANULES IN PACKET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>pantoprazole 40 mg RECON SOLUTION</i> <b>MO</b>	1	
<i>peg 3350-electrolytes 236-22.74-6.74 -5.86 gram RECON SOLUTION</i> <b>MO</b>	1	
<i>peg-electrolyte soln 420 gram RECON SOLUTION</i> <b>MO</b>	1	
<i>peg-prep 5-210 mg-gram KIT</i> <b>MO</b>	1	
<i>peg3350-sod sul-nacl-kcl-asb-c 100-7.5-2.691 gram POWDER IN PACKET</i> <b>MO</b>	1	ST
<i>pepcid 20 mg, 40 mg TABLET</i> <b>MO</b>	3	PA
PLENVU 140-9-5.2 GRAM POWDER IN PACKET, SEQUENTIAL <b>MO</b>	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PREVACID 30 MG CAPSULE, DR/EC <b>MO</b>	3	PA,QL(60 per 30 days)
PREVACID SOLUTAB 15 MG, 30 MG TABLET, DISINTEGRATING DR <b>MO</b>	3	QL(30 per 30 days)
PRILOSEC 10 MG, 2.5 MG SUSPENSION, DR FOR RECON <b>MO</b>	3	
PROTONIX 20 MG, 40 MG TABLET, DR/EC <b>MO</b>	3	PA,QL(60 per 30 days)
PROTONIX 40 MG DR GRANULES IN PACKET <b>MO</b>	3	QL(30 per 30 days)
PROTONIX 40 MG RECON SOLUTION <b>MO</b>	3	PA
PYLERA 140-125-125 MG CAPSULE <b>MO</b>	3	ST,QL(120 per 30 days)
<i>rabeprazole 20 mg TABLET, DR/EC <b>MO</b></i>	1	QL(60 per 30 days)
RELISTOR 12 MG/0.6 ML SOLUTION <b>DL</b>	4	PA,QL(36 per 30 days)
RELISTOR 12 MG/0.6 ML SYRINGE <b>DL</b>	4	PA,QL(36 per 28 days)
RELISTOR 150 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
RELISTOR 8 MG/0.4 ML SYRINGE <b>DL</b>	4	PA,QL(12 per 30 days)
RELTONE 200 MG CAPSULE <b>DL</b>	4	PA,QL(150 per 30 days)
RELTONE 400 MG CAPSULE <b>DL</b>	4	PA,QL(60 per 30 days)
ROBINUL 1 MG TABLET <b>MO</b>	3	PA
ROBINUL FORTE 2 MG TABLET <b>MO</b>	3	PA
<i>sodium,potassium,mag sulfates 17.5-3.13-1.6 gram RECON SOLUTION <b>MO</b></i>	1	
<i>sucralfate 1 gram TABLET <b>MO</b></i>	1	
<i>sucralfate 100 mg/ml SUSPENSION <b>MO</b></i>	1	
SUFLAVE 178.7-7.3-0.5 GRAM RECON SOLUTION <b>MO</b>	3	ST
SUPREP BOWEL PREP KIT 17.5-3.13-1.6 GRAM RECON SOLUTION <b>MO</b>	3	ST
SUTAB 1.479-0.188- 0.225 GRAM TABLET <b>MO</b>	3	ST
SYMPROIC 0.2 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
TALICIA 10-250-12.5 MG CAPSULE, IR/DR, BIPHASIC <b>MO</b>	3	ST
TRULANCE 3 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
URSO 250 250 MG TABLET <b>MO</b>	3	PA
URSO FORTE 500 MG TABLET <b>MO</b>	3	PA
<i>ursodiol 200 mg CAPSULE <b>DL</b></i>	4	PA,QL(150 per 30 days)
<i>ursodiol 250 mg, 500 mg TABLET <b>MO</b></i>	1	
<i>ursodiol 300 mg CAPSULE <b>MO</b></i>	1	
<i>ursodiol 400 mg CAPSULE <b>DL</b></i>	4	PA,QL(60 per 30 days)
VIBERZI 100 MG, 75 MG TABLET	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VOQUEZNA 10 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
VOQUEZNA 20 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
VOQUEZNA DUAL PAK 20 MG (28)- 500 MG (84) COMBO PACK <b>MO</b>	3	ST,QL(112 per 30 days)
VOQUEZNA TRIPLE PAK 20-500-500 MG COMBO PACK <b>MO</b>	3	ST,QL(112 per 30 days)
XERMELO 250 MG TABLET <b>DL</b>	4	PA,QL(84 per 28 days)
XIFAXAN 200 MG TABLET <b>MO</b>	3	PA,QL(9 per 30 days)
XIFAXAN 550 MG TABLET	4	PA,QL(84 per 28 days)
ZEGERID 20-1,680 MG, 40-1,680 MG PACKET <b>DL</b>	4	ST,QL(30 per 30 days)
ZEGERID 20-1.1 MG-GRAM, 40-1.1 MG-GRAM CAPSULE <b>DL</b>	4	ST,QL(30 per 30 days)
ZINPLAVA 25 MG/ML SOLUTION <b>DL</b>	4	PA
<b>GENETIC/ENZYME/PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT</b>		
ALDURAZYME 2.9 MG/5 ML SOLUTION <b>DL</b>	4	PA
AMVUTTRA 25 MG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(0.5 per 90 days)
ARALAST NP 1,000 MG, 500 MG RECON SOLUTION <b>DL</b>	4	PA
<i>betaine 1 gram/scoop POWDER</i> <b>DL</b>	4	
BUPHENYL 0.94 GRAM/GRAM POWDER <b>DL</b>	4	PA
BUPHENYL 500 MG TABLET <b>DL</b>	4	PA
CERDELGA 84 MG CAPSULE <b>DL</b>	4	PA
CEREZYME 400 UNIT RECON SOLUTION <b>DL</b>	4	PA
CHOLBAM 250 MG, 50 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
CREON 12,000-38,000 -60,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000- 180,000 UNIT, 6,000-19,000 -30,000 UNIT CAPSULE, DR/EC <b>MO</b>	2	
CREON 24,000-76,000 -120,000 UNIT CAPSULE, DR/EC <b>MO</b>	2	
CRYSVITA 10 MG/ML, 20 MG/ML SOLUTION <b>DL</b>	4	PA,QL(2 per 28 days)
CRYSVITA 30 MG/ML SOLUTION <b>DL</b>	4	PA,QL(6 per 28 days)
CYSTADANE 1 GRAM/SCOOP POWDER <b>DL</b>	4	PA
CYSTAGON 150 MG, 50 MG CAPSULE <b>MO</b>	3	
<i>dichlorphenamide 50 mg TABLET</i> <b>DL</b>	4	PA,QL(120 per 30 days)
ELAPRASE 6 MG/3 ML SOLUTION <b>DL</b>	4	PA
ELELYSO 200 UNIT RECON SOLUTION <b>DL</b>	4	PA
ELEVIDYS 1.33 X 10EXP13 VG/ML SUSPENSION <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ELFABRIO 2 MG/ML SOLUTION <b>DL</b>	4	PA
EVRYSDI 0.75 MG/ML RECON SOLUTION <b>DL</b>	4	PA,QL(240 per 30 days)
FABRAZYME 35 MG, 5 MG RECON SOLUTION <b>DL</b>	4	PA
GALAFOLD 123 MG CAPSULE <b>DL</b>	4	PA,QL(14 per 28 days)
GLASSIA 1 GRAM/50 ML (2 %) SOLUTION <b>DL</b>	4	PA
<i>javygtor 100 mg TABLET, SOLUBLE</i> <b>DL</b>	4	PA
<i>javygtor 100 mg, 500 mg POWDER IN PACKET</i> <b>DL</b>	4	PA
JOENJA 70 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
KANUMA 2 MG/ML SOLUTION <b>DL</b>	4	PA
KEVEYIS 50 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
KUVAN 100 MG TABLET, SOLUBLE <b>DL</b>	4	PA
KUVAN 100 MG, 500 MG POWDER IN PACKET <b>DL</b>	4	PA
LAMZEDE 10 MG RECON SOLUTION <b>DL</b>	4	PA
LUMIZYME 50 MG RECON SOLUTION <b>DL</b>	4	PA
MEPSEVII 2 MG/ML SOLUTION <b>DL</b>	4	PA
<i>miglustat 100 mg CAPSULE</i> <b>DL</b>	4	PA,QL(90 per 30 days)
NAGLAZYME 5 MG/5 ML SOLUTION <b>DL</b>	4	PA
NEXVIAZYME 100 MG RECON SOLUTION <b>DL</b>	4	PA
<i>nitisinone 10 mg, 2 mg, 20 mg, 5 mg CAPSULE</i> <b>DL</b>	4	
NITYR 10 MG, 2 MG, 5 MG TABLET <b>DL</b>	4	
NULIBRY 9.5 MG RECON SOLUTION <b>DL</b>	4	PA
OLPRUVA 2 GRAM, 3 GRAM, 4 GRAM, 5 GRAM, 6 GRAM, 6.67 GRAM PELLETS IN PACKET <b>DL</b>	4	PA
ONPATTRO 2 MG/ML SOLUTION <b>DL</b>	4	PA
OPFOLDA 65 MG CAPSULE <b>MO</b>	3	PA
ORFADIN 10 MG, 2 MG, 20 MG, 5 MG CAPSULE <b>DL</b>	4	
ORFADIN 4 MG/ML SUSPENSION <b>DL</b>	4	
<i>ormalvi 50 mg TABLET</i> <b>DL</b>	4	PA,QL(120 per 30 days)
PALYNZIQ 10 MG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(15 per 30 days)
PALYNZIQ 2.5 MG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(4 per 28 days)
PALYNZIQ 20 MG/ML SYRINGE <b>DL</b>	4	PA,QL(90 per 30 days)
PANCREAZE 10,500-35,500- 61,500 UNIT, 4,200-14,200- 24,600 UNIT CAPSULE, DR/EC <b>MO</b>	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PANCREAZE 16,800-56,800- 98,400 UNIT, 2,600-8,800- 15,200 UNIT, 21,000-54,700- 83,900 UNIT CAPSULE, DR/EC	4	ST
PANCREAZE 37,000-97,300- 149,900 UNIT CAPSULE, DR/EC <b>DL</b>	4	ST
PERTZYE 16,000-57,500- 60,500 UNIT, 24,000-86,250- 90,750 UNIT, 4,000-14,375- 15,125 UNIT, 8,000-28,750- 30,250 UNIT CAPSULE, DR/EC <b>DL</b>	4	ST
PHEBURANE 483 MG/GRAM GRANULES <b>DL</b>	4	PA
POMBILITI 105 MG RECON SOLUTION <b>DL</b>	4	PA
PROCYSBI 25 MG CAPSULE, DR SPRINKLE <b>DL</b>	4	PA,QL(120 per 30 days)
PROCYSBI 300 MG DR GRANULES IN PACKET <b>DL</b>	4	PA,QL(210 per 30 days)
PROCYSBI 75 MG CAPSULE, DR SPRINKLE <b>DL</b>	4	PA,QL(780 per 30 days)
PROCYSBI 75 MG DR GRANULES IN PACKET <b>DL</b>	4	PA,QL(780 per 30 days)
PROLASTIN-C 1,000 MG (+-)/20 ML SOLUTION <b>DL</b>	4	PA
RAVICTI 1.1 GRAM/ML LIQUID <b>DL</b>	4	PA,QL(525 per 30 days)
REVCovi 2.4 MG/1.5 ML (1.6 MG/ML) SOLUTION <b>DL</b>	4	
<i>sapropterin 100 mg TABLET, SOLUBLE</i> <b>DL</b>	4	PA
<i>sapropterin 100 mg, 500 mg POWDER IN PACKET</i> <b>DL</b>	4	PA
<i>sodium phenylbutyrate 0.94 gram/gram POWDER</i> <b>DL</b>	4	
<i>sodium phenylbutyrate 500 mg TABLET</i> <b>DL</b>	4	
STRENSIQ 18 MG/0.45 ML, 28 MG/0.7 ML, 40 MG/ML, 80 MG/0.8 ML SOLUTION <b>DL</b>	4	PA
SUCRAID 8,500 UNIT/ML SOLUTION <b>DL</b>	4	
TEGSEDI 284 MG/1.5 ML SYRINGE <b>DL</b>	4	PA,QL(6 per 28 days)
VIJOICE 125 MG, 50 MG TABLET <b>DL</b>	4	PA,QL(28 per 28 days)
VIJOICE 250 MG/DAY (200 MG X1-50 MG X1) TABLET <b>DL</b>	4	PA,QL(56 per 28 days)
VIOKACE 10,440-39,150- 39,150 UNIT, 20,880-78,300- 78,300 UNIT TABLET <b>DL</b>	4	ST
VPRIV 400 UNIT RECON SOLUTION <b>DL</b>	4	PA
VYNDAMAX 61 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
VYNDAQEL 20 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
WAINUA 45 MG/0.8 ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(0.8 per 28 days)
XENPOZYME 20 MG, 4 MG RECON SOLUTION <b>DL</b>	4	PA
XURIDEN 2 GRAM GRANULES IN PACKET <b>DL</b>	4	PA,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
yargesa 100 mg CAPSULE <b>DL</b>	4	PA,QL(90 per 30 days)
ZAVESCA 100 MG CAPSULE <b>DL</b>	4	PA,QL(90 per 30 days)
ZEMAIRA 1,000 MG, 4,000 MG, 5,000 MG RECON SOLUTION <b>DL</b>	4	PA
ZENPEP 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT CAPSULE, DR/EC <b>MO</b>	3	
ZENPEP 25,000-79,000- 105,000 UNIT CAPSULE, DR/EC <b>MO</b>	3	
ZOKINVY 50 MG, 75 MG CAPSULE <b>DL</b>	4	PA,QL(120 per 30 days)
<b>GENITOURINARY AGENTS</b>		
alfuzosin 10 mg TABLET, ER 24 HR. <b>MO</b>	1	
AVODART 0.5 MG CAPSULE <b>MO</b>	3	PA,QL(30 per 30 days)
bethanechol chloride 10 mg, 25 mg, 5 mg, 50 mg TABLET <b>MO</b>	1	
CIALIS 2.5 MG, 5 MG TABLET <b>MO</b>	3	PA
darifenacin 15 mg, 7.5 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
DETROL 1 MG, 2 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
DETROL LA 2 MG, 4 MG CAPSULE, ER 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
DITROPAN XL 10 MG, 5 MG TABLET, ER 24 HR. <b>MO</b>	3	PA,QL(60 per 30 days)
dutasteride 0.5 mg CAPSULE <b>MO</b>	1	QL(30 per 30 days)
dutasteride-tamsulosin 0.5-0.4 mg CAPSULE ER MULTIPHASE 24 HR. <b>MO</b>	1	QL(30 per 30 days)
ELMIRON 100 MG CAPSULE <b>MO</b>	3	QL(90 per 30 days)
ENTADFI 5-5 MG CAPSULE <b>MO</b>	3	PA,QL(182 per 365 days)
fesoterodine 4 mg, 8 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
finasteride 5 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
flavoxate 100 mg TABLET <b>MO</b>	1	
FLOMAX 0.4 MG CAPSULE <b>MO</b>	3	
GELNIQUE 10 % (100 MG/GRAM) GEL IN PACKET <b>MO</b>	3	ST,QL(30 per 30 days)
GEMTESA 75 MG TABLET <b>MO</b>	3	QL(30 per 30 days)
JALYN 0.5-0.4 MG CAPSULE ER MULTIPHASE 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
MYRBETRIQ 25 MG, 50 MG TABLET, ER 24 HR. <b>MO</b>	2	QL(30 per 30 days)
MYRBETRIQ 8 MG/ML SUSPENSION, ER, RECON <b>MO</b>	2	QL(300 per 30 days)
oxybutynin chloride 10 mg, 5 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)
oxybutynin chloride 15 mg TABLET, ER 24 HR. <b>MO</b>	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
oxybutynin chloride 2.5 mg TABLET <b>MO</b>	1	QL(90 per 30 days)
oxybutynin chloride 5 mg TABLET <b>MO</b>	1	
oxybutynin chloride 5 mg/5 ml SYRUP <b>MO</b>	1	
OXYTROL 3.9 MG/24 HR PATCH, SEMIWEEKLY <b>MO</b>	3	ST,QL(8 per 28 days)
PROSCAR 5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
RAPAFLO 4 MG, 8 MG CAPSULE <b>MO</b>	3	PA,QL(30 per 30 days)
silodosin 4 mg, 8 mg CAPSULE <b>MO</b>	1	QL(30 per 30 days)
solifenacin 10 mg, 5 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
tadalafil 2.5 mg, 5 mg TABLET <b>MO</b>	1	PA
tamsulosin 0.4 mg CAPSULE <b>MO</b>	1	
THIOLA 100 MG TABLET <b>DL</b>	4	
THIOLA EC 100 MG, 300 MG TABLET, DR/EC <b>DL</b>	4	
tiopronin 100 mg TABLET <b>DL</b>	4	
tiopronin 100 mg, 300 mg TABLET, DR/EC <b>DL</b>	4	
tolterodine 1 mg, 2 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
tolterodine 2 mg, 4 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
TOVIAZ 4 MG, 8 MG TABLET, ER 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
tropium 20 mg TABLET <b>MO</b>	1	
tropium 60 mg CAPSULE, ER 24 HR. <b>MO</b>	1	QL(30 per 30 days)
UROXATRAL 10 MG TABLET, ER 24 HR. <b>MO</b>	3	
VESICARE 10 MG, 5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
VESICARE LS 1 MG/ML SUSPENSION <b>MO</b>	3	PA,QL(300 per 30 days)
<b>HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (ADRENAL)</b>		
ACTHAR 80 UNIT/ML GEL <b>DL</b>	4	PA,QL(30 per 30 days)
AGAMREE 40 MG/ML SUSPENSION <b>DL</b>	4	PA,QL(225 per 30 days)
ALKINDI SPRINKLE 0.5 MG, 1 MG, 2 MG, 5 MG CAPSULE, SPRINKLE <b>DL</b>	4	PA
betamethasone acet,sod phos 6 mg/ml SUSPENSION <b>MO</b>	1	
CELESTONE SOLUSPAN 6 MG/ML SUSPENSION <b>MO</b>	3	
CORTROPHIN GEL 80 UNIT/ML GEL <b>DL</b>	4	PA,QL(30 per 30 days)
deflazacort 18 mg, 30 mg, 36 mg, 6 mg TABLET <b>DL</b>	4	PA
DEPO-MEDROL 20 MG/ML, 40 MG/ML, 80 MG/ML SUSPENSION <b>MO</b>	3	
dexabliss 1.5 mg (39 tabs) TABLET, DOSE PACK <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
dexamethasone 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg TABLET <b>MO</b>	1	
dexamethasone 0.5 mg/5 ml ELIXIR <b>MO</b>	1	
dexamethasone 0.5 mg/5 ml SOLUTION <b>MO</b>	1	
dexamethasone 1.5 mg (21 tabs), 1.5 mg (35 tabs), 1.5 mg (51 tabs) TABLET, DOSE PACK <b>MO</b>	1	
dexamethasone intensol 1 mg/ml DROPS <b>MO</b>	1	
dexamethasone sodium phos (pf) 10 mg/ml SOLUTION <b>MO</b>	1	
dexamethasone sodium phos (pf) 10 mg/ml SYRINGE <b>MO</b>	1	
dexamethasone sodium phosphate 10 mg/ml, 4 mg/ml SOLUTION <b>MO</b>	1	
dexamethasone sodium phosphate 4 mg/ml SYRINGE <b>MO</b>	1	
EMFLAZA 18 MG, 30 MG, 36 MG, 6 MG TABLET <b>DL</b>	4	PA
EMFLAZA 22.75 MG/ML SUSPENSION <b>DL</b>	4	PA
fludrocortisone 0.1 mg TABLET <b>MO</b>	1	
HEMADY 20 MG TABLET <b>MO</b>	3	PA,QL(24 per 28 days)
KENALOG 0.147 MG/GRAM AEROSOL <b>MO</b>	3	QL(200 per 30 days)
KENALOG 10 MG/ML, 40 MG/ML SUSPENSION <b>MO</b>	3	
KENALOG-80 80 MG/ML SUSPENSION <b>MO</b>	3	
MEDROL 16 MG, 2 MG, 32 MG, 4 MG, 8 MG TABLET <b>MO</b>	3	BvsD
MEDROL (PAK) 4 MG TABLET, DOSE PACK <b>MO</b>	3	
methylprednisolone 16 mg, 32 mg, 4 mg, 8 mg TABLET <b>MO</b>	1	BvsD
methylprednisolone 4 mg TABLET, DOSE PACK <b>MO</b>	1	
methylprednisolone acetate 40 mg/ml, 80 mg/ml SUSPENSION <b>MO</b>	1	
methylprednisolone sodium succ 1,000 mg, 125 mg, 40 mg, 500 mg RECON SOLUTION <b>MO</b>	1	
millipred 5 mg TABLET <b>MO</b>	1	BvsD
millipred dp 5 mg (21 tabs), 5 mg (48 tabs) TABLET, DOSE PACK <b>MO</b>	1	
ORAPRED ODT 10 MG, 15 MG, 30 MG TABLET, DISINTEGRATING <b>MO</b>	3	
PEDIAPRED 5 MG BASE/5 ML (6.7 MG/5 ML) SOLUTION <b>MO</b>	3	
prednisolone 15 mg/5 ml SOLUTION <b>MO</b>	1	
prednisolone 5 mg TABLET <b>MO</b>	1	BvsD
prednisolone sodium phosphate 10 mg, 15 mg, 30 mg TABLET, DISINTEGRATING <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
prednisolone sodium phosphate 10 mg/5 ml, 15 mg/5 ml (3 mg/ml), 20 mg/5 ml (4 mg/ml), 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml) SOLUTION <b>MO</b>	1	
prednisone 1 mg, 2.5 mg, 50 mg TABLET <b>MO</b>	1	BvsD
prednisone 10 mg, 20 mg, 5 mg TABLET <b>MO</b>	1	BvsD
prednisone 10 mg, 5 mg TABLET, DOSE PACK <b>MO</b>	1	
prednisone 5 mg/5 ml SOLUTION <b>MO</b>	1	BvsD
prednisone intensol 5 mg/ml CONCENTRATE <b>MO</b>	1	BvsD
RAYOS 1 MG, 2 MG, 5 MG TABLET, DR/EC <b>DL</b>	4	PA
SOLU-CORTEF 100 MG RECON SOLUTION <b>MO</b>	3	
SOLU-CORTEF ACT-O-VIAL (PF) 1,000 MG/8 ML, 100 MG/2 ML, 250 MG/2 ML, 500 MG/4 ML RECON SOLUTION <b>MO</b>	3	
SOLU-MEDROL 1,000 MG, 2 GRAM, 500 MG RECON SOLUTION <b>MO</b>	3	
SOLU-MEDROL (PF) 1,000 MG/8 ML, 125 MG/2 ML, 40 MG/ML, 500 MG/4 ML RECON SOLUTION <b>MO</b>	3	
taperdex 1.5 mg (21 tabs), 1.5 mg (27 tabs), 1.5 mg (49 tabs) TABLET, DOSE PACK <b>MO</b>	1	
triamcinolone acetonide 0.025 %, 0.05 %, 0.1 %, 0.5 % OINTMENT <b>MO</b>	1	
triamcinolone acetonide 0.025 %, 0.1 % LOTION <b>MO</b>	1	
triamcinolone acetonide 0.025 %, 0.5 % CREAM <b>MO</b>	1	
triamcinolone acetonide 0.1 % CREAM <b>MO</b>	1	
triamcinolone acetonide 0.147 mg/gram AEROSOL <b>MO</b>	1	QL(200 per 30 days)
triamcinolone acetonide 40 mg/ml SUSPENSION <b>MO</b>	1	
trianex 0.05 % OINTMENT <b>MO</b>	1	
triderm 0.1 %, 0.5 % CREAM <b>MO</b>	1	
tritocin 0.05 % OINTMENT <b>MO</b>	1	
VERIPRED 20 20 MG/5 ML (4 MG/ML) SOLUTION <b>MO</b>	1	
ZCORT 1.5 MG (25 TABS) TABLET, DOSE PACK <b>MO</b>	1	
ZILRETTA 32 MG SUSPENSION, ER, RECON <b>MO</b>	3	PA
<b>HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PITUITARY)</b>		
CHORIONIC GONADOTROPIN, HUMAN 10,000 UNIT RECON SOLUTION <b>MO</b>	3	PA
DDAVP 0.1 MG TABLET <b>MO</b>	3	PA
DDAVP 0.2 MG TABLET <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DDAVP 4 MCG/ML SOLUTION <b>MO</b>	3	PA
desmopressin 0.1 mg, 0.2 mg TABLET <b>MO</b>	1	
desmopressin 10 mcg/spray (0.1 ml) SPRAY WITH PUMP <b>MO</b>	1	PA,QL(25 per 30 days)
desmopressin 10 mcg/spray (0.1 ml) SPRAY, NON-AEROSOL <b>MO</b>	1	PA,QL(25 per 30 days)
desmopressin 4 mcg/ml SOLUTION <b>DL</b>	4	
EGRIFTA SV 2 MG RECON SOLUTION <b>DL</b>	4	PA,QL(30 per 30 days)
GENOTROPIN 12 MG/ML (36 UNIT/ML), 5 MG/ML (15 UNIT/ML) CARTRIDGE <b>DL</b>	4	PA
GENOTROPIN MINIQUICK 0.2 MG/0.25 ML, 0.4 MG/0.25 ML, 0.6 MG/0.25 ML, 0.8 MG/0.25 ML, 1 MG/0.25 ML, 1.2 MG/0.25 ML, 1.4 MG/0.25 ML, 1.6 MG/0.25 ML, 1.8 MG/0.25 ML, 2 MG/0.25 ML SYRINGE <b>DL</b>	4	PA
HUMATROPE 12 MG (36 UNIT), 24 MG (72 UNIT), 6 MG (18 UNIT) CARTRIDGE <b>DL</b>	4	PA
HUMATROPE 5 (15 UNIT) MG RECON SOLUTION <b>DL</b>	4	PA
INCRELEX 10 MG/ML SOLUTION <b>DL</b>	4	PA
NGENLA 24 MG/1.2 ML (20 MG/ML), 60 MG/1.2 ML (50 MG/ML) PEN INJECTOR <b>DL</b>	4	PA
NOCDURNA (MEN) 55.3 MCG TABLET, DISINTEGRATING <b>MO</b>	3	PA,QL(30 per 30 days)
NOCDURNA (WOMEN) 27.7 MCG TABLET, DISINTEGRATING <b>MO</b>	3	PA,QL(30 per 30 days)
NORDITROPIN FLEXPRO 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) PEN INJECTOR <b>DL</b>	4	PA
NOVAREL 5,000 UNIT RECON SOLUTION <b>MO</b>	3	PA
NUTROPIN AQ NUSPIN 10 MG/2 ML (5 MG/ML), 20 MG/2 ML (10 MG/ML), 5 MG/2 ML (2.5 MG/ML) PEN INJECTOR <b>DL</b>	4	PA
OMNITROPE 10 MG/1.5 ML (6.7 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) CARTRIDGE <b>DL</b>	4	PA
OMNITROPE 5.8 MG RECON SOLUTION <b>DL</b>	4	PA
PREGNYL 10,000 UNIT RECON SOLUTION <b>MO</b>	3	PA
SAIZEN 5 MG RECON SOLUTION <b>DL</b>	4	PA,QL(28 per 28 days)
SAIZEN 8.8 MG RECON SOLUTION <b>DL</b>	4	PA
SAIZEN SAIZENPREP 8.8 MG/1.51 ML (FINAL CONC.) CARTRIDGE <b>DL</b>	4	PA
SEROSTIM 4 MG, 5 MG, 6 MG RECON SOLUTION <b>DL</b>	4	PA,QL(28 per 28 days)
SKYTROFA 11 MG, 7.6 MG, 9.1 MG CARTRIDGE <b>DL</b>	4	PA,QL(8 per 28 days)
SKYTROFA 13.3 MG, 3 MG, 3.6 MG, 4.3 MG, 5.2 MG, 6.3 MG CARTRIDGE <b>DL</b>	4	PA,QL(4 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SOGROYA 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) PEN INJECTOR <b>DL</b>	4	PA,QL(6 per 28 days)
ZOMACTON 10 MG RECON SOLUTION <b>DL</b>	4	PA
ZOMACTON 5 MG RECON SOLUTION <b>DL</b>	4	PA,QL(28 per 28 days)
<b>HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PROSTAGLANDINS)</b>		
carboprost tromethamine 250 mcg/ml SOLUTION <b>MO</b>	1	
carboprost tromethamine 250 mcg/ml SYRINGE <b>MO</b>	1	
HEMABATE 250 MCG/ML SOLUTION <b>MO</b>	3	
<b>HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS)</b>		
ACTIVELLA 1-0.5 MG TABLET <b>MO</b>	3	
afirmelle 0.1-20 mg-mcg TABLET <b>MO</b>	1	
altavera (28) 0.15-0.03 mg TABLET <b>MO</b>	1	
alyacen 1/35 (28) 1-35 mg-mcg TABLET <b>MO</b>	1	
alyacen 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET <b>MO</b>	1	
amabelz 0.5-0.1 mg, 1-0.5 mg TABLET <b>MO</b>	1	
amethia 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH <b>MO</b>	3	QL(91 per 90 days)
amethyst (28) 90-20 mcg (28) TABLET <b>MO</b>	1	
ANDRODERM 2 MG/24 HOUR PATCH, 24 HR. <b>MO</b>	3	PA,QL(90 per 30 days)
ANDRODERM 4 MG/24 HR PATCH, 24 HR. <b>MO</b>	3	PA,QL(30 per 30 days)
ANDROGEL 1 % (25 MG/2.5GRAM), 1 % (50 MG/5 GRAM) GEL IN PACKET <b>MO</b>	3	PA,QL(300 per 30 days)
ANDROGEL 1.62 % (20.25 MG/1.25 GRAM) GEL IN PACKET <b>DL</b>	4	PA,QL(37.5 per 30 days)
ANDROGEL 1.62 % (40.5 MG/2.5 GRAM) GEL IN PACKET <b>DL</b>	4	PA,QL(150 per 30 days)
ANDROGEL 20.25 MG/1.25 GRAM (1.62 %) GEL IN METERED DOSE PUMP <b>DL</b>	4	PA,QL(150 per 30 days)
ANGELIQ 0.25-0.5 MG, 0.5-1 MG TABLET <b>MO</b>	3	
ANNOVERA 0.15-0.013 MG/24 HOUR RING <b>MO</b>	3	QL(1 per 365 days)
apri 0.15-0.03 mg TABLET <b>MO</b>	1	
aranelle (28) 0.5/1/0.5-35 mg-mcg TABLET <b>MO</b>	1	
ashlyna 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH <b>MO</b>	1	QL(91 per 90 days)
aubra 0.1-20 mg-mcg TABLET <b>MO</b>	1	
aubra eq 0.1-20 mg-mcg TABLET <b>MO</b>	1	
aurovela 1.5/30 (21) 1.5-30 mg-mcg TABLET <b>MO</b>	1	
aurovela 1/20 (21) 1-20 mg-mcg TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>aurovela 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET MO</i>	1	
<i>aurovela fe 1-20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO</i>	1	
<i>aurovela fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO</i>	1	
AVEED 750 MG/3 ML (250 MG/ML) SOLUTION	4	PA
<i>aviane 0.1-20 mg-mcg TABLET MO</i>	1	
AYGESTIN 5 MG TABLET MO	1	
<i>ayuna 0.15-0.03 mg TABLET MO</i>	1	
<i>azurette (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO</i>	1	
BALCOLTRA 0.1 MG-0.02 MG (21)/IRON (7) TABLET MO	3	
<i>balziva (28) 0.4-35 mg-mcg TABLET MO</i>	1	
BEYAZ 3-0.02-0.451 MG (24) (4) TABLET MO	3	
BIJUVA 0.5-100 MG, 1-100 MG CAPSULE MO	3	QL(30 per 30 days)
<i>blisovi 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET MO</i>	1	
<i>blisovi fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO</i>	1	
<i>blisovi fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO</i>	1	
<i>briellyn 0.4-35 mg-mcg TABLET MO</i>	1	
<i>camila 0.35 mg TABLET MO</i>	1	
<i>camrese 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO</i>	3	QL(91 per 90 days)
<i>camrese lo 0.1 mg-20 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO</i>	1	QL(91 per 90 days)
<i>caziant (28) 0.1/.125/.15-25 mg-mcg TABLET MO</i>	1	
<i>charlotte 24 fe 1 mg-20 mcg(24) /75 mg (4) CHEWABLE TABLET MO</i>	1	
<i>chateal (28) 0.15-0.03 mg TABLET MO</i>	1	
<i>chateal eq (28) 0.15-0.03 mg TABLET MO</i>	1	
CLIMARA 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.06 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR PATCH, WEEKLY MO	3	QL(4 per 28 days)
CLIMARA PRO 0.045-0.015 MG/24 HR PATCH, WEEKLY MO	3	QL(4 per 28 days)
COMBIPATCH 0.05-0.14 MG/24 HR, 0.05-0.25 MG/24 HR PATCH, SEMIWEEKLY MO	3	QL(8 per 28 days)
CRINONE 4 %, 8 % GEL MO	3	
<i>cryselle (28) 0.3-30 mg-mcg TABLET MO</i>	1	
<i>cyclafem 1/35 (28) 1-35 mg-mcg TABLET MO</i>	1	
<i>cyclafem 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET MO</i>	1	
<i>cyred 0.15-0.03 mg TABLET MO</i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>cyred eq 0.15-0.03 mg TABLET MO</i>	1	
<i>danazol 100 mg, 200 mg, 50 mg CAPSULE MO</i>	1	
<i>dasetta 1/35 (28) 1-35 mg-mcg TABLET MO</i>	1	
<i>dasetta 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET MO</i>	1	
<i>daysee 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO</i>	1	QL(91 per 90 days)
<i>deblitane 0.35 mg TABLET MO</i>	1	
DELESTROGEN 10 MG/ML, 20 MG/ML, 40 MG/ML OIL MO	3	
DEPO-ESTRADIOL 5 MG/ML OIL MO	1	QL(5 per 30 days)
DEPO-PROVERA 150 MG/ML SUSPENSION MO	3	QL(1 per 90 days)
DEPO-PROVERA 150 MG/ML SYRINGE MO	3	QL(1 per 90 days)
DEPO-SUBQ PROVERA 104 104 MG/0.65 ML SYRINGE MO	3	QL(0.65 per 90 days)
DEPO-TESTOSTERONE 100 MG/ML, 200 MG/ML OIL MO	1	
<i>desog-e.estradiol/e.estradiol 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO</i>	1	
<i>desogestrel-ethinyl estradiol 0.15-0.03 mg TABLET MO</i>	1	
DIVIGEL 0.25 MG/0.25 GRAM (0.1 %), 0.5 MG/0.5 GRAM (0.1 %), 0.75 MG/0.75 GRAM (0.1%), 1 MG/GRAM (0.1 %), 1.25 MG/1.25 GRAM (0.1 %) GEL IN PACKET MO	3	
<i>dolishale 90-20 mcg (28) TABLET MO</i>	1	
<i>dotti 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr PATCH, SEMIWEEKLY MO</i>	1	QL(8 per 28 days)
<i>drospirenone-e.estradiol-lm.f.a 3-0.02-0.451 mg (24) (4), 3-0.03-0.451 mg (21) (7) TABLET MO</i>	1	
<i>drospirenone-ethinyl estradiol 3-0.02 mg, 3-0.03 mg TABLET MO</i>	1	
DUAVEE 0.45-20 MG TABLET MO	3	PA,QL(30 per 30 days)
ELESTRIN 0.87 GRAM/ACTUATION GEL IN METERED DOSE PUMP MO	3	QL(52 per 30 days)
<i>elinest 0.3-30 mg-mcg TABLET MO</i>	1	
ELLA 30 MG TABLET MO	2	QL(1 per 30 days)
<i>eluryng 0.12-0.015 mg/24 hr RING MO</i>	1	QL(1 per 28 days)
<i>emzahh 0.35 mg TABLET MO</i>	1	
ENDOMETRIN 100 MG INSERT MO	3	
<i>enilloring 0.12-0.015 mg/24 hr RING MO</i>	1	QL(1 per 28 days)
<i>enpresse 50-30 (6)/75-40 (5)/125-30(10) TABLET MO</i>	1	
<i>enskyce 0.15-0.03 mg TABLET MO</i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>errin</i> 0.35 mg TABLET <b>MO</b>	1	
<i>estarylla</i> 0.25-35 mg-mcg TABLET <b>MO</b>	1	
ESTRACE 0.01 % (0.1 MG/GRAM) CREAM <b>MO</b>	3	PA
ESTRACE 0.5 MG, 1 MG, 2 MG TABLET <b>MO</b>	1	
<i>estradiol</i> 0.01 % (0.1 mg/gram) CREAM <b>MO</b>	1	
<i>estradiol</i> 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr PATCH, WEEKLY <b>MO</b>	1	QL(4 per 28 days)
<i>estradiol</i> 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr PATCH, SEMIWEEKLY <b>MO</b>	1	QL(8 per 28 days)
<i>estradiol</i> 0.25 mg/0.25 gram (0.1 %), 0.5 mg/0.5 gram (0.1 %), 0.75 mg/0.75 gram (0.1%), 1 mg/gram (0.1 %), 1.25 mg/1.25 gram (0.1 %) GEL IN PACKET <b>MO</b>	1	
<i>estradiol</i> 0.5 mg, 1 mg, 10 mcg, 2 mg TABLET <b>MO</b>	1	
<i>estradiol valerate</i> 10 mg/ml, 20 mg/ml, 40 mg/ml OIL <b>MO</b>	1	
<i>estradiol-norethindrone acet</i> 0.5-0.1 mg, 1-0.5 mg TABLET <b>MO</b>	1	
ESTRING 2 MG (7.5 MCG /24 HOUR) RING <b>MO</b>	3	QL(1 per 90 days)
ESTROGEL 1.25 GRAM/ACTUATION GEL IN METERED DOSE PUMP <b>MO</b>	3	
<i>ethynodiol diac-eth estradiol</i> 1-35 mg-mcg, 1-50 mg-mcg TABLET <b>MO</b>	1	
<i>etonogestrel-ethinyl estradiol</i> 0.12-0.015 mg/24 hr RING <b>MO</b>	1	QL(1 per 28 days)
EVAMIST 1.53 MG/SPRAY (1.7%) SPRAY, NON-AEROSOL <b>MO</b>	3	
EVISTA 60 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
<i>falmina</i> (28) 0.1-20 mg-mcg TABLET <b>MO</b>	1	
FEMHRT LOW DOSE 0.5-2.5 MG-MCG TABLET <b>MO</b>	3	
FEMRING 0.05 MG/24 HR, 0.1 MG/24 HR RING <b>MO</b>	3	QL(1 per 90 days)
<i>femynor</i> 0.25-35 mg-mcg TABLET <b>MO</b>	1	
<i>finzala</i> 1 mg-20 mcg(24) /75 mg (4) CHEWABLE TABLET <b>MO</b>	1	
FORTESTA 10 MG/0.5 GRAM /ACTUATION GEL IN METERED DOSE PUMP <b>MO</b>	3	PA,QL(120 per 30 days)
<i>fyavolv</i> 0.5-2.5 mg-mcg, 1-5 mg-mcg TABLET <b>MO</b>	1	
<i>gemmily</i> 1 mg-20 mcg (24)/75 mg (4) CAPSULE <b>MO</b>	1	
GENERESS FE 0.8MG-25MCG(24) AND 75 MG (4) CHEWABLE TABLET <b>MO</b>	3	
<i>hailey</i> 1.5-30 mg-mcg TABLET <b>MO</b>	1	
<i>hailey 24 fe</i> 1 mg-20 mcg (24)/75 mg (4) TABLET <b>MO</b>	1	
<i>hailey fe</i> 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET <b>MO</b>	1	
<i>hailey fe 1/20</i> (28) 1 mg-20 mcg (21)/75 mg (7) TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
haloette 0.12-0.015 mg/24 hr RING <b>MO</b>	1	QL(1 per 28 days)
heather 0.35 mg TABLET <b>MO</b>	1	
iclevia 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH <b>MO</b>	1	QL(91 per 90 days)
incassia 0.35 mg TABLET <b>MO</b>	1	
isibloom 0.15-0.03 mg TABLET <b>MO</b>	1	
jaimiess 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH <b>MO</b>	1	QL(91 per 90 days)
jasmiel (28) 3-0.02 mg TABLET <b>MO</b>	1	
JATENZO 158 MG, 198 MG CAPSULE <b>MO</b>	3	PA,QL(120 per 30 days)
JATENZO 237 MG CAPSULE <b>MO</b>	3	PA,QL(60 per 30 days)
jencycla 0.35 mg TABLET <b>MO</b>	1	
jjinteli 1-5 mg-mcg TABLET <b>MO</b>	1	
jolessa 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH <b>MO</b>	1	QL(91 per 90 days)
joyeaux 0.1 mg-0.02 mg (21)/iron (7) TABLET <b>MO</b>	1	
juleber 0.15-0.03 mg TABLET <b>MO</b>	1	
junel 1.5/30 (21) 1.5-30 mg-mcg TABLET <b>MO</b>	1	
junel 1/20 (21) 1-20 mg-mcg TABLET <b>MO</b>	1	
junel fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET <b>MO</b>	1	
junel fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET <b>MO</b>	1	
junel fe 24 1 mg-20 mcg (24)/75 mg (4) TABLET <b>MO</b>	1	
kaitlib fe 0.8mg-25mcg(24) and 75 mg (4) CHEWABLE TABLET <b>MO</b>	1	
kalliga 0.15-0.03 mg TABLET <b>MO</b>	1	
kariva (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET <b>MO</b>	1	
kelnor 1-50 (28) 1-50 mg-mcg TABLET <b>MO</b>	1	
kelnor 1/35 (28) 1-35 mg-mcg TABLET <b>MO</b>	1	
kurvelo (28) 0.15-0.03 mg TABLET <b>MO</b>	1	
l norgest/e.estradiol-e.estrad 0.1 mg-20 mcg (84)/10 mcg (7), 0.15 mg-20 mcg/ 0.15 mg-25 mcg, 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH <b>MO</b>	1	QL(91 per 90 days)
larin 1.5/30 (21) 1.5-30 mg-mcg TABLET <b>MO</b>	1	
larin 1/20 (21) 1-20 mg-mcg TABLET <b>MO</b>	1	
larin 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET <b>MO</b>	1	
larin fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET <b>MO</b>	1	
larin fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
larissia 0.1-20 mg-mcg TABLET <b>MO</b>	1	
LAYOLIS FE 0.8MG-25MCG(24) AND 75 MG (4) CHEWABLE TABLET <b>MO</b>	3	
leena 28 0.5/1/0.5-35 mg-mcg TABLET <b>MO</b>	1	
lessina 0.1-20 mg-mcg TABLET <b>MO</b>	1	
levonest (28) 50-30 (6)/75-40 (5)/125-30(10) TABLET <b>MO</b>	1	
levonorg-eth estrad triphasic 50-30 (6)/75-40 (5)/125-30(10) TABLET <b>MO</b>	1	
levonorgest-eth.estradiol-iron 0.1 mg-0.02 mg (21)/iron (7) TABLET <b>MO</b>	3	
levonorgestrel-ethinyl estrad 0.1-20 mg-mcg, 0.15-0.03 mg, 90-20 mcg (28) TABLET <b>MO</b>	1	
levonorgestrel-ethinyl estrad 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH <b>MO</b>	1	QL(91 per 90 days)
levora-28 0.15-0.03 mg TABLET <b>MO</b>	1	
lillow (28) 0.15-0.03 mg TABLET <b>MO</b>	1	
LO LOESTRIN FE 1 MG-10 MCG (24)/10 MCG (2) TABLET <b>MO</b>	3	
lo-zumandimine (28) 3-0.02 mg TABLET <b>MO</b>	1	
LOESTRIN 1.5/30 (21) 1.5-30 MG-MCG TABLET <b>MO</b>	1	
LOESTRIN 1/20 (21) 1-20 MG-MCG TABLET <b>MO</b>	1	
LOESTRIN FE 1.5/30 (28-DAY) 1.5 MG-30 MCG (21)/75 MG (7) TABLET <b>MO</b>	1	
LOESTRIN FE 1/20 (28-DAY) 1 MG-20 MCG (21)/75 MG (7) TABLET <b>MO</b>	1	
lojaimiess 0.1 mg-20 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH <b>MO</b>	1	QL(91 per 90 days)
loryna (28) 3-0.02 mg TABLET <b>MO</b>	1	
LOSEASONIQUE 0.1 MG-20 MCG (84)/10 MCG (7) TABLET, DOSE PACK, 3 MONTH <b>MO</b>	3	QL(91 per 90 days)
low-ogestrel (28) 0.3-30 mg-mcg TABLET <b>MO</b>	1	
lutera (28) 0.1-20 mg-mcg TABLET <b>MO</b>	1	
lyleq 0.35 mg TABLET <b>MO</b>	1	
lyllana 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr PATCH, SEMIWEEKLY <b>MO</b>	1	QL(8 per 28 days)
lyza 0.35 mg TABLET <b>MO</b>	1	
marlissa (28) 0.15-0.03 mg TABLET <b>MO</b>	1	
medroxyprogesterone 10 mg, 2.5 mg, 5 mg TABLET <b>MO</b>	1	
medroxyprogesterone 150 mg/ml SUSPENSION <b>MO</b>	1	QL(1 per 90 days)
medroxyprogesterone 150 mg/ml SYRINGE <b>MO</b>	1	QL(1 per 90 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
megestrol 20 mg, 40 mg TABLET <b>MO</b>	1	
megestrol 400 mg/10 ml (10 ml), 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml) SUSPENSION <b>MO</b>	1	
MENEST 0.3 MG, 0.625 MG, 1.25 MG, 2.5 MG TABLET <b>MO</b>	1	
MENOSTAR 14 MCG/24 HR PATCH, WEEKLY <b>MO</b>	3	QL(8 per 28 days)
merzee 1 mg-20 mcg (24)/75 mg (4) CAPSULE <b>MO</b>	1	
METHITEST 10 MG TABLET <b>DL</b>	4	
methyltestosterone 10 mg CAPSULE <b>DL</b>	4	
mibelas 24 fe 1 mg-20 mcg(24) /75 mg (4) CHEWABLE TABLET <b>MO</b>	1	
microgestin 1.5/30 (21) 1.5-30 mg-mcg TABLET <b>MO</b>	1	
microgestin 1/20 (21) 1-20 mg-mcg TABLET <b>MO</b>	1	
microgestin 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET <b>MO</b>	1	
microgestin fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET <b>MO</b>	1	
microgestin fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET <b>MO</b>	1	
mili 0.25-35 mg-mcg TABLET <b>MO</b>	1	
mimvey 1-0.5 mg TABLET <b>MO</b>	1	
MINASTRIN 24 FE 1 MG-20 MCG(24) /75 MG (4) CHEWABLE TABLET <b>MO</b>	3	
MINIVELLE 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR PATCH, SEMIWEEKLY <b>MO</b>	3	QL(8 per 28 days)
MIRCETTE (28) 0.15-0.02 MGX21 /0.01 MG X 5 TABLET <b>MO</b>	1	
mono-lynyah 0.25-35 mg-mcg TABLET <b>MO</b>	1	
NATAZIA 3 MG/2 MG-2 MG/ 2 MG-3 MG/1 MG TABLET <b>MO</b>	3	
NATESTO 5.5 MG/0.122 GRAM/ACTUATION GEL IN METERED DOSE PUMP <b>MO</b>	3	PA,QL(21.96 per 30 days)
necon 0.5/35 (28) 0.5-35 mg-mcg TABLET <b>MO</b>	1	
NEXTSTELLIS 3 MG- 14.2 MG (28) TABLET <b>MO</b>	3	
nikki (28) 3-0.02 mg TABLET <b>MO</b>	1	
NORA-BE 0.35 MG TABLET <b>MO</b>	1	
nora-be 0.35 mg TABLET <b>MO</b>	1	
norelgestromin-ethin.estradiol 150-35 mcg/24 hr PATCH, WEEKLY <b>MO</b>	1	QL(3 per 28 days)
noreth-ethinyl estradiol-iron 0.4mg-35mcg(21) and 75 mg (7), 0.8mg-25mcg(24) and 75 mg (4) CHEWABLE TABLET <b>MO</b>	1	
norethindrone (contraceptive) 0.35 mg TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
norethindrone ac-eth estradiol 0.5-2.5 mg-mcg, 1-20 mg-mcg, 1-5 mg-mcg, 1.5-30 mg-mcg TABLET <b>MO</b>	1	
norethindrone acetate 5 mg TABLET <b>MO</b>	1	
norethindrone-e.estradiol-iron 1 mg-20 mcg (21)/75 mg (7), 1-20(5)/1-30(7) /1mg-35mcg (9), 1.5 mg-30 mcg (21)/75 mg (7) TABLET <b>MO</b>	1	
norethindrone-e.estradiol-iron 1 mg-20 mcg (24)/75 mg (4) CAPSULE <b>MO</b>	1	
norethindrone-e.estradiol-iron 1 mg-20 mcg(24) /75 mg (4) CHEWABLE TABLET <b>MO</b>	1	
norgestimate-ethinyl estradiol 0.18/0.215/0.25 mg-25 mcg, 0.18/0.215/0.25 mg-35 mcg (28), 0.25-35 mg-mcg TABLET <b>MO</b>	1	
norlyda 0.35 mg TABLET <b>MO</b>	1	
nortrel 0.5/35 (28) 0.5-35 mg-mcg TABLET <b>MO</b>	1	
nortrel 1/35 (21) 1-35 mg-mcg (21) TABLET <b>MO</b>	1	
nortrel 1/35 (28) 1-35 mg-mcg TABLET <b>MO</b>	1	
nortrel 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET <b>MO</b>	1	
NUVARING 0.12-0.015 MG/24 HR RING <b>MO</b>	3	QL(1 per 28 days)
nylia 1/35 (28) 1-35 mg-mcg TABLET <b>MO</b>	1	
nylia 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET <b>MO</b>	1	
nymyo 0.25-35 mg-mcg TABLET <b>MO</b>	1	
ocella 3-0.03 mg TABLET <b>MO</b>	1	
orsythia 0.1-20 mg-mcg TABLET <b>MO</b>	1	
ORTHO TRI-CYCLEN (28) 0.18/0.215/0.25 MG-35 MCG (28) TABLET <b>MO</b>	3	
ORTHO-NOVUM 7/7/7 (28) 0.5/0.75/1 MG- 35 MCG TABLET <b>MO</b>	1	
OSPHENA 60 MG TABLET <b>MO</b>	2	PA
oxandrolone 10 mg TABLET <b>MO</b>	1	PA,QL(60 per 30 days)
oxandrolone 2.5 mg TABLET <b>MO</b>	1	PA,QL(120 per 30 days)
philith 0.4-35 mg-mcg TABLET <b>MO</b>	1	
pimtrea (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET <b>MO</b>	1	
pirmella 0.5/0.75/1 mg- 35 mcg, 1-35 mg-mcg TABLET <b>MO</b>	1	
portia 28 0.15-0.03 mg TABLET <b>MO</b>	1	
PREFEST 1 MG (15)/1 MG- 0.09 MG (15) TABLET <b>MO</b>	1	
PREMARIN 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG TABLET <b>MO</b>	3	
PREMARIN 0.625 MG/GRAM CREAM <b>MO</b>	2	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PREMARIN 25 MG RECON SOLUTION <b>MO</b>	3	
PREMPHASE 0.625 MG (14)/ 0.625MG-5MG(14) TABLET <b>MO</b>	3	
PREMPRO 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG TABLET <b>MO</b>	3	
previfem 0.25-35 mg-mcg TABLET <b>MO</b>	1	
progesterone 50 mg/ml OIL <b>MO</b>	1	
progesterone micronized 100 mg, 200 mg CAPSULE <b>MO</b>	1	
PROMETRIUM 100 MG, 200 MG CAPSULE <b>MO</b>	3	
PROVERA 10 MG, 2.5 MG, 5 MG TABLET <b>MO</b>	3	
QUARTETTE 0.15 MG-20 MCG/ 0.15 MG-25 MCG TABLET, DOSE PACK, 3 MONTH <b>MO</b>	3	QL(91 per 90 days)
raloxifene 60 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
reclipsen (28) 0.15-0.03 mg TABLET <b>MO</b>	1	
rivalsa 0.15 mg-20 mcg/ 0.15 mg-25 mcg TABLET, DOSE PACK, 3 MONTH <b>MO</b>	1	QL(91 per 90 days)
SAFYRAL 3-0.03-0.451 MG (21) (7) TABLET <b>MO</b>	3	
SEASONIQUE 0.15 MG-30 MCG (84)/10 MCG (7) TABLET, DOSE PACK, 3 MONTH <b>MO</b>	3	QL(91 per 90 days)
setlakin 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH <b>MO</b>	1	QL(91 per 90 days)
sharobel 0.35 mg TABLET <b>MO</b>	1	
simliya (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET <b>MO</b>	1	
simpesse 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH <b>MO</b>	1	QL(91 per 90 days)
SLYND 4 MG (28) TABLET <b>MO</b>	3	
sprintec (28) 0.25-35 mg-mcg TABLET <b>MO</b>	1	
sronyx 0.1-20 mg-mcg TABLET <b>MO</b>	1	
syeda 3-0.03 mg TABLET <b>MO</b>	1	
tarina 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET <b>MO</b>	1	
tarina fe 1-20 eq (28) 1 mg-20 mcg (21)/75 mg (7) TABLET <b>MO</b>	1	
tarina fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET <b>MO</b>	1	
taysofy 1 mg-20 mcg (24)/75 mg (4) CAPSULE <b>MO</b>	1	
TAYTULLA 1 MG-20 MCG (24)/75 MG (4) CAPSULE <b>MO</b>	3	
TESTIM 50 MG/5 GRAM (1 %) GEL <b>MO</b>	3	PA,QL(300 per 30 days)
testosterone 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram) GEL IN PACKET <b>MO</b>	1	PA,QL(300 per 30 days)
testosterone 1.62 % (20.25 mg/1.25 gram) GEL IN PACKET <b>MO</b>	1	PA,QL(37.5 per 30 days)
testosterone 1.62 % (40.5 mg/2.5 gram) GEL IN PACKET <b>MO</b>	1	PA,QL(150 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
testosterone 10 mg/0.5 gram /actuation GEL IN METERED DOSE PUMP <b>MO</b>	1	PA,QL(120 per 30 days)
testosterone 12.5 mg/ 1.25 gram (1 %) GEL IN METERED DOSE PUMP <b>MO</b>	1	PA,QL(300 per 30 days)
testosterone 20.25 mg/1.25 gram (1.62 %) GEL IN METERED DOSE PUMP <b>MO</b>	1	PA,QL(150 per 30 days)
testosterone 30 mg/actuation (1.5 ml) SOLUTION IN METERED DOSE PUMP <b>MO</b>	3	PA,QL(180 per 30 days)
testosterone 50 mg/5 gram (1 %) GEL <b>MO</b>	3	PA,QL(300 per 30 days)
testosterone cypionate 100 mg/ml, 200 mg/ml OIL <b>MO</b>	1	
testosterone enanthate 200 mg/ml OIL <b>MO</b>	1	QL(25 per 90 days)
tilia fe 1-20(5)/1-30(7) /1mg-35mcg (9) TABLET <b>MO</b>	1	
TLANDO 112.5 MG CAPSULE <b>MO</b>	3	PA,QL(120 per 30 days)
tri femynor 0.18/0.215/0.25 mg-35 mcg (28) TABLET <b>MO</b>	1	
tri-estarylla 0.18/0.215/0.25 mg-35 mcg (28) TABLET <b>MO</b>	1	
tri-legest fe 1-20(5)/1-30(7) /1mg-35mcg (9) TABLET <b>MO</b>	1	
tri-linyah 0.18/0.215/0.25 mg-35 mcg (28) TABLET <b>MO</b>	1	
tri-lo-estarylla 0.18/0.215/0.25 mg-25 mcg TABLET <b>MO</b>	1	
tri-lo-marzia 0.18/0.215/0.25 mg-25 mcg TABLET <b>MO</b>	1	
tri-lo-mili 0.18/0.215/0.25 mg-25 mcg TABLET <b>MO</b>	1	
tri-lo-sprintec 0.18/0.215/0.25 mg-25 mcg TABLET <b>MO</b>	1	
tri-mili 0.18/0.215/0.25 mg-35 mcg (28) TABLET <b>MO</b>	1	
tri-nymyo 0.18/0.215/0.25 mg-35 mcg (28) TABLET <b>MO</b>	1	
tri-sprintec (28) 0.18/0.215/0.25 mg-35 mcg (28) TABLET <b>MO</b>	1	
tri-vylibra 0.18/0.215/0.25 mg-35 mcg (28) TABLET <b>MO</b>	1	
tri-vylibra lo 0.18/0.215/0.25 mg-25 mcg TABLET <b>MO</b>	1	
trivora (28) 50-30 (6)/75-40 (5)/125-30(10) TABLET <b>MO</b>	1	
tulana 0.35 mg TABLET <b>MO</b>	1	
turqoz (28) 0.3-30 mg-mcg TABLET <b>MO</b>	1	
TYBLUME 0.1 MG- 20 MCG CHEWABLE TABLET <b>MO</b>	3	
tydemy 3-0.03-0.451 mg (21) (7) TABLET <b>MO</b>	1	
VAGIFEM 10 MCG TABLET <b>MO</b>	3	PA
velivet triphasic regimen (28) 0.1/.125/.15-25 mg-mcg TABLET <b>MO</b>	1	
vestura (28) 3-0.02 mg TABLET <b>MO</b>	1	
vienva 0.1-20 mg-mcg TABLET <b>MO</b>	1	
violele (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VIVELLE-DOT 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR PATCH, SEMIWEEKLY <b>MO</b>	3	QL(8 per 28 days)
VOGELXO 1 % (50 MG/5 GRAM) GEL IN PACKET <b>MO</b>	3	PA,QL(300 per 30 days)
VOGELXO 12.5 MG/ 1.25 GRAM (1 %) GEL IN METERED DOSE PUMP <b>MO</b>	3	PA,QL(300 per 30 days)
VOGELXO 50 MG/5 GRAM (1 %) GEL <b>MO</b>	3	PA,QL(300 per 30 days)
volnea (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET <b>MO</b>	1	
vyfemla (28) 0.4-35 mg-mcg TABLET <b>MO</b>	1	
vylibra 0.25-35 mg-mcg TABLET <b>MO</b>	1	
wera (28) 0.5-35 mg-mcg TABLET <b>MO</b>	1	
wymzya fe 0.4mg-35mcg(21) and 75 mg (7) CHEWABLE TABLET <b>MO</b>	1	
xulane 150-35 mcg/24 hr PATCH, WEEKLY <b>MO</b>	1	QL(3 per 28 days)
XYOSTED 100 MG/0.5 ML, 50 MG/0.5 ML, 75 MG/0.5 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(2 per 28 days)
YASMIN (28) 3-0.03 MG TABLET <b>MO</b>	3	
YAZ (28) 3-0.02 MG TABLET <b>MO</b>	3	
yuvafem 10 mcg TABLET <b>MO</b>	1	
zafemy 150-35 mcg/24 hr PATCH, WEEKLY <b>MO</b>	1	QL(3 per 28 days)
zarah 3-0.03 mg TABLET <b>MO</b>	1	
zovia 1-35 (28) 1-35 mg-mcg TABLET <b>MO</b>	1	
zumandimine (28) 3-0.03 mg TABLET <b>MO</b>	1	
<b>HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (THYROID)</b>		
ARMOUR THYROID 120 MG, 15 MG, 180 MG, 240 MG, 30 MG, 300 MG, 60 MG, 90 MG TABLET <b>MO</b>	2	
CYTOMEL 25 MCG, 5 MCG, 50 MCG TABLET <b>MO</b>	3	
ERMEZA 30 MCG/ML SOLUTION <b>MO</b>	3	
EUTHYROX 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG TABLET <b>MO</b>	1	
LEVO-T 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET <b>MO</b>	2	
levothyroxine 100 mcg RECON SOLUTION <b>MO</b>	1	
levothyroxine 100 mcg, 112 mcg, 125 mcg, 13 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg CAPSULE <b>MO</b>	1	
levothyroxine 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
levothyroxine 100 mcg/ml, 20 mcg/ml, 40 mcg/ml SOLUTION <b>MO</b>	1	
levothyroxine 175 mcg, 200 mcg, 300 mcg TABLET <b>MO</b>	1	
levothyroxine 200 mcg, 500 mcg RECON SOLUTION <b>DL</b>	4	
LEVOXYL 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG TABLET <b>MO</b>	1	
liothyronine 10 mcg/ml SOLUTION <b>MO</b>	1	
liothyronine 25 mcg, 5 mcg, 50 mcg TABLET <b>MO</b>	1	
np thyroid 120 mg, 15 mg, 30 mg, 60 mg, 90 mg TABLET <b>MO</b>	2	
SYNTHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET <b>MO</b>	2	
THYQUIDITY 20 MCG/ML SOLUTION <b>MO</b>	3	
TIROSINT 100 MCG, 112 MCG, 125 MCG, 13 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 37.5 MCG, 44 MCG, 50 MCG, 62.5 MCG, 75 MCG, 88 MCG CAPSULE <b>MO</b>	3	
TIROSINT-SOL 100 MCG/ML, 112 MCG/ML, 125 MCG/ML, 13 MCG/ML, 137 MCG/ML, 150 MCG/ML, 175 MCG/ML, 200 MCG/ML, 25 MCG/ML, 37.5 MCG/ML, 44 MCG/ML, 50 MCG/ML, 62.5 MCG/ML, 75 MCG/ML, 88 MCG/ML SOLUTION <b>MO</b>	3	
TRIOSTAT 10 MCG/ML SOLUTION <b>MO</b>	3	
UNITHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET <b>MO</b>	2	
<b>HORMONAL AGENTS, SUPPRESSANT (ADRENAL)</b>		
ISTURISA 1 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
ISTURISA 10 MG TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
ISTURISA 5 MG TABLET <b>DL</b>	4	PA,QL(360 per 30 days)
LYSODREN 500 MG TABLET <b>DL</b>	4	
RECORLEV 150 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
<b>HORMONAL AGENTS, SUPPRESSANT (PITUITARY)</b>		
cabergoline 0.5 mg TABLET <b>MO</b>	1	
ELIGARD 7.5 MG (1 MONTH) SYRINGE <b>MO</b>	3	PA
ELIGARD (3 MONTH) 22.5 MG SYRINGE <b>MO</b>	3	PA
ELIGARD (4 MONTH) 30 MG SYRINGE <b>MO</b>	3	PA
ELIGARD (6 MONTH) 45 MG SYRINGE <b>MO</b>	3	PA
FENSOLVI 45 MG SYRINGE	4	PA,QL(1 per 180 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
FIRMAGON 120 MG RECON SOLUTION <b>DL</b>	4	PA
FIRMAGON KIT W DILUENT SYRINGE 120 MG RECON SOLUTION <b>DL</b>	4	PA
FIRMAGON KIT W DILUENT SYRINGE 80 MG RECON SOLUTION <b>MO</b>	3	PA
lanreotide 120 mg/0.5 ml SYRINGE <b>DL</b>	4	PA,QL(0.5 per 28 days)
leuprolide 1 mg/0.2 ml KIT <b>MO</b>	1	
leuprolide (3 month) 22.5 mg SUSPENSION FOR RECONSTITUTION <b>MO</b>	3	PA,QL(1 per 90 days)
LUPRON DEPOT 3.75 MG SYRINGE KIT <b>MO</b>	3	PA,QL(1 per 30 days)
LUPRON DEPOT 7.5 MG SYRINGE KIT <b>DL</b>	4	PA,QL(1 per 30 days)
LUPRON DEPOT (3 MONTH) 11.25 MG, 22.5 MG SYRINGE KIT <b>MO</b>	3	PA,QL(1 per 90 days)
LUPRON DEPOT (4 MONTH) 30 MG SYRINGE KIT <b>MO</b>	3	PA,QL(1 per 112 days)
LUPRON DEPOT (6 MONTH) 45 MG SYRINGE KIT	4	PA,QL(1 per 168 days)
LUPRON DEPOT-PED 11.25 MG KIT <b>DL</b>	4	PA,QL(1 per 28 days)
LUPRON DEPOT-PED 15 MG, 7.5 MG (PED) KIT <b>DL</b>	4	PA,QL(1 per 28 days)
LUPRON DEPOT-PED 45 MG SYRINGE KIT	4	PA,QL(1 per 168 days)
LUPRON DEPOT-PED (3 MONTH) 11.25 MG, 30 MG SYRINGE KIT	4	PA,QL(1 per 90 days)
MYCAPSSA 20 MG CAPSULE, DR/EC <b>DL</b>	4	PA,QL(112 per 28 days)
octreotide acetate 1,000 mcg/ml, 100 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml SOLUTION <b>MO</b>	1	PA
octreotide acetate 100 mcg/ml (1 ml), 50 mcg/ml (1 ml), 500 mcg/ml (1 ml) SYRINGE <b>MO</b>	1	PA
ORGOVYX 120 MG TABLET <b>DL</b>	4	PA,QL(32 per 30 days)
ORILISSA 150 MG TABLET <b>DL</b>	4	PA,QL(28 per 28 days)
ORILISSA 200 MG TABLET <b>DL</b>	4	PA,QL(56 per 28 days)
SANDOSTATIN 100 MCG/ML, 50 MCG/ML, 500 MCG/ML SOLUTION <b>DL</b>	4	PA
SANDOSTATIN LAR DEPOT 10 MG, 20 MG, 30 MG SUSPENSION, ER, RECON <b>DL</b>	4	PA
SIGNIFOR 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) SOLUTION <b>DL</b>	4	PA,QL(60 per 30 days)
SIGNIFOR LAR 10 MG, 20 MG, 30 MG, 40 MG, 60 MG SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	PA,QL(1 per 28 days)
SOMATULINE DEPOT 120 MG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(0.5 per 28 days)
SOMATULINE DEPOT 60 MG/0.2 ML SYRINGE <b>DL</b>	4	PA,QL(0.2 per 28 days)
SOMATULINE DEPOT 90 MG/0.3 ML SYRINGE <b>DL</b>	4	PA,QL(0.3 per 28 days)
SOMAVERT 10 MG, 15 MG, 20 MG RECON SOLUTION <b>DL</b>	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SOMAVERT 25 MG, 30 MG RECON SOLUTION <b>DL</b>	4	PA,QL(30 per 30 days)
SYNAREL 2 MG/ML SPRAY, NON-AEROSOL <b>DL</b>	4	
TRELSTAR 11.25 MG, 22.5 MG, 3.75 MG SUSPENSION FOR RECONSTITUTION <b>MO</b>	3	PA
TRIPTODUR 22.5 MG SUSPENSION FOR RECONSTITUTION	4	PA,QL(1 per 168 days)
ZOLADEX 10.8 MG IMPLANT <b>MO</b>	3	PA,QL(1 per 84 days)
ZOLADEX 3.6 MG IMPLANT <b>MO</b>	3	PA,QL(1 per 28 days)
<b>HORMONAL AGENTS, SUPPRESSANT (THYROID)</b>		
<i>methimazole 10 mg, 5 mg TABLET</i> <b>MO</b>	1	
<i>propylthiouracil 50 mg TABLET</i> <b>MO</b>	1	
<b>IMMUNOLOGICAL AGENTS</b>		
ABRILADA(CF) 20 MG/0.4 ML SYRINGE KIT <b>DL</b>	4	PA,QL(2 per 28 days)
ABRILADA(CF) 40 MG/0.8 ML SYRINGE KIT <b>DL</b>	4	PA,QL(6 per 28 days)
ABRILADA(CF) PEN 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
ABRYSVO 120 MCG/0.5 ML RECON SOLUTION <b>\$0,DL</b>	1	
ACTEMRA 162 MG/0.9 ML SYRINGE <b>DL</b>	4	PA,QL(3.6 per 28 days)
ACTEMRA ACTPEN 162 MG/0.9 ML PEN INJECTOR <b>DL</b>	4	PA,QL(3.6 per 28 days)
ACTHIB (PF) 10 MCG/0.5 ML RECON SOLUTION <b>\$0,DL</b>	1	
ACTIMMUNE 100 MCG/0.5 ML SOLUTION <b>DL</b>	4	PA
ADACEL(TDAP ADOLESN/ADULT)(PF) 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML SUSPENSION <b>\$0,DL</b>	1	
ADACEL(TDAP ADOLESN/ADULT)(PF) 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML SYRINGE <b>\$0,DL</b>	1	
ADALIMUMAB-AACF 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
ADALIMUMAB-AATY 20 MG/0.2 ML, 40 MG/0.4 ML SYRINGE KIT <b>DL</b>	4	PA,QL(6 per 28 days)
ADALIMUMAB-AATY 40 MG/0.4 ML, 80 MG/0.8 ML AUTO-INJECTOR, KIT <b>DL</b>	4	PA,QL(6 per 28 days)
ADALIMUMAB-ADAZ 40 MG/0.4 ML PEN INJECTOR <b>DL</b>	4	PA,QL(2.4 per 28 days)
ADALIMUMAB-ADAZ 40 MG/0.4 ML SYRINGE <b>DL</b>	4	PA,QL(2.4 per 28 days)
ADALIMUMAB-ADBM 10 MG/0.2 ML, 20 MG/0.4 ML SYRINGE KIT <b>DL</b>	4	PA,QL(2 per 28 days)
ADALIMUMAB-ADBM 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
ADALIMUMAB-ADBM 40 MG/0.8 ML SYRINGE KIT <b>DL</b>	4	PA,QL(6 per 28 days)
ADALIMUMAB-ADBM(CF) PEN CROHNS 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
ADALIMUMAB-ADBM(CF) PEN PS-UV 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ADALIMUMAB-FKJP 20 MG/0.4 ML SYRINGE KIT <b>DL</b>	4	PA,QL(2 per 28 days)
ADALIMUMAB-FKJP 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
ADALIMUMAB-FKJP 40 MG/0.8 ML SYRINGE KIT <b>DL</b>	4	PA,QL(6 per 28 days)
ADBRY 150 MG/ML SYRINGE <b>DL</b>	4	PA,QL(6 per 28 days)
ALYGLO 10 % SOLUTION <b>DL</b>	4	PA
AMJEVITA(CF) 10 MG/0.2 ML, 20 MG/0.2 ML SYRINGE <b>DL</b>	4	PA,QL(1.2 per 28 days)
AMJEVITA(CF) 20 MG/0.4 ML, 40 MG/0.4 ML SYRINGE <b>DL</b>	4	PA,QL(2.4 per 28 days)
AMJEVITA(CF) 40 MG/0.8 ML SYRINGE <b>DL</b>	4	PA,QL(4.8 per 28 days)
AMJEVITA(CF) AUTOINJECTOR 40 MG/0.4 ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(2.4 per 28 days)
AMJEVITA(CF) AUTOINJECTOR 40 MG/0.8 ML, 80 MG/0.8 ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(4.8 per 28 days)
ARAVA 10 MG, 20 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
ARCALYST 220 MG RECON SOLUTION <b>DL</b>	4	PA
AREXVY (PF) 120 MCG/0.5 ML SUSPENSION FOR RECONSTITUTION <b>\$0,DL</b>	1	
ASCENIV 10 % SOLUTION <b>DL</b>	4	PA
ASTAGRAF XL 0.5 MG, 1 MG, 5 MG CAPSULE, ER 24 HR. <b>MO</b>	3	BvsD
ATGAM 50 MG/ML SOLUTION <b>DL</b>	4	PA
AVSOLA 100 MG RECON SOLUTION <b>DL</b>	4	PA
AZASAN 100 MG, 75 MG TABLET <b>MO</b>	1	BvsD
<i>azathioprine 100 mg, 50 mg, 75 mg TABLET <b>MO</b></i>	1	BvsD
<i>azathioprine sodium 100 mg RECON SOLUTION <b>MO</b></i>	1	BvsD
BCG VACCINE, LIVE (PF) 50 MG SUSPENSION FOR RECONSTITUTION <b>\$0,DL</b>	1	
BENLYSTA 120 MG RECON SOLUTION <b>DL</b>	4	PA,QL(20 per 28 days)
BENLYSTA 200 MG/ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(8 per 28 days)
BENLYSTA 200 MG/ML SYRINGE <b>DL</b>	4	PA,QL(8 per 28 days)
BENLYSTA 400 MG RECON SOLUTION <b>DL</b>	4	PA,QL(6 per 28 days)
BERINERT 500 UNIT (10 ML) KIT <b>DL</b>	4	PA,QL(15 per 30 days)
BERINERT 500 UNIT (10 ML) RECON SOLUTION <b>DL</b>	4	PA,QL(15 per 30 days)
BESREMI 500 MCG/ML SYRINGE <b>DL</b>	4	PA,QL(2 per 28 days)
BEXSERO 50-50-50-25 MCG/0.5 ML SYRINGE <b>\$0,DL</b>	1	
BIMZELX 160 MG/ML SYRINGE <b>DL</b>	4	PA,QL(2 per 28 days)
BIMZELX AUTOINJECTOR 160 MG/ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(2 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BIVIGAM 10 % SOLUTION <b>DL</b>	4	PA
BOOSTRIX TDAP 2.5-8-5 LF-MCG-LF/0.5ML SUSPENSION <b>\$0,DL</b>	1	
BOOSTRIX TDAP 2.5-8-5 LF-MCG-LF/0.5ML SYRINGE <b>\$0,DL</b>	1	
CELLCEPT 200 MG/ML SUSPENSION FOR RECONSTITUTION	4	BvsD
CELLCEPT 250 MG CAPSULE	4	BvsD
CELLCEPT 500 MG TABLET	4	BvsD
CELLCEPT INTRAVENOUS 500 MG RECON SOLUTION <b>MO</b>	3	BvsD
CIBINQO 100 MG, 200 MG, 50 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
CIMZIA 400 MG/2 ML (200 MG/ML X 2) SYRINGE KIT <b>DL</b>	4	PA,QL(3 per 30 days)
CIMZIA POWDER FOR RECONST 400 MG (200 MG X 2 VIALS) KIT <b>DL</b>	4	PA,QL(3 per 30 days)
CIMZIA STARTER KIT 400 MG/2 ML (200 MG/ML X 2) SYRINGE KIT <b>DL</b>	4	PA,QL(3 per 30 days)
CINRYZE 500 UNIT (5 ML) RECON SOLUTION <b>DL</b>	4	PA,QL(20 per 30 days)
COSENTYX 150 MG/ML SYRINGE <b>DL</b>	4	PA,QL(8 per 28 days)
COSENTYX 25 MG/ML SOLUTION <b>DL</b>	4	PA
COSENTYX 75 MG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(2 per 28 days)
COSENTYX (2 SYRINGES) 150 MG/ML SYRINGE <b>DL</b>	4	PA,QL(8 per 28 days)
COSENTYX PEN 150 MG/ML PEN INJECTOR <b>DL</b>	4	PA,QL(8 per 28 days)
COSENTYX PEN (2 PENS) 150 MG/ML PEN INJECTOR <b>DL</b>	4	PA,QL(8 per 28 days)
COSENTYX UNOREADY PEN 300 MG/2 ML (150 MG/ML) PEN INJECTOR <b>DL</b>	4	PA,QL(8 per 28 days)
CUTAQUIG 16.5 % SOLUTION <b>DL</b>	4	PA
<i>cyclosporine 100 mg, 25 mg CAPSULE <b>MO</b></i>	1	BvsD
<i>cyclosporine modified 100 mg, 25 mg, 50 mg CAPSULE <b>MO</b></i>	1	BvsD
<i>cyclosporine modified 100 mg/ml SOLUTION <b>MO</b></i>	1	BvsD
CYLTEZO(CF) 10 MG/0.2 ML, 20 MG/0.4 ML SYRINGE KIT <b>DL</b>	4	PA,QL(2 per 28 days)
CYLTEZO(CF) 40 MG/0.8 ML SYRINGE KIT <b>DL</b>	4	PA,QL(6 per 28 days)
CYLTEZO(CF) PEN 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
CYLTEZO(CF) PEN CROHN'S-UC-HS 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
CYLTEZO(CF) PEN PSORIASIS-UV 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
CYTOGAM 50 MG/ML SOLUTION <b>DL</b>	4	PA
DAPTACEL (DTAP PEDIATRIC) (PF) 15-10-5 LF-MCG-LF/0.5ML SUSPENSION <b>\$0,DL</b>	1	
DENGVAXIA (PF) 10EXP4.5-6 CCID50/0.5 ML SUSPENSION FOR RECONSTITUTION <b>DL</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DUPIXENT PEN 200 MG/1.14 ML PEN INJECTOR <b>DL</b>	4	PA,QL(3.42 per 28 days)
DUPIXENT PEN 300 MG/2 ML PEN INJECTOR <b>DL</b>	4	PA,QL(8 per 28 days)
DUPIXENT SYRINGE 100 MG/0.67 ML SYRINGE <b>DL</b>	4	PA,QL(1.34 per 28 days)
DUPIXENT SYRINGE 200 MG/1.14 ML SYRINGE <b>DL</b>	4	PA,QL(3.42 per 28 days)
DUPIXENT SYRINGE 300 MG/2 ML SYRINGE <b>DL</b>	4	PA,QL(8 per 28 days)
ENBREL 25 MG (1 ML) RECON SOLUTION <b>DL</b>	4	PA,QL(8 per 28 days)
ENBREL 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) SYRINGE <b>DL</b>	4	PA,QL(8 per 28 days)
ENBREL 25 MG/0.5 ML SOLUTION <b>DL</b>	4	PA,QL(8 per 28 days)
ENBREL MINI 50 MG/ML (1 ML) CARTRIDGE <b>DL</b>	4	PA,QL(8 per 28 days)
ENBREL SURECLICK 50 MG/ML (1 ML) PEN INJECTOR <b>DL</b>	4	PA,QL(8 per 28 days)
ENGERIX-B (PF) 20 MCG/ML SUSPENSION <b>\$0,DL</b>	1	BvsD
ENGERIX-B (PF) 20 MCG/ML SYRINGE <b>\$0,DL</b>	1	BvsD
ENGERIX-B PEDIATRIC (PF) 10 MCG/0.5 ML SYRINGE <b>\$0,DL</b>	1	BvsD
ENJAYMO 50 MG/ML SOLUTION <b>DL</b>	4	PA
ENSPRYNG 120 MG/ML SYRINGE <b>DL</b>	4	PA,QL(2 per 28 days)
ENTYVIO 300 MG RECON SOLUTION	4	PA,QL(8 per 365 days)
ENTYVIO PEN 108 MG/0.68 ML PEN INJECTOR <b>DL</b>	4	PA,QL(1.36 per 28 days)
ENVARUSUS XR 0.75 MG, 1 MG TABLET, ER 24 HR. <b>MO</b>	3	PA
ENVARUSUS XR 4 MG TABLET, ER 24 HR. <b>DL</b>	3	PA
<i>everolimus (immunosuppressive) 0.25 mg TABLET</i> <b>MO</b>	1	BvsD,QL(60 per 30 days)
<i>everolimus (immunosuppressive) 0.5 mg TABLET</i>	4	BvsD,QL(120 per 30 days)
<i>everolimus (immunosuppressive) 0.75 mg TABLET</i>	4	BvsD,QL(60 per 30 days)
<i>everolimus (immunosuppressive) 1 mg TABLET</i> <b>DL</b>	4	BvsD,QL(60 per 30 days)
FABHALTA 200 MG CAPSULE <b>DL</b>	4	PA,QL(60 per 30 days)
FIRAZYR 30 MG/3 ML SYRINGE <b>DL</b>	4	PA,QL(18 per 30 days)
FLEBOGAMMA DIF 10 %, 5 % SOLUTION <b>DL</b>	4	PA
GAMASTAN 15-18 % RANGE SOLUTION <b>MO</b>	3	PA
GAMIFANT 5 MG/ML SOLUTION <b>DL</b>	4	PA
GAMMAGARD LIQUID 10 % SOLUTION <b>DL</b>	4	PA
GAMMAGARD S-D (IGA < 1 MCG/ML) 10 GRAM, 5 GRAM RECON SOLUTION <b>DL</b>	4	PA
GAMMAKED 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 20 GRAM/200 ML (10 %), 5 GRAM/50 ML (10 %) SOLUTION <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GAMMAPLEX 10 % SOLUTION <b>DL</b>	4	PA
GAMMAPLEX (WITH SORBITOL) 5 % SOLUTION <b>DL</b>	4	PA
GAMUNEX-C 1 GRAM/10 ML (10 %) SOLUTION <b>DL</b>	4	PA
GAMUNEX-C 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 40 GRAM/400 ML (10 %), 5 GRAM/50 ML (10 %) SOLUTION <b>DL</b>	4	PA
GARDASIL 9 (PF) 0.5 ML SUSPENSION <b>\$0,DL</b>	1	
GARDASIL 9 (PF) 0.5 ML SYRINGE <b>\$0,DL</b>	1	
<i>gengraf</i> 100 mg, 25 mg CAPSULE <b>MO</b>	1	BvsD
<i>gengraf</i> 100 mg/ml SOLUTION <b>MO</b>	1	BvsD
HADLIMA 40 MG/0.8 ML SYRINGE <b>DL</b>	4	PA,QL(4.8 per 28 days)
HADLIMA PUSH TOUCH 40 MG/0.8 ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(4.8 per 28 days)
HADLIMA(CF) 40 MG/0.4 ML SYRINGE <b>DL</b>	4	PA,QL(2.4 per 28 days)
HADLIMA(CF) PUSH TOUCH 40 MG/0.4 ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(2.4 per 28 days)
HAEGARDA 2,000 UNIT, 3,000 UNIT RECON SOLUTION <b>DL</b>	4	PA,QL(24 per 28 days)
HAVRIX (PF) 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML SYRINGE <b>\$0,DL</b>	1	
HEPLISAV-B (PF) 20 MCG/0.5 ML SYRINGE <b>\$0,DL</b>	1	BvsD
HIBERIX (PF) 10 MCG/0.5 ML RECON SOLUTION <b>\$0,DL</b>	1	
HIZENTRA 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SOLUTION <b>DL</b>	4	PA
HIZENTRA 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SYRINGE <b>DL</b>	4	PA
HULIO(CF) 20 MG/0.4 ML SYRINGE KIT <b>DL</b>	4	PA,QL(2 per 28 days)
HULIO(CF) 40 MG/0.8 ML SYRINGE KIT <b>DL</b>	4	PA,QL(6 per 28 days)
HULIO(CF) PEN 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
HUMIRA 40 MG/0.8 ML SYRINGE KIT <b>DL</b>	4	PA,QL(6 per 28 days)
HUMIRA PEN 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
HUMIRA PEN CROHNS-UC-HS START 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
HUMIRA PEN PSOR-UVEITS-ADOL HS 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
HUMIRA(CF) 10 MG/0.1 ML SYRINGE KIT <b>DL</b>	4	PA,QL(2 per 28 days)
HUMIRA(CF) 20 MG/0.2 ML, 40 MG/0.4 ML SYRINGE KIT <b>DL</b>	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEDI CROHNS STARTER 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML SYRINGE KIT <b>DL</b>	4	PA,QL(6 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HUMIRA(CF) PEN 40 MG/0.4 ML, 80 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEN CROHNS-UC-HS 80 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEN PEDIATRIC UC 80 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEN PSOR-UV-ADOL HS 80 MG/0.8 ML-40 MG/0.4 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
HYPERRAB (PF) 300 UNIT/ML SOLUTION <b>DL</b>	4	BvsD
HYPERTET (PF) 250 UNIT/ML SYRINGE <b>DL</b>	3	BvsD
HYRIMOZ PEN CROHN'S-UC STARTER 80 MG/0.8 ML PEN INJECTOR <b>DL</b>	4	PA,QL(4.8 per 28 days)
HYRIMOZ PEN PSORIASIS STARTER 80MG/0.8ML(X1)- 40 MG/0.4ML(X2) PEN INJECTOR <b>DL</b>	4	PA,QL(3.2 per 28 days)
HYRIMOZ(CF) 10 MG/0.1 ML SYRINGE <b>DL</b>	4	PA,QL(0.2 per 28 days)
HYRIMOZ(CF) 20 MG/0.2 ML SYRINGE <b>DL</b>	4	PA,QL(1.2 per 28 days)
HYRIMOZ(CF) 40 MG/0.4 ML SYRINGE <b>DL</b>	4	PA,QL(2.4 per 28 days)
HYRIMOZ(CF) PEDI CROHN STARTER 80 MG/0.8 ML SYRINGE <b>DL</b>	4	PA,QL(4.8 per 28 days)
HYRIMOZ(CF) PEDI CROHN STARTER 80 MG/0.8 ML - 40 MG/0.4 ML SYRINGE <b>DL</b>	4	PA,QL(3.6 per 28 days)
HYRIMOZ(CF) PEN 40 MG/0.4 ML PEN INJECTOR <b>DL</b>	4	PA,QL(2.4 per 28 days)
HYRIMOZ(CF) PEN 80 MG/0.8 ML PEN INJECTOR <b>DL</b>	4	PA,QL(4.8 per 28 days)
<i>icatibant 30 mg/3 ml SYRINGE</i> <b>DL</b>	4	PA,QL(18 per 30 days)
IDACIO(CF) 40 MG/0.8 ML SYRINGE KIT <b>DL</b>	4	PA,QL(6 per 28 days)
IDACIO(CF) PEN 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
IDACIO(CF) PEN CROHN-UC STARTR 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
IDACIO(CF) PEN PSORIASIS START 40 MG/0.8 ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(6 per 28 days)
ILUMYA 100 MG/ML SYRINGE	4	PA,QL(6 per 365 days)
IMOGAM RABIES-HT (PF) 150 UNIT/ML SOLUTION <b>DL</b>	3	BvsD
IMOVAX RABIES VACCINE (PF) 2.5 UNIT RECON SOLUTION <b>\$0,DL</b>	1	BvsD
IMURAN 50 MG TABLET <b>MO</b>	3	PA
INFANRIX (DTAP) (PF) 25-58-10 LF-MCG-LF/0.5ML SYRINGE <b>\$0,DL</b>	1	
INFLECTRA 100 MG RECON SOLUTION <b>DL</b>	4	PA
INFLIXIMAB 100 MG RECON SOLUTION <b>DL</b>	4	PA
INTRON A 10 MILLION UNIT (1 ML), 18 MILLION UNIT (1 ML) RECON SOLUTION <b>MO</b>	3	PA
INTRON A 50 MILLION UNIT (1 ML) RECON SOLUTION <b>MO</b>	2	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
IPOL 40-8-32 UNIT/0.5 ML SUSPENSION \$0,DL	1	
IXCHIQ 1,000 TCID50/0.5 ML RECON SOLUTION DL	1	
IXIARO (PF) 6 MCG/0.5 ML SYRINGE \$0,DL	1	
JYNNEOS (PF) 0.5X TO 3.95X 10EXP8 UNIT/0.5 SUSPENSION \$0,DL	1	
KEDRAB (PF) 150 UNIT/ML SOLUTION DL	4	BvsD
KEVZARA 150 MG/1.14 ML, 200 MG/1.14 ML PEN INJECTOR DL	4	PA,QL(2.28 per 28 days)
KEVZARA 150 MG/1.14 ML, 200 MG/1.14 ML SYRINGE DL	4	PA,QL(2.28 per 28 days)
KINERET 100 MG/0.67 ML SYRINGE DL	4	PA,QL(20.1 per 30 days)
KINRIX (PF) 25 LF-58 MCG-10 LF/0.5 ML SYRINGE \$0,DL	1	
leflunomide 10 mg, 20 mg TABLET MO	1	QL(30 per 30 days)
LUPKYNIS 7.9 MG CAPSULE DL	4	PA,QL(180 per 30 days)
M-M-R II (PF) 1,000-12,500 TCID50/0.5 ML RECON SOLUTION \$0,DL	1	
MENACTRA (PF) 4 MCG/0.5 ML SOLUTION \$0,DL	1	
MENQUADFI (PF) 10 MCG/0.5 ML SOLUTION \$0,DL	1	
MENVEO A-C-Y-W-135-DIP (PF) 10-5 MCG/0.5 ML KIT \$0,DL	1	
MENVEO A-C-Y-W-135-DIP (PF) 10-5 MCG/0.5 ML SOLUTION \$0,DL	1	
methotrexate sodium 2.5 mg TABLET MO	1	BvsD
methotrexate sodium 25 mg/ml SOLUTION MO	1	
methotrexate sodium (pf) 1 gram RECON SOLUTION MO	1	
methotrexate sodium (pf) 25 mg/ml SOLUTION MO	1	
MONJUVI 200 MG RECON SOLUTION DL	4	PA
mycophenolate mofetil 200 mg/ml SUSPENSION FOR RECONSTITUTION MO	1	BvsD
mycophenolate mofetil 250 mg CAPSULE MO	1	BvsD
mycophenolate mofetil 500 mg TABLET MO	1	BvsD
mycophenolate mofetil (hcl) 500 mg RECON SOLUTION MO	1	BvsD
mycophenolate sodium 180 mg, 360 mg TABLET, DR/EC MO	1	BvsD
MYFORTIC 180 MG TABLET, DR/EC MO	3	BvsD
MYFORTIC 360 MG TABLET, DR/EC	4	BvsD
NEORAL 100 MG, 25 MG CAPSULE MO	3	BvsD
NEORAL 100 MG/ML SOLUTION MO	3	BvsD
OCTAGAM 10 %, 5 % SOLUTION DL	4	PA
OLUMIANT 1 MG, 2 MG, 4 MG TABLET DL	4	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OMVOH 300 MG/15 ML (20 MG/ML) SOLUTION <b>DL</b>	4	PA
OMVOH PEN 100 MG/ML PEN INJECTOR <b>DL</b>	4	PA,QL(2 per 28 days)
ORENCIA 125 MG/ML SYRINGE <b>DL</b>	4	PA,QL(4 per 28 days)
ORENCIA 50 MG/0.4 ML SYRINGE <b>DL</b>	4	PA,QL(1.6 per 28 days)
ORENCIA 87.5 MG/0.7 ML SYRINGE <b>DL</b>	4	PA,QL(2.8 per 28 days)
ORENCIA CLICKJECT 125 MG/ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(4 per 28 days)
ORLADEYO 110 MG, 150 MG CAPSULE <b>DL</b>	4	PA,QL(28 per 28 days)
OTREXUP (PF) 10 MG/0.4 ML, 12.5 MG/0.4 ML, 15 MG/0.4 ML, 17.5 MG/0.4 ML, 20 MG/0.4 ML, 22.5 MG/0.4 ML, 25 MG/0.4 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(1.6 per 28 days)
PANZYGA 10 % SOLUTION <b>DL</b>	4	PA
PEDIARIX (PF) 10 MCG-25LF-25 MCG-10LF/0.5 ML SYRINGE <b>\$0,DL</b>	1	
PEDVAX HIB (PF) 7.5 MCG/0.5 ML SOLUTION <b>\$0,DL</b>	1	
PEGASYS 180 MCG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(2 per 28 days)
PEGASYS 180 MCG/ML SOLUTION <b>DL</b>	4	PA,QL(4 per 28 days)
PENBRAYA (PF) 5-120 MCG/0.5 ML KIT <b>\$0,DL</b>	1	
PENTACEL (PF) 15 LF UNIT-20 MCG-5 LF/0.5 ML, 15LF-48MCG-62DU -10 MCG/0.5ML KIT <b>\$0,DL</b>	1	
PREHEVBRIO (PF) 10 MCG/ML SUSPENSION <b>\$0,DL</b>	1	BvsD
PRIORIX (PF) 10EXP3.4-4.2- 3.3CCID50/0.5ML SUSPENSION FOR RECONSTITUTION <b>\$0,DL</b>	1	
PRIVIGEN 10 % SOLUTION <b>DL</b>	4	PA
PROGRAF 0.2 MG, 1 MG GRANULES IN PACKET <b>MO</b>	3	BvsD
PROGRAF 0.5 MG, 1 MG, 5 MG CAPSULE <b>MO</b>	3	BvsD
PROQUAD (PF) 10EXP3-4.3-3- 3.99 TCID50/0.5 SUSPENSION FOR RECONSTITUTION <b>\$0,DL</b>	1	
QUADRACEL (PF) 15 LF-48 MCG- 5 LF UNIT/0.5ML SUSPENSION <b>\$0,DL</b>	1	
QUADRACEL (PF) 15 LF-48 MCG- 5 LF UNIT/0.5ML SYRINGE <b>\$0,DL</b>	1	
RABAVERT (PF) 2.5 UNIT SUSPENSION FOR RECONSTITUTION <b>\$0,DL</b>	1	BvsD
RAPAMUNE 0.5 MG, 1 MG, 2 MG TABLET	4	BvsD
RAPAMUNE 1 MG/ML SOLUTION	4	BvsD
RASUVO (PF) 10 MG/0.2 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(0.8 per 28 days)
RASUVO (PF) 12.5 MG/0.25 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(1 per 28 days)
RASUVO (PF) 15 MG/0.3 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(1.2 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RASUVO (PF) 17.5 MG/0.35 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(1.4 per 28 days)
RASUVO (PF) 20 MG/0.4 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(1.6 per 28 days)
RASUVO (PF) 22.5 MG/0.45 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(1.8 per 28 days)
RASUVO (PF) 25 MG/0.5 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(2 per 28 days)
RASUVO (PF) 30 MG/0.6 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(2.4 per 28 days)
RASUVO (PF) 7.5 MG/0.15 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(0.6 per 28 days)
RECOMBIVAX HB (PF) 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML SUSPENSION <b>\$0,DL</b>	1	BvsD
RECOMBIVAX HB (PF) 10 MCG/ML, 5 MCG/0.5 ML SYRINGE <b>\$0,DL</b>	1	BvsD
REDITREX (PF) 10 MG/0.4 ML SYRINGE <b>MO</b>	3	PA,QL(1.6 per 28 days)
REDITREX (PF) 12.5 MG/0.5 ML SYRINGE <b>MO</b>	3	PA,QL(2 per 28 days)
REDITREX (PF) 15 MG/0.6 ML SYRINGE <b>MO</b>	3	PA,QL(2.4 per 28 days)
REDITREX (PF) 17.5 MG/0.7 ML SYRINGE <b>MO</b>	3	PA,QL(2.8 per 28 days)
REDITREX (PF) 20 MG/0.8 ML SYRINGE <b>MO</b>	3	PA,QL(3.2 per 28 days)
REDITREX (PF) 22.5 MG/0.9 ML SYRINGE <b>MO</b>	3	PA,QL(3.6 per 28 days)
REDITREX (PF) 25 MG/ML SYRINGE <b>MO</b>	3	PA,QL(4 per 28 days)
REDITREX (PF) 7.5 MG/0.3 ML SYRINGE <b>MO</b>	3	PA,QL(1.2 per 28 days)
REMICADE 100 MG RECON SOLUTION <b>DL</b>	4	PA
RENFLEXIS 100 MG RECON SOLUTION <b>DL</b>	4	PA
REZUROCK 200 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
RHOPHYLAC 1,500 UNIT (300 MCG)/2 ML SYRINGE <b>MO</b>	3	
RIDAURA 3 MG CAPSULE <b>DL</b>	4	PA
RINVOQ 15 MG, 30 MG TABLET, ER 24 HR. <b>DL</b>	4	PA,QL(30 per 30 days)
RINVOQ 45 MG TABLET, ER 24 HR. <b>DL</b>	4	PA,QL(168 per 365 days)
ROTARIX 10EXP6 CCID50 /1.5 ML SUSPENSION <b>\$0,DL</b>	1	
ROTARIX 10EXP6 CCID50/ML SUSPENSION FOR RECONSTITUTION <b>\$0,DL</b>	1	
ROTATEQ VACCINE 2 ML SOLUTION <b>\$0,DL</b>	1	
RUCONEST 2,100 UNIT RECON SOLUTION <b>DL</b>	4	PA,QL(8 per 28 days)
RYSTIGGO 140 MG/ML SOLUTION <b>DL</b>	4	PA
<i>sajazir</i> 30 mg/3 ml SYRINGE <b>DL</b>	4	PA,QL(18 per 30 days)
SANDIMMUNE 100 MG, 25 MG CAPSULE <b>MO</b>	3	BvsD
SANDIMMUNE 100 MG/ML SOLUTION <b>MO</b>	3	BvsD

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SAPHNELO 300 MG/2 ML (150 MG/ML) SOLUTION <b>DL</b>	4	PA,QL(2 per 28 days)
SHINGRIX (PF) 50 MCG/0.5 ML SUSPENSION FOR RECONSTITUTION <b>\$0,DL</b>	1	
SILIQ 210 MG/1.5 ML SYRINGE <b>DL</b>	4	PA,QL(6 per 28 days)
SIMLANDI(CF) AUTOINJECTOR 40 MG/0.4 ML AUTO-INJECTOR, KIT <b>DL</b>	4	PA,QL(6 per 28 days)
SIMPONI 100 MG/ML PEN INJECTOR <b>DL</b>	4	PA,QL(3 per 28 days)
SIMPONI 100 MG/ML SYRINGE <b>DL</b>	4	PA,QL(3 per 28 days)
SIMPONI 50 MG/0.5 ML PEN INJECTOR <b>DL</b>	4	PA,QL(0.5 per 30 days)
SIMPONI 50 MG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(0.5 per 30 days)
SIMPONI ARIA 12.5 MG/ML SOLUTION <b>DL</b>	4	PA,QL(20 per 28 days)
SIMULECT 10 MG, 20 MG RECON SOLUTION <b>DL</b>	4	BvsD
<i>sirolimus 0.5 mg, 1 mg, 2 mg TABLET</i> <b>MO</b>	1	BvsD
<i>sirolimus 1 mg/ml SOLUTION</i> <b>MO</b>	1	BvsD
SKYRIZI 150 MG/ML PEN INJECTOR	4	PA,QL(6 per 365 days)
SKYRIZI 150 MG/ML SYRINGE	4	PA,QL(6 per 365 days)
SKYRIZI 180 MG/1.2 ML (150 MG/ML) WEARABLE INJECTOR <b>DL</b>	4	PA,QL(8.4 per 365 days)
SKYRIZI 360 MG/2.4 ML (150 MG/ML) WEARABLE INJECTOR <b>DL</b>	4	PA,QL(16.8 per 365 days)
SKYRIZI 60 MG/ML SOLUTION <b>DL</b>	4	PA,QL(30 per 365 days)
SOLIRIS 300 MG/30 ML SOLUTION <b>DL</b>	4	PA
SOTYKTU 6 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
SPEVIGO 150 MG/ML SYRINGE <b>DL</b>	4	PA,QL(4 per 28 days)
SPEVIGO 60 MG/ML SOLUTION <b>DL</b>	4	PA,QL(30 per 84 days)
STELARA 130 MG/26 ML SOLUTION <b>DL</b>	4	PA,QL(104 per 30 days)
STELARA 45 MG/0.5 ML SOLUTION <b>DL</b>	4	PA,QL(1.5 per 84 days)
STELARA 45 MG/0.5 ML SYRINGE <b>DL</b>	4	PA,QL(1.5 per 84 days)
STELARA 90 MG/ML SYRINGE <b>DL</b>	4	PA,QL(3 per 84 days)
SYLVANT 100 MG, 400 MG RECON SOLUTION <b>DL</b>	4	PA
<i>tacrolimus 0.5 mg, 1 mg, 5 mg CAPSULE</i> <b>MO</b>	1	BvsD
TAKHZYRO 150 MG/ML SYRINGE <b>DL</b>	4	PA,QL(2 per 28 days)
TAKHZYRO 300 MG/2 ML (150 MG/ML) SOLUTION <b>DL</b>	4	PA,QL(4 per 28 days)
TAKHZYRO 300 MG/2 ML (150 MG/ML) SYRINGE <b>DL</b>	4	PA,QL(4 per 28 days)
TALTZ AUTOINJECTOR 80 MG/ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(4 per 28 days)
TALTZ AUTOINJECTOR (2 PACK) 80 MG/ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(4 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TALTZ AUTOINJECTOR (3 PACK) 80 MG/ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(4 per 28 days)
TALTZ SYRINGE 80 MG/ML SYRINGE <b>DL</b>	4	PA,QL(4 per 28 days)
TAVNEOS 10 MG CAPSULE <b>DL</b>	4	PA,QL(180 per 30 days)
TDVAX 2-2 LF UNIT/0.5 ML SUSPENSION <b>\$0,DL</b>	1	
TENIVAC (PF) 5 LF UNIT- 2 LF UNIT/0.5ML SUSPENSION <b>\$0,DL</b>	1	
TENIVAC (PF) 5-2 LF UNIT/0.5 ML SYRINGE <b>\$0,DL</b>	1	
TETANUS,DIPHTHERIA TOX PED(PF) 5-25 LF UNIT/0.5 ML SUSPENSION <b>\$0,DL</b>	1	
TEZSPIRE 210 MG/1.91 ML (110 MG/ML) PEN INJECTOR <b>DL</b>	4	PA,QL(1.91 per 28 days)
TEZSPIRE 210 MG/1.91 ML (110 MG/ML) SYRINGE <b>DL</b>	4	PA,QL(1.91 per 28 days)
THYMOGLOBULIN 25 MG RECON SOLUTION <b>MO</b>	3	PA
TICOVAC 1.2 MCG/0.25 ML, 2.4 MCG/0.5 ML SYRINGE <b>DL</b>	1	
TREMFYA 100 MG/ML AUTO-INJECTOR	4	PA,QL(8 per 365 days)
TREMFYA 100 MG/ML SYRINGE	4	PA,QL(8 per 365 days)
TREXALL 10 MG, 15 MG, 5 MG, 7.5 MG TABLET <b>MO</b>	1	BvsD
TRUMENBA 120 MCG/0.5 ML SYRINGE <b>\$0,DL</b>	1	
TWINRIX (PF) 720 ELISA UNIT- 20 MCG/ML SYRINGE <b>\$0,DL</b>	1	
TYPHIM VI 25 MCG/0.5 ML SOLUTION <b>\$0,DL</b>	1	
TYPHIM VI 25 MCG/0.5 ML SYRINGE <b>\$0,DL</b>	1	
ULTOMIRIS 100 MG/ML SOLUTION	4	PA
UPLIZNA 10 MG/ML SOLUTION <b>DL</b>	4	PA,QL(120 per 365 days)
VAQTA (PF) 25 UNIT/0.5 ML, 50 UNIT/ML SUSPENSION <b>\$0,DL</b>	1	
VAQTA (PF) 25 UNIT/0.5 ML, 50 UNIT/ML SYRINGE <b>\$0,DL</b>	1	
VARIVAX (PF) 1,350 UNIT/0.5 ML SUSPENSION FOR RECONSTITUTION <b>\$0,DL</b>	1	
VARIZIG 125 UNIT/1.2 ML SOLUTION <b>DL</b>	4	PA,QL(12 per 30 days)
VELSIPITY 2 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
VEOPOZ 200 MG/ML SOLUTION <b>DL</b>	4	PA
VOYDEYA 100 MG, 150 MG (50 MG X 1-100 MG X 1) TABLET <b>DL</b>	4	PA,QL(180 per 30 days)
VYVGART 20 MG/ML SOLUTION <b>DL</b>	4	PA
VYVGART HYTRULO 1,008 MG-11,200 UNIT/5.6 ML SOLUTION <b>DL</b>	4	PA,QL(22.4 per 28 days)
WINRHO SDF 1,500 UNIT (300 MCG)/1.3 ML, 15000 UNIT(3000 MCG)/13 ML, 2,500 UNIT (500 MCG)/2.2 ML, 5,000 UNIT(1000 MCG)/4.4 ML SOLUTION <b>DL</b>	4	BvsD
XATMEP 2.5 MG/ML SOLUTION <b>MO</b>	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
XELJANZ 1 MG/ML SOLUTION <b>DL</b>	4	PA,QL(300 per 30 days)
XELJANZ 10 MG, 5 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
XELJANZ XR 11 MG, 22 MG TABLET, ER 24 HR. <b>DL</b>	4	PA,QL(30 per 30 days)
XEMBIFY 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SOLUTION <b>DL</b>	4	PA
XOLAIR 150 MG RECON SOLUTION <b>DL</b>	4	PA,QL(8 per 28 days)
XOLAIR 150 MG/ML, 300 MG/2 ML AUTO-INJECTOR <b>DL,LA</b>	4	PA,QL(8 per 28 days)
XOLAIR 150 MG/ML, 300 MG/2 ML SYRINGE <b>DL,LA</b>	4	PA,QL(8 per 28 days)
XOLAIR 75 MG/0.5 ML AUTO-INJECTOR <b>DL,LA</b>	4	PA,QL(4 per 28 days)
XOLAIR 75 MG/0.5 ML SYRINGE <b>DL,LA</b>	4	PA,QL(4 per 28 days)
YF-VAX (PF) 10 EXP4.74 UNIT/0.5 ML SUSPENSION FOR RECONSTITUTION <b>\$0,DL</b>	1	
YUFLYMA(CF) 20 MG/0.2 ML, 40 MG/0.4 ML SYRINGE KIT <b>DL</b>	4	PA,QL(6 per 28 days)
YUFLYMA(CF) AI CROHN'S-UC-HS 80 MG/0.8 ML AUTO-INJECTOR, KIT <b>DL</b>	4	PA,QL(6 per 28 days)
YUFLYMA(CF) AUTOINJECTOR 40 MG/0.4 ML, 80 MG/0.8 ML AUTO-INJECTOR, KIT <b>DL</b>	4	PA,QL(6 per 28 days)
YUSIMRY(CF) PEN 40 MG/0.8 ML PEN INJECTOR <b>DL</b>	4	PA,QL(4.8 per 28 days)
ZILBRYSQ 16.6 MG/0.416 ML, 23 MG/0.574 ML, 32.4 MG/0.81 ML SYRINGE <b>DL</b>	4	PA
ZORTRESS 0.25 MG, 0.75 MG, 1 MG TABLET	4	BvsD,QL(60 per 30 days)
ZORTRESS 0.5 MG TABLET	4	BvsD,QL(120 per 30 days)
ZYMFENTRA 120 MG/ML PEN INJECTOR KIT <b>DL</b>	4	PA,QL(2 per 28 days)
ZYMFENTRA 120 MG/ML SYRINGE KIT <b>DL</b>	4	PA,QL(2 per 28 days)
<b>INFLAMMATORY BOWEL DISEASE AGENTS</b>		
APRISO 0.375 GRAM CAPSULE, ER 24 HR. <b>MO</b>	3	ST,QL(120 per 30 days)
ASACOL HD 800 MG TABLET, DR/EC <b>MO</b>	3	ST,QL(180 per 30 days)
AZULFIDINE 500 MG TABLET <b>MO</b>	3	
AZULFIDINE EN-TABS 500 MG TABLET, DR/EC <b>MO</b>	3	
<i>balsalazide 750 mg CAPSULE</i> <b>MO</b>	1	
<i>budesonide 2 mg/actuation FOAM</i> <b>MO</b>	1	PA
<i>budesonide 3 mg CAPSULE, DR/EC</i> <b>MO</b>	1	
<i>budesonide 9 mg TABLET, DR/ER</i>	4	PA,QL(30 per 30 days)
CANASA 1,000 MG SUPPOSITORY	4	ST,QL(30 per 30 days)
COLAZAL 750 MG CAPSULE	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CORTENEMA 100 MG/60 ML ENEMA <b>MO</b>	3	
CORTIFOAM 10 % (80 MG) FOAM <b>MO</b>	3	
DELZICOL 400 MG CAPSULE (WITH DR TABLETS) <b>MO</b>	3	ST,QL(180 per 30 days)
DIPENTUM 250 MG CAPSULE	4	ST,QL(120 per 30 days)
<i>hydrocortisone 100 mg/60 ml ENEMA</i> <b>MO</b>	1	
LIALDA 1.2 GRAM TABLET, DR/EC <b>MO</b>	3	ST,QL(120 per 30 days)
<i>mesalamine 0.375 gram CAPSULE, ER 24 HR.</i> <b>MO</b>	1	QL(120 per 30 days)
<i>mesalamine 1,000 mg SUPPOSITORY</i> <b>MO</b>	1	ST,QL(30 per 30 days)
<i>mesalamine 1.2 gram TABLET, DR/EC</i> <b>MO</b>	1	ST,QL(120 per 30 days)
<i>mesalamine 4 gram/60 ml ENEMA</i> <b>MO</b>	1	QL(1800 per 30 days)
<i>mesalamine 400 mg CAPSULE (WITH DR TABLETS)</i> <b>MO</b>	1	ST,QL(180 per 30 days)
<i>mesalamine 500 mg CAPSULE, ER</i> <b>MO</b>	1	ST,QL(300 per 30 days)
<i>mesalamine 800 mg TABLET, DR/EC</i> <b>MO</b>	1	ST,QL(180 per 30 days)
ORTIKOS 6 MG, 9 MG CAPSULE, ER <b>DL</b>	4	PA,QL(30 per 30 days)
PENTASA 250 MG CAPSULE, ER <b>MO</b>	3	ST,QL(150 per 30 days)
PENTASA 500 MG CAPSULE, ER	4	ST,QL(300 per 30 days)
PROCTOFOAM HC 1-1 % FOAM <b>MO</b>	1	
ROWASA 4 GRAM/60 ML ENEMA <b>MO</b>	3	QL(1800 per 30 days)
SFROWASA 4 GRAM/60 ML ENEMA <b>MO</b>	3	QL(1800 per 30 days)
<i>sulfasalazine 500 mg TABLET</i> <b>MO</b>	1	
<i>sulfasalazine 500 mg TABLET, DR/EC</i> <b>MO</b>	1	
TARPEYO 4 MG CAPSULE, DR/EC <b>DL</b>	4	PA,QL(120 per 30 days)
UCERIS 2 MG/ACTUATION FOAM <b>MO</b>	3	PA
UCERIS 9 MG TABLET, DR/ER <b>MO</b>	3	PA,QL(30 per 30 days)
<b>METABOLIC BONE DISEASE AGENTS</b>		
ACTONEL 150 MG TABLET <b>MO</b>	3	PA,QL(1 per 30 days)
ACTONEL 35 MG TABLET <b>MO</b>	3	PA,QL(4 per 28 days)
<i>alendronate 10 mg, 5 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>alendronate 35 mg TABLET</i> <b>MO</b>	1	QL(4 per 28 days)
<i>alendronate 70 mg TABLET</i> <b>MO</b>	1	QL(4 per 28 days)
<i>alendronate 70 mg/75 ml SOLUTION</i> <b>MO</b>	1	QL(300 per 28 days)
ATELVIA 35 MG TABLET, DR/EC <b>MO</b>	3	PA,QL(4 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BINOSTO 70 MG TABLET, EFFERVESCENT <b>MO</b>	3	ST,QL(4 per 28 days)
BONIVA 150 MG TABLET <b>MO</b>	3	PA,QL(1 per 28 days)
calcitonin (salmon) 200 unit/actuation SPRAY, NON-AEROSOL <b>MO</b>	1	QL(3.7 per 28 days)
calcitonin (salmon) 200 unit/ml SOLUTION <b>DL</b>	4	
calcitriol 0.25 mcg, 0.5 mcg CAPSULE <b>MO</b>	1	
calcitriol 1 mcg/ml SOLUTION <b>MO</b>	1	
cinacalcet 30 mg, 60 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
cinacalcet 90 mg TABLET <b>MO</b>	1	QL(120 per 30 days)
doxercalciferol 0.5 mcg, 1 mcg, 2.5 mcg CAPSULE <b>MO</b>	1	
doxercalciferol 4 mcg/2 ml SOLUTION <b>MO</b>	1	
EVENITY 105 MG/1.17 ML, 210MG/2.34ML ( 105MG/1.17MLX2) SYRINGE <b>DL</b>	4	PA,QL(2.34 per 30 days)
FORTEO 20 MCG/DOSE (600MCG/2.4ML) PEN INJECTOR <b>DL</b>	4	PA,QL(2.4 per 28 days)
FOSAMAX 70 MG TABLET <b>MO</b>	3	PA,QL(4 per 28 days)
FOSAMAX PLUS D 70 MG- 2,800 UNIT, 70 MG- 5,600 UNIT TABLET <b>MO</b>	3	ST,QL(4 per 28 days)
HECTOROL 4 MCG/2 ML SOLUTION <b>MO</b>	3	
ibandronate 150 mg TABLET <b>MO</b>	1	QL(1 per 28 days)
ibandronate 3 mg/3 ml SOLUTION <b>MO</b>	1	PA,QL(3 per 90 days)
ibandronate 3 mg/3 ml SYRINGE <b>MO</b>	1	PA,QL(3 per 90 days)
MIACALCIN 200 UNIT/ML SOLUTION <b>DL</b>	4	
NATPARA 100 MCG/DOSE, 25 MCG/DOSE, 50 MCG/DOSE, 75 MCG/DOSE CARTRIDGE <b>DL,LA</b>	4	PA,QL(2 per 28 days)
pamidronate 30 mg/10 ml (3 mg/ml) SOLUTION <b>MO</b>	1	QL(30 per 21 days)
pamidronate 60 mg/10 ml (6 mg/ml), 90 mg/10 ml (9 mg/ml) SOLUTION <b>MO</b>	1	QL(10 per 21 days)
paricalcitol 1 mcg, 2 mcg CAPSULE <b>MO</b>	1	QL(30 per 30 days)
paricalcitol 2 mcg/ml SOLUTION <b>MO</b>	1	QL(24 per 30 days)
paricalcitol 4 mcg CAPSULE <b>MO</b>	1	QL(12 per 30 days)
paricalcitol 5 mcg/ml SOLUTION <b>MO</b>	1	QL(48 per 28 days)
PROLIA 60 MG/ML SYRINGE <b>MO</b>	3	QL(1 per 180 days)
RAYALDEE 30 MCG CAPSULE, ER 24 HR. <b>DL</b>	4	QL(60 per 30 days)
RECLAST 5 MG/100 ML PIGGYBACK <b>MO</b>	3	PA,QL(100 per 365 days)
risedronate 150 mg TABLET <b>MO</b>	1	QL(1 per 30 days)
risedronate 30 mg, 5 mg TABLET <b>MO</b>	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>risedronate 35 mg TABLET</i> <b>MO</b>	1	QL(4 per 28 days)
<i>risedronate 35 mg TABLET, DR/EC</i> <b>MO</b>	1	QL(4 per 28 days)
ROCALTROL 0.25 MCG, 0.5 MCG CAPSULE <b>MO</b>	3	
ROCALTROL 1 MCG/ML SOLUTION <b>MO</b>	3	
SENSIPAR 30 MG TABLET <b>MO</b>	3	QL(60 per 30 days)
SENSIPAR 60 MG TABLET	4	QL(60 per 30 days)
SENSIPAR 90 MG TABLET	4	QL(120 per 30 days)
TYMLOS 80 MCG (3,120 MCG/1.56 ML) PEN INJECTOR <b>DL</b>	4	PA,QL(1.56 per 30 days)
XGEVA 120 MG/1.7 ML (70 MG/ML) SOLUTION <b>DL</b>	4	PA,QL(1.7 per 28 days)
ZEMPLAR 1 MCG, 2 MCG CAPSULE <b>MO</b>	3	QL(30 per 30 days)
ZEMPLAR 2 MCG/ML SOLUTION <b>DL</b>	4	QL(24 per 30 days)
ZEMPLAR 5 MCG/ML SOLUTION <b>DL</b>	4	QL(48 per 28 days)
<i>zoledronic ac-mannitol-0.9nacl 4 mg/100 ml PIGGYBACK</i> <b>MO</b>	1	QL(300 per 21 days)
<i>zoledronic acid 4 mg RECON SOLUTION</i> <b>MO</b>	1	
<i>zoledronic acid 4 mg/5 ml SOLUTION</i> <b>MO</b>	1	QL(15 per 21 days)
<i>zoledronic acid-mannitol-water 4 mg/100 ml PIGGYBACK</i> <b>MO</b>	1	QL(300 per 21 days)
<i>zoledronic acid-mannitol-water 5 mg/100 ml PIGGYBACK</i> <b>MO</b>	1	PA,QL(100 per 365 days)
<b>MISCELLANEOUS THERAPEUTIC AGENTS</b>		
ACETADOTE 200 MG/ML (20 %) SOLUTION <b>MO</b>	3	
acetaminophen 1,000 mg/100 ml (10 mg/ml), 500 mg/50 ml (10 mg/ml) SOLUTION <b>MO</b>	1	
acetic acid 0.25 % SOLUTION <b>MO</b>	1	
acetylcysteine 200 mg/ml (20 %) SOLUTION <b>MO</b>	1	
ADAKVEO 10 MG/ML SOLUTION <b>DL</b>	4	PA
ADSTILADRIN 3X10EXP11 VP/ML SUSPENSION	4	PA
ALCOHOL PADS PADS, MEDICATED <b>\$0,MO</b>	1	
ALCOHOL PREP PADS PADS, MEDICATED <b>\$0,MO</b>	1	
ALCOHOL SWABS PADS, MEDICATED <b>\$0,MO</b>	1	
ALCOHOL WIPES PADS, MEDICATED <b>\$0,MO</b>	1	
ALLZITAL 25-325 MG TABLET <b>MO</b>	1	QL(360 per 30 days)
AMMONUL 10-10 % SOLUTION <b>DL</b>	4	
AUTOJECT 2 INJECTION DEVICE INSULIN PEN <b>\$0,MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AUTOPEN 1 TO 21 UNITS INSULIN PEN \$0,MO	1	
AUTOPEN 2 TO 42 UNITS INSULIN PEN \$0,MO	1	
BAND-AID GAUZE PADS 2 X 2 " BANDAGE \$0,MO	1	
BD ALCOHOL SWABS PADS, MEDICATED \$0,MO	1	
BD AUTOSHIELD DUO PEN NEEDLE 30 GAUGE X 3/16" NEEDLE \$0,PDS,MO	1	
BD ECLIPSE LUER-LOK 1 ML 30 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.5 ML 29 GAUGE X 1/2", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE (HALF UNIT) 0.3 ML 31 GAUGE X 5/16" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE MICRO-FINE 1 ML 28 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE U-500 1/2 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE ULTRA-FINE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16" SYRINGE \$0,PDS,MO	1	
BD LO-DOSE MICRO-FINE IV 1/2 ML 28 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
BD NANO 2ND GEN PEN NEEDLE 32 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	
BD SAFETYGLIDE INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 1 ML 29 GAUGE X 1/2", 1 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
BD SAFETYGLIDE SYRINGE 1 ML 27 GAUGE X 5/8" SYRINGE \$0,PDS,MO	1	
BD ULTRA-FINE MICRO PEN NEEDLE 32 GAUGE X 1/4" NEEDLE \$0,PDS,MO	1	
BD ULTRA-FINE MINI PEN NEEDLE 31 GAUGE X 3/16" NEEDLE \$0,PDS,MO	1	
BD ULTRA-FINE NANO PEN NEEDLE 32 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	
BD ULTRA-FINE ORIG PEN NEEDLE 29 GAUGE X 1/2" NEEDLE \$0,PDS,MO	1	
BD ULTRA-FINE SHORT PEN NEEDLE 31 GAUGE X 5/16" NEEDLE \$0,PDS,MO	1	
BD VEO INSULIN SYR (HALF UNIT) 0.3 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
BD VEO INSULIN SYRINGE UF 0.3 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 15/64", 1/2 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
BEYFORTUS 100 MG/ML, 50 MG/0.5 ML SYRINGE DL	4	
BORDERED GAUZE 2 X 2 " BANDAGE \$0,MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
bupap 50-300 mg TABLET <b>MO</b>	1	QL(180 per 30 days)
butalbital-acetaminop-caf-cod 50-300-40-30 mg CAPSULE <b>DL</b>	1	QL(180 per 30 days)
butalbital-acetaminop-caf-cod 50-325-40-30 mg CAPSULE <b>DL</b>	1	QL(360 per 30 days)
butalbital-acetaminophen 50-300 mg CAPSULE <b>MO</b>	1	QL(180 per 30 days)
butalbital-acetaminophen 50-300 mg, 50-325 mg TABLET <b>MO</b>	1	QL(180 per 30 days)
butalbital-acetaminophen-caff 50-300-40 mg, 50-325-40 mg CAPSULE <b>MO</b>	1	QL(180 per 30 days)
butalbital-acetaminophen-caff 50-325-40 mg TABLET <b>MO</b>	1	QL(180 per 30 days)
butalbital-aspirin-caffeine 50-325-40 mg CAPSULE <b>MO</b>	1	QL(180 per 30 days)
butalbital-aspirin-caffeine 50-325-40 mg TABLET <b>MO</b>	1	QL(180 per 30 days)
BYLVAY 1,200 MCG CAPSULE <b>DL</b>	4	PA,QL(150 per 30 days)
BYLVAY 200 MCG PELLETT <b>DL</b>	4	PA,QL(360 per 30 days)
BYLVAY 400 MCG CAPSULE <b>DL</b>	4	PA,QL(420 per 30 days)
BYLVAY 600 MCG PELLETT <b>DL</b>	4	PA,QL(120 per 30 days)
CAFCIT 60 MG/3 ML (20 MG/ML) SOLUTION <b>MO</b>	3	
caffeine citrate 60 mg/3 ml (20 mg/ml) SOLUTION <b>MO</b>	1	
calcium disodium versenate 200 mg/ml SOLUTION <b>MO</b>	1	
CARETOUCH ALCOHOL PREP PAD PADS, MEDICATED <b>\$0,MO</b>	1	
CERVIDIL 10 MG INSERT, ER <b>MO</b>	3	
CINVANTI 7.2 MG/ML EMULSION <b>MO</b>	3	PA,QL(36 per 28 days)
CLARINEX-D 12 HOUR 2.5-120 MG TABLET, ER 12 HR., MULTIPHASE <b>MO</b>	3	ST,QL(60 per 30 days)
COMBOGESIC IV 300-1,000 MG/100 ML SOLUTION <b>MO</b>	3	
CURITY ALCOHOL SWABS PADS, MEDICATED <b>\$0,MO</b>	1	
CURITY GAUZE 2 X 2 " BANDAGE <b>\$0,MO</b>	1	
DEFITELIO 80 MG/ML SOLUTION <b>DL</b>	4	PA
DERMACEA 2 X 2 " BANDAGE <b>\$0,MO</b>	1	
DOJOLVI 8.3 KCAL/ML LIQUID <b>DL</b>	4	PA
DROPLET INSULIN SYR(HALF UNIT) 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 0.5 ML 31 GAUGE X 5/16", 0.5ML 30 GAUGE X 15/64" SYRINGE <b>\$0,PDS,MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DROPLET INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 15/64", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 15/64", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16 SYRINGE \$0,PDS,MO	1	
DROPLET MICRON PEN NEEDLE 34 GAUGE X 9/64" NEEDLE \$0,PDS,MO	1	
DROPLET PEN NEEDLE 29 GAUGE X 1/2", 29 GAUGE X 3/8", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	
DROPSAFE ALCOHOL PREP PADS PADS, MEDICATED \$0,MO	1	
DROPSAFE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16" NEEDLE \$0,PDS,MO	1	
DROXIA 200 MG, 300 MG, 400 MG CAPSULE MO	2	
EASY COMFORT ALCOHOL PAD PADS, MEDICATED \$0,MO	1	
EASY TOUCH ALCOHOL PREP PADS PADS, MEDICATED \$0,MO	1	
edetate calcium disodium 200 mg/ml SOLUTION DL	4	
ELYXYB 120 MG/4.8 ML (25 MG/ML) SOLUTION DL	4	ST,QL(43.2 per 30 days)
EMPAVELI 1,080 MG/20 ML SOLUTION DL	4	PA,QL(160 per 28 days)
EOHILIA 2 MG/10 ML SUSPENSION IN PACKET DL	4	PA
ESGIC 50-325-40 MG CAPSULE MO	1	QL(180 per 30 days)
ESGIC 50-325-40 MG TABLET MO	1	QL(180 per 30 days)
FILSPARI 200 MG, 400 MG TABLET DL	4	PA,QL(30 per 30 days)
FILSUVEZ 10 % GEL DL	4	PA
fioricet 50-300-40 mg CAPSULE MO	1	QL(180 per 30 days)
FIORICET WITH CODEINE 50-300-40-30 MG CAPSULE DL	3	QL(180 per 30 days)
flumazenil 0.1 mg/ml SOLUTION MO	1	
fomepizole 1 gram/ml SOLUTION MO	1	
GAUZE BANDAGE 2 X 2 " BANDAGE \$0,MO	1	
GAUZE PAD 2 X 2 " BANDAGE \$0,MO	1	
GIVLAARI 189 MG/ML SOLUTION DL	4	PA
IGALMI 120 MCG, 180 MCG FILM MO	3	PA
INCONTROL ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
INSULIN SYRINGE 0.5 ML 29 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
INSULIN SYRINGE MICROFINE 1 ML 27 GAUGE X 5/8", 1/2 ML 28 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
INSULIN SYRINGE NEEDLELESS 1 ML SYRINGE \$0,PDS,MO	1	
INSULIN SYRINGE-NEEDLE U-100 1 ML 28 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
IV PREP WIPES PADS, MEDICATED \$0,MO	1	
KORLYM 300 MG TABLET DL	4	PA,QL(120 per 30 days)
<i>lactated ringers SOLUTION</i> MO	1	
LAGEVRIO (EUA) 200 MG CAPSULE MO	2	QL(40 per 5 days)
LITFULO 50 MG CAPSULE DL	4	PA,QL(28 per 28 days)
LITHOSTAT 250 MG TABLET MO	3	
LIVMARLI 9.5 MG/ML SOLUTION DL	4	PA,QL(90 per 30 days)
<i>methylergonovine 0.2 mg TABLET</i> DL	4	
<i>methylergonovine 0.2 mg/ml (1 ml) SOLUTION</i> MO	1	
<i>mifepristone 300 mg TABLET</i> DL	4	PA,QL(120 per 30 days)
MYFEMBREE 40-1-0.5 MG TABLET DL	4	PA,QL(28 per 28 days)
<i>neomycin-polymyxin b gu 40 mg-200,000 unit/ml SOLUTION</i> MO	1	
<i>nitroglycerin 0.4 % (w/w) OINTMENT</i> MO	1	QL(30 per 30 days)
NOVOPEN ECHO INSULIN PEN \$0,MO	1	
NURTEC ODT 75 MG TABLET, DISINTEGRATING	4	PA,QL(18 per 30 days)
OMNIPOD 5 G6 INTRO KIT (GEN 5) CARTRIDGE \$0,MO	2	
OMNIPOD 5 G6 PODS (GEN 5) CARTRIDGE \$0,MO	2	
OMNIPOD 5 G6-G7 INTRO KT(GEN5) CARTRIDGE \$0,MO	2	
OMNIPOD 5 G6-G7 PODS (GEN 5) CARTRIDGE \$0,MO	2	
OMNIPOD CLASSIC PODS (GEN 3) CARTRIDGE \$0,MO	2	
OMNIPOD DASH INTRO KIT (GEN 4) CARTRIDGE \$0,MO	2	
OMNIPOD DASH PODS (GEN 4) CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 10 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 15 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 20 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 25 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 30 UNITS/DAY CARTRIDGE \$0,MO	2	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OMNIPOD GO PODS 40 UNITS/DAY CARTRIDGE <b>\$0,MO</b>	2	
ORIAHNN 300-1-0.5MG(AM) /300 MG(PM) CAPSULE, SEQUENTIAL <b>DL</b>	4	PA,QL(56 per 28 days)
<i>orlistat 120 mg CAPSULE</i> <b>MO</b>	3	PA
OXBRYTA 300 MG TABLET <b>DL</b>	4	PA,QL(240 per 30 days)
OXBRYTA 300 MG TABLET FOR SUSPENSION <b>DL</b>	4	PA,QL(150 per 30 days)
OXBRYTA 500 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
OXLUMO 94.5 MG/0.5 ML SOLUTION	4	PA
<i>oxytocin 10 unit/ml SOLUTION</i> <b>MO</b>	1	
PALFORZIA (LEVEL 1) 3 MG (1 MG X 3) CAPSULE, SPRINKLE <b>DL</b>	3	PA
PALFORZIA (LEVEL 2) 6 MG (1 MG X 6) CAPSULE, SPRINKLE <b>DL</b>	3	PA
PALFORZIA (LEVEL 3) 12 MG (1 MG X 2, 10 MG X 1) CAPSULE, SPRINKLE <b>DL</b>	3	PA
PALFORZIA (LEVEL 4) 20 MG CAPSULE, SPRINKLE <b>DL</b>	3	PA
PALFORZIA (LEVEL 5) 40 MG (20 MG X 2) CAPSULE, SPRINKLE <b>DL</b>	3	PA
PALFORZIA (LEVEL 6) 80 MG (20 MG X 4) CAPSULE, SPRINKLE <b>DL</b>	3	PA
PALFORZIA (LEVEL 7) 120 MG (20 MG X 1, 100 MG X 1) CAPSULE, SPRINKLE <b>DL</b>	3	PA
PALFORZIA (LEVEL 8) 160 MG (20 MG X 3, 100 MG X1) CAPSULE, SPRINKLE <b>DL</b>	3	PA
PALFORZIA (LEVEL 9) 200 MG (100 MG X 2) CAPSULE, SPRINKLE <b>DL</b>	3	PA
PALFORZIA (LEVEL 10) 240 MG (20 MG X 2, 100 MG X 2) CAPSULE, SPRINKLE <b>DL</b>	3	PA
PALFORZIA (LEVEL 11 UP-DOSE) 300 MG POWDER IN PACKET <b>DL</b>	3	PA
PALFORZIA INITIAL DOSE 0.5/1/1.5/3/6 MG CAPSULE, SPRINKLE <b>MO</b>	3	PA
PALFORZIA LEVEL 11 MAINTENANCE 300 MG POWDER IN PACKET <b>DL</b>	3	PA
PAXLOVID 150-100 MG TABLET, DOSE PACK <b>\$0,MO</b>	2	QL(40 per 10 days)
PAXLOVID 300 MG (150 MG X 2)-100 MG TABLET, DOSE PACK <b>\$0,MO</b>	2	QL(60 per 10 days)
PEN NEEDLE, DIABETIC 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 5/32" NEEDLE <b>\$0,PDS,MO</b>	1	
<i>phenazopyridine 100 mg, 200 mg TABLET</i> <b>MO</b>	1	
PHEXXI 1.8-1-0.4 % GEL <b>MO</b>	3	QL(60 per 30 days)
PHYSIOLYTE 140-5-3-98 MEQ/L SOLUTION <b>MO</b>	1	
PHYSIOSOL IRRIGATION 140-5-3-98 MEQ/L SOLUTION <b>MO</b>	1	
PITOCIN 10 UNIT/ML SOLUTION <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PREVDUO 0.6 MG-3 MG/3ML (0.2 MG-1MG/ML) SYRINGE <b>MO</b>	3	
PRIALT 100 MCG/ML, 25 MCG/ML SOLUTION <b>DL</b>	4	PA
PRO COMFORT ALCOHOL PADS PADS, MEDICATED <b>\$0,MO</b>	1	
<i>promethazine vc 6.25-5 mg/5 ml SYRUP <b>MO</b></i>	1	
<i>promethazine-phenylephrine 6.25-5 mg/5 ml SYRUP <b>MO</b></i>	1	
<i>protamine 10 mg/ml SOLUTION <b>MO</b></i>	1	
PURE COMFORT ALCOHOL PADS PADS, MEDICATED <b>\$0,MO</b>	1	
PYRIDIDIUM 100 MG, 200 MG TABLET <b>MO</b>	3	
QUTENZA 8 % KIT <b>DL</b>	4	PA
REBYOTA 150 ML ENEMA <b>DL</b>	4	PA
RECTIV 0.4 % (W/W) OINTMENT <b>MO</b>	3	QL(30 per 30 days)
RENACIDIN 1980.6 MG-59.4 MG-980.4MG/30ML SOLUTION <b>MO</b>	3	
REZDIFFRA 100 MG, 60 MG, 80 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
<i>ribavirin 6 gram RECON SOLUTION <b>DL</b></i>	4	BvsD
RIMSO-50 50 % SOLUTION <b>DL</b>	4	
<i>ringer's SOLUTION <b>MO</b></i>	1	
RIVFLOZA 128 MG/0.8 ML, 160 MG/ML SYRINGE <b>DL</b>	4	PA
RIVFLOZA 80 MG/0.5 ML (160 MG/ML) SOLUTION <b>DL</b>	4	PA
SIKLOS 1,000 MG, 100 MG TABLET <b>MO</b>	3	PA
<i>sodium benzoate-sod phenylacet 10-10 % SOLUTION <b>DL</b></i>	4	
<i>sodium chloride 0.9 % SOLUTION <b>MO</b></i>	1	
SOHONOS 1 MG, 1.5 MG, 10 MG, 2.5 MG, 5 MG CAPSULE <b>DL</b>	4	PA
<i>sorbitol-mannitol 2.7-0.54 gram/100 ml SOLUTION <b>MO</b></i>	1	
SURE COMFORT ALCOHOL PREP PADS PADS, MEDICATED <b>\$0,MO</b>	1	
SURE-PREP ALCOHOL PREP PADS PADS, MEDICATED <b>\$0,MO</b>	1	
SYNAGIS 100 MG/ML, 50 MG/0.5 ML SOLUTION <b>DL</b>	4	PA
<i>tencon 50-325 mg TABLET <b>MO</b></i>	1	QL(180 per 30 days)
TEPEZZA 500 MG RECON SOLUTION <b>DL</b>	4	PA
TRUE COMFORT ALCOHOL PADS PADS, MEDICATED <b>\$0,MO</b>	1	
TRUE COMFORT PRO ALCOHOL PADS PADS, MEDICATED <b>\$0,MO</b>	1	
TZIELD 1 MG/ML SOLUTION <b>DL</b>	4	PA,QL(28 per 365 days)
UBRELVY 100 MG, 50 MG TABLET <b>MO</b>	2	PA,QL(16 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ULTILET ALCOHOL SWAB PADS, MEDICATED \$0,MO	1	
V-GO 20 DEVICE \$0,MO	2	
V-GO 30 DEVICE \$0,MO	2	
V-GO 40 DEVICE \$0,MO	2	
VEOZAH 45 MG TABLET MO	3	PA,QL(30 per 30 days)
VIRAZOLE 6 GRAM RECON SOLUTION DL	4	BvsD
VOWST CAPSULE DL	4	PA
VOXZOGO 0.4 MG, 0.56 MG, 1.2 MG RECON SOLUTION DL	4	PA,QL(30 per 30 days)
vtol lq 50-325-40 mg/15 ml SOLUTION DL	4	QL(450 per 30 days)
VYJUVEK 5 X 10EXP9 PFU/2.5 ML GEL DL	4	PA,QL(10 per 28 days)
water for irrigation, sterile SOLUTION MO	1	
WEBCOL PADS, MEDICATED \$0,MO	1	
WEGOVY 0.25 MG/0.5 ML, 0.5 MG/0.5 ML, 1 MG/0.5 ML, 1.7 MG/0.75 ML, 2.4 MG/0.75 ML PEN INJECTOR MO	3	PA
XDEMVI 0.25 % DROPS	4	PA,QL(10 per 42 days)
XENICAL 120 MG CAPSULE MO	3	PA
YCANTH 0.7 % SOLUTION W/APPLICATOR DL	4	PA
ZAVZPRET 10 MG/ACTUATION SPRAY, NON-AEROSOL DL	4	PA,QL(8 per 30 days)
ZEBUTAL 50-325-40 MG CAPSULE MO	1	QL(180 per 30 days)
ZEVALIN (Y-90) 3.2 MG/2 ML KIT DL	4	PA
zingiber 1.2 mg-40 mg- 124.1 mg-100 mg TABLET MO	1	
ZYNRELEF 200 MG-6 MG /7 ML, 400 MG-12 MG /14 ML ER SOLUTION MO	3	
<b>OPHTHALMIC AGENTS</b>		
ACULAR 0.5 % DROPS MO	3	ST,QL(10 per 30 days)
ACULAR LS 0.4 % DROPS MO	3	ST,QL(10 per 30 days)
ACUVAIL (PF) 0.45 % DROPPERETTE MO	3	ST
ak-poly-bac 500-10,000 unit/gram OINTMENT MO	1	
ALCAINE 0.5 % DROPS MO	1	
ALOCRI 2 % DROPS MO	3	
ALOMIDE 0.1 % DROPS MO	3	
ALPHAGAN P 0.1 % DROPS MO	2	
ALPHAGAN P 0.15 % DROPS MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ALREX 0.2 % DROPS, SUSPENSION <b>MO</b>	3	ST
<i>apraclonidine 0.5 % DROPS</i> <b>MO</b>	1	
<i>atropine 1 % DROPS</i> <b>MO</b>	1	
ATROPINE SULFATE (PF) 1 % DROPPERETTE <b>MO</b>	1	
AZASITE 1 % DROPS <b>MO</b>	3	ST,QL(2.5 per 25 days)
<i>azelastine 0.05 % DROPS</i> <b>MO</b>	1	
AZOPT 1 % DROPS, SUSPENSION <b>MO</b>	3	ST,QL(10 per 28 days)
<i>bacitracin 500 unit/gram OINTMENT</i> <b>MO</b>	1	
<i>bacitracin-polymyxin b 500-10,000 unit/gram OINTMENT</i> <b>MO</b>	1	
<i>balanced salt SOLUTION</i> <b>MO</b>	1	
<i>bepotastine besilate 1.5 % DROPS</i> <b>MO</b>	1	ST,QL(5 per 25 days)
BEPREVE 1.5 % DROPS <b>MO</b>	3	ST,QL(5 per 25 days)
BESIVANCE 0.6 % DROPS, SUSPENSION <b>MO</b>	3	ST
BETADINE OPHTHALMIC PREP 5 % SOLUTION <b>MO</b>	3	
<i>betaxolol 0.5 % DROPS</i> <b>MO</b>	1	
BETIMOL 0.25 %, 0.5 % DROPS <b>MO</b>	3	ST
BETOPTIC S 0.25 % DROPS, SUSPENSION <b>MO</b>	3	ST
<i>bimatoprost 0.03 % DROPS</i> <b>MO</b>	1	QL(2.5 per 25 days)
BLEPHAMIDE 10-0.2 % DROPS, SUSPENSION <b>MO</b>	3	
<i>brimonidine 0.15 % DROPS</i> <b>MO</b>	1	
<i>brimonidine 0.2 % DROPS</i> <b>MO</b>	1	
<i>brinzolamide 1 % DROPS, SUSPENSION</i> <b>MO</b>	1	ST,QL(10 per 28 days)
<i>bromfenac 0.07 % DROPS</i> <b>MO</b>	1	ST,QL(3 per 30 days)
<i>bromfenac 0.075 % DROPS</i> <b>MO</b>	1	ST,QL(5 per 30 days)
<i>bromfenac 0.09 % DROPS</i> <b>MO</b>	1	QL(1.7 per 30 days)
BROMSITE 0.075 % DROPS <b>MO</b>	3	ST,QL(5 per 30 days)
BSS SOLUTION <b>MO</b>	3	
BSS PLUS SOLUTION <b>MO</b>	3	
<i>carteolol 1 % DROPS</i> <b>MO</b>	1	
CEQUA 0.09 % DROPPERETTE <b>MO</b>	3	PA,QL(60 per 30 days)
CILOXAN 0.3 % OINTMENT <b>MO</b>	3	
<i>ciprofloxacin hcl 0.3 % DROPS</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
COMBIGAN 0.2-0.5 % DROPS <b>MO</b>	2	QL(5 per 25 days)
COSOPT 22.3-6.8 MG/ML DROPS <b>MO</b>	3	ST
COSOPT (PF) 2-0.5 % DROPPERETTE <b>MO</b>	3	ST,QL(60 per 30 days)
<i>cromolyn 4 % DROPS <b>MO</b></i>	1	
<i>cyclopentolate 0.5 %, 1 %, 2 % DROPS <b>MO</b></i>	1	
CYSTADROPS 0.37 % DROPS <b>DL</b>	4	PA,QL(20 per 28 days)
CYSTARAN 0.44 % DROPS <b>DL</b>	4	PA,QL(60 per 28 days)
<i>dexamethasone sodium phosphate 0.1 % DROPS <b>MO</b></i>	1	
DEXTENZA 0.4 MG INSERT <b>MO</b>	3	QL(1 per 30 days)
<i>diclofenac sodium 0.1 % DROPS <b>MO</b></i>	1	
<i>difluprednate 0.05 % DROPS <b>MO</b></i>	1	ST
<i>dorzolamide 2 % DROPS <b>MO</b></i>	1	
<i>dorzolamide-timolol 22.3-6.8 mg/ml DROPS <b>MO</b></i>	1	
<i>dorzolamide-timolol (pf) 2-0.5 % DROPPERETTE <b>MO</b></i>	1	QL(60 per 30 days)
DUREZOL 0.05 % DROPS <b>MO</b>	3	ST
DURYSTA 10 MCG IMPLANT <b>DL</b>	4	PA
<i>epinastine 0.05 % DROPS <b>MO</b></i>	1	ST,QL(5 per 25 days)
<i>erythromycin 5 mg/gram (0.5 %) OINTMENT <b>MO</b></i>	1	QL(3.5 per 28 days)
EYSUVIS 0.25 % DROPS, SUSPENSION <b>MO</b>	2	QL(16.6 per 30 days)
FLAREX 0.1 % DROPS, SUSPENSION <b>MO</b>	3	ST
<i>fluorometholone 0.1 % DROPS, SUSPENSION <b>MO</b></i>	1	
<i>flurbiprofen sodium 0.03 % DROPS <b>MO</b></i>	1	
FML FORTE 0.25 % DROPS, SUSPENSION <b>MO</b>	3	ST
FML LIQUIFILM 0.1 % DROPS, SUSPENSION <b>MO</b>	3	ST
<i>gatifloxacin 0.5 % DROPS <b>MO</b></i>	1	QL(2.5 per 25 days)
<i>gentak 0.3 % (3 mg/gram) OINTMENT <b>MO</b></i>	1	
<i>gentamicin 0.3 % DROPS <b>MO</b></i>	1	
ILEVRO 0.3 % DROPS, SUSPENSION <b>MO</b>	2	QL(3 per 30 days)
INVELTYS 1 % DROPS, SUSPENSION <b>MO</b>	3	ST
IOPIDINE 1 % DROPPERETTE <b>MO</b>	3	
ISOPTO CARPINE 1 % DROPS <b>MO</b>	3	
ISTALOL 0.5 % DROPS, ONCE DAILY <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
IYUZEH 0.005 % DROPPERETTE <b>MO</b>	3	ST,QL(30 per 30 days)
<i>ketorolac 0.4 % DROPS</i> <b>MO</b>	1	QL(10 per 30 days)
<i>ketorolac 0.5 % DROPS</i> <b>MO</b>	1	QL(10 per 30 days)
LACRISERT 5 MG INSERT <b>MO</b>	3	
<i>latanoprost 0.005 % DROPS</i> <b>MO</b>	1	QL(5 per 25 days)
<i>levobunolol 0.5 % DROPS</i> <b>MO</b>	1	
<i>levofloxacin 0.5 %, 1.5 % DROPS</i> <b>MO</b>	1	
LOTEMAX 0.5 % DROPS, GEL <b>MO</b>	3	ST
LOTEMAX 0.5 % DROPS, SUSPENSION <b>MO</b>	3	ST
LOTEMAX 0.5 % OINTMENT <b>MO</b>	3	ST
LOTEMAX SM 0.38 % DROPS, GEL <b>MO</b>	3	
<i>loteprednol etabonate 0.2 %, 0.5 % DROPS, SUSPENSION</i> <b>MO</b>	1	ST
<i>loteprednol etabonate 0.5 % DROPS, GEL</i> <b>MO</b>	1	ST
LUMIGAN 0.01 % DROPS <b>MO</b>	2	QL(2.5 per 25 days)
MAXIDEX 0.1 % DROPS, SUSPENSION <b>MO</b>	3	ST
MAXITROL 3.5 MG/G-10,000 UNIT/G-0.1 % OINTMENT <b>MO</b>	3	
MAXITROL 3.5MG/ML-10,000 UNIT/ML-0.1 % DROPS, SUSPENSION <b>MO</b>	1	
MIEBO 100 % DROPS <b>MO</b>	3	PA,QL(3 per 30 days)
MIOSTAT 0.01 % SOLUTION <b>MO</b>	3	
<i>moxifloxacin 0.5 % DROPS</i> <b>MO</b>	1	
<i>moxifloxacin 0.5 % DROPS, VISCOUS</i> <b>MO</b>	1	ST
NATACYN 5 % DROPS, SUSPENSION <b>MO</b>	3	
<i>neo-polycin 3.5-400-10,000 mg-unit-unit/g OINTMENT</i> <b>MO</b>	1	
<i>neo-polycin hc 3.5-400-10,000 mg-unit/g-1% OINTMENT</i> <b>MO</b>	1	
<i>neomycin-bacitracin-poly-hc 3.5-400-10,000 mg-unit/g-1% OINTMENT</i> <b>MO</b>	1	
<i>neomycin-bacitracin-polymyxin 3.5-400-10,000 mg-unit-unit/g OINTMENT</i> <b>MO</b>	1	
<i>neomycin-polymyxin b-dexameth 3.5 mg/g-10,000 unit/g-0.1 % OINTMENT</i> <b>MO</b>	1	
<i>neomycin-polymyxin b-dexameth 3.5mg/ml-10,000 unit/ml-0.1 % DROPS, SUSPENSION</i> <b>MO</b>	1	
<i>neomycin-polymyxin-gramicidin 1.75 mg-10,000 unit-0.025mg/ml DROPS</i> <b>MO</b>	1	
<i>neomycin-polymyxin-hc 3.5-10,000-10 mg-unit-mg/ml DROPS, SUSPENSION</i> <b>MO</b>	1	
NEVANAC 0.1 % DROPS, SUSPENSION <b>MO</b>	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OCUFLOX 0.3 % DROPS <b>MO</b>	3	
ofloxacin 0.3 % DROPS <b>MO</b>	1	
olopatadine 0.1 %, 0.2 % DROPS <b>MO</b>	1	
OXERVATE 0.002 % DROPS <b>DL</b>	4	PA,QL(112 per 365 days)
PHOSPHOLINE IODIDE 0.125 % DROPS <b>MO</b>	3	
pilocarpine hcl 1 %, 2 %, 4 % DROPS <b>MO</b>	1	
polycin 500-10,000 unit/gram OINTMENT <b>MO</b>	1	
polymyxin b sulf-trimethoprim 10,000 unit- 1 mg/ml DROPS <b>MO</b>	1	
POLYTRIM 10,000 UNIT- 1 MG/ML DROPS <b>MO</b>	3	
PRED FORTE 1 % DROPS, SUSPENSION <b>MO</b>	3	ST
PRED MILD 0.12 % DROPS, SUSPENSION <b>MO</b>	3	ST
PRED-G 0.3-1 % DROPS, SUSPENSION <b>MO</b>	3	
prednisolone acetate 1 % DROPS, SUSPENSION <b>MO</b>	1	
prednisolone sodium phosphate 1 % DROPS <b>MO</b>	1	
PROLENSA 0.07 % DROPS <b>MO</b>	3	ST,QL(3 per 30 days)
proparacaine 0.5 % DROPS <b>MO</b>	1	
RESTASIS 0.05 % DROPPERETTE <b>MO</b>	2	QL(60 per 30 days)
RESTASIS MULTIDOSE 0.05 % DROPS <b>MO</b>	2	QL(5.5 per 25 days)
RHOPRESSA 0.02 % DROPS <b>MO</b>	2	ST,QL(2.5 per 25 days)
ROCKLATAN 0.02-0.005 % DROPS <b>MO</b>	2	ST,QL(2.5 per 25 days)
SIMBRINZA 1-0.2 % DROPS, SUSPENSION <b>MO</b>	3	QL(16 per 30 days)
sulfacetamide sodium 10 % DROPS <b>MO</b>	1	
sulfacetamide-prednisolone 10 %-0.23 % (0.25 %) DROPS <b>MO</b>	1	
tafluprost (pf) 0.0015 % DROPPERETTE <b>MO</b>	3	ST,QL(30 per 30 days)
timolol maleate 0.25 % DROPS <b>MO</b>	1	
timolol maleate 0.25 %, 0.5 % GEL FORMING SOLUTION <b>MO</b>	1	
timolol maleate 0.5 % DROPS <b>MO</b>	1	
timolol maleate 0.5 % DROPS, ONCE DAILY <b>MO</b>	1	
timolol maleate (pf) 0.25 %, 0.5 % DROPPERETTE <b>MO</b>	1	
TIMOPTIC 0.25 %, 0.5 % DROPS <b>MO</b>	3	ST
TIMOPTIC OCUDOSE (PF) 0.25 %, 0.5 % DROPPERETTE <b>MO</b>	3	ST
TIMOPTIC-XE 0.25 %, 0.5 % GEL FORMING SOLUTION <b>MO</b>	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TOBRADEX 0.3-0.1 % DROPS, SUSPENSION <b>MO</b>	3	
TOBRADEX 0.3-0.1 % OINTMENT <b>MO</b>	3	
TOBRADEX ST 0.3-0.05 % DROPS, SUSPENSION <b>MO</b>	3	
<i>tobramycin 0.3 % DROPS</i> <b>MO</b>	1	
<i>tobramycin-dexamethasone 0.3-0.1 % DROPS, SUSPENSION</i> <b>MO</b>	1	
TOBREX 0.3 % OINTMENT <b>MO</b>	3	
TRAVATAN Z 0.004 % DROPS <b>MO</b>	3	ST,QL(2.5 per 25 days)
<i>travoprost 0.004 % DROPS</i> <b>MO</b>	1	QL(2.5 per 25 days)
<i>trifluridine 1 % DROPS</i> <b>MO</b>	1	
<i>tropicamide 0.5 %, 1 % DROPS</i> <b>MO</b>	1	
TRUSOPT 2 % DROPS <b>MO</b>	3	
TYRVAYA 0.03 MG/SPRAY SPRAY, METERED, NON-AEROSOL <b>MO</b>	3	PA,QL(8.4 per 30 days)
VERKAZIA 0.1 % DROPPERETTE <b>DL</b>	4	PA,QL(120 per 30 days)
VEVYE 0.1 % DROPS <b>MO</b>	3	PA,QL(2 per 30 days)
VIGAMOX 0.5 % DROPS <b>MO</b>	3	PA
VUITY 1.25 % DROPS <b>MO</b>	3	
VYZULTA 0.024 % DROPS <b>MO</b>	3	QL(2.5 per 25 days)
XALATAN 0.005 % DROPS <b>MO</b>	3	PA,QL(5 per 25 days)
XELPROS 0.005 % DROPS, EMULSION <b>MO</b>	3	ST,QL(2.5 per 25 days)
XIIDRA 5 % DROPPERETTE <b>MO</b>	3	PA,QL(60 per 30 days)
ZERVIATE 0.24 % DROPPERETTE <b>MO</b>	3	QL(60 per 30 days)
ZIOPTAN (PF) 0.0015 % DROPPERETTE <b>MO</b>	3	ST,QL(30 per 30 days)
ZYLET 0.3-0.5 % DROPS, SUSPENSION <b>MO</b>	3	
ZYMAXID 0.5 % DROPS <b>MO</b>	3	ST,QL(2.5 per 25 days)
<b>OTIC AGENTS</b>		
CIPRO HC 0.2-1 % DROPS, SUSPENSION <b>MO</b>	3	
CIPRODEX 0.3-0.1 % DROPS, SUSPENSION <b>MO</b>	3	QL(7.5 per 30 days)
<i>ciprofloxacin hcl 0.2 % DROPPERETTE</i> <b>MO</b>	1	
<i>ciprofloxacin-dexamethasone 0.3-0.1 % DROPS, SUSPENSION</i> <b>MO</b>	3	QL(7.5 per 30 days)
<i>ciprofloxacin-fluocinolone 0.3-0.025 % (0.25 ml) SOLUTION</i> <b>MO</b>	3	
CORTISPORIN-TC 3.3-3-10-0.5 MG/ML DROPS, SUSPENSION <b>MO</b>	3	
DERMOTIC OIL 0.01 % DROPS <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
flac otic oil 0.01 % DROPS <b>MO</b>	1	
fluocinolone acetonide oil 0.01 % DROPS <b>MO</b>	1	
hydrocortisone-acetic acid 1-2 % DROPS <b>MO</b>	1	
neomycin-polymyxin-hc 3.5-10,000-1 mg/ml-unit/ml-% DROPS, SUSPENSION <b>MO</b>	1	
neomycin-polymyxin-hc 3.5-10,000-1 mg/ml-unit/ml-% SOLUTION <b>MO</b>	1	
ofloxacin 0.3 % DROPS <b>MO</b>	1	
OTOVEL 0.3-0.025 % (0.25 ML) SOLUTION <b>MO</b>	3	
<b>RESPIRATORY TRACT/PULMONARY AGENTS</b>		
ACCOLATE 10 MG, 20 MG TABLET <b>MO</b>	3	PA,QL(60 per 30 days)
acetylcysteine 100 mg/ml (10 %), 200 mg/ml (20 %) SOLUTION <b>MO</b>	1	BvsD
ADCIRCA 20 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
ADEMPAS 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG TABLET <b>DL,LA</b>	4	PA,QL(90 per 30 days)
ADRENALIN 1 MG/ML, 1 MG/ML (1 ML) SOLUTION <b>MO</b>	3	
ADVAIR DISKUS 100-50 MCG/DOSE, 250-50 MCG/DOSE, 500-50 MCG/DOSE BLISTER WITH DEVICE <b>MO</b>	3	ST,QL(60 per 30 days)
ADVAIR HFA 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	2	QL(12 per 30 days)
AIRDUO DIGIHALER 113 MCG-14 MCG/ACTUATION, 232-14 MCG/ACTUATION, 55-14 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. <b>MO</b>	3	ST,QL(1 per 30 days)
AIRDUO RESPICLICK 113-14 MCG/ACTUATION, 232-14 MCG/ACTUATION, 55-14 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. <b>MO</b>	3	ST,QL(1 per 30 days)
AIRSUPRA 90-80 MCG/ACTUATION HFA AEROSOL INHALER <b>DL</b>	4	PA,QL(32.1 per 30 days)
albuterol sulfate 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml SOLUTION FOR NEBULIZATION <b>MO</b>	1	BvsD
albuterol sulfate 2 mg, 4 mg TABLET <b>MO</b>	1	
albuterol sulfate 2 mg/5 ml SYRUP <b>MO</b>	1	
albuterol sulfate 4 mg, 8 mg TABLET, ER 12 HR. <b>MO</b>	1	
albuterol sulfate 90 mcg/actuation HFA AEROSOL INHALER <b>MO</b>	1	QL(36 per 30 days)
ALVESCO 160 MCG/ACTUATION, 80 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	3	ST,QL(18.3 per 28 days)
alyq 20 mg TABLET <b>MO</b>	1	PA,QL(60 per 30 days)
ambrisentan 10 mg, 5 mg TABLET <b>DL</b>	4	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>aminophylline 250 mg/10 ml, 500 mg/20 ml SOLUTION</i> <b>MO</b>	1	
ANORO ELLIPTA 62.5-25 MCG/ACTUATION BLISTER WITH DEVICE <b>MO</b>	3	PA,QL(60 per 30 days)
<i>arformoterol 15 mcg/2 ml SOLUTION FOR NEBULIZATION</i> <b>MO</b>	1	BvsD,QL(120 per 30 days)
ARMONAIR DIGIHALER 113 MCG/ACTUATION, 232 MCG/ACTUATION, 55 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. <b>MO</b>	3	ST,QL(1 per 30 days)
ARNUITY ELLIPTA 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION BLISTER WITH DEVICE <b>MO</b>	2	QL(30 per 30 days)
ASMANEX HFA 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	3	ST,QL(13 per 30 days)
ASMANEX TWISTHALER 110 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (120), 220 MCG/ ACTUATION (14), 220 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (60) AEROSOL POWDER BREATH ACTIV. <b>MO</b>	3	ST,QL(1 per 28 days)
ATROVENT HFA 17 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	3	QL(25.8 per 30 days)
AUVI-Q 0.1 MG/0.1 ML, 0.15 MG/0.15 ML, 0.3 MG/0.3 ML AUTO-INJECTOR <b>MO</b>	2	QL(4 per 30 days)
<i>azelastine 137 mcg (0.1 %) AEROSOL SPRAY</i> <b>MO</b>	1	QL(30 per 25 days)
<i>azelastine 205.5 mcg (0.15 %) SPRAY, NON-AEROSOL</i> <b>MO</b>	1	QL(30 per 25 days)
<i>azelastine-fluticasone 137-50 mcg/spray SPRAY, NON-AEROSOL</i> <b>MO</b>	1	ST,QL(23 per 28 days)
BECONASE AQ 42 MCG (0.042 %) SPRAY, NON-AEROSOL <b>MO</b>	3	ST,QL(50 per 30 days)
BEVESPI AEROSPHERE 9-4.8 MCG HFA AEROSOL INHALER <b>MO</b>	3	QL(10.7 per 30 days)
<i>bosentan 125 mg, 62.5 mg TABLET</i> <b>DL</b>	4	PA,QL(60 per 30 days)
BREO ELLIPTA 100-25 MCG/DOSE, 200-25 MCG/DOSE BLISTER WITH DEVICE <b>MO</b>	2	QL(60 per 30 days)
BREO ELLIPTA 50-25 MCG/DOSE BLISTER WITH DEVICE <b>MO</b>	2	QL(60 per 30 days)
BREZTRI AEROSPHERE 160-9-4.8 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	2	QL(10.7 per 30 days)
BRONCHITOL 40 MG CAPSULE, W/INHALATION DEVICE <b>DL</b>	4	PA,QL(560 per 28 days)
BROVANA 15 MCG/2 ML SOLUTION FOR NEBULIZATION	4	BvsD,QL(120 per 30 days)
<i>budesonide 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml SUSPENSION FOR NEBULIZATION</i> <b>MO</b>	1	BvsD
<i>carbinoxamine maleate 4 mg TABLET</i> <b>MO</b>	1	
<i>carbinoxamine maleate 4 mg/5 ml LIQUID</i> <b>MO</b>	1	
<i>carbinoxamine maleate 6 mg TABLET</i> <b>DL</b>	4	QL(120 per 30 days)
CAYSTON 75 MG/ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA,QL(84 per 28 days)
<i>cetirizine 1 mg/ml SOLUTION</i> <b>MO</b>	1	QL(300 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CINQAIR 10 MG/ML SOLUTION <b>DL</b>	4	PA
CLARINEX 5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
clemastine 0.5 mg/5 ml SYRUP <b>DL</b>	4	PA,QL(1800 per 30 days)
clemastine 2.68 mg TABLET <b>MO</b>	1	
COMBIVENT RESPIMAT 20-100 MCG/ACTUATION MIST <b>MO</b>	3	QL(4 per 20 days)
cromolyn 100 mg/5 ml CONCENTRATE <b>MO</b>	1	
cromolyn 20 mg/2 ml SOLUTION FOR NEBULIZATION <b>MO</b>	1	BvsD
cyproheptadine 2 mg/5 ml SYRUP <b>MO</b>	1	
cyproheptadine 4 mg TABLET <b>MO</b>	1	
DALIRESP 250 MCG TABLET <b>MO</b>	3	PA,QL(28 per 365 days)
DALIRESP 500 MCG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
desloratadine 2.5 mg, 5 mg TABLET, DISINTEGRATING <b>MO</b>	1	ST,QL(30 per 30 days)
desloratadine 5 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
dexchlorpheniramine maleate 2 mg/5 ml SOLUTION <b>MO</b>	1	PA
DIPHEN 12.5 MG/5 ML ELIXIR <b>MO</b>	1	
diphen 12.5 mg/5 ml ELIXIR <b>MO</b>	1	
diphenhydramine hcl 12.5 mg/5 ml ELIXIR <b>MO</b>	1	
diphenhydramine hcl 50 mg/ml SOLUTION <b>MO</b>	1	
diphenhydramine hcl 50 mg/ml SYRINGE <b>MO</b>	1	
DOPRAM 20 MG/ML SOLUTION <b>MO</b>	3	
DUAKLIR PRESSAIR 400-12 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. <b>MO</b>	3	PA,QL(1 per 30 days)
DULERA 100-5 MCG/ACTUATION, 200-5 MCG/ACTUATION, 50-5 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	3	ST,QL(13 per 30 days)
DYMISTA 137-50 MCG/SPRAY SPRAY, NON-AEROSOL <b>MO</b>	3	ST,QL(23 per 28 days)
ELIXOPHYLLIN 80 MG/15 ML ELIXIR <b>MO</b>	1	
epinephrine 0.15 mg/0.15 ml, 0.15 mg/0.3 ml, 0.3 mg/0.3 ml AUTO-INJECTOR <b>MO</b>	1	QL(4 per 30 days)
EPIPEN 0.3 MG/0.3 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(4 per 30 days)
EPIPEN 2-PAK 0.3 MG/0.3 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(4 per 30 days)
EPIPEN JR 0.15 MG/0.3 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(4 per 30 days)
EPIPEN JR 2-PAK 0.15 MG/0.3 ML AUTO-INJECTOR <b>MO</b>	3	PA,QL(4 per 30 days)
epoprostenol 0.5 mg, 1.5 mg RECON SOLUTION <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>epoprostenol (glycine) 0.5 mg, 1.5 mg RECON SOLUTION</i> <b>DL</b>	4	PA
ESBRIET 267 MG CAPSULE <b>DL</b>	4	PA,QL(270 per 30 days)
ESBRIET 267 MG TABLET <b>DL</b>	4	PA,QL(270 per 30 days)
ESBRIET 801 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
FASENRA 30 MG/ML SYRINGE <b>DL</b>	4	PA,QL(1 per 28 days)
FASENRA PEN 30 MG/ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(1 per 28 days)
<i>flunisolide 25 mcg (0.025 %) SPRAY, NON-AEROSOL</i> <b>MO</b>	1	QL(50 per 30 days)
<i>fluticasone propion-salmeterol 100-50 mcg/dose, 500-50 mcg/dose BLISTER WITH DEVICE</i> <b>MO</b>	1	QL(60 per 30 days)
<i>fluticasone propion-salmeterol 113-14 mcg/actuation, 232-14 mcg/actuation, 55-14 mcg/actuation AEROSOL POWDER BREATH ACTIV.</i> <b>MO</b>	2	QL(1 per 30 days)
<i>fluticasone propion-salmeterol 250-50 mcg/dose BLISTER WITH DEVICE</i> <b>MO</b>	1	QL(60 per 30 days)
<i>fluticasone propionate 100 mcg/actuation, 250 mcg/actuation, 50 mcg/actuation BLISTER WITH DEVICE</i> <b>MO</b>	3	ST,QL(60 per 30 days)
<i>fluticasone propionate 110 mcg/actuation, 220 mcg/actuation HFA AEROSOL INHALER</i> <b>MO</b>	3	ST,QL(24 per 30 days)
<i>fluticasone propionate 44 mcg/actuation HFA AEROSOL INHALER</i> <b>MO</b>	3	ST,QL(10.6 per 30 days)
<i>fluticasone propionate 50 mcg/actuation SPRAY, SUSPENSION</i> <b>MO</b>	1	QL(16 per 30 days)
<i>formoterol fumarate 20 mcg/2 ml SOLUTION FOR NEBULIZATION</i> <b>MO</b>	1	BvsD,QL(120 per 30 days)
GASTROCROM 100 MG/5 ML CONCENTRATE <b>MO</b>	3	
GRASTEK 2,800 BAU SUBLINGUAL TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
<i>hydroxyzine pamoate 100 mg, 50 mg CAPSULE</i> <b>MO</b>	1	
<i>hydroxyzine pamoate 25 mg CAPSULE</i> <b>MO</b>	1	
INCRUSE ELLIPTA 62.5 MCG/ACTUATION BLISTER WITH DEVICE <b>MO</b>	3	PA,QL(30 per 30 days)
<i>ipratropium bromide 0.02 % SOLUTION</i> <b>MO</b>	1	BvsD
<i>ipratropium bromide 21 mcg (0.03 %) SPRAY, NON-AEROSOL</i> <b>MO</b>	1	QL(30 per 30 days)
<i>ipratropium bromide 42 mcg (0.06 %) SPRAY, NON-AEROSOL</i> <b>MO</b>	1	QL(45 per 30 days)
<i>ipratropium-albuterol 0.5 mg-3 mg(2.5 mg base)/3 ml SOLUTION FOR NEBULIZATION</i> <b>MO</b>	1	BvsD
KALYDECO 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG GRANULES IN PACKET <b>DL</b>	4	PA,QL(56 per 28 days)
KALYDECO 150 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
KARBINAL ER 4 MG/5 ML SUSPENSION, ER 12 HR. <b>MO</b>	3	
LETAIRIS 10 MG, 5 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
levalbuterol hcl 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml SOLUTION FOR NEBULIZATION <b>MO</b>	1	BvsD
levalbuterol tartrate 45 mcg/actuation HFA AEROSOL INHALER <b>MO</b>	1	ST,QL(30 per 30 days)
levocetirizine 2.5 mg/5 ml SOLUTION <b>MO</b>	1	QL(300 per 30 days)
levocetirizine 5 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
LIQREV 10 MG/ML SUSPENSION <b>DL</b>	4	PA,QL(180 per 30 days)
LONHALA MAGNAIR REFILL 25 MCG/ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA,QL(60 per 30 days)
LONHALA MAGNAIR STARTER 25 MCG/ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA,QL(60 per 365 days)
mometasone 50 mcg/actuation SPRAY, NON-AEROSOL <b>MO</b>	1	QL(34 per 30 days)
montelukast 10 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
montelukast 4 mg GRANULES IN PACKET <b>MO</b>	1	QL(30 per 30 days)
montelukast 4 mg, 5 mg CHEWABLE TABLET <b>MO</b>	1	QL(30 per 30 days)
NUCALA 100 MG RECON SOLUTION <b>DL</b>	4	PA,QL(3 per 28 days)
NUCALA 100 MG/ML AUTO-INJECTOR <b>DL</b>	4	PA,QL(3 per 28 days)
NUCALA 100 MG/ML SYRINGE <b>DL</b>	4	PA,QL(3 per 28 days)
NUCALA 40 MG/0.4 ML SYRINGE <b>DL</b>	4	PA,QL(0.4 per 28 days)
ODACTRA 12 SQ-HDM SUBLINGUAL TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
OFEV 100 MG, 150 MG CAPSULE <b>DL,LA</b>	4	PA,QL(60 per 30 days)
olopatadine 0.6 % SPRAY, NON-AEROSOL <b>MO</b>	1	ST,QL(30.5 per 30 days)
OMNARIS 50 MCG SPRAY, NON-AEROSOL <b>MO</b>	3	ST,QL(12.5 per 30 days)
OPSUMIT 10 MG TABLET <b>DL,LA</b>	4	PA,QL(30 per 30 days)
OPSYNVI 10-20 MG, 10-40 MG TABLET <b>DL</b>	4	PA,QL(30 per 30 days)
ORALAIR 100 INDX REACTIVITY, 100 IR (3) /300 IR (6), 300 INDX REACTIVITY SUBLINGUAL TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
ORENITRAM 0.125 MG TABLET ER <b>DL</b>	4	PA,QL(1000 per 30 days)
ORENITRAM 0.25 MG TABLET ER <b>DL</b>	4	PA,QL(500 per 30 days)
ORENITRAM 1 MG TABLET ER <b>DL</b>	4	PA,QL(720 per 30 days)
ORENITRAM 2.5 MG TABLET ER <b>DL</b>	4	PA,QL(300 per 30 days)
ORENITRAM 5 MG TABLET ER <b>DL</b>	4	PA,QL(150 per 30 days)
ORENITRAM MONTH 1 TITRATION KT 0.125 MG (126)- 0.25 MG (42) TABLET, ER, DOSE PACK <b>DL</b>	4	PA,QL(168 per 28 days)
ORENITRAM MONTH 2 TITRATION KT 0.125 MG (126)- 0.25 MG (210) TABLET, ER, DOSE PACK <b>DL</b>	4	PA,QL(336 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ORENITRAM MONTH 3 TITRATION KT 0.125 MG (126)- 0.25 MG(42)-1MG TABLET, ER, DOSE PACK <b>DL</b>	4	PA,QL(252 per 28 days)
ORKAMBI 100-125 MG, 150-188 MG, 75-94 MG GRANULES IN PACKET <b>DL</b>	4	PA,QL(56 per 28 days)
ORKAMBI 100-125 MG, 200-125 MG TABLET <b>DL</b>	4	PA,QL(112 per 28 days)
PATANASE 0.6 % SPRAY, NON-AEROSOL <b>MO</b>	3	ST,QL(30.5 per 30 days)
PERFORMIST 20 MCG/2 ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	BvsD,QL(120 per 30 days)
<i>pirfenidone</i> 267 mg CAPSULE <b>DL</b>	4	PA,QL(270 per 30 days)
<i>pirfenidone</i> 267 mg TABLET <b>DL</b>	4	PA,QL(270 per 30 days)
<i>pirfenidone</i> 534 mg, 801 mg TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
PROAIR DIGIHALER 90 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. <b>MO</b>	3	ST,QL(2 per 30 days)
PROAIR HFA 90 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	3	ST,QL(36 per 30 days)
PROAIR RESPICLICK 90 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. <b>MO</b>	3	ST,QL(2 per 30 days)
PROVENTIL HFA 90 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	3	ST,QL(36 per 30 days)
PULMICORT 0.25 MG/2 ML, 0.5 MG/2 ML, 1 MG/2 ML SUSPENSION FOR NEBULIZATION <b>MO</b>	3	BvsD
PULMICORT FLEXHALER 180 MCG/ACTUATION, 90 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. <b>MO</b>	3	ST,QL(2 per 30 days)
PULMOZYME 1 MG/ML SOLUTION <b>DL</b>	4	BvsD
QNASL 40 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	3	ST,QL(6.8 per 30 days)
QNASL 80 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	3	ST,QL(10.6 per 30 days)
QUZYTIR 10 MG/ML SOLUTION <b>MO</b>	3	
QVAR REDHALER 40 MCG/ACTUATION HFA AEROSOL BREATH ACTIVATED <b>MO</b>	3	ST,QL(10.6 per 30 days)
QVAR REDHALER 80 MCG/ACTUATION HFA AEROSOL BREATH ACTIVATED <b>MO</b>	3	ST,QL(21.2 per 30 days)
RAGWITEK 12 AMB A 1 UNIT SUBLINGUAL TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
REMODULIN 1 MG/ML, 10 MG/ML, 2.5 MG/ML, 5 MG/ML SOLUTION <b>DL</b>	4	PA
REVATIO 10 MG/ML SUSPENSION FOR RECONSTITUTION <b>DL</b>	4	PA,QL(180 per 30 days)
REVATIO 20 MG TABLET <b>DL</b>	4	PA,QL(90 per 30 days)
<i>roflumilast</i> 250 mcg TABLET <b>MO</b>	1	QL(28 per 365 days)
<i>roflumilast</i> 500 mcg TABLET <b>MO</b>	1	QL(30 per 30 days)
RYALTRIS 665-25 MCG/SPRAY SPRAY, NON-AEROSOL <b>MO</b>	3	ST,QL(29 per 30 days)
RYCLORA 2 MG/5 ML SOLUTION <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RYVENT 6 MG TABLET <b>MO</b>	1	QL(120 per 30 days)
SEREVENT DISKUS 50 MCG/DOSE BLISTER WITH DEVICE <b>MO</b>	3	PA,QL(60 per 30 days)
<i>sildenafil (pulm.hypertension) 10 mg/ml SUSPENSION FOR RECONSTITUTION</i> <b>DL</b>	4	PA,QL(180 per 30 days)
<i>sildenafil (pulm.hypertension) 20 mg TABLET</i> <b>MO</b>	1	PA,QL(90 per 30 days)
SINGULAIR 10 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
SINGULAIR 4 MG GRANULES IN PACKET <b>MO</b>	3	PA,QL(30 per 30 days)
SINGULAIR 4 MG, 5 MG CHEWABLE TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
SPIRIVA RESPIMAT 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION MIST <b>MO</b>	2	QL(4 per 28 days)
SPIRIVA WITH HANDIHALER 18 MCG CAPSULE, W/INHALATION DEVICE <b>MO</b>	2	QL(30 per 30 days)
STIOLTO RESPIMAT 2.5-2.5 MCG/ACTUATION MIST <b>MO</b>	2	QL(4 per 28 days)
STRIVERDI RESPIMAT 2.5 MCG/ACTUATION MIST <b>MO</b>	2	QL(4 per 30 days)
SYMBICORT 160-4.5 MCG/ACTUATION, 80-4.5 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	2	QL(10.2 per 30 days)
SYMDEKO 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N) TABLET, SEQUENTIAL <b>DL</b>	4	PA,QL(56 per 28 days)
SYMJEPI 0.15 MG/0.3 ML, 0.3 MG/0.3 ML SYRINGE <b>MO</b>	2	QL(4 per 30 days)
<i>tadalafil (pulm. hypertension) 20 mg TABLET</i> <b>MO</b>	1	PA,QL(60 per 30 days)
TADLIQ 20 MG/5 ML (4 MG/ML) SUSPENSION <b>DL</b>	4	PA,QL(300 per 30 days)
<i>terbutaline 1 mg/ml SOLUTION</i> <b>MO</b>	1	
<i>terbutaline 2.5 mg, 5 mg TABLET</i> <b>MO</b>	1	
THEO-24 100 MG, 200 MG, 300 MG, 400 MG CAPSULE, ER 24 HR. <b>MO</b>	1	
<i>theophylline 100 mg, 200 mg, 300 mg, 450 mg TABLET, ER 12 HR.</i> <b>MO</b>	1	
<i>theophylline 400 mg, 600 mg TABLET, ER 24 HR.</i> <b>MO</b>	1	
<i>theophylline 80 mg/15 ml ELIXIR</i> <b>MO</b>	1	
<i>theophylline 80 mg/15 ml SOLUTION</i> <b>MO</b>	1	
<i>theophylline in dextrose 5 % 200 mg/100 ml, 200 mg/50 ml, 400 mg/250 ml, 800 mg/250 ml PARENTERAL SOLUTION</i> <b>MO</b>	1	
TOBI PODHALER 28 MG CAPSULE, W/INHALATION DEVICE <b>DL</b>	4	PA,QL(224 per 28 days)
TRACLEER 125 MG, 62.5 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
TRACLEER 32 MG TABLET FOR SUSPENSION <b>DL</b>	4	PA,QL(120 per 30 days)
TRELEGY ELLIPTA 100-62.5-25 MCG, 200-62.5-25 MCG BLISTER WITH DEVICE <b>MO</b>	2	QL(60 per 30 days)
<i>treprostinil sodium 1 mg/ml, 10 mg/ml, 2.5 mg/ml, 5 mg/ml SOLUTION</i> <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TRIKAFTA 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N) TABLET, SEQUENTIAL <b>DL</b>	4	PA,QL(84 per 28 days)
TRIKAFTA 100-50-75MG (D) /75 MG (N), 80-40-60 MG (D) /59.5 MG (N) GRANULES IN PACKET, SEQUENTIAL <b>DL</b>	4	PA,QL(56 per 28 days)
TUDORZA PRESSAIR 400 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. <b>MO</b>	3	PA,QL(1 per 30 days)
TYVASO 1.74 MG/2.9 ML (0.6 MG/ML) SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
TYVASO DPI 16 MCG (112)- 32 MCG (84) CARTRIDGE WITH INHALER <b>DL</b>	4	PA,QL(196 per 28 days)
TYVASO DPI 16 MCG, 32 MCG, 48 MCG, 64 MCG CARTRIDGE WITH INHALER <b>DL</b>	4	PA,QL(112 per 28 days)
TYVASO DPI 16(112)-32(112) -48(28) MCG CARTRIDGE WITH INHALER <b>DL</b>	4	PA,QL(252 per 28 days)
TYVASO DPI 32-48 MCG CARTRIDGE WITH INHALER <b>DL</b>	4	PA,QL(224 per 28 days)
TYVASO INSTITUTIONAL START KIT 1.74 MG/2.9 ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
TYVASO REFILL KIT 1.74 MG/2.9 ML (0.6 MG/ML) SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
TYVASO STARTER KIT 1.74 MG/2.9 ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
UPTRAVI 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
UPTRAVI 1,800 MCG RECON SOLUTION <b>DL</b>	4	PA
UPTRAVI 200 MCG (140)- 800 MCG (60) TABLET, DOSE PACK <b>DL</b>	4	PA,QL(200 per 30 days)
VELETRI 0.5 MG, 1.5 MG RECON SOLUTION <b>DL</b>	4	PA
VENTAVIS 10 MCG/ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA,QL(150 per 30 days)
VENTAVIS 20 MCG/ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA,QL(90 per 30 days)
VENTOLIN HFA 90 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	2	QL(36 per 30 days)
VISTARIL 25 MG, 50 MG CAPSULE <b>MO</b>	3	
WINREVAIR 45 MG, 60 MG KIT <b>DL</b>	4	PA
wixela inhub 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose BLISTER WITH DEVICE <b>MO</b>	1	QL(60 per 30 days)
XHANCE 93 MCG/ACTUATION AEROSOL BREATH ACTIVATED <b>MO</b>	3	PA,QL(32 per 30 days)
XOPENEX HFA 45 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	3	ST,QL(30 per 30 days)
YUPELRI 175 MCG/3 ML SOLUTION FOR NEBULIZATION	4	PA,QL(90 per 30 days)
zafirlukast 10 mg TABLET <b>MO</b>	1	QL(60 per 30 days)
zafirlukast 20 mg TABLET <b>MO</b>	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZETONNA 37 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	3	ST,QL(6.1 per 28 days)
<i>zileuton 600 mg TABLET, ER 12 HR., MULTIPHASE</i>	4	ST,QL(120 per 30 days)
ZYFLO 600 MG TABLET <b>DL</b>	4	ST,QL(120 per 30 days)
<b>SKELETAL MUSCLE RELAXANTS</b>		
AMRIX 15 MG, 30 MG CAPSULE, ER 24 HR. <b>DL</b>	4	ST,QL(21 per 30 days)
<i>carisoprodol 250 mg, 350 mg TABLET <b>MO</b></i>	1	QL(120 per 30 days)
<i>carisoprodol-aspirin 200-325 mg TABLET <b>MO</b></i>	1	
<i>carisoprodol-aspirin-codeine 200-325-16 mg TABLET <b>DL</b></i>	1	QL(360 per 30 days)
<i>chlorzoxazone 250 mg TABLET <b>DL</b></i>	4	ST,QL(360 per 30 days)
<i>chlorzoxazone 375 mg, 750 mg TABLET <b>MO</b></i>	1	ST,QL(120 per 30 days)
<i>chlorzoxazone 500 mg TABLET <b>MO</b></i>	1	ST
<i>cyclobenzaprine 10 mg, 5 mg TABLET <b>MO</b></i>	1	
<i>cyclobenzaprine 15 mg, 30 mg CAPSULE, ER 24 HR. <b>MO</b></i>	1	ST,QL(21 per 30 days)
<i>cyclobenzaprine 7.5 mg TABLET <b>MO</b></i>	1	QL(90 per 30 days)
FEXMID 7.5 MG TABLET <b>MO</b>	1	ST,QL(90 per 30 days)
LORZONE 375 MG TABLET <b>MO</b>	1	ST,QL(120 per 30 days)
LORZONE 750 MG TABLET <b>DL</b>	4	ST,QL(120 per 30 days)
<i>metaxalone 400 mg, 800 mg TABLET <b>MO</b></i>	1	ST,QL(120 per 30 days)
<i>methocarbamol 1,000 mg TABLET <b>DL</b></i>	4	PA
<i>methocarbamol 100 mg/ml SOLUTION <b>MO</b></i>	1	
<i>methocarbamol 500 mg, 750 mg TABLET <b>MO</b></i>	1	
<i>norgesic 25-385-30 mg TABLET <b>DL</b></i>	4	PA,QL(240 per 30 days)
NORGESIC FORTE 50-770-60 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
<i>orphenadrine citrate 100 mg TABLET ER <b>MO</b></i>	1	
<i>orphenadrine citrate 30 mg/ml SOLUTION <b>MO</b></i>	1	ST
<i>orphenadrine-asa-caffeine 25-385-30 mg TABLET <b>DL</b></i>	4	PA,QL(240 per 30 days)
<i>orphenadrine-asa-caffeine 50-770-60 mg TABLET <b>DL</b></i>	4	PA,QL(120 per 30 days)
<i>orphengesic forte 50-770-60 mg TABLET <b>DL</b></i>	4	PA,QL(120 per 30 days)
ROBAXIN 100 MG/ML SOLUTION <b>DL</b>	4	
SOMA 250 MG, 350 MG TABLET <b>DL</b>	4	PA,QL(120 per 30 days)
<i>vanadom 350 mg TABLET <b>MO</b></i>	1	QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<b>SLEEP DISORDER AGENTS</b>		
AMBIEN 10 MG, 5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
AMBIEN CR 12.5 MG, 6.25 MG TABLET, ER MULTIPHASE <b>MO</b>	3	PA,QL(30 per 30 days)
armodafinil 150 mg, 200 mg, 250 mg TABLET <b>MO</b>	1	PA,QL(30 per 30 days)
armodafinil 50 mg TABLET <b>MO</b>	1	PA,QL(60 per 30 days)
BELSOMRA 10 MG TABLET <b>MO</b>	2	QL(60 per 30 days)
BELSOMRA 15 MG, 20 MG TABLET <b>MO</b>	2	QL(30 per 30 days)
BELSOMRA 5 MG TABLET <b>MO</b>	2	QL(120 per 30 days)
DAYVIGO 10 MG, 5 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
doxepin 3 mg, 6 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
EDLUAR 10 MG SUBLINGUAL TABLET <b>MO</b>	3	
EDLUAR 5 MG SUBLINGUAL TABLET <b>MO</b>	3	QL(30 per 30 days)
estazolam 1 mg, 2 mg TABLET <b>DL</b>	1	QL(30 per 30 days)
eszopiclone 1 mg, 2 mg, 3 mg TABLET <b>MO</b>	1	QL(30 per 30 days)
flurazepam 15 mg CAPSULE <b>DL</b>	1	QL(60 per 30 days)
flurazepam 30 mg CAPSULE <b>DL</b>	1	QL(30 per 30 days)
HALCION 0.25 MG TABLET <b>DL</b>	3	PA,QL(30 per 30 days)
HETLIOZ 20 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
HETLIOZ LQ 4 MG/ML SUSPENSION <b>DL</b>	4	PA,QL(158 per 30 days)
LUMRYZ 4.5 GRAM, 6 GRAM, 7.5 GRAM, 9 GRAM ER GRANULES, PACKET <b>DL</b>	4	PA,QL(30 per 30 days)
LUNESTA 1 MG, 2 MG, 3 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)
modafinil 100 mg, 200 mg TABLET <b>MO</b>	1	PA,QL(60 per 30 days)
NUVIGIL 150 MG, 200 MG, 250 MG TABLET	4	PA,QL(30 per 30 days)
NUVIGIL 50 MG TABLET	4	PA,QL(60 per 30 days)
PROVIGIL 100 MG, 200 MG TABLET	4	PA,QL(60 per 30 days)
QUVIVIQ 25 MG, 50 MG TABLET <b>MO</b>	3	ST,QL(30 per 30 days)
ramelteon 8 mg TABLET <b>MO</b>	1	ST,QL(30 per 30 days)
RESTORIL 15 MG, 22.5 MG, 30 MG, 7.5 MG CAPSULE <b>DL</b>	4	PA,QL(30 per 30 days)
ROZEREM 8 MG TABLET <b>MO</b>	3	ST,QL(30 per 30 days)
SILENOR 3 MG, 6 MG TABLET <b>MO</b>	3	QL(30 per 30 days)
sodium oxybate 500 mg/ml SOLUTION <b>DL</b>	4	PA,QL(540 per 30 days)
SUNOSI 150 MG, 75 MG TABLET <b>MO</b>	3	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

<b>DRUG NAME</b>	<b>TIER</b>	<b>UTILIZATION MANAGEMENT REQUIREMENTS</b>
<i>tasimelteon 20 mg CAPSULE</i> <b>DL</b>	4	PA,QL(30 per 30 days)
<i>temazepam 15 mg, 30 mg CAPSULE</i> <b>DL</b>	1	QL(30 per 30 days)
<i>temazepam 22.5 mg, 7.5 mg CAPSULE</i> <b>DL</b>	1	QL(30 per 30 days)
<i>triazolam 0.125 mg, 0.25 mg TABLET</i> <b>DL</b>	1	QL(30 per 30 days)
WAKIX 17.8 MG, 4.45 MG TABLET <b>DL</b>	4	PA,QL(60 per 30 days)
XYREM 500 MG/ML SOLUTION <b>DL</b>	4	PA,QL(540 per 30 days)
XYWAV 0.5 GRAM/ML SOLUTION <b>DL</b>	4	PA,QL(540 per 30 days)
<i>zaleplon 10 mg, 5 mg CAPSULE</i> <b>MO</b>	1	QL(30 per 30 days)
<i>zolpidem 1.75 mg, 3.5 mg SUBLINGUAL TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>zolpidem 10 mg, 5 mg TABLET</i> <b>MO</b>	1	QL(30 per 30 days)
<i>zolpidem 12.5 mg, 6.25 mg TABLET, ER MULTIPHASE</i> <b>MO</b>	1	QL(30 per 30 days)
ZOLPIDEM 7.5 MG CAPSULE <b>MO</b>	3	QL(30 per 30 days)
ZOLPIMIST 5 MG/SPRAY (0.1 ML) SPRAY, NON-AEROSOL <b>MO</b>	3	QL(23.1 per 365 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 5.

B vs D – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Paxlovid/Vaccine/Diabetic • ST – Step Therapy

## Humana Group Medicare Plan Coverage of Additional Prescription Drugs

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<b>Cough/Cold - Mail Order Available</b>		
<i>benzonatate 100 mg, 150 mg, 200 mg CAPSULE</i>	1	
<i>bromfed dm 2-30-10 mg/5 ml SYRUP</i>	1	
<i>brompheniramine-pseudoeph-dm 2-30-10 mg/5 ml SYRUP</i>	1	
HYCODAN 5-1.5 MG/5 ML (5 ML) SYRUP	1	
HYCODAN (WITH HOMATROPINE) 5-1.5 MG TABLET	1	
HYCODAN (WITH HOMATROPINE) 5-1.5 MG/5 ML SYRUP	1	
<i>hydrocodone-chlorpheniramine 10-8 mg/5 ml SUSPENSION, ER 12 HR.</i>	1	
<i>hydrocodone-homatropine 5-1.5 mg TABLET</i>	1	
<i>hydrocodone-homatropine 5-1.5 mg/5 ml, 5-1.5 mg/5 ml (5 ml) SYRUP</i>	1	
<i>hydromet 5-1.5 mg/5 ml SYRUP</i>	1	
OBREDON 2.5-200 MG/5 ML SOLUTION	3	
<i>promethazine vc-codeine 6.25-5-10 mg/5 ml SYRUP</i>	1	
<i>promethazine-codeine 6.25-10 mg/5 ml SYRUP</i>	1	
<i>promethazine-dm 6.25-15 mg/5 ml SYRUP</i>	1	
<i>promethazine-phenyleph-codeine 6.25-5-10 mg/5 ml SYRUP</i>	1	
RESPA-AR 8-90-0.24 MG TABLET, ER 12 HR.	3	
TUXARIN ER 8-54.3 MG TABLET, ER 12 HR.	3	
TUZISTRA XR 14.7-2.8 MG/5 ML SUSPENSION, ER 12 HR.	3	

Your Humana Group Medicare Plan has additional coverage for some drugs. These drugs are not normally covered under Medicare Part D. These drugs are not subject to the Medicare appeals process. The amount you pay when you fill a prescription for these drugs does not count toward your total drug costs (in other words, the amount you pay does not help you qualify for catastrophic coverage).

B vs D - Part B vs Part D • CI - Covered Insulin Products • DL - Dispensing Limit • LA - Limited Access • MO - Mail Order • PA - Prior Authorization • PDS - BD/HTL- Droplet are the Preferred Diabetic Supplies • QL - Quantity Limit • \$0 - Vaccine/Diabetic • ST - Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<b>Fertility - Mail Order Available</b>		
<i>cetorelix 0.25 mg KIT</i>	1	
CETROTIDE 0.25 MG KIT	3	
<i>clomid 50 mg TABLET</i>	1	
<i>clomiphene citrate 50 mg TABLET</i>	1	
FOLLISTIM AQ 300 UNIT/0.36 ML, 600 UNIT/0.72 ML, 900 UNIT/1.08 ML CARTRIDGE	3	
<i>fyremadel 250 mcg/0.5 ml SYRINGE</i>	1	
GANIRELIX 250 MCG/0.5 ML SYRINGE	3	
<i>ganirelix 250 mcg/0.5 ml SYRINGE</i>	3	
GONAL-F 1,050 UNIT, 450 UNIT RECON SOLUTION	3	
GONAL-F RFF 75 UNIT RECON SOLUTION	3	
GONAL-F RFF REDI-JECT 300/0.5 UNIT/ML, 450/0.75 UNIT/ML, 900/1.5 UNIT/ML PEN INJECTOR	3	
MENOPUR 75 UNIT RECON SOLUTION	3	
OVIDREL 250 MCG/0.5 ML SYRINGE	3	
<b>Vitamins/Minerals - Mail Order Available</b>		
<i>ascorbic acid (vitamin c) 500 mg/ml SOLUTION</i>	1	
<i>b complex 100 100-2-100-2-2 mg/ml SOLUTION</i>	1	
<i>b-complex injection 100-2-100-2-2 mg/ml SOLUTION</i>	1	
<i>cyanocobalamin (vitamin b-12) 1,000 mcg/ml SOLUTION</i>	1	
<i>cyanocobalamin (vitamin b-12) 500 mcg/spray SPRAY, NON-AEROSOL</i>	1	

Your Humana Group Medicare Plan has additional coverage for some drugs. These drugs are not normally covered under Medicare Part D. These drugs are not subject to the Medicare appeals process. The amount you pay when you fill a prescription for these drugs does not count toward your total drug costs (in other words, the amount you pay does not help you qualify for catastrophic coverage).

B vs D - Part B vs Part D • CI - Covered Insulin Products • DL - Dispensing Limit • LA - Limited Access • MO - Mail Order • PA - Prior Authorization • PDS - BD/HTL- Droplet are the Preferred Diabetic Supplies • QL - Quantity Limit • \$0 - Vaccine/Diabetic • ST - Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<b>Vitamins/Minerals - Mail Order Available</b>		
<i>dodex 1,000 mcg/ml SOLUTION</i>	1	
DRISDOL 1,250 MCG (50,000 UNIT) CAPSULE	3	
<i>ergocalciferol (vitamin d2) 1,250 mcg (50,000 unit) CAPSULE</i>	1	
<i>folic acid 1 mg TABLET</i>	1	
<i>folic acid 5 mg/ml SOLUTION</i>	1	
<i>hydroxocobalamin 1,000 mcg/ml SOLUTION</i>	1	
INFUVITE ADULT 3,300 UNIT- 150 MCG/10 ML SOLUTION	3	
INFUVITE PEDIATRIC 80 MG-400 UNIT- 200 MCG/5 ML SOLUTION	3	
MEPHYTON 5 MG TABLET	3	
NASCOBAL 500 MCG/SPRAY SPRAY, NON-AEROSOL	3	
<i>phytonadione (vitamin k1) 1 mg/0.5 ml SYRINGE</i>	1	
<i>phytonadione (vitamin k1) 1 mg/0.5 ml, 10 mg/ml SOLUTION</i>	1	
<i>phytonadione (vitamin k1) 5 mg TABLET</i>	1	
POTABA 500 MG CAPSULE	3	
<i>pyridoxine (vitamin b6) 100 mg/ml SOLUTION</i>	1	
<i>thiamine hcl (vitamin b1) 100 mg/ml SOLUTION</i>	1	
<i>vitamin d2 1,250 mcg (50,000 unit) CAPSULE</i>	1	
<i>vitamin k 1 mg/0.5 ml SOLUTION</i>	1	
<i>vitamin k1 10 mg/ml SOLUTION</i>	1	

Your Humana Group Medicare Plan has additional coverage for some drugs. These drugs are not normally covered under Medicare Part D. These drugs are not subject to the Medicare appeals process. The amount you pay when you fill a prescription for these drugs does not count toward your total drug costs (in other words, the amount you pay does not help you qualify for catastrophic coverage).

B vs D - Part B vs Part D • CI - Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA - Prior Authorization • PDS - BD/HTL- Droplet are the Preferred Diabetic Supplies • QL - Quantity Limit • \$0 – Vaccine/Diabetic • ST - Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<b>Weight Loss - Mail Order Available</b>		
<i>adipex-p 37.5 mg CAPSULE</i>	1	
ADIPEX-P 37.5 MG TABLET	1	
<i>benzphetamine 50 mg TABLET</i>	1	
CONTRAVE 8-90 MG TABLET ER	3	QL(120 per 30 days)
<i>diethylpropion 25 mg TABLET</i>	1	
<i>diethylpropion 75 mg TABLET ER</i>	1	
<i>lomaira 8 mg TABLET</i>	1	
<i>phendimetrazine tartrate 105 mg CAPSULE, ER</i>	3	
<i>phendimetrazine tartrate 35 mg TABLET</i>	1	
<i>phentermine 15 mg, 30 mg, 37.5 mg CAPSULE</i>	1	
<i>phentermine 37.5 mg TABLET</i>	1	
PLENITY 0.75 GRAM CAPSULE	3	
PLENITY (WELCOME KIT) 0.75 GRAM CAPSULE	3	
QSYMIA 11.25-69 MG, 15-92 MG, 3.75-23 MG, 7.5-46 MG CAPSULE ER MULTIPHASE 24 HR.	3	QL(30 per 30 days)
SAXENDA 3 MG/0.5 ML (18 MG/3 ML) PEN INJECTOR	3	
ZEPBOUND 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML PEN INJECTOR	3	

Your Humana Group Medicare Plan has additional coverage for some drugs. These drugs are not normally covered under Medicare Part D. These drugs are not subject to the Medicare appeals process. The amount you pay when you fill a prescription for these drugs does not count toward your total drug costs (in other words, the amount you pay does not help you qualify for catastrophic coverage).

B vs D - Part B vs Part D • CI - Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA - Prior Authorization • PDS - BD/HTL- Droplet are the Preferred Diabetic Supplies • QL - Quantity Limit • \$0 – Vaccine/Diabetic • ST - Step Therapy

# Index

## A

- abacavir... 74
- abacavir-lamivudine... 74
- ABELCET... 45
- ABILIFY ASIMTUFI... 69
- ABILIFY MAINTENA... 69
- ABILIFY MYCITE MAINTENANCE KIT... 69, 70
- ABILIFY MYCITE STARTER KIT... 70
- ABILIFY MYCITE... 69
- ABILIFY... 69
- abiraterone... 52
- ABRAXANE... 52
- ABRILADA(CF) PEN... 158
- ABRILADA(CF)... 158
- ABRYSVO... 158
- ABSORICA LD... 115
- ABSORICA... 115
- acamprosate... 21
- ACANYA... 115
- acarbose... 82
- ACCOLATE... 185
- ACCUPRIL... 93
- ACCURETIC... 93
- accutane... 115
- acebutolol... 93
- ACETADOTE... 172
- acetaminophen... 172
- acetaminophen-caff-dihydrocod... 11
- acetaminophen-codeine... 11
- acetazolamide sodium... 93
- acetazolamide... 93
- acetic acid... 22, 172
- acetylcysteine... 172, 185
- ACIPHEX SPRINKLE... 133
- ACIPHEX... 132
- acitretin... 115
- ACTEMRA ACTPEN... 158
- ACTEMRA... 158
- ACTHAR... 141
- ACTHIB (PF)... 158
- ACTICLATE... 22
- ACTIMMUNE... 158
- ACTIQ... 11
- ACTIVELLA... 145
- ACTONEL... 170
- ACTOPLUS MET... 82
- ACTOS... 82
- ACULAR LS... 179
- ACULAR... 179
- ACUVAIL (PF)... 179
- acyclovir sodium... 75
- acyclovir... 74, 75
- ACZONE... 115
- ADACEL(TDAP ADOLESN/ADULT)(PF)... 158
- ADAKVEO... 172
- ADALIMUMAB-AACF... 158
- ADALIMUMAB-AATY... 158
- ADALIMUMAB-ADAZ... 158
- ADALIMUMAB-ADBM... 158
- ADALIMUMAB-ADBM(CF) PEN CROHNS... 158
- ADALIMUMAB-ADBM(CF) PEN PS-UV... 158
- ADALIMUMAB-FKJP... 159
- adapalene... 116
- adapalene-benzoyl peroxide... 116
- ADBRY... 159
- ADCETRIS... 52
- ADCIRCA... 185
- ADDERALL XR... 108
- ADDERALL... 108
- adefovir... 75
- ADEMPAS... 185
- adenosine... 93
- adipex-p... 199
- ADLARITY... 38
- ADLYXIN... 82



ADMELOG SOLOSTAR U-100 INSULIN... 82	AKEEGA... 52	allopurinol... 48
ADMELOG U-100 INSULIN LISPRO... 82	AKLIEF... 116	ALLZITAL... 172
ADRENALIN... 185	AKYNZEO (FOSNETUPITANT)... 43	almotriptan malate... 49
ADRIAMYCIN... 52	AKYNZEO (NETUPITANT)... 43	ALOCIL... 179
adrucil... 52	ALA-CORT... 116	ALOMIDE... 179
ADSTILADRIN... 172	ALA-SCALP... 116	ALOPRIM... 48
ADVAIR DISKUS... 185	albendazole... 66	alosetron... 133
ADVAIR HFA... 185	ALBENZA... 66	ALPHAGAN P... 179
ADZENYS XR-ODT... 108	albuterol sulfate... 185	alprazolam intensol... 81
ADZYNMA... 88	ALCAINE... 179	alprazolam... 80
AEMCOLO... 133	alclometasone... 116	ALREX... 180
AFINITOR DISPERZ... 52	ALCOHOL PADS... 172	ALTABAX... 116
AFINITOR... 52	ALCOHOL PREP PADS... 172	ALTACE... 93
afirmelle... 145	ALCOHOL SWABS... 172	altavera (28)... 145
AFREZZA... 82	ALCOHOL WIPES... 172	ALTOPREV... 93
AGAMREE... 141	ALDACTAZIDE... 93	ALTRENO... 116
AGGRASTAT CONCENTRATE... 88	ALDACTONE... 93	ALUNBRIG... 52, 53
AGGRASTAT IN SODIUM CHLORIDE... 88	ALDURAZYME... 137	ALVAIZ... 88, 89
AGRYLIN... 88	ALECENSA... 52	ALVESCO... 185
AIMOVIG AUTOINJECTOR... 49	alendronate... 170	alyacen 1/35 (28)... 145
AIRDUO DIGIHALER... 185	alfuzosin... 140	alyacen 7/7/7 (28)... 145
AIRDUO RESPICLICK... 185	ALIMTA... 52	ALYGLO... 159
AIRSUPRA... 185	ALIQOPA... 52	ALYMSYS... 53
AJOVY AUTOINJECTOR... 49	aliskiren... 93	alyq... 185
AJOVY SYRINGE... 49	ALKERAN (AS HCL)... 52	amabelz... 145
ak-poly-bac... 179	ALKERAN... 52	amantadine hcl... 67
	ALKINDI SPRINKLE... 141	AMARYL... 82
	allopurinol sodium... 48	AMBIEN CR... 194

AMBIEN... 194	amiodarone... 93	AMPYRA... 109
AMBISOME... 45	AMITIZA... 133	AMRIX... 193
ambrisentan... 185	amitriptyline... 39	AMVUTTRA... 137
amcinonide... 116	amitriptyline-chlordiazepoxide... 39	AMZEEQ... 116
AMERGE... 49	AMJEVITA(CF) AUTOINJECTOR... 159	ANAFRANIL... 39
amethia... 145	AMJEVITA(CF)... 159	anagrelide... 89
amethyst (28)... 145	amlodipine... 93	ANAPROX DS... 11
amikacin... 22	amlodipine-atorvastatin... 93	anastrozole... 53
amiloride... 93	amlodipine-benazepril... 93, 94	ANCOBON... 45
amiloride-hydrochlorothiazide... 93	amlodipine-olmesartan... 94	ANDRODERM... 145
aminocaproic acid... 89	amlodipine-valsartan... 94	ANDROGEL... 145
aminophylline... 186	amlodipine-valsartan-hcthiazyd... 94	ANGELIQ... 145
AMINOSYN II 10 %... 125	ammonium lactate... 116	ANNOVERA... 145
AMINOSYN II 15 %... 125	AMMONUL... 172	ANORO ELLIPTA... 186
AMINOSYN II 7 %... 125	amnesteem... 116	ANTIVERT... 43
AMINOSYN II 8.5 %... 125	amoxapine... 39	anusol-hc... 116
AMINOSYN II 8.5 %-ELECTROLYTES... 125	amoxicil-clarithromy-lansopraz... 133	ANZEMET... 43
AMINOSYN M 3.5 %... 125	amoxicillin... 22, 23	APADAZ... 11
AMINOSYN 10 %... 125	amoxicillin-pot clavulanate... 23	apexicon e... 116
AMINOSYN 7 % WITH ELECTROLYTES... 125	amphetamine sulfate... 109	APIDRA SOLOSTAR U-100 INSULIN... 82
AMINOSYN 8.5 %... 125	amphetamine... 108	APIDRA U-100 INSULIN... 82
AMINOSYN 8.5 %-ELECTROLYTES... 125	amphotericin b liposome... 45	APLENZIN... 39
AMINOSYN-PF 10 %... 125	amphotericin b... 45	APOKYN... 67
AMINOSYN-PF 7 % (SULFITE-FREE)... 125	ampicillin sodium... 23	apomorphine... 67
AMINOSYN-RF 5.2 %... 125	ampicillin... 23	APONVIE... 43
	ampicillin-sulbactam... 23	apraclonidine... 180
		aprepitant... 43

APRETUDE... 75	ARTHROTEC 50... 11	ATRIPLA... 75
apri... 145	ARTHROTEC 75... 11	ATROPINE SULFATE (PF)... 180
APRISO... 169	ASACOL HD... 169	atropine... 133, 180
APTENSIO XR... 109	ASCENIV... 159	ATROVENT HFA... 186
APTIOM... 33	ascomp with codeine... 11	AUBAGIO... 109
APTIVUS... 75	ascorbic acid (vitamin c)... 197	aubra eq... 145
ARALAST NP... 137	asenapine maleate... 70	aubra... 145
aranelle (28)... 145	ashlyna... 145	AUGMENTIN ES-600... 23
ARANESP (IN POLYSORBATE)... 89	ASMANEX HFA... 186	AUGMENTIN XR... 23
ARAVA... 159	ASMANEX TWISTHALER... 186	AUGMENTIN... 23
ARAZLO... 116	ASPARLAS... 53	AUGTYRO... 53
ARCALYST... 159	aspirin-dipyridamole... 89	aurovela fe 1.5/30 (28)... 146
AREXVY (PF)... 159	ASPRUZYO SPRINKLE... 94	aurovela fe 1-20 (28)... 146
arformoterol... 186	ASTAGRAF XL... 159	aurovela 1.5/30 (21)... 145
ARICEPT... 38	ATACAND HCT... 94	aurovela 1/20 (21)... 145
ARIKAYCE... 23	ATACAND... 94	aurovela 24 fe... 146
ARIMIDEX... 53	atazanavir... 75	AURYXIA... 125
aripiprazole... 70	ATELVIA... 170	AUSTEDO XR TITRATION KT(WK1-4)... 109
ARISTADA INITIO... 70	atenolol... 94	AUSTEDO XR... 109
ARISTADA... 70	atenolol-chlorthalidone... 94	AUSTEDO... 109
ARIXTRA... 89	ATGAM... 159	AUTOJECT 2 INJECTION DEVICE... 172
armodafinil... 194	ATIVAN... 81	AUTOPEN 1 TO 21 UNITS... 173
ARMONAIR DIGIHALER... 186	atomoxetine... 109	AUTOPEN 2 TO 42 UNITS... 173
ARMOUR THYROID... 155	ATORVALIQ... 94	AUVELITY... 39
ARNUIITY ELLIPTA... 186	atorvastatin... 94	AUVI-Q... 186
AROMASIN... 53	atovaquone... 66	AVALIDE... 94
ARRANON... 53	atovaquone-proguanil... 66	
arsenic trioxide... 53	ATRALIN... 116	

AVAPRO... 94	AZOR... 94	BASAGLAR TEMPO
AVASTIN... 53	AZSTARYS... 109	PEN(U-100)INSLN... 83
AVEED... 146	aztreonam... 24	BAVENCIO... 53
AVELOX IN NACL (ISO-OSMOTIC)... 23	AZULFIDINE EN-TABS... 169	BAXDELA... 24
aviane... 146	AZULFIDINE... 169	BCG VACCINE, LIVE (PF)... 159
avidoxy... 23	azurette (28)... 146	BD ALCOHOL SWABS... 173
AVITA... 116	<b>B</b>	BD AUTOSHIELD DUO PEN NEEDLE... 173
AVODART... 140	b complex 100... 197	BD ECLIPSE LUER-LOK... 173
AVONEX... 109	b-complex injection... 197	BD INSULIN SYRINGE (HALF UNIT)... 173
AVSOLA... 159	bacitracin... 24, 180	BD INSULIN SYRINGE MICRO-FINE... 173
AVYCAZ... 23	bacitracin-polymyxin b... 180	BD INSULIN SYRINGE U-500... 173
AYGESTIN... 146	baclofen... 74	BD INSULIN SYRINGE ULTRA-FINE... 173
ayuna... 146	BACTRIM DS... 24	BD INSULIN SYRINGE... 173
AYVAKIT... 53	BACTRIM... 24	BD LO-DOSE MICRO-FINE IV... 173
azacitidine... 53	BAFIERTAM... 109	BD NANO 2ND GEN PEN NEEDLE... 173
AZACTAM... 23	bal-care dha... 125	BD SAFETYGLIDE INSULIN SYRINGE... 173
AZASAN... 159	balanced salt... 180	BD SAFETYGLIDE SYRINGE... 173
AZASITE... 180	BALCOLTRA... 146	BD ULTRA-FINE MICRO PEN NEEDLE... 173
azathioprine sodium... 159	balsalazide... 169	BD ULTRA-FINE MINI PEN NEEDLE... 173
azathioprine... 159	BALVERSA... 53	BD ULTRA-FINE NANO PEN NEEDLE... 173
azelaic acid... 116	balziva (28)... 146	BD ULTRA-FINE ORIG PEN NEEDLE... 173
azelastine... 180, 186	BAND-AID GAUZE PADS... 173	
azelastine-fluticasone... 186	BANZEL... 33	
AZELEX... 116	BAQSIMI... 82	
AZILECT... 67	BARACLUDE... 75	
azithromycin... 23	BASAGLAR KWIKPEN U-100 INSULIN... 83	
AZOPT... 180		

BD ULTRA-FINE SHORT PEN NEEDLE... 173	BESIVANCE... 180	BIDIL... 94
BD VEO INSULIN SYR (HALF UNIT)... 173	BESPONSA... 53	BIJUVA... 146
BD VEO INSULIN SYRINGE UF... 173	BESREMI... 159	BIKTARVY... 75
BECONASE AQ... 186	BETADINE OPHTHALMIC PREP... 180	BILTRICIDE... 66
BELBUCA... 11	betaine... 137	bimatoprost... 180
BELEODAQ... 53	betamethasone acet,sod phos... 141	BIMZELX AUTOINJECTOR... 159
BELRAPZO... 53	betamethasone dipropionate... 116, 117	BIMZELX... 159
BELSOMRA... 194	betamethasone valerate... 117	BINOSTO... 171
benazepril... 94	betamethasone, augmented... 117	BIORPHEN... 94
benazepril-hydrochlorothiazide... 94	BETAPACE AF... 94	bismuth subcit k-metronidz-tcn... 133
bendamustine... 53	BETAPACE... 94	bisoprolol fumarate... 94
BENDEKA... 53	BETASERON... 109	bisoprolol-hydrochlorothiazide... 94
BENICAR HCT... 94	betaxolol... 94, 180	BIVIGAM... 160
BENICAR... 94	bethanechol chloride... 140	bleomycin... 53
BENLYSTA... 159	BETHKIS... 24	BLEPHAMIDE... 180
BENTYL... 133	BETIMOL... 180	blisovi fe 1.5/30 (28)... 146
BENZAMYCIN... 116	BETOPTIC S... 180	blisovi fe 1/20 (28)... 146
benzhydrocodone-acetaminophen... 11	BEVESPI AEROSPHERE... 186	blisovi 24 fe... 146
benznidazole... 66	bexarotene... 53	BONIVA... 171
benzonatate... 196	BEXSERO... 159	BONJESTA... 43
benzphetamine... 199	BEYAZ... 146	BOOSTRIX TDAP... 160
benztropine... 67	BEYFORTUS... 173	BORDERED GAUZE... 173
bepotastine besilate... 180	bicalutamide... 53	BORTEZOMIB... 53
BEPREVE... 180	BICILLIN C-R... 24	bosentan... 186
BERINERT... 159	BICILLIN L-A... 24	BOSULIF... 53, 54
beser... 116	BICNU... 53	BRAFTOVI... 54
		BREO ELLIPTA... 186

bretylium tosylate... 94	bupivacaine hcl... 19	c-nate dha... 125
BREVIBLOC IN NACL (ISO-OSM)... 95	bupivacaine-dextrose-water(pf)... 19	CABENUVA... 75
BREVIBLOC... 94	bupivacaine-epinephrine (pf)... 19	cabergoline... 156
BREZTRI AEROSPHERE... 186	bupivacaine-epinephrine... 19	CABLIVI... 89
briellyn... 146	BUPRENEX... 11	CABOMETYX... 54
BRILINTA... 89	buprenorphine hcl... 11, 21	CABTREO... 117
brimonidine... 117, 180	buprenorphine... 11	CADUET... 95
brinzolamide... 180	buprenorphine-naloxone... 21	CAFCIT... 174
BRISDELLE... 39	bupropion hcl (smoking deter)... 21	caffeine citrate... 174
BRIUMVI... 109	bupropion hcl... 39, 40	CALAN SR... 95
BRIVIACT... 33	buspirone... 81	calcipotriene... 117
bromfed dm... 196	busulfan... 54	calcipotriene-betamethasone... 117
bromfenac... 180	BUSULFEX... 54	calcitonin (salmon)... 171
bromocriptine... 67	butalbital compound w/codeine... 11	calcitriol... 117, 171
brompheniramine-pseudoeph-dm... 196	butalbital-acetaminop-caf-cod... 174	calcium acetate(phosphat bind)... 125
BROMSITE... 180	butalbital-acetaminophen... 174	calcium chloride... 125
BRONCHITOL... 186	butalbital-acetaminophen-caff... 174	calcium disodium versenate... 174
BROVANA... 186	butalbital-aspirin-caffeine... 174	calcium gluconate... 125
BRUKINSA... 54	butorphanol... 11	CALDOLOR... 11
BRYHALI... 117	BUTRANS... 11	CALQUENCE (ACALABRUTINIB MAL)... 54
BSS PLUS... 180	BYDUREON BCISE... 83	CALQUENCE... 54
BSS... 180	BYETTA... 83	CAMBIA... 11
budesonide... 169, 186	BYLVAY... 174	camila... 146
bumetanide... 95	BYSTOLIC... 95	CAMPTOSAR... 54
bupap... 174		camrese lo... 146
BUPHENYL... 137		camrese... 146
bupivacaine (pf)... 19		

**C**

CAMZYOS... 95	CARDIZEM... 95	cefazolin... 24
CANASA... 169	CARDURA XL... 95	cefdinir... 24
CANCIDAS... 45	CARDURA... 95	cefepime in dextrose 5 %... 24
candesartan... 95	CARETOUCH ALCOHOL PREP PAD... 174	cefepime in dextrose,iso-osm... 24
candesartan-hydrochlorothiazid... 95	carglumic acid... 126	cefepime... 24
CAPEX... 117	carisoprodol... 193	cefixime... 24
CAPLYTA... 70	carisoprodol-aspirin... 193	cefotaxime... 24
CAPRELSA... 54	carisoprodol-aspirin-codeine... 193	cefotetan... 24
captopril... 95	carmustine... 54	cefoxitin in dextrose, iso-osm... 24
captopril-hydrochlorothiazide... 95	CARNITOR (SUGAR-FREE)... 126	cefoxitin... 24
CARAC... 117	CARNITOR... 126	cefpodoxime... 25
CARAFATE... 133	CAROSPIR... 95	cefprozil... 25
CARBAGLU... 125	carteolol... 180	ceftazidime in d5w... 25
carbamazepine... 33	cartia xt... 95	ceftazidime... 25
CARBATROL... 33	carvedilol phosphate... 95	ceftriaxone in dextrose,iso-os... 25
carbidopa... 68	carvedilol... 95	ceftriaxone... 25
carbidopa-levodopa... 68	CASODEX... 54	cefuroxime axetil... 25
carbidopa-levodopa-entacapone... 68	caspofungin... 45	cefuroxime sodium... 25
carbinoxamine maleate... 186	cataflam... 11	CELEBREX... 11
CARBOCAINE (PF)... 19	CATAPRES-TTS-1... 95	celecoxib... 11
CARBOCAINE WITH NEO-COBEFRIN... 20	CATAPRES-TTS-2... 95	CELESTONE SOLUSPAN... 141
CARBOCAINE... 19	CATAPRES-TTS-3... 96	CELEXA... 40
carboplatin... 54	CAYSTON... 186	CELLCEPT INTRAVENOUS... 160
carboprost tromethamine... 145	caziant (28)... 146	CELLCEPT... 160
CARDIZEM CD... 95	cefaclor... 24	CELONTIN... 33
CARDIZEM LA... 95	cefadroxil... 24	CENTANY... 117
	cefazolin in dextrose (iso-os)... 24	cephalexin... 25
		CEQUA... 180

CERDELGA... 137	cholestyramine (with sugar)... 96	ciprofloxacin... 25
CEREBYX... 33	cholestyramine light... 96	ciprofloxacin-dexamethasone... 184
CEREZYME... 137	cholestyramine-aspartame... 96	ciprofloxacin-fluocinolone... 184
CERVIDIL... 174	CHORIONIC GONADOTROPIN, HUMAN... 143	cisplatin... 54
cetirizine... 186	CIALIS... 140	citalopram... 40
cetrotelix... 197	CIBINQO... 160	CITRANATAL B-CALM (FE GLUC)... 126
CETROTIDE... 197	ciclodan... 45	cladribine... 54
cevimeline... 115	ciclopirox... 45, 46	CLAFORAN... 25
CHANTIX CONTINUING MONTH BOX... 22	cidofovir... 75	claravis... 117
CHANTIX STARTING MONTH BOX... 22	cilostazol... 89	CLARINEX... 187
CHANTIX... 21	CILOXAN... 180	CLARINEX-D 12 HOUR... 174
charlotte 24 fe... 146	CIMDUO... 75	clarithromycin... 25
chateal (28)... 146	cimetidine hcl... 133	clemastine... 187
chateal eq (28)... 146	cimetidine... 133	CLENPIQ... 133
CHEMET... 126	CIMZIA POWDER FOR RECONST... 160	CLEOCIN HCL... 25
CHENODAL... 133	CIMZIA STARTER KIT... 160	CLEOCIN PEDIATRIC... 25
chloramphenicol sod succinate... 25	CIMZIA... 160	CLEOCIN T... 117
chlordiazepoxide hcl... 81	cinacalcet... 171	CLEOCIN... 25
chlorhexidine gluconate... 115	CINQAIR... 187	CLEVIPREX... 96
chlorprocaine (pf)... 20	CINRYZE... 160	CLIMARA PRO... 146
chloroquine phosphate... 66	CINVANTI... 174	CLIMARA... 146
chlorothiazide sodium... 96	CIPRO HC... 184	clindacin etz... 117
chlorpromazine... 70	CIPRO... 25	clindacin p... 117
chlorthalidone... 96	CIPRODEX... 184	clindacin... 117
chlorzoxazone... 193	ciprofloxacin hcl... 25, 180, 184	CLINDAGEL... 117
CHOLBAM... 137	ciprofloxacin in 5 % dextrose... 25	clindamycin hcl... 26



clindamycin in 0.9 % sod chlor... 26	CLINIMIX 6%-D5W (SULFITE-FREE)... 126	COARTEM... 66
clindamycin in 5 % dextrose... 26	CLINIMIX 8%-D10W(SULFITE-FREE)... 126	codeine sulfate... 12
clindamycin palmitate hcl... 26	CLINIMIX 8%-D14W(SULFITE-FREE)... 126	codeine-butalbital-asa-caff... 12
clindamycin pediatric... 26	CLINISOL SF 15 %... 126	COLAZAL... 169
clindamycin phosphate... 26, 117, 118	CLINOLIPID... 126	colchicine... 48
clindamycin-benzoyl peroxide... 118	clobazam... 33	colesevelam... 96
clindamycin-tretinoin... 118	clobetasol... 118	COLESTID FLAVORED... 96
CLINDESSE... 26	clobetasol-emollient... 118	COLESTID... 96
CLINIMIX E 2.75%/D5W SULF FREE... 126	CLOBEX... 118	colestipol... 96
CLINIMIX E 4.25%/D10W SUL FREE... 126	clodan... 118	colistin (colistimethate na)... 26
CLINIMIX E 4.25%/D5W SULF FREE... 126	clofarabine... 54	COLUMVI... 54
CLINIMIX E 5%/D15W SULFIT FREE... 126	CLOLAR... 54	COLY-MYCIN M PARENTERAL... 26
CLINIMIX E 5%/D20W SULFIT FREE... 126	clomid... 197	COMBIGAN... 181
CLINIMIX E 8%-D10W SULFITEFREE... 126	clomiphene citrate... 197	COMBIPATCH... 146
CLINIMIX E 8%-D14W SULFITEFREE... 126	clomipramine... 40	COMBIVENT RESPIMAT... 187
CLINIMIX 4.25%/D10W SULF FREE... 126	clonazepam... 81	COMBIVIR... 75
CLINIMIX 4.25%/D5W SULFIT FREE... 126	clonidine hcl... 96, 109	COMBOGESIC IV... 174
CLINIMIX 5%-D20W(SULFITE-FREE)... 126	clonidine... 96	COMETRIQ... 54
CLINIMIX 5%/D15W SULFITE FREE... 126	clopidogrel... 89	COMPАЗINE... 44
	clorazepate dipotassium... 81	COMPLERA... 75
	CLOROTEKAL... 20	complete natal dha... 126
	clotrimazole... 46	compro... 44
	clotrimazole-betamethasone... 46	COMTAN... 68
	clozapine... 70	CONCERTA... 109
	CLOZARIL... 70	CONDYLOX... 118
		CONJUPRI... 96
		constulose... 133
		CONTRAVE... 199

CONZIP... 12	CREON... 137	CYLTEZO(CF) PEN CROHN'S-UC-HS... 160
COPAXONE... 109	CRESEMBA... 46	CYLTEZO(CF) PEN PSORIASIS-UV... 160
COPIKTRA... 54	CRESTOR... 97	CYLTEZO(CF) PEN... 160
CORDRAN TAPE LARGE ROLL... 118	CRINONE... 146	CYLTEZO(CF)... 160
CORDRAN... 118	cromolyn... 181, 187	CYMBALTA... 40
COREG CR... 96	crotan... 118	cyproheptadine... 187
COREG... 96	cryselle (28)... 146	CYRAMZA... 54
coremino... 26	CRYSVITA... 137	cyred eq... 147
CORGARD... 96	CUBICIN RF... 26	cyred... 146
CORLANOR... 96	CUBICIN... 26	CYSTADANE... 137
CORLOPAM... 96	CUPRIMINE... 126	CYSTADROPS... 181
CORTEF... 118	CURITY ALCOHOL SWABS... 174	CYSTAGON... 137
CORTENEMA... 170	CURITY GAUZE... 174	CYSTARAN... 181
CORTIFOAM... 170	CUTAQUIG... 160	cytarabine (pf)... 55
CORTISPORIN-TC... 184	CUVPOSA... 133	cytarabine... 55
CORTROPHIN GEL... 141	CUVRIOR... 126	CYTOGAM... 160
CORVERT... 96	cyanocobalamin (vitamin b-12)... 197	CYTOMEL... 155
COSENTYX (2 SYRINGES)... 160	cyclafem 1/35 (28)... 146	CYTOTEC... 133
COSENTYX PEN (2 PENS)... 160	cyclafem 7/7/7 (28)... 146	<b>D</b>
COSENTYX PEN... 160	cyclobenzaprine... 193	D.H.E.45... 49
COSENTYX UNOREADY PEN... 160	cyclopentolate... 181	dabigatran etexilate... 89
COSENTYX... 160	cyclophosphamide... 54	dacarbazine... 55
COSMEGEN... 54	cycloserine... 51	DACOGEN... 55
COSOPT (PF)... 181	CYCLOSET... 83	dactinomycin... 55
COSOPT... 181	cyclosporine modified... 160	dalfampridine... 109
COTELLIC... 54	cyclosporine... 160	DALIRESP... 187
COTEMPLA XR-ODT... 109	CYKLOKAPRON... 89	
COZAAR... 97		

DALVANCE... 26	deferasirox... 126, 127	dermacinrx lidocan... 20
danazol... 147	deferiprone... 127	DERMOTIC OIL... 184
DANTRIUM... 74	deferoxamine... 127	DESCOVY... 75
dantrolene... 74	DEFITELIO... 174	DEFERAL... 127
DANYELZA... 55	deflazacort... 141	desipramine... 40
dapsone... 52, 119	DELESTROGEN... 147	desloratadine... 187
DAPTACEL (DTAP PEDIATRIC) (PF)... 160	DELSTRIGO... 75	desmopressin... 144
daptomycin in 0.9 % sod chlor... 26	DELZICOL... 170	desog-e.estradiol/e.estradiol... 147
daptomycin... 26	demeclocycline... 26	desogestrel-ethinyl estradiol... 147
DARAPRIM... 66	DEMEROL (PF)... 12	desonide... 119
darifenacin... 140	DEMEROL... 12	DESOWEN... 119
DARTISLA... 133	DEMSE... 97	desoximetasone... 119
darunavir... 75	DENAVIR... 75	DESOXYN... 109
DARZALEX FASPRO... 55	DENGVAXIA (PF)... 160	desrx... 119
DARZALEX... 55	DEPAKOTE ER... 33	desvenlafaxine succinate... 40
dasetta 1/35 (28)... 147	DEPAKOTE SPRINKLES... 33	desvenlafaxine... 40
dasetta 7/7/7 (28)... 147	DEPAKOTE... 33	DETROL LA... 140
daunorubicin... 55	DEPEN TITRATABS... 127	DETROL... 140
DAURISMO... 55	DEPO-ESTRADIOL... 147	dexabliss... 141
DAYBUE... 109	DEPO-MEDROL... 141	dexamethasone intensol... 142
DAYPRO... 12	DEPO-PROVERA... 147	dexamethasone sodium phos (pf)... 142
daysee... 147	DEPO-SUBQ PROVERA 104... 147	dexamethasone sodium phosphate... 142, 181
DAYTRANA... 109	DEPO-TESTOSTERONE... 147	dexamethasone... 142
DAYVIGO... 194	DERMA-SMOOTH/FS BODY OIL... 119	dexchlorpheniramine maleate... 187
DDAVP... 143, 144	DERMA-SMOOTH/FS SCALP OIL... 119	DEXEDRINE SPANSULE... 109, 110
deblitane... 147	DERMACEA... 174	DEXILANT... 133
decitabine... 55		

dexlansoprazole... 133	DIASTAT... 33	DILANTIN-125... 34
dexmethylphenidate... 110	diazepam intensol... 81	DILAUDID... 12
dexrazoxane hcl... 55	diazepam... 34, 81	dilt-xr... 97
DEXTENZA... 181	diazoxide... 83	diltiazem hcl... 97
dextroamphetamine sulfate... 110	DIBENZYLINE... 97	dimenhydrinate... 44
dextroamphetamine-amphetamine... 110	dichlorphenamide... 137	dimethyl fumarate... 110
dextrose 10 % and 0.2 % nacl... 127	DICLEGIS... 44	DIOVAN HCT... 97
dextrose 10 % in water (d10w)... 127	diclofenac epolamine... 12	DIOVAN... 97
dextrose 20 % in water (d20w)... 127	diclofenac potassium... 12	DIPENTUM... 170
dextrose 25 % in water (d25w)... 127	diclofenac sodium... 12, 119, 181	DIPHEN... 187
dextrose 30 % in water (d30w)... 127	diclofenac-misoprostol... 12	diphenhydramine hcl... 187
dextrose 40 % in water (d40w)... 127	dicloxacillin... 26	diphenoxylate-atropine... 133
dextrose 5 % in water (d5w)... 127	dicyclomine... 133	DIPROLENE (AUGMENTED)... 119
dextrose 5 %-lactated ringers... 127	didanosine... 75	dipyridamole... 89
dextrose 5%-0.2 % sod chloride... 127	diethylpropion... 199	disopyramide phosphate... 97
dextrose 5%-0.3 % sod.chloride... 127	DIFFERIN... 119	disulfiram... 22
dextrose 50 % in water (d50w)... 127	DIFICID... 26	DITROPAN XL... 140
dextrose 70 % in water (d70w)... 127	diflorasone... 119	DIURIL... 97
DHIVY... 68	DIFLUCAN... 46	divalproex... 34
DIACOMIT... 33	diflunisal... 12	DIVIGEL... 147
DIASTAT ACUDIAL... 33	difluprednate... 181	dobutamine in d5w... 97
	digitek... 97	dobutamine... 97
	digox... 97	DOCEFREZ... 55
	digoxin... 97	docetaxel... 55
	dihydroergotamine... 49	dodex... 198
	DILANTIN EXTENDED... 34	dofetilide... 97
	DILANTIN INFATABS... 34	DOJOLVI... 174
	DILANTIN... 34	dolishale... 147

donepezil... 38, 39	droperidol... 71	dutasteride... 140
dopamine in 5 % dextrose... 98	DROPLET INSULIN SYR(HALF UNIT)... 174	dutasteride-tamsulosin... 140
dopamine... 97	DROPLET INSULIN SYRINGE... 175	DUZALLO... 48
DOPRAM... 187	DROPLET MICRON PEN NEEDLE... 175	DYANAVEL XR... 110
DOPTelet (10 TAB PACK)... 89	DROPLET PEN NEEDLE... 175	DYMISTA... 187
DOPTelet (15 TAB PACK)... 89	DROPSAFE ALCOHOL PREP PADS... 175	DYRENIUM... 98
DOPTelet (30 TAB PACK)... 89	DROPSAFE PEN NEEDLE... 175	d10 %-0.45 % sodium chloride... 126
DORYX MPC... 26	drosiprenone-e.estradiol-lm.fa... 147	d2.5 %-0.45 % sodium chloride... 126
DORYX... 26	drosiprenone-ethinyl estradiol... 147	d5 % and 0.9 % sodium chloride... 126
dorzolamide... 181	DROXIA... 175	d5 %-0.45 % sodium chloride... 126
dorzolamide-timolol (pf)... 181	droxidopa... 98	<b>E</b>
dorzolamide-timolol... 181	DUAKLIR PRESSAIR... 187	E.E.S. GRANULES... 27
dotti... 147	DUAVEE... 147	E.E.S. 400... 27
DOVATO... 75	DUET DHA WITH OMEGA-3... 127	EASY COMFORT ALCOHOL PAD... 175
DOVONEX... 119	DUETACT... 83	EASY TOUCH ALCOHOL PREP PADS... 175
doxazosin... 98	DUEXIS... 12	EC-NAPROSYN... 12
doxepin... 81, 119, 194	DULERA... 187	ec-naproxen... 13
doxercalciferol... 171	duloxetine... 40	econazole... 46
DOXIL... 55	DUOBRII... 119	EDARBI... 98
doxorubicin... 55	DUOPA... 68	EDARBYCLOR... 98
doxorubicin, peg-liposomal... 55	DUPIXENT PEN... 161	EDECRIN... 98
doxy-100... 26	DUPIXENT SYRINGE... 161	edetate calcium disodium... 175
doxycycline hyclate... 26, 27	DURAMORPH (PF)... 12	EDLUAR... 194
doxycycline monohydrate... 27	DUREZOL... 181	EDURANT... 75
doxylamine-pyridoxine (vit b6)... 44	DURYSTA... 181	efavirenz... 75, 76
DRISDOL... 198		
DRIZALMA SPRINKLE... 40		
dronabinol... 44		

efavirenz-emtricitabin-tenofov... 76	ELIXOPHYLLIN... 187	ENDARI... 133
efavirenz-lamivu-tenofov disop... 76	ELLA... 147	endocet... 13
EFFEXOR XR... 40	ELLEENCE... 55	ENDOMETRIN... 147
EFFIENT... 90	ELMIRON... 140	ENGERIX-B (PF)... 161
EFUDEX... 119	ELREXFIO... 55	ENGERIX-B PEDIATRIC (PF)... 161
EGATEN... 66	eluryng... 147	ENHERTU... 55
EGRIFTA SV... 144	ELYXYB... 175	enilloring... 147
ELAPRASE... 137	ELZONRIS... 55	ENJAYMO... 161
electrolyte-a... 127	EMCYT... 55	enoxaparin... 90
electrolyte-148... 127	EMEND (FOSAPREPITANT)... 44	enpresse... 147
electrolyte-48 in d5w... 127	EMEND... 44	enskyce... 147
ELELYSO... 137	EMFLAZA... 142	ENSPRYNG... 161
ELESTRIN... 147	EMGALITY PEN... 49	ENSTILAR... 119
eletriptan... 49	EMGALITY SYRINGE... 49	entacapone... 68
ELEVIDYS... 137	EMPAVELI... 175	ENTADFI... 140
ELFABRIO... 138	EMPLICITI... 55	entecavir... 76
ELIDEL... 119	EMSAM... 40	ENTRESTO... 98
ELIGARD (3 MONTH)... 156	emtricitabine... 76	ENTYVIO PEN... 161
ELIGARD (4 MONTH)... 156	emtricitabine-tenofovir (tdf)... 76	ENTYVIO... 161
ELIGARD (6 MONTH)... 156	EMTRIVA... 76	enulose... 133
ELIGARD... 156	emverm... 66	ENVARUSUS XR... 161
ELIMITE... 119	emzahh... 147	EOHILIA... 175
elinest... 147	enalapril maleate... 98	EPANED... 98
ELIQUIS DVT-PE TREAT 30D START... 90	enalapril-hydrochlorothiazide... 98	EPCLUSA... 76
ELIQUIS... 90	enalaprilat... 98	EPIDIOLEX... 34
ELITEK... 55	ENBREL MINI... 161	EPIDUO FORTE... 119
	ENBREL SURECLICK... 161	EPIDUO... 119
	ENBREL... 161	EPIFOAM... 120

epinastine... 181	ERIVEDGE... 56	estarylla... 148
epinephrine... 187	ERLEADA... 56	estazolam... 194
EPIPEN JR 2-PAK... 187	erlotinib... 56	ESTRACE... 148
EPIPEN JR... 187	ERMEZA... 155	estradiol valerate... 148
EPIPEN 2-PAK... 187	errin... 148	estradiol... 148
EPIPEN... 187	ERTACZO... 46	estradiol-norethindrone acet... 148
epirubicin... 55	ertapenem... 27	ESTRING... 148
epitol... 34	ery pads... 120	ESTROGEL... 148
EPIVIR HBV... 76	ERY-TAB... 27	eszopiclone... 194
EPIVIR... 76	ERYGEL... 120	ethacrynate sodium... 98
EPKINLY... 55	ERYPED 200... 27	ethacrynic acid... 98
eplerenone... 98	ERYPED 400... 27	ethambutol... 52
EPOGEN... 90	ERYTHROCIN (AS STEARATE)... 27	ethosuximide... 34
epoprostenol (glycine)... 188	ERYTHROCIN... 27	ethynodiol diac-eth estradiol... 148
epoprostenol... 187	erythromycin ethylsuccinate... 27	ETHYOL... 56
EPRONTIA... 49	erythromycin lactobionate... 27	etodolac... 13
eprosartan... 98	erythromycin with ethanol... 120	etonogestrel-ethinyl estradiol... 148
EPSOLAY... 120	erythromycin... 27, 181	ETOPOPHOS... 56
eptifibatide... 90	erythromycin-benzoyl peroxide... 120	etoposide... 56
EPZICOM... 76	ESBRIET... 188	etravirine... 76
EQUETRO... 34	escitalopram oxalate... 40	EUCRISA... 120
ERAXIS(WATER DILUENT)... 46	ESGIC... 175	EULEXIN... 56
ERBITUX... 55	esmolol in nacl (iso-osm)... 98	EURAX... 120
ergocalciferol (vitamin d2)... 198	esmolol... 98	EUTHYROX... 155
ergoloid... 39	esomeprazole magnesium... 133	EVAMIST... 148
ERGOMAR... 49	esomeprazole sodium... 134	EVEKEO ODT... 110
ergotamine-caffeine... 49	ESOMEPRAZOLE STRONTIUM... 134	EVEKEO... 110
eribulin... 56		EVENITY... 171

everolimus (antineoplastic)... 56	FABHALTA... 161	FENOGLIDE... 99
everolimus (immunosuppressive)... 161	FABIOR... 120	fenoprofen... 13
EVISTA... 148	FABRAZYME... 138	FENSOLVI... 156
EVKEEZA... 98	falmina (28)... 148	fentanyl citrate (pf)... 13
EVOCLIN... 120	famciclovir... 76	fentanyl citrate... 13
EVOMELA... 56	famotidine (pf)... 134	fentanyl... 13
EVOTAZ... 76	famotidine (pf)-nacl (iso-os)... 134	FENTORA... 13
EVOXAC... 115	famotidine... 134	FERRIPROX (2 TIMES A DAY)... 127
EVRYSDI... 138	FANAPT... 71	FERRIPROX... 127
EXELDERM... 46	FARESTON... 56	fesoterodine... 140
EXELON PATCH... 39	FARXIGA... 83	FETROJA... 28
exemestane... 56	FASENRA PEN... 188	FETZIMA... 40, 41
EXFORGE HCT... 98	FASENRA... 188	FEXMID... 193
EXFORGE... 98	FASLODEX... 56	FIASP FLEXTOUCH U-100 INSULIN... 83
EXJADE... 127	febuxostat... 48	FIASP PENFILL U-100 INSULIN... 83
EXKIVITY... 56	felbamate... 34	FIASP U-100 INSULIN... 83
EXPAREL (PF)... 20	FELBATOL... 34	FIBRICOR... 99
EXSERVAN... 110	FELDENE... 13	FILSPARI... 175
EXTAVIA... 110	felodipine... 98	FILSUVEZ... 175
EXTINA... 46	FEMARA... 56	FINACEA... 120
EYSUVIS... 181	FEMHRT LOW DOSE... 148	finasteride... 140
EZALLOR SPRINKLE... 98	FEMRING... 148	fingolimod... 110
ezetimibe... 98	femynor... 148	FINTEPLA... 34
ezetimibe-atorvastatin... 98	fenofibrate micronized... 99	finzala... 148
ezetimibe-rosuvastatin... 98	fenofibrate nanocrystallized... 99	FIORICET WITH CODEINE... 175
ezetimibe-simvastatin... 98	fenofibrate... 99	fioricet... 175
	fenofibric acid (choline)... 99	FIRAZYR... 161
	fenofibric acid... 99	

**F**



FIRDAPSE... 111	fluocinonide-e... 120	formoterol fumarate... 188
FIRMAGON KIT W DILUENT SYRINGE... 157	fluocinonide-emollient... 120	FORTEO... 171
FIRMAGON... 157	fluorometholone... 181	FORTESTA... 148
FIRVANQ... 28	FLUOROPLEX... 120	FOSAMAX PLUS D... 171
flac otic oil... 185	fluorouracil... 56, 120	FOSAMAX... 171
FLAGYL... 28	fluoxetine... 41	fosamprenavir... 76
FLAREX... 181	fluphenazine decanoate... 71	fosaprepitant... 44
flavoxate... 140	fluphenazine hcl... 71	foscarnet... 76
FLEBOGAMMA DIF... 161	flurandrenolide... 120, 121	FOSCAVIR... 76
flecainide... 99	flurazepam... 194	fosfomycin tromethamine... 28
FLECTOR... 13	flurbiprofen sodium... 181	fosinopril... 99
FLEQSUVY... 74	flurbiprofen... 13	fosinopril-hydrochlorothiazide... 99
FLOLIPID... 99	flutamide... 56	fosphenytoin... 34
FLOMAX... 140	fluticasone propion-salmeterol... 188	FOSRENOL... 127
floxuridine... 56	fluticasone propionate... 121, 188	FOTIVDA... 56
fluconazole in nacl (iso-osm)... 46	fluvastatin... 99	FRAGMIN... 90
fluconazole... 46	fluvoxamine... 41	FROVA... 49
flucytosine... 46	FML FORTE... 181	frovatriptan... 49
fludarabine... 56	FML LIQUIFILM... 181	FRUZAQLA... 56
fludrocortisone... 142	FOCALIN XR... 111	FULPHILA... 90
FLUMADINE... 76	FOCALIN... 111	fulvestrant... 56
flumazenil... 175	folic acid... 198	FURADANTIN... 28
flunisolide... 188	FOLLISTIM AQ... 197	FUROSCIX... 99
fluocinolone acetonide oil... 185	FOLOTYN... 56	furosemide... 99
fluocinolone and shower cap... 120	fomepizole... 175	FUSILEV... 56
fluocinolone... 120	fondaparinux... 90	FUZEON... 76
fluocinonide... 120	FORFIVO XL... 41	FYARRO... 56
		fyavolv... 148

FYCOMPA... 34	GAVRETO... 56	GLEOSTINE... 57
FYLNETRA... 90	GAZYVA... 57	glimepiride... 83
fyremadel... 197	gefitinib... 57	glipizide... 83
<b>G</b>	GELNIQUE... 140	glipizide-metformin... 83
gabapentin... 34, 111	gemcitabine... 57	GLOPERBA... 49
GABITRIL... 34	gemfibrozil... 99	GLUCAGEN HYPOKIT... 83
GALAFOLD... 138	gemmily... 148	GLUCAGON (HCL) EMERGENCY KIT... 83
galantamine... 39	GEMTESA... 140	GLUCAGON EMERGENCY KIT (HUMAN)... 83
GAMASTAN... 161	GENERESS FE... 148	GLUCOTROL XL... 83
GAMIFANT... 161	generlac... 134	GLUMETZA... 83
GAMMAGARD LIQUID... 161	gengraf... 162	glyburide micronized... 83
GAMMAGARD S-D (IGA < 1 MCG/ML)... 161	GENOTROPIN MINIQUICK... 144	glyburide... 83
GAMMAKED... 161	GENOTROPIN... 144	glyburide-metformin... 83
GAMMAPLEX (WITH SORBITOL)... 162	gentak... 181	GLYCATE... 134
GAMMAPLEX... 162	gentamicin in nacl (iso-osm)... 28	GLYCOPHOS... 127
GAMUNEX-C... 162	gentamicin sulfate (ped) (pf)... 28	glycopyrrolate (pf) in water... 134
ganciclovir sodium... 76	gentamicin sulfate (pf)... 28	glycopyrrolate (pf)... 134
GANIRELIX... 197	gentamicin... 28, 181	glycopyrrolate... 134
GARDASIL 9 (PF)... 162	GENVOYA... 76	glydo... 20
GASTROCROM... 188	GEODON... 71	GLYNASE... 83
gatifloxacin... 181	GILENYA... 111	GLYXAMBI... 84
GATTEX ONE-VIAL... 134	GILOTRIF... 57	GOCOVRI... 68
GATTEX 30-VIAL... 134	GIMOTI... 44	GOLYTELY... 134
GAUZE BANDAGE... 175	GIVLAARI... 175	GONAL-F RFF REDI-JECT... 197
GAUZE PAD... 175	GLASSIA... 138	GONAL-F RFF... 197
gavilyte-c... 134	glatiramer... 111	GONAL-F... 197
gavilyte-g... 134	glatopa... 111	
	GLEEEVC... 57	

GONITRO... 99	HALDOL DECANOATE... 71	HULIO(CF)... 162
GRALISE... 111	halobetasol propionate... 121	HUMALOG JUNIOR KWIKPEN U-100... 84
granisetron (pf)... 44	haloette... 149	HUMALOG KWIKPEN INSULIN... 84
granisetron hcl... 44	HALOG... 121	HUMALOG MIX 50-50 INSULN U-100... 84
GRANIX... 90	haloperidol decanoate... 71	HUMALOG MIX 50-50 KWIKPEN... 84
GRASTEK... 188	haloperidol lactate... 71	HUMALOG MIX 75-25 KWIKPEN... 84
griseofulvin microsize... 46	haloperidol... 71	HUMALOG MIX 75-25(U-100)INSULN... 84
griseofulvin ultramicrosize... 46	HARVONI... 76, 77	HUMALOG TEMPO PEN(U-100)INSULN... 84
guanfacine... 99, 111	HAVRIX (PF)... 162	HUMALOG U-100 INSULIN... 84
GVOKE HYPOPEN 1-PACK... 84	heather... 149	HUMATIN... 28
GVOKE HYPOPEN 2-PACK... 84	HECTOROL... 171	HUMATROPE... 144
GVOKE PFS 1-PACK SYRINGE... 84	HEMABATE... 145	HUMIRA PEN CROHNS-UC-HS START... 162
GVOKE PFS 2-PACK SYRINGE... 84	HEMADY... 142	HUMIRA PEN PSOR-UEVETS-ADOL HS... 162
GVOKE... 84	HEMANGEOL... 99	HUMIRA PEN... 162
gynazole-1... 46	heparin (porcine)... 90, 91	HUMIRA... 162
<b>H</b>	heparin, porcine (pf)... 91	HUMIRA(CF) PEDI CROHNS STARTER... 162
HADLIMA PUSHTOUCH... 162	HEPLISAV-B (PF)... 162	HUMIRA(CF) PEN CROHNS-UC-HS... 163
HADLIMA... 162	HEPSERA... 77	HUMIRA(CF) PEN PEDIATRIC UC... 163
HADLIMA(CF) PUSHTOUCH... 162	HERCEPTIN HYLECTA... 57	HUMIRA(CF) PEN PSOR-UV-ADOL HS... 163
HADLIMA(CF)... 162	HERCEPTIN... 57	HUMIRA(CF) PEN... 163
HAEGARDA... 162	HERZUMA... 57	HUMIRA(CF)... 162
hailey fe 1.5/30 (28)... 148	HETLIOZ LQ... 194	
hailey fe 1/20 (28)... 148	HETLIOZ... 194	
hailey 24 fe... 148	HIBERIX (PF)... 162	
hailey... 148	HIPREX... 28	
HALAVEN... 57	HIZENTRA... 162	
halcinonide... 121	HORIZANT... 111	
HALCION... 194	HULIO(CF) PEN... 162	

HUMULIN N NPH INSULIN KWIKPEN... 84	hydrocortisone... 121, 170	ibuprofen-famotidine... 14
HUMULIN N NPH U-100 INSULIN... 84	hydrocortisone-acetic acid... 185	ibutilide fumarate... 100
HUMULIN R REGULAR U-100 INSULN... 84	hydromet... 196	icatibant... 163
HUMULIN R U-500 (CONC) INSULIN... 84	hydromorphone (pf)... 14	iclevia... 149
HUMULIN R U-500 (CONC) KWIKPEN... 84	HYDROMORPHONE... 13, 14	ICLUSIG... 57
HUMULIN 70/30 U-100 INSULIN... 84	hydroxocobalamin... 198	IDACIO(CF) PEN CROHN-UC STARTR... 163
HUMULIN 70/30 U-100 KWIKPEN... 84	hydroxychloroquine... 66	IDACIO(CF) PEN PSORIASIS START... 163
HYCAMTIN... 57	hydroxyurea... 57	IDACIO(CF) PEN... 163
HYCODAN (WITH HOMATROPINE)... 196	hydroxyzine hcl... 81	IDACIO(CF)... 163
HYCODAN... 196	hydroxyzine pamoate... 188	IDAMYCIN PFS... 57
hydralazine... 100	HYFTOR... 121	idarubicin... 57
HYDREA... 57	HYPERRAB (PF)... 163	IDHIFA... 57
hydrochlorothiazide... 100	HYPERTET (PF)... 163	IFEX... 57
hydrocodone bitartrate... 13	HYRIMOZ PEN CROHN'S-UC STARTER... 163	ifosfamide... 57
hydrocodone-acetaminophen... 13	HYRIMOZ PEN PSORIASIS STARTER... 163	IGALMI... 175
hydrocodone-chlorpheniramine... 196	HYRIMOZ(CF) PEDI CROHN STARTER... 163	ILEVRO... 181
hydrocodone-homatropine... 196	HYRIMOZ(CF) PEN... 163	ILUMYA... 163
hydrocodone-ibuprofen... 13	HYRIMOZ(CF)... 163	imatinib... 57
hydrocortisone butyr-emollient... 121	HYSINGLA ER... 14	IMBRUVICA... 57, 58
hydrocortisone butyrate... 121	HYZAAR... 100	IMFINZI... 58
hydrocortisone valerate... 121	<b>I</b>	imipenem-cilastatin... 28
	ibandronate... 171	imipramine hcl... 41
	IBRANCE... 57	imipramine pamoate... 41
	IBSRELA... 134	imiquimod... 121
	ibu... 14	IMITREX STATDOSE PEN... 49
	ibuprofen... 14	IMITREX STATDOSE REFILL... 49

IMITREX... 49	INLYTA... 58	INVEGA SUSTENNA... 71
IMJUDO... 58	INNOPRAN XL... 100	INVEGA TRINZA... 71
IMLYGIC... 58	INPEFA... 84	INVEGA... 71
IMMPHENTIV... 100	INQOVI... 58	INVELTYS... 181
IMOGAM RABIES-HT (PF)... 163	INREBIC... 58	INVOKAMET XR... 85
IMOVAX RABIES VACCINE (PF)... 163	INSPIRA... 100	INVOKAMET... 85
IMPAVIDO... 67	INSULIN ASP PRT-INSULIN ASPART... 84	INVOKANA... 85
IMPEKLO... 121	INSULIN ASPART U-100... 84	IONOSOL-B IN D5W... 128
IMURAN... 163	INSULIN DEGLUDEC... 85	IONOSOL-MB IN D5W... 128
INBRIJA... 68	INSULIN GLARGINE U-300 CONC... 85	IOPIDINE... 181
incassia... 149	INSULIN GLARGINE... 85	IPOL... 164
INCONTROL ALCOHOL PADS... 175	INSULIN GLARGINE-YFGN... 85	ipratropium bromide... 188
INCRELEX... 144	INSULIN LISPRO PROTAMIN-LISPRO... 85	ipratropium-albuterol... 188
INCRUSE ELLIPTA... 188	INSULIN LISPRO... 85	irbesartan... 100
indapamide... 100	INSULIN SYRINGE MICROFINE... 176	irbesartan-hydrochlorothiazide... 100
INDERAL LA... 100	INSULIN SYRINGE NEEDLELESS... 176	IRESSA... 58
INDOCIN... 14	INSULIN SYRINGE... 175	irinotecan... 58
indomethacin sodium... 14	INSULIN SYRINGE-NEEDLE U-100... 176	ISENTRESS HD... 77
indomethacin... 14	INTELENCE... 77	ISENTRESS... 77
INFANRIX (DTAP) (PF)... 163	INTRALIPID... 128	isibloom... 149
INFLECTRA... 163	INTRON A... 163	ISOLYTE S PH 7.4... 128
INFLIXIMAB... 163	INTUNIV ER... 111	ISOLYTE-P IN 5 % DEXTROSE... 128
INFUGEM... 58	INVANZ... 28	ISOLYTE-S... 128
INFUMORPH P/F... 14	INVEGA HAFYERA... 71	isoniazid... 52
INFUVITE ADULT... 198		ISOPTO CARPINE... 181
INFUVITE PEDIATRIC... 198		ISORDIL TITRADOSE... 100
INGREZZA INITIATION PACK... 111		ISORDIL... 100
INGREZZA... 111		

isosorbide dinitrate... 100	jasmiel (28)... 149	KADCYLA... 58
isosorbide mononitrate... 100	JATENZO... 149	kaitlib fe... 149
isosorbide-hydralazine... 100	javygtor... 138	KALETRA... 77
isotretinoin... 121, 122	JAYPIRCA... 58	kalliga... 149
isradipine... 100	JEMPERLI... 58	KALYDECO... 188
ISTALOL... 181	jencycla... 149	KANJINTI... 58
ISTODAX... 58	JENTADUETO XR... 85	KANUMA... 138
ISTURISA... 156	JENTADUETO... 85	KAPSPARGO SPRINKLE... 100
ISUPREL... 100	JEVTANA... 58	KAPVAY... 111
itraconazole... 46	jinteli... 149	KARBINAL ER... 188
IV PREP WIPES... 176	JOENJA... 138	kariva (28)... 149
ivermectin... 67, 122	jolessa... 149	KATERZIA... 100
IWILFIN... 58	JORNAY PM... 111	KAZANO... 85
IXCHIQ... 164	joyeaux... 149	KEDRAB (PF)... 164
IXEMPRA... 58	JUBLIA... 46	kelnor 1-50 (28)... 149
IXIARO (PF)... 164	juleber... 149	kelnor 1/35 (28)... 149
IYUZEH... 182	JULUCA... 77	KENALOG... 142
<b>J</b>	junel fe 1.5/30 (28)... 149	KENALOG-80... 142
JADENU SPRINKLE... 128	junel fe 1/20 (28)... 149	KENGREAL... 91
JADENU... 128	junel fe 24... 149	KEPIVANCE... 115
jaimiess... 149	junel 1.5/30 (21)... 149	KEPPRA XR... 34
JAKAFI... 58	junel 1/20 (21)... 149	KEPPRA... 34
JALYN... 140	JUXTAPID... 100	KERENDIA... 101
jantoven... 91	JYNARQUE... 128	KERYDIN... 46
JANUMET XR... 85	JYNNEOS (PF)... 164	KESIMPTA PEN... 111
JANUMET... 85	<b>K</b>	ketoconazole... 46, 47
JANUVIA... 85	K-TAB... 128	ketodan... 47
JARDIANCE... 85	KABIVEN... 128	ketoprofen... 14, 15

ketorolac... 15, 182	KOSHER PRENATAL PLUS IRON... 128	LAMICTAL STARTER (ORANGE) KIT... 35
KEVEYIS... 138	kourzeq... 115	LAMICTAL XR STARTER (BLUE)... 35
KEVZARA... 164	KRAZATI... 59	LAMICTAL XR STARTER (GREEN)... 35
KEYTRUDA... 58	KRINTAFEL... 67	LAMICTAL XR STARTER (ORANGE)... 35
KHAPZORY... 58	KRISTALOSE... 134	LAMICTAL XR... 35
KIMMTRAK... 58	kurvelo (28)... 149	LAMICTAL... 35
KIMYRSA... 28	KUVAN... 138	lamivudine... 77
KINERET... 164	KYPROLIS... 59	lamivudine-zidovudine... 77
KINRIX (PF)... 164	<b>L</b>	lamotrigine... 35, 36
kiprofen... 15	l norgest/e.estradiol-e.estrad... 149	LAMPIT... 67
KISQALI FEMARA CO-PACK... 58, 59	LABETALOL IN DEXTROSE,ISO-OSM... 101	LAMZEDE... 138
KISQALI... 58	LABETALOL IN NACL (ISO-OSMOT)... 101	LANOXIN PEDIATRIC... 101
KITABIS PAK... 28	labetalol... 101	LANOXIN... 101
KLARON... 28	lacosamide... 35	lanreotide... 157
klayesta... 47	LACRISERT... 182	lansoprazole... 134
KLISYRI... 122	lactated ringers... 128, 176	lanthanum... 128
KLONOPIN... 81	lactulose... 134	LANTUS SOLOSTAR U-100 INSULIN... 85
klor-con m10... 128	LAGEVRIO (EUA)... 176	LANTUS U-100 INSULIN... 85
KLOR-CON M15... 128	LAMICTAL ODT STARTER (BLUE)... 35	lapatinib... 59
klor-con m20... 128	LAMICTAL ODT STARTER (GREEN)... 35	larin fe 1.5/30 (28)... 149
KLOR-CON 10... 128	LAMICTAL ODT STARTER (ORANGE)... 35	larin fe 1/20 (28)... 149
KLOR-CON 8... 128	LAMICTAL ODT... 35	larin 1.5/30 (21)... 149
klor-con... 128	LAMICTAL STARTER (BLUE) KIT... 35	larin 1/20 (21)... 149
KLOXXADO... 22	LAMICTAL STARTER (GREEN) KIT... 35	larin 24 fe... 149
KONVOMEPE... 134	LAMICTAL STARTER (ORANGE)... 35	larissia... 150
KORLYM... 176	LAMICTAL STARTER (GREEN) KIT... 35	LASIX... 101
KOSELUGO... 59		

latanoprost... 182	LEVO-T... 155	lidocaine viscous... 20
LATUDA... 71	levobunolol... 182	lidocaine... 20
LAYOLIS FE... 150	levocarnitine (with sugar)... 128	lidocaine-epinephrine bit... 20
LAZANDA... 15	levocarnitine... 128	lidocaine-epinephrine... 20
leena 28... 150	levocetirizine... 189	lidocaine-prilocaine... 20
leflunomide... 164	levofloxacin in d5w... 28	lidocan iii... 20
LEMTRADA... 111	levofloxacin... 28, 182	lidocan iv... 20
lenalidomide... 59	levoleucovorin calcium... 59	lidocan v... 20
LENVIMA... 59	levonest (28)... 150	LIDODERM... 20
LEQVIO... 101	levonorg-eth estrad triphasic... 150	lignospan standard... 20
LESCOL XL... 101	levonorgest-eth.estradiol-iron... 150	lillow (28)... 150
lessina... 150	levonorgestrel-ethinyl estrad... 150	LINCOCIN... 28
LETAIRIS... 188	LEVOPHED (BITARTRATE)... 101	lincomycin... 28
letrozole... 59	levora-28... 150	lindane... 122
leucovorin calcium... 59	levorphanol tartrate... 15	linezolid in dextrose 5%... 28
LEUKERAN... 59	levothyroxine... 155, 156	linezolid... 28
LEUKINE... 91	LEVOXYL... 156	linezolid-0.9% sodium chloride... 28
leuprolide (3 month)... 157	LEVULAN... 59	LINZESS... 134
leuprolide... 157	LEXAPRO... 41	liothyronine... 156
levalbuterol hcl... 189	LEXETTE... 122	LIPITOR... 101
levalbuterol tartrate... 189	LEXIVA... 77	LIPOFEN... 101
levamlodipine... 101	LIALDA... 170	LIQREV... 189
LEVEMIR FLEXPEN... 85	LIBTAYO... 59	lisdexamfetamine... 111
LEVEMIR FLEXTOUCH U100 INSULIN... 86	LICART... 15	lisinopril... 101
LEVEMIR U-100 INSULIN... 86	lidocaine (pf) in d7.5w... 20	lisinopril-hydrochlorothiazide... 101
levetiracetam in nacl (iso-os)... 36	lidocaine (pf)... 20, 101	LITFULO... 176
levetiracetam... 36	lidocaine hcl... 20	lithium carbonate... 82
	lidocaine in 5 % dextrose (pf)... 101	lithium citrate... 82



LITHOBID... 82	LOPROX (AS OLAMINE)... 47	LUMAKRAS... 59
LITHOSTAT... 176	LOPROX... 47	LUMIGAN... 182
LIVALO... 101	LOQTORZI... 59	LUMIZYME... 138
LIVMARLI... 176	lorazepam intensol... 81	LUMRYZ... 194
LIVTENCITY... 77	lorazepam... 81	LUNESTA... 194
LO LOESTRIN FE... 150	LORBRENA... 59	LUNSUMIO... 59
lo-zumandimine (28)... 150	LOREEV XR... 82	LUPKYNIS... 164
LOCOID LIPOCREAM... 122	lortab elixir... 15	LUPRON DEPOT (3 MONTH)... 157
LOCOID... 122	loryna (28)... 150	LUPRON DEPOT (4 MONTH)... 157
LODINE... 15	LORZONE... 193	LUPRON DEPOT (6 MONTH)... 157
LODOCO... 101	losartan... 101	LUPRON DEPOT... 157
LODOSYN... 68	losartan-hydrochlorothiazide... 101	LUPRON DEPOT-PED (3 MONTH)... 157
LOESTRIN FE 1.5/30 (28-DAY)... 150	LOSEASONIQUE... 150	LUPRON DEPOT-PED... 157
LOESTRIN FE 1/20 (28-DAY)... 150	LOTEMAX SM... 182	lurasidone... 71, 72
LOESTRIN 1.5/30 (21)... 150	LOTEMAX... 182	lutera (28)... 150
LOESTRIN 1/20 (21)... 150	LOTENSIN HCT... 101	LUXIQ... 122
lofena... 15	LOTENSIN... 101	LUZU... 47
lojaimiess... 150	loteprednol etabonate... 182	LYBALVI... 72
LOKELMA... 128	LOTREL... 101, 102	lyleq... 150
lomaira... 199	LOTRONEX... 134	lyllana... 150
LOMOTIL... 134	lovastatin... 102	LYNPARZA... 60
LONHALA MAGNAIR REFILL... 189	LOVAZA... 102	LYRICA CR... 111, 112
LONHALA MAGNAIR STARTER... 189	LOVENOX... 91	LYRICA... 111
LONSURF... 59	low-ogestrel (28)... 150	LYSODREN... 156
loperamide... 134	loxapine succinate... 71	LYSTEDA... 91
LOPID... 101	lubiprostone... 134	LYTGOBI... 60
lopinavir-ritonavir... 77	LUCEMYRA... 22	
LOPRESSOR... 101	luliconazole... 47	

LYUMJEV KWIKPEN U-100 INSULIN... 86	MARCAINE... 20	meclizine... 44
LYUMJEV KWIKPEN U-200 INSULIN... 86	MARCAINE-EPINEPHRINE (PF)... 21	meclofenamate... 15
LYUMJEV TEMPO PEN(U-100)INSULN... 86	MARCAINE-EPINEPHRINE... 20	MEDROL (PAK)... 142
LYUMJEV U-100 INSULIN... 86	MARGENZA... 60	MEDROL... 142
LYVISPAH... 74	MARINOL... 44	medroxyprogesterone... 150
lyza... 150	marlissa (28)... 150	mefenamic acid... 15
<b>M</b>	MARPLAN... 41	mefloquine... 67
M-M-R II (PF)... 164	MATULANE... 60	megestrol... 151
m-natal plus... 128	matzim la... 102	MEKINIST... 60
MACROBID... 28	MAVENCLAD (10 TABLET PACK)... 112	MEKTOVI... 60
MACRODANTIN... 28	MAVENCLAD (4 TABLET PACK)... 112	meloxicam submicronized... 15
mafenide acetate... 122	MAVENCLAD (5 TABLET PACK)... 112	meloxicam... 15
magnesium sulfate in d5w... 128	MAVENCLAD (6 TABLET PACK)... 112	melphalan hcl... 60
magnesium sulfate in water... 128, 129	MAVENCLAD (7 TABLET PACK)... 112	melphalan... 60
magnesium sulfate... 128	MAVENCLAD (8 TABLET PACK)... 112	memantine... 39
MALARONE PEDIATRIC... 67	MAVENCLAD (9 TABLET PACK)... 112	MENACTRA (PF)... 164
MALARONE... 67	MAVYRET... 77	MENEST... 151
malathion... 122	MAXALT... 49	MENOPUR... 197
mannitol 10 %... 102	MAXALT-MLT... 50	MENOSTAR... 151
mannitol 20 %... 102	MAXIDEX... 182	MENQUADFI (PF)... 164
mannitol 25 %... 102	MAXITROL... 182	MENTAX... 47
mannitol 5 %... 102	MAXZIDE... 102	MENVEO A-C-Y-W-135-DIP (PF)... 164
maraviroc... 77	MAXZIDE-25MG... 102	meperidine (pf)... 15
MARCAINE (PF)... 20	MAYZENT STARTER(FOR 1MG MAINT)... 112	meperidine... 15
MARCAINE SPINAL (PF)... 20	MAYZENT STARTER(FOR 2MG MAINT)... 112	MEPHYTON... 198
	MAYZENT... 112	meprobamate... 82
		MEPRON... 67

MEPSEVII... 138  
 mercaptopurine... 60  
 meropenem... 29  
 meropenem-0.9% sodium chloride... 29  
 merzee... 151  
 mesalamine... 170  
 mesna... 60  
 MESNEX... 60  
 MESTINON TIMESPAN... 51  
 MESTINON... 51  
 METADATE CD... 112  
 metadate er... 112  
 metaxalone... 193  
 metformin... 86  
 methadone intensol... 15  
 methadone... 15  
 METHADOSE... 16  
 methamphetamine... 112  
 methazolamide... 102  
 methenamine hippurate... 29  
 methimazole... 158  
 METHITEST... 151  
 methocarbamol... 193  
 methotrexate sodium (pf)... 164  
 methotrexate sodium... 164  
 methoxsalen... 122  
 methscopolamine... 134  
 methsuximide... 36  
 methyl dopa... 102  
 methyl dopa-hydrochlorothiazide... 102  
 methyl dopate... 102  
 methyl ergonovine... 176  
 METHYLIN... 112  
 methylphenidate hcl... 112, 113  
 methylphenidate... 112  
 methylprednisolone acetate... 142  
 methylprednisolone sodium succ... 142  
 methylprednisolone... 142  
 methyltestosterone... 151  
 metoclopramide hcl... 44  
 metolazone... 102  
 metoprolol succinate... 102  
 metoprolol ta-hydrochlorothiaz... 102  
 metoprolol tartrate... 102  
 METRO I.V... 29  
 METROCREAM... 29  
 METROGEL... 29  
 METROLOTION... 29  
 metronidazole in nacl (iso-os)... 29  
 metronidazole... 29  
 metyrosine... 102  
 mexiletine... 102  
 MIACALCIN... 171  
 mibelas 24 fe... 151  
 micafungin... 47  
 MICARDIS HCT... 102  
 MICARDIS... 102  
 miconazole nitrate-zinc ox-pet... 47  
 miconazole-3... 47  
 microgestin fe 1.5/30 (28)... 151  
 microgestin fe 1/20 (28)... 151  
 microgestin 1.5/30 (21)... 151  
 microgestin 1/20 (21)... 151  
 microgestin 24 fe... 151  
 midodrine... 102  
 MIEBO... 182  
 mifepristone... 176  
 migergot... 50  
 miglitol... 86  
 miglustat... 138  
 MIGRANAL... 50  
 mili... 151  
 millipred dp... 142  
 millipred... 142  
 milrinone in 5 % dextrose... 103  
 milrinone... 102  
 mimvey... 151  
 MINASTRIN 24 FE... 151  
 MINIPRESS... 103  
 MINIVELLE... 151  
 MINOCIN... 29

minocycline... 29	MOTPOLY XR... 36	myorisan... 122
minoxidil... 103	MOUNJARO... 86	MYRBETRIQ... 140
MIOSTAT... 182	MOVANTIK... 135	MYSOLINE... 36
MIRAPEX ER... 68	MOVIPREP... 135	MYTESI... 135
MIRCETTE (28)... 151	moxifloxacin... 29, 182	<b>N</b>
mirtazapine... 41	moxifloxacin-sod.ace,sul-water... 29	nabumetone... 16
MIRVASO... 122	moxifloxacin-sod.chloride(iso)... 29	nadolol... 103
misoprostol... 135	MOZOBIL... 91	nafcillin in dextrose iso-osm... 29
MITIGARE... 49	MS CONTIN... 16	nafcillin... 29
mitigo (pf)... 16	MULPLETA... 91	naftifine... 47
mitomycin... 60	MULTAQ... 103	NAFTIN... 47
mitoxantrone... 60	mupirocin calcium... 122	NAGLAZYME... 138
modafinil... 194	mupirocin... 122	nalbuphine... 17
moexipril... 103	MUTAMYCIN... 60	NALFON... 17
molindone... 72	MVASI... 60	nalmefene... 22
mometasone... 122, 189	MYALEPT... 135	nalocet... 17
mondoxyne nl... 29	MYAMBUTOL... 52	naloxone... 22
MONJUVI... 164	MYCAMINE... 47	naltrexone... 22
mono-lynyah... 151	MYCAPSSA... 157	NAMENDA TITRATION PAK... 39
MONODOX... 29	MYCOBUTIN... 52	NAMENDA XR... 39
montelukast... 189	mycophenolate mofetil (hcl)... 164	NAMENDA... 39
MONUROL... 29	mycophenolate mofetil... 164	NAMZARIC... 39
morgidox... 29	mycophenolate sodium... 164	NAPRELAN CR... 17
morphine (pf)... 16	MYDAYIS... 113	NAPROSYN... 17
morphine concentrate... 16	MYFEMBREE... 176	naproxen sodium... 17
morphine... 16	MYFORTIC... 164	naproxen... 17
MOTTEGRITY... 135	MYLOTARG... 60	naproxen-esomeprazole... 17
MOTOFEN... 135		naratriptan... 50

NARCAN... 22	neomycin-polymyxin-gramicidin... 182	NEXVIAZYME... 138
NARDIL... 41	neomycin-polymyxin-hc... 182, 185	NGENLA... 144
NAROPIN (PF)... 21	NEONATAL COMPLETE... 129	niacin... 103
NASCOBAL... 198	NEONATAL PLUS VITAMIN... 129	niacor... 103
NATACHEW (FE BIS-GLYCINATE)... 129	NEONATAL-DHA... 129	nicardipine... 103
NATACYN... 182	NEORAL... 164	NICOTROL NS... 22
NATAZIA... 151	NERLYNX... 60	NICOTROL... 22
nateglinide... 86	NESACAINE... 21	nifedipine... 103
NATESTO... 151	NESACAINE-MPF... 21	nikki (28)... 151
NATPARA... 171	NESINA... 86	NILANDRON... 60
NATROBA... 122	neuac... 122	nilutamide... 60
NAYZILAM... 36	NEULASTA ONPRO... 91	nimodipine... 103
nebivolol... 103	NEULASTA... 91	NINLARO... 60
NEBUPENT... 67	NEUPOGEN... 91	NIPENT... 60
necon 0.5/35 (28)... 151	NEUPRO... 68	nisoldipine... 103
nefazodone... 41	NEURONTIN... 36	nitazoxanide... 67
nelarabine... 60	NEVANAC... 182	nitisinone... 138
NEMBUTAL SODIUM... 36	nevirapine... 77, 78	NITRO-BID... 103
neo-polycin hc... 182	NEXAVAR... 60	NITRO-DUR... 103
neo-polycin... 182	NEXICLON XR... 103	nitrofurantoin macrocrystal... 30
NEO-SYNALAR... 122	NEXIUM IV... 135	nitrofurantoin monohyd/m-cryst... 30
neomycin... 29	NEXIUM PACKET... 135	nitrofurantoin... 30
neomycin-bacitracin-poly-hc... 182	NEXIUM... 135	nitroglycerin in 5 % dextrose... 104
neomycin-bacitracin-polymyxin... 182	NEXLETOL... 103	nitroglycerin... 103, 104, 176
neomycin-polymyxin b gu... 176	NEXLIZET... 103	NITROLINGUAL... 104
neomycin-polymyxin b-dexameth... 182	NEXTERONE... 103	NITROSTAT... 104
	NEXTSTELLIS... 151	NITYR... 138

NIVESTYM... 91	NORPACE CR... 104	NOVOLOG PENFILL U-100
nizatidine... 135	NORPACE... 104	INSULIN... 86
NOCDURNA (MEN)... 144	NORPRAMIN... 41	NOVOLOG U-100 INSULIN ASPART... 87
NOCDURNA (WOMEN)... 144	NORTHERA... 104	NOVOPEN ECHO... 176
nolix... 122	nortrel 0.5/35 (28)... 152	NOXAFIL... 47
NORA-BE... 151	nortrel 1/35 (21)... 152	np thyroid... 156
NORDITROPIN FLEXPEN... 144	nortrel 1/35 (28)... 152	NUBEQA... 60
norelgestromin-ethin.estradiol... 151	nortrel 7/7/7 (28)... 152	NUCALA... 189
norepinephrine bitartrate... 104	nortriptyline... 41	NUCYNTA ER... 17
noreth-ethinyl estradiol-iron... 151	NORVASC... 104	NUCYNTA... 17
norethindrone (contraceptive)... 151	NORVIR... 78	NUEDEXTA... 113
norethindrone ac-eth estradiol... 152	NOURIANZ... 68	NULIBRY... 138
norethindrone acetate... 152	NOVAREL... 144	NULYTELY LEMON-LIME... 135
norethindrone-e.estradiol-iron... 152	NOVOLIN N FLEXPEN... 86	NUPLAZID... 72
NORGESIC FORTE... 193	NOVOLIN N NPH U-100 INSULIN... 86	NURTEC ODT... 176
norgesic... 193	NOVOLIN R FLEXPEN... 86	NUTRILIPID... 129
norgestimate-ethinyl estradiol... 152	NOVOLIN R REGULAR U100 INSULIN... 86	NUTROPIN AQ NUSPIN... 144
NORITATE... 30	NOVOLIN 70-30 FLEXPEN U-100... 86	NUVARING... 152
NORLIQVA... 104	NOVOLIN 70/30 U-100 INSULIN... 86	NUVESSA... 30
norlyda... 152	NOVOLOG FLEXPEN U-100 INSULIN... 86	NUVIGIL... 194
NORMOSOL-M IN 5 % DEXTROSE... 129	NOVOLOG MIX 70-30 U-100 INSULIN... 86	NUZYRA... 30
NORMOSOL-R IN 5 % DEXTROSE... 129	NOVOLOG MIX 70-30FLEXPEN U-100... 86	nyamyc... 47
NORMOSOL-R PH 7.4... 129		nylia 1/35 (28)... 152
NORMOSOL-R... 129		nylia 7/7/7 (28)... 152
		NYMALIZE... 104
		nymyo... 152
		nystatin... 47

nystatin-triamcinolone... 47	olmesartan-hydrochlorothiazide... 104	OMNIPOD GO PODS... 176
nystop... 47	olopatadine... 183, 189	OMNIPOD 5 G6 INTRO KIT (GEN 5)... 176
NYVEPRIA... 91	OLPRUVA... 138	OMNIPOD 5 G6 PODS (GEN 5)... 176
<b>O</b>	OLUMIANT... 164	OMNIPOD 5 G6-G7 INTRO KT(GEN5)... 176
OB COMPLETE ONE... 129	OLUX... 122	OMNIPOD 5 G6-G7 PODS (GEN 5)... 176
OB COMPLETE PETITE... 129	OLUX-E... 122	OMNITROPE... 144
OB COMPLETE PREMIER... 129	OMECLAMOX-PAK... 135	OMVOH PEN... 165
OBREDON... 196	omega-3 acid ethyl esters... 104	OMVOH... 165
OCALIVA... 135	OMEGAVEN... 129	ONCASPAR... 61
ocella... 152	omeprazole... 135	ondansetron hcl (pf)... 44
OCREVUS... 113	omeprazole-sodium bicarbonate... 135	ondansetron hcl... 44
OCTAGAM... 164	OMNARIS... 189	ondansetron... 44
octreotide acetate... 157	OMNIPOD CLASSIC PODS (GEN 3)... 176	ONEXTON... 122
OCUFLOX... 183	OMNIPOD DASH INTRO KIT (GEN 4)... 176	ONFI... 36
ODACTRA... 189	OMNIPOD DASH PODS (GEN 4)... 176	ONGENTYS... 68
ODEFSEY... 78	OMNIPOD GO PODS 10 UNITS/DAY... 176	ONIVYDE... 61
ODOMZO... 60	OMNIPOD GO PODS 15 UNITS/DAY... 176	ONPATTRO... 138
OFEV... 189	OMNIPOD GO PODS 20 UNITS/DAY... 176	ONTRUZANT... 61
ofloxacin... 30, 183, 185	OMNIPOD GO PODS 25 UNITS/DAY... 176	ONUREG... 61
OGIVRI... 60	OMNIPOD GO PODS 30 UNITS/DAY... 176	ONZETRA XSAIL... 50
OGSIVEO... 60	OMNIPOD GO PODS 40 UNITS/DAY... 177	OPDIVO... 61
OJJAARA... 60		OPDUALAG... 61
olanzapine... 72		OPFOLDA... 138
olanzapine-fluoxetine... 41		opium tincture... 135
OLINVYK... 17		OPSUMIT... 189
olmesartan... 104		OPSYNVI... 189
olmesartan-amlodipin-hcthiazyd... 104		

OPVEE... 22	ORTHO TRI-CYCLEN (28)... 152	oxiconazole... 48
OPZELURA... 122	ORTHO-NOVUM 7/7/7 (28)... 152	OXISTAT... 48
ORACEA... 30	ORTIKOS... 170	OXLUMO... 177
ORALAIR... 189	oseltamivir... 78	OXTELLAR XR... 36
oralone... 115	OSENI... 87	oxybutynin chloride... 140, 141
ORAPRED ODT... 142	OSMITROL 10 %... 104	oxycodone... 17, 18
ORBACTIV... 30	OSMITROL 15 %... 104	oxycodone-acetaminophen... 18
ORENCIA CLICKJECT... 165	OSMITROL 20 %... 104	OXYCONTIN... 18
ORENCIA... 165	OSMITROL 5 %... 104	oxymorphone... 18
ORENITRAM MONTH 1 TITRATION KT... 189	OSMOLEX ER... 68	oxytocin... 177
ORENITRAM MONTH 2 TITRATION KT... 189	OSMOPREP... 135	OXYTROL... 141
ORENITRAM MONTH 3 TITRATION KT... 190	OSPHENA... 152	OZEMPIC... 87
ORENITRAM... 189	OTEZLA STARTER... 122	OZOBAX DS... 74
ORFADIN... 138	OTEZLA... 122	OZOBAX... 74
ORGOVYX... 157	OTOVEL... 185	<b>P</b>
ORIAHNN... 177	OTREXUP (PF)... 165	PACERONE... 104
ORILISSA... 157	OVIDE... 122	paclitaxel protein-bound... 61
ORKAMBI... 190	OVIDREL... 197	paclitaxel... 61
ORLADEYO... 165	oxacillin in dextrose(iso-osm)... 30	PADCEV... 61
orlistat... 177	oxacillin... 30	PALFORZIA (LEVEL 1)... 177
ormalvi... 138	oxaliplatin... 61	PALFORZIA (LEVEL 10)... 177
orphenadrine citrate... 193	oxandrolone... 152	PALFORZIA (LEVEL 11 UP-DOSE)... 177
orphenadrine-asa-caffeine... 193	oxaprozin... 17	PALFORZIA (LEVEL 2)... 177
orphengesic forte... 193	OXAYDO... 17	PALFORZIA (LEVEL 3)... 177
ORSERDU... 61	oxazepam... 82	PALFORZIA (LEVEL 4)... 177
orsythia... 152	OXBRYTA... 177	PALFORZIA (LEVEL 5)... 177
	oxcarbazepine... 36	PALFORZIA (LEVEL 6)... 177
	OXERVATE... 183	



PALFORZIA (LEVEL 7)... 177	PAXLOVID... 177	pentamidine... 67
PALFORZIA (LEVEL 8)... 177	pazopanib... 61	PENTASA... 170
PALFORZIA (LEVEL 9)... 177	PEDIAPRED... 142	pentazocine-naloxone... 18
PALFORZIA INITIAL DOSE... 177	PEDIARIX (PF)... 165	pentobarbital sodium... 36
PALFORZIA LEVEL 11 MAINTENANCE... 177	PEDMARK... 61	pentoxifylline... 104
paliperidone... 72	PEDVAX HIB (PF)... 165	pepcid... 135
PALYNZIQ... 138	peg 3350-electrolytes... 135	PERCOCET... 18
PAMELOR... 41	peg-electrolyte soln... 135	PERFOROMIST... 190
pamidronate... 171	peg-prep... 135	PERIKABIVEN... 129
PANCREAZE... 138, 139	PEGASYS... 165	perindopril erbumine... 104
PANDEL... 123	peg3350-sod sul-nacl-kcl-asb-c... 135	periogard... 115
PANRETIN... 61	PEMAZYRE... 61	PERJETA... 61
pantoprazole... 135	pemetrexed disodium... 61	permethrin... 123
PANZYGA... 165	pemetrexed... 61	perphenazine... 72
paraplatin... 61	PEMRYDI RTU... 61	perphenazine-amitriptyline... 42
paricalcitol... 171	PEN NEEDLE, DIABETIC... 177	PERSERIS... 72
PARLODEL... 68	PENBRAYA (PF)... 165	PERTZYE... 139
PARNATE... 41	penciclovir... 78	PEXEVA... 42
paroex oral rinse... 115	penicillamine... 129	pfizerpen-g... 30
paromomycin... 30	penicillin g pot in dextrose... 30	PHEBURANE... 139
paroxetine hcl... 41, 42	penicillin g potassium... 30	phenazopyridine... 177
paroxetine mesylate(menop.sym)... 42	penicillin g procaine... 30	phendimetrazine tartrate... 199
PASER... 52	penicillin g sodium... 30	phenelzine... 42
PATANASE... 190	penicillin v potassium... 30	PHENERGAN... 45
PAXIL CR... 42	PENNSAID... 18	phenobarbital sodium... 36
PAXIL... 42	PENTACEL (PF)... 165	phenobarbital... 36
	PENTAM... 67	phenoxybenzamine... 104
		phentermine... 199

phenylephrine hcl... 104	PITOCIN... 177	portia 28... 152
PHENYTEK... 36	PLAQUENIL... 67	PORTRAZZA... 62
phenytoin sodium extended... 37	PLASMA-LYTE A... 129	posaconazole... 48
phenytoin sodium... 36, 37	PLASMA-LYTE 148... 129	POTABA... 198
phenytoin... 36	PLAVIX... 91	potassium acetate... 129
PHESGO... 61	PLEGRIDY... 113	potassium chlorid-d5-0.45%nacl... 129
PHEXXI... 177	PLENAMINE... 129	potassium chloride in lr-d5... 130
philith... 152	PLENITY (WELCOME KIT)... 199	potassium chloride in water... 130
PHOSLYRA... 129	PLENITY... 199	potassium chloride in 0.9%nacl... 130
PHOSPHOLINE IODIDE... 183	PLENVU... 135	potassium chloride in 5 % dex... 130
PHYSIOLYTE... 177	plerixafor... 91	potassium chloride... 129, 130
PHYSIOSOL IRRIGATION... 177	PLIAGLIS... 21	potassium chloride-d5-0.2%nacl... 130
phytonadione (vitamin k1)... 198	pnv-dha... 129	potassium chloride-d5-0.3%nacl... 130
PIFELTRO... 78	pnv-omega... 129	potassium chloride-d5-0.9%nacl... 130
pilocarpine hcl... 115, 183	podofilox... 123	potassium chloride-0.45 % nacl... 130
pimecrolimus... 123	POLIVY... 62	potassium citrate... 130
pimozide... 72	polocaine... 21	POTELIGEO... 62
pimtrea (28)... 152	polocaine-mpf... 21	pr natal 400 ec... 130
pindolol... 105	polycin... 183	pr natal 400... 130
pioglitazone... 87	polymyxin b sulf-trimethoprim... 183	pr natal 430 ec... 130
pioglitazone-glimepiride... 87	polymyxin b sulfate... 30	pr natal 430... 130
pioglitazone-metformin... 87	POLYTRIM... 183	PRADAXA... 91
piperacillin-tazobactam... 30	POMALYST... 62	pralatrexate... 62
PIQRAY... 61	POMBILITI... 139	
pirfenidone... 190	PONVORY 14-DAY STARTER PACK... 113	
pirmella... 152	PONVORY... 113	
piroxicam... 18		
pitavastatin calcium... 105		

PRALUENT PEN... 105	prenatal plus dha... 130	PROAIR DIGIHALER... 190
pramipexole... 68	prenatal plus vitamin-mineral... 130	PROAIR HFA... 190
prasugrel... 91	prenatal vitamin plus low iron... 130	PROAIR RESPICLICK... 190
pravastatin... 105	prenatal-u... 130	probenecid... 49
praziquantel... 67	PRENATE ELITE... 130	probenecid-colchicine... 49
prazosin... 105	preplus... 130	procainamide... 105
PRECOSE... 87	PRESTALIA... 105	PROCALAMINE 3%... 130
PRED FORTE... 183	PRETOMANID... 52	PROCARDIA XL... 105
PRED MILD... 183	PREVACID SOLUTAB... 136	procentra... 113
PRED-G... 183	PREVACID... 136	prochlorperazine edisylate... 45
prednicarbate... 123	prevalite... 105	prochlorperazine maleate... 45
prednisolone acetate... 183	PREVDUO... 178	prochlorperazine... 45
prednisolone sodium phosphate... 142, 143, 183	previfem... 153	PROCROT... 91, 92
prednisolone... 142	PREVYMIS... 78	procto-med hc... 123
prednisone intensol... 143	PREZCOBIX... 78	PROCTOFOAM HC... 170
prednisone... 143	PREZISTA... 78	proctosol hc... 123
PREFEST... 152	PRIALT... 178	proctozone-hc... 123
pregabalin... 113	PRIFTIN... 52	PROCYSBI... 139
PREGNYL... 144	PRILOSEC... 136	progesterone micronized... 153
PREHEVBRIO (PF)... 165	primaquine... 67	progesterone... 153
PREMARIN... 152, 153	PRIMAXIN IV... 30	PROGLYCEM... 87
PREMASOL 10 %... 130	primidone... 37	PROGRAF... 165
PREMPHASE... 153	primlev... 18	PROLASTIN-C... 139
PREMPRO... 153	PRIMSOL... 30	prolate... 18
PRENATA... 130	PRIORIX (PF)... 165	PROLENSA... 183
PRENATABS FA... 130	PRISTIQ... 42	PROLEUKIN... 62
prenatal plus (calcium carb)... 130	PRIVIGEN... 165	PROLIA... 171
	PRO COMFORT ALCOHOL PADS... 178	PROMACTA... 92

promethazine vc... 178	PULMICORT FLEXHALER... 190	QUESTRAN... 105
promethazine vc-codeine... 196	PULMICORT... 190	quetiapine... 72
promethazine... 45	PULMOZYME... 190	QUILLICHEW ER... 113
promethazine-codeine... 196	PURE COMFORT ALCOHOL PADS... 178	QUILLIVANT XR... 113
promethazine-dm... 196	PURIXAN... 62	quinapril... 105
promethazine-phenyleph-codeine... 196	PYLERA... 136	quinapril-hydrochlorothiazide... 105
promethazine-phenylephrine... 178	pyrazinamide... 52	quinidine gluconate... 105
promethegan... 45	PYRIDIDIUM... 178	quinidine sulfate... 105
PROMETRIUM... 153	pyridostigmine bromide... 51	quinine sulfate... 67
propafenone... 105	pyridoxine (vitamin b6)... 198	QULIPTA... 50
proparacaine... 183	pyrimethamine... 67	QUTENZA... 178
propranolol... 105	PYRUKYND... 92	QUVIVIQ... 194
propranolol-hydrochlorothiazid... 105	<b>Q</b>	QUZYTIR... 190
propylthiouracil... 158	QALSODY... 113	QVAR REDIHALER... 190
PROQUAD (PF)... 165	QBRELIS... 105	<b>R</b>
PROSCAR... 141	QBREXZA... 123	RABAVERT (PF)... 165
PROSOL 20 %... 130	QDOLO... 18	rabeprazole... 136
protamine... 178	QELBREE... 113	RADICAVA ORS STARTER KIT SUSP... 113
PROTONIX... 136	QINLOCK... 62	RADICAVA ORS... 113
PROTOPIC... 123	QNASL... 190	RADICAVA... 113
protriptyline... 42	QSYMIA... 199	RAGWITEK... 190
PROVENTIL HFA... 190	QTERN... 87	raloxifene... 153
PROVERA... 153	QUADRACEL (PF)... 165	ramelteon... 194
PROVIGIL... 194	QUALAQUIN... 67	ramipril... 105
PROZAC... 42	QUARTETTE... 153	RANEXA... 105
PRUDOXIN... 123	QUDEXY XR... 50	ranolazine... 105
	QUESTRAN LIGHT... 105	RAPAFLO... 141

RAPAMUNE... 165	RELPAK... 50	REYATAZ... 78
rasagiline... 68	RELTONE... 136	REYVOW... 50
RASUVO (PF)... 165, 166	REMERON SOLTAB... 42	REZDIFFRA... 178
RAVICTI... 139	REMERON... 42	REZLIDHIA... 62
RAYALDEE... 171	REMICADE... 166	REZUROCK... 166
RAYOS... 143	REMODULIN... 190	REZVOGLAR KWIKPEN... 87
RAZADYNE ER... 39	RENACIDIN... 178	REZZAYO... 48
REBIF (WITH ALBUMIN)... 113	RENAGEL... 130	RHOPHYLAC... 166
REBIF REBIDOSE... 113	RENFLEXIS... 166	RHOPRESSA... 183
REBIF TITRATION PACK... 113	REVELA... 130, 131	RIABNI... 62
REBLOZYL... 92	repaglinide... 87	RIASTAP... 92
REBYOTA... 178	REPATHA PUSHTRONEX... 105	ribavirin... 78, 178
RECARBRIO... 30	REPATHA SURECLICK... 105	RIDAURA... 166
RECLAST... 171	REPATHA SYRINGE... 105	rifabutin... 52
reclipsen (28)... 153	RESPA-AR... 196	RIFADIN... 52
RECOMBIVAX HB (PF)... 166	RESTASIS MULTIDOSE... 183	rifampin... 52
RECORLEV... 156	RESTASIS... 183	RILUTEK... 114
RECTIV... 178	RESTORIL... 194	riluzole... 114
REDITREX (PF)... 166	RETACRIT... 92	rimantadine... 78
REGLAN... 45	RETEVMO... 62	RIMSO-50... 178
REGONOL... 51	RETIN-A MICRO PUMP... 123	ringer's... 131, 178
REGRANEX... 123	RETIN-A MICRO... 123	RINVOQ... 166
RELAFEN DS... 18	RETIN-A... 123	RIOMET ER... 87
RELAFEN... 18	RETROVIR... 78	RIOMET... 87
RELENZA DISKHALER... 78	REVATIO... 190	risedronate... 171, 172
RELEUKO... 92	REVCOVI... 139	RISPERDAL CONSTA... 72
RELEXII... 113, 114	revonto... 74	RISPERDAL... 72
RELISTOR... 136	REXULTI... 72	risperidone... 73



SEMGLEE(INSULIN GLARGINE-YFGN)... 87	SILVADENE... 123	sodium chloride 3 % hypertonic... 131
SENSIPAR... 172	silver sulfadiazine... 123	sodium chloride 5 % hypertonic... 131
SENSORCAINE... 21	SIMBRINZA... 183	sodium chloride... 131, 178
sensorcaine-epinephrine... 21	SIMLANDI(CF) AUTOINJECTOR... 167	SODIUM EDECRIN... 106
sensorcaine-mpf spinal... 21	simliya (28)... 153	sodium oxybate... 194
SENSORCAINE-MPF... 21	simpesse... 153	sodium phenylbutyrate... 139
sensorcaine-mpf/epinephrine... 21	SIMPONI ARIA... 167	sodium phosphate... 131
SEREVENT DISKUS... 191	SIMPONI... 167	sodium polystyrene sulfonate... 131
SEROQUEL XR... 73	SIMULECT... 167	sodium,potassium,mag sulfates... 136
SEROQUEL... 73	simvastatin... 106	SOGROYA... 145
SEROSTIM... 144	SINEMET... 69	SOHONOS... 178
sertraline... 42	SINGULAIR... 191	solifenacin... 141
setlakin... 153	sirolimus... 167	SOLQUA 100/33... 87
sevelamer carbonate... 131	SIRTURO... 52	SOLIRIS... 167
sevelamer hcl... 131	sitagliptin... 87	SOLODYN... 30
SEYSARA... 30	SIVEXTRO... 30	SOLOSEC... 31
SEZABY... 37	SKYCLARYS... 114	SOLTAMOX... 62
SFROWASA... 170	SKYRIZI... 167	SOLU-CORTEF ACT-O-VIAL (PF)... 143
sharobel... 153	SKYTROFA... 144	SOLU-CORTEF... 143
SHINGRIX (PF)... 167	SLYND... 153	SOLU-MEDROL (PF)... 143
SIGNIFOR LAR... 157	SMOFLIPID... 131	SOLU-MEDROL... 143
SIGNIFOR... 157	SOANZ... 106	SOMA... 193
SIKLOS... 178	sodium benzoate-sod phenylacet... 178	SOMATULINE DEPOT... 157
sildenafil (pulm.hypertension)... 191	sodium bicarbonate... 131	SOMAVERT... 157, 158
SILENOR... 194	sodium chloride 0.45 %... 131	SOOLANTRA... 123
SILIQ... 167	sodium chloride 0.9 %... 131	
silodosin... 141		

sorafenib... 62	STALEVO 150... 69	sulfacetamide sodium... 31, 183
sorbitol-mannitol... 178	STALEVO 200... 69	sulfacetamide-prednisolone... 183
SORILUX... 123	STALEVO 50... 69	sulfadiazine... 31
sorine... 106	STALEVO 75... 69	sulfamethoxazole-trimethoprim... 31
sotalol af... 106	stavudine... 79	SULFAMYLON... 123
sotalol... 106	STEGLATRO... 87	sulfasalazine... 170
SOTYKTU... 167	STEGLUJAN... 87	SULFATRIM... 31
SOTYLIZE... 106	STELARA... 167	sulindac... 19
SOVALDI... 79	STIMUFEND... 92	sumatriptan succinate... 50
SOVUNA... 67	STIOLTO RESPIMAT... 191	sumatriptan... 50
SPEVIGO... 167	STIVARGA... 63	sumatriptan-naproxen... 50
spinosad... 123	STRATTERA... 114	sunitinib malate... 63
SPIRIVA RESPIMAT... 191	STRENSIQ... 139	SUNLENCA... 79
SPIRIVA WITH HANDIHALER... 191	streptomycin... 31	SUNOSI... 194
spironolacton-hydrochlorothiaz... 106	STRIBILD... 79	SUPRAX... 31
spironolactone... 106	STRIVERDI RESPIMAT... 191	SUPREP BOWEL PREP KIT... 136
SPORANOX PULSEPAK... 48	STROMECTOL... 67	SURE COMFORT ALCOHOL PREP PADS... 178
SPORANOX... 48	SUBOXONE... 22	SURE-PREP ALCOHOL PREP PADS... 178
sprintec (28)... 153	SUBSYS... 19	SUSTIVA... 79
SPRITAM... 37	subvenite starter (blue) kit... 37	SUTAB... 136
SPRIX... 18	subvenite starter (green) kit... 37	SUTENT... 63
SPRYCEL... 62, 63	subvenite starter (orange) kit... 37	syeda... 153
SPS (WITH SORBITOL)... 131	subvenite... 37	SYLVANT... 167
sronyx... 153	SUCRAID... 139	SYMBICORT... 191
SSD... 123	sucralfate... 136	SYMBYAX... 42
STALEVO 100... 69	SUFLAVE... 136	SYMDEKO... 191
STALEVO 125... 69	SULAR... 106	
	sulfacetamide sodium (acne)... 31	



SYMFI LO... 79	tafluprost (pf)... 183	TAVALISSE... 92
SYMFI... 79	TAGRISSO... 63	TAVNEOS... 168
SYMJEPI... 191	TAKHZYRO... 167	taysofy... 153
SYMLINPEN 120... 87	TALICIA... 136	TAYTULLA... 153
SYMLINPEN 60... 87	TALTZ AUTOINJECTOR (2 PACK)... 167	tazarotene... 124
SYMPAZAN... 37	TALTZ AUTOINJECTOR (3 PACK)... 168	tazicef... 31
SYMPROIC... 136	TALTZ AUTOINJECTOR... 167	TAZORAC... 124
SYMTUZA... 79	TALTZ SYRINGE... 168	taztia xt... 106
SYNAGIS... 178	TALVEY... 63	TAZVERIK... 63
SYNALAR... 123	TALZENNA... 63	TDVAX... 168
SYNAREL... 158	TAMIFLU... 79	TECENTRIQ... 63
SYNDROS... 45	tamoxifen... 63	TECFIDERA... 114
SYNERA... 21	tamsulosin... 141	TECVAYLI... 63
SYNERCID... 31	taperdex... 143	TEFLARO... 31
SYNJARDY XR... 88	TARCEVA... 63	TEGLUTIK... 114
SYNJARDY... 88	TARGADOX... 31	TEGRETOL XR... 37
SYNRIBO... 63	TARGRETIN... 63	TEGRETOL... 37
SYNTHROID... 156	tarina fe 1-20 eq (28)... 153	TEGSEDI... 139
SYPRINE... 131	tarina fe 1/20 (28)... 153	TEKURNA HCT... 106
<b>T</b>	tarina 24 fe... 153	TEKURNA... 106
TABLOID... 63	TARPEYO... 170	telmisartan... 106
TABRECTA... 63	TASCENSO ODT... 114	telmisartan-amlodipine... 106
TACLONEX... 123, 124	TASIGNA... 63	telmisartan-hydrochlorothiazid... 106
tacrolimus... 124, 167	tasimelteon... 195	temazepam... 195
tadalafil (pulm. hypertension)... 191	TASMAR... 69	TEMIXYS... 79
tadalafil... 141	tavaborole... 48	TEMODAR... 63
TADLIQ... 191		TEMOVATE... 124
TAFINLAR... 63		

temsirolimus... 63	THAM... 131	tiopronin... 141
tencon... 178	THEO-24... 191	tirofiban-0.9% sodium chloride... 92
teniposide... 63	theophylline in dextrose 5 %... 191	TIROSINT... 156
TENIVAC (PF)... 168	theophylline... 191	TIROSINT-SOL... 156
tenofovir disoproxil fumarate... 79	thiamine hcl (vitamin b1)... 198	TIVDAK... 64
TENORETIC 100... 106	THIOLA EC... 141	TIVICAY PD... 79
TENORETIC 50... 106	THIOLA... 141	TIVICAY... 79
TENORMIN... 106	thioridazine... 73	tizanidine... 74
TEPADINA... 63	thiotepa... 64	TLANDO... 154
TEPEZZA... 178	thiothixene... 73	TOBI PODHALER... 191
TEPMETKO... 63	THYMOGLOBULIN... 168	TOBI... 31
terazosin... 106	THYQUIDITY... 156	TOBRADEX ST... 184
terbinafine hcl... 48	tiadylt er... 107	TOBRADEX... 184
terbutaline... 191	tiagabine... 37	tobramycin in 0.225 % nacl... 31
terconazole... 48	TIAZAC... 107	tobramycin sulfate... 31
teriflunomide... 114	TIBSOVO... 64	tobramycin with nebulizer... 31
TESTIM... 153	TICOVAC... 168	tobramycin... 31, 184
testosterone cypionate... 154	TIGAN... 45	tobramycin-dexamethasone... 184
testosterone enanthate... 154	tigecycline... 31	TOBEX... 184
testosterone... 153, 154	TIGLUTIK... 114	TOLAK... 124
TETANUS,DIPHTHERIA TOX PED(PF)... 168	TIKOSYN... 107	tolcapone... 69
tetrabenazine... 114	tilia fe... 154	tolmetin... 19
tetracycline... 31	timolol maleate (pf)... 183	TOLSURA... 48
TEXACORT... 124	timolol maleate... 107, 183	tolterodine... 141
TEZSPIRE... 168	TIMOPTIC OCUDOSE (PF)... 183	tolvaptan... 131
THALITONE... 107	TIMOPTIC... 183	TOPAMAX... 50
THALOMID... 63	TIMOPTIC-XE... 183	TOPICORT... 124
	tinidazole... 31	topiramate... 50, 51

toposar... 64	trazodone... 42	tri-vylibra... 154
topotecan... 64	TREANDA... 64	triamcinolone acetonide... 115, 143
TOPROL XL... 107	TRECATOR... 52	triamterene... 107
toremifene... 64	TRELEGY ELLIPTA... 191	triamterene-hydrochlorothiazid... 107
TORISEL... 64	TRELSTAR... 158	trianex... 143
torse mide... 107	TREMFYA... 168	triazolam... 195
TOSYMRA... 51	treprostinil sodium... 191	TRIBENZOR... 107
TOTECT... 64	TRESIBA FLEXTOUCH U-100... 88	TRICARE... 131
TOUJEO MAX U-300 SOLOSTAR... 88	TRESIBA FLEXTOUCH U-200... 88	TRICOR... 107
TOUJEO SOLOSTAR U-300 INSULIN... 88	TRESIBA U-100 INSULIN... 88	triderm... 143
tovet emollient... 124	tretinoin (antineoplastic)... 64	trientine... 131, 132
TOVIAZ... 141	tretinoin microspheres... 124	trifluoperazine... 73
TPN ELECTROLYTES... 131	tretinoin... 124	trifluridine... 184
TRACLEER... 191	TREXALL... 168	trihexyphenidyl... 69
TRADJENTA... 88	TREXIMET... 51	TRIJARDY XR... 88
tramadol... 19	TREZIX... 19	TRIKAFTA... 192
tramadol-acetaminophen... 19	tri femynor... 154	TRILEPTAL... 37
trandolapril... 107	tri-estarylla... 154	TRILIPIX... 107
trandolapril-verapamil... 107	tri-legest fe... 154	trimethobenzamide... 45
tranexamic acid... 92	tri-linyah... 154	trimethoprim... 31
TRANSDERM-SCOP... 45	tri-lo-estarylla... 154	trimipramine... 42
TRANXENE T-TAB... 82	tri-lo-marzia... 154	trinatal rx 1... 132
tranylcypromine... 42	tri-lo-mili... 154	TRINTELLIX... 42
TRAVASOL 10 %... 131	tri-lo-sprintec... 154	TRIOSTAT... 156
TRAVATAN Z... 184	tri-mili... 154	TRIPTODUR... 158
travoprost... 184	tri-nymyo... 154	TRISENOX... 64
TRAZIMERA... 64	tri-sprintec (28)... 154	TRISTART DHA... 132
	tri-vylibra lo... 154	

tritocin... 143	turqoz (28)... 154	ULTILET ALCOHOL SWAB... 179
TRIUMEQ PD... 79	TUXARIN ER... 196	ULTOMIRIS... 168
TRIUMEQ... 79	TUZISTRA XR... 196	ULTRACET... 19
trivora (28)... 154	TWINRIX (PF)... 168	ULTRAM... 19
TRIZIVIR... 79	TWYNEO... 124	ULTRAVATE... 124
TRODELVY... 64	TYBLUME... 154	UNASYN... 31
TROGARZO... 79	TYBOST... 80	UNITHROID... 156
TROKENDI XR... 51	tydemy... 154	UNITUXIN... 64
TROPHAMINE 10 %... 132	TYGACIL... 31	UPLIZNA... 168
tropicamide... 184	TYKERB... 64	UPTRAVI... 192
tropium... 141	TYMLOS... 172	UROCIT-K 10... 132
TRUDHESA... 51	TYPHIM VI... 168	UROCIT-K 15... 132
TRUE COMFORT ALCOHOL PADS... 178	TYRVAYA... 184	UROCIT-K 5... 132
TRUE COMFORT PRO ALCOHOL PADS... 178	TYTABRI... 114	UROXATRAL... 141
TRULANCE... 136	TYVASO DPI... 192	URSO FORTE... 136
TRULICITY... 88	TYVASO INSTITUTIONAL START KIT... 192	URSO 250... 136
TRUMENBA... 168	TYVASO REFILL KIT... 192	ursodiol... 136
TRUQAP... 64	TYVASO STARTER KIT... 192	UVADEX... 124
TRUSELTIQ... 64	TYVASO... 192	UZEDY... 73
TRUSOPT... 184	TZIELD... 178	<b>V</b>
TRUVADA... 80	<b>U</b>	V-GO 20... 179
TRUXIMA... 64	UBRELVY... 178	V-GO 30... 179
TUDORZA PRESSAIR... 192	UCERIS... 170	V-GO 40... 179
TUKYSA... 64	UDENYCA AUTOINJECTOR... 92	VABOMERE... 31
tulana... 154	UDENYCA ONBODY... 92	VAGIFEM... 154
TURALIO... 64	UDENYCA... 92	valacyclovir... 80
	ULORIC... 49	VALCHLOR... 64
		VALCYTE... 80

valganciclovir... 80	VASCEPA... 107	VERELAN... 108
VALIUM... 82	VASERETIC... 107	VERIPRED 20... 143
valproate sodium... 37	VASOTEC... 107	VERKAZIA... 184
valproic acid (as sodium salt)... 38	VAZCULEP... 107	VERQUOVO... 108
valproic acid... 37	vecamyl... 108	VERSACLOZ... 73
valrubicin... 64	VECTIBIX... 64	VERZENIO... 65
valsartan... 107	VECTICAL... 124	VESICARE LS... 141
valsartan-hydrochlorothiazide... 107	VEGZELMA... 64	VESICARE... 141
VALSTAR... 64	VELCADE... 65	vestura (28)... 154
VALTOCO... 38	VELETRI... 192	VEVYE... 184
VALTRES... 80	velivet triphasic regimen (28)... 154	VFEND IV... 48
vanadom... 193	VELPHORO... 132	VFEND... 48
VANCOGIN... 31	VELSIPITY... 168	VIBATIV... 32
vancomycin in dextrose 5 %... 32	VELTASSA... 132	VIBERZI... 136
vancomycin in 0.9 % sodium chl... 32	VELTIN... 124	VIBRAMYCIN (CALCIUM)... 32
vancomycin... 32	VEMLIDY... 80	VIBRAMYCIN... 32
vancomycin-diluent combo no.1... 32	VENCLEXTA STARTING PACK... 65	VICTOZA 2-PAK... 88
VANDAZOLE... 32	VENCLEXTA... 65	VICTOZA 3-PAK... 88
VANFLYTA... 64	VENLAFAXINE BESYLATE... 43	VIDAZA... 65
VANOS... 124	venlafaxine... 42, 43	vienva... 154
VAPRISOL IN 5 % DEXTROSE... 132	VENTAVIS... 192	vigabatrin... 38
VAQTA (PF)... 168	VENTOLIN HFA... 192	vigadrone... 38
varenicline... 22	VEOPOZ... 168	VIGAMOX... 184
VARIVAX (PF)... 168	VEOZAH... 179	vigpoder... 38
VARIZIG... 168	verapamil... 108	VIIBRYD... 43
VARUBI... 45	VERDESO... 124	VIJOICE... 139
	VEREGEN... 124	vilazodone... 43
	VERELAN PM... 108	VIMOVO... 19

VIMPAT... 38	VIVELLE-DOT... 155	VYJUVEK... 179
vinblastine... 65	VIVITROL... 22	vylibra... 155
vincasar pfs... 65	VIVJOA... 48	VYNDAMAX... 139
vincristine... 65	VIVLODEX... 19	VYNDAQEL... 139
vinorelbine... 65	VIZIMPRO... 65	VYTORIN 10-10... 108
VIOKACE... 139	VOCABRIA... 80	VYTORIN 10-20... 108
viorele (28)... 154	VOGELXO... 155	VYTORIN 10-40... 108
VIRACEPT... 80	volnea (28)... 155	VYTORIN 10-80... 108
VIRAZOLE... 179	VONJO... 65	VYVANSE... 114
VIREAD... 80	VOQUEZNA DUAL PAK... 137	VYVGART HYTRULO... 168
virt-c dha... 132	VOQUEZNA TRIPLE PAK... 137	VYVGART... 168
virt-nate dha... 132	VOQUEZNA... 137	VYXEOS... 65
virt-pn dha... 132	voriconazole... 48	VYZULTA... 184
VISTARIL... 192	VOSEVI... 80	<b>W</b>
VISTOGARD... 65	VOTRIENT... 65	WAINUA... 139
VITAFOL FE PLUS... 132	VOWST... 179	WAKIX... 195
VITAFOL GUMMIES... 132	VOXZOGO... 179	warfarin... 92
VITAFOL NANO... 132	VOYDEYA... 168	water for irrigation, sterile... 179
VITAFOL ULTRA... 132	VP-PNV-DHA... 132	WEBCOL... 179
VITAFOL-OB... 132	VPRIV... 139	WEGOVY... 179
VITAFOL-OB+DHA... 132	VRAYLAR... 73	WELCHOL... 108
VITAFOL-ONE... 132	VTAMA... 124	WELIREG... 65
VITAMEDMD ONE RX... 132	vtol lq... 179	WELLBUTRIN SR... 43
vitamin d2... 198	VUITY... 184	WELLBUTRIN XL... 43
vitamin k... 198	VUMERITY... 114	wera (28)... 155
vitamin k1... 198	VUSION... 48	wescap-pn dha... 132
VITRAKVI... 65	VYEPTI... 51	wesnata dha complete... 132
vivacaine... 21	vyfemla (28)... 155	wesnate dha... 132

westab plus... 132  
westgel dha... 132  
WINLEVI... 124  
WINREVAIR... 192  
WINRHO SDF... 168  
wixela inhub... 192  
wymzya fe... 155

**X**

XACIATO... 32  
XADAGO... 69  
XALATAN... 184  
XALKORI... 65  
XANAX XR... 82  
XANAX... 82  
XARELTO DVT-PE TREAT 30D  
START... 93  
XARELTO... 92  
XATMEP... 168  
XCOPRI MAINTENANCE PACK... 38  
XCOPRI TITRATION PACK... 38  
XCOPRI... 38  
XDEMVI... 179  
XELJANZ XR... 169  
XELJANZ... 169  
XELPROS... 184  
XELSTRYM... 114  
XEMBIFY... 169  
XENAZINE... 114

XENICAL... 179  
XENLETA... 32  
XENPOZYME... 139  
XEPI... 124  
XERAVA... 32  
XERESE... 80  
XERMELO... 137  
XGEVA... 172  
XHANCE... 192  
XIFAXAN... 137  
XIGDUO XR... 88  
XIIDRA... 184  
XIMINO... 32  
XOFLUZA... 80  
XOLAIR... 169  
XOLEGEL... 48  
XOPENEX HFA... 192  
XOSPATA... 65  
XPHOZAH... 132  
XPOVIO... 65  
XTAMPZA ER... 19  
XTANDI... 65, 66  
xulane... 155  
XULTOPHY 100/3.6... 88  
XURIDEN... 139  
XYOSTED... 155  
XYREM... 195  
XYWAV... 195

**Y**

yargesa... 140  
YASMIN (28)... 155  
YAZ (28)... 155  
YCANTH... 179  
YERVOY... 66  
YF-VAX (PF)... 169  
YONDELIS... 66  
YONSA... 66  
YOSPRALA... 93  
YUFLYMA(CF) AI CROHN'S-UC-HS...  
169  
YUFLYMA(CF) AUTOINJECTOR... 169  
YUFLYMA(CF)... 169  
YUPELRI... 192  
YUSIMRY(CF) PEN... 169  
yuvaferm... 155

**Z**

zafemy... 155  
zafirlukast... 192  
zaleplon... 195  
ZALTRAP... 66  
ZANAFLEX... 74  
ZANOSAR... 66  
zarah... 155  
ZARONTIN... 38  
ZARXIO... 93  
zatean-pn dha... 132

zatean-pn plus... 132	ZERVIATE... 184	ZOCOR... 108
ZAVESCA... 140	ZESTORETIC... 108	ZOKINVY... 140
ZAVZPRET... 179	ZESTRIL... 108	ZOLADEX... 158
ZCORT... 143	ZETIA... 108	zoledronic ac-mannitol-0.9nacl... 172
ZEBUTAL... 179	ZETONNA... 193	zoledronic acid... 172
ZEGALOGUE AUTOINJECTOR... 88	ZEVALIN (Y-90)... 179	zoledronic acid-mannitol-water... 172
ZEGALOGUE SYRINGE... 88	ZIAC... 108	ZOLINZA... 66
ZEGERID... 137	ZIAGEN... 80	zolmitriptan... 51
ZEJULA... 66	ZIANA... 125	ZOLOFT... 43
ZELAPAR... 69	zidovudine... 80	zolpidem... 195
ZELBORAF... 66	ZIEXTENZO... 93	ZOLPIMIST... 195
ZEMAIRA... 140	ZILBRYSQ... 169	ZOMACTON... 145
ZEMBRACE SYMTOUCH... 51	zileuton... 193	zomig... 51
ZEMDRI... 32	ZILRETTA... 143	ZONALON... 125
ZEMPLAR... 172	ZILXI... 125	ZONEGRAN... 38
zenatane... 125	ZIMHI... 22	ZONISADE... 38
ZENPEP... 140	zingiber... 179	zonisamide... 38
zenzedi... 114, 115	ZINPLAVA... 137	ZONTIVITY... 93
ZEPATIER... 80	ZIOPTAN (PF)... 184	ZORTRESS... 169
ZEPBOUND... 199	ziprasidone hcl... 73	ZORVOLEX... 19
ZEPOSIA STARTER KIT (28-DAY)... 115	ziprasidone mesylate... 73	ZORYVE... 125
ZEPOSIA STARTER KIT (37-DAY)... 115	ZIPSOR... 19	ZOSYN IN DEXTROSE (ISO-OSM)... 33
ZEPOSIA STARTER PACK (7-DAY)... 115	ZIRABEV... 66	zovia 1-35 (28)... 155
ZEPOSIA... 115	ZIRGAN... 80	ZOVIRAX... 80
ZEPZELCA... 66	ZITHROMAX TRI-PAK... 32	ZTALMY... 38
ZERBAXA... 32	ZITHROMAX Z-PAK... 32	ZTLIDO... 21
	ZITHROMAX... 32	
	ZITUVIO... 88	



ZUBSOLV... 22  
ZULRESSO... 43  
zumandimine (28)... 155  
ZURZUVAE... 43  
ZYCLARA... 125  
ZYDELIG... 66  
ZYFLO... 193  
ZYKADIA... 66  
ZYLET... 184  
ZYLOPRIM... 49  
ZYMAXID... 184  
ZYMFENTRA... 169  
ZYNLONTA... 66  
ZYNRELEF... 179  
ZYNYZ... 66  
ZYPITAMAG... 108  
ZYPREXA RELPREVV... 74  
ZYPREXA ZYDIS... 74  
ZYPREXA... 73, 74  
ZYTIGA... 66  
ZYVOX... 33

## Important

---

### At Humana, it is important you are treated fairly.

Humana Inc. and its subsidiaries do not discriminate or exclude people because of their race, color, national origin, age, disability, sex, sexual orientation, gender, gender identity, ancestry, ethnicity, marital status, religion, or language. Discrimination is against the law. Humana and its subsidiaries comply with applicable federal civil rights laws. If you believe that you have been discriminated against by Humana or its subsidiaries, there are ways to get help.

- You may file a complaint, also known as a grievance:  
Discrimination Grievances, P.O. Box 14618, Lexington, KY 40512-4618  
If you need help filing a grievance, call **1-888-700-2263** or if you use a TTY, call **711**.
- You can also file a civil rights complaint with the **U.S. Department of Health and Human Services**, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at **<https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>**, or at **U.S. Department of Health and Human Services**, 200 Independence Avenue, SW, Room 509F, HHH Building, Washington, DC 20201, **1-800-368-1019**, **800-537-7697 (TDD)**.
- **California residents:** You may also call the California Department of Insurance toll-free hotline number: **1-800-927-HELP (4357)**, to file a grievance.

Complaint forms are available at **<https://www.hhs.gov/ocr/office/file/index.html>**.

**Auxiliary aids and services, free of charge, are available to you. 1-888-700-2263 (TTY: 711)**

Humana provides free auxiliary aids and services, such as qualified sign language interpreters, video remote interpretation, and written information in other formats to people with disabilities when such auxiliary aids and services are necessary to ensure an equal opportunity to participate.

## Multi-Language Insert

### Multi-language Interpreter Services

**English:** We have free interpreter services to answer any questions you may have about our health or drug plan. To get an interpreter, just call us at 1-877-320-1235 (TTY: 711). Someone who speaks English can help you. This is a free service.

**Spanish:** Tenemos servicios de intérprete sin costo alguno para responder cualquier pregunta que pueda tener sobre nuestro plan de salud o medicamentos. Para hablar con un intérprete, por favor llame al 1-877-320-1235 (TTY: 711). Alguien que hable español le podrá ayudar. Este es un servicio gratuito.

**Chinese Mandarin:** 我们提供免费的翻译服务，帮助您解答关于健康或药物保险的任何疑问。如果您需要此翻译服务，请致电 1-877-320-1235 (听障专线：711)。我们的中文工作人员很乐意帮助您。这是一项免费服务。

**Chinese Cantonese:** 您對我們的健康或藥物保險可能存有疑問，為此我們提供免費的翻譯服務。如需翻譯服務，請致電 1-877-320-1235 (聽障專線：711)。我們講中文的人員將樂意為您提供幫助。這是一項免費服務。

**Tagalog:** Mayroon kaming libreng serbisyo sa pagsasaling-wika upang masagot ang anumang mga katanungan ninyo hinggil sa aming planong pangkalusugan o panggagamot. Upang makakuha ng tagasaling-wika, tawagan lamang kami sa 1-877-320-1235 (TTY: 711). Maaari kayong tulungan ng isang nakakapagsalita ng Tagalog. Ito ay libreng serbisyo.

**French:** Nous proposons des services gratuits d'interprétation pour répondre à toutes vos questions relatives à notre régime de santé ou d'assurance-médicaments. Pour accéder au service d'interprétation, il vous suffit de nous appeler au 1-877-320-1235 (TTY: 711). Un interlocuteur parlant Français pourra vous aider. Ce service est gratuit.

**Vietnamese:** Chúng tôi có dịch vụ thông dịch miễn phí để trả lời các câu hỏi về chương sức khỏe và chương trình thuốc men. Nếu quý vị cần thông dịch viên xin gọi 1-877-320-1235 (TTY: 711) sẽ có nhân viên nói tiếng Việt giúp đỡ quý vị. Đây là dịch vụ miễn phí.

**German:** Unser kostenloser Dolmetscherservice beantwortet Ihren Fragen zu unserem Gesundheits- und Arzneimittelplan. Unsere Dolmetscher erreichen Sie unter 1-877-320-1235 (TTY: 711). Man wird Ihnen dort auf Deutsch weiterhelfen. Dieser Service ist kostenlos.

**Korean:** 당사는 의료 보험 또는 약품 보험에 관한 질문에 대해 드리고자 무료 통역 서비스를 제공하고 있습니다. 통역 서비스를 이용하려면 전화 1-877-320-1235 (TTY: 711) 번으로 문의해 주십시오. 한국어를 하는 담당자가 도와 드릴 것입니다. 이 서비스는 무료로 운영됩니다.

**Russian:** Если у вас возникнут вопросы относительно страхового или медикаментного плана, вы можете воспользоваться нашими бесплатными услугами переводчиков. Чтобы воспользоваться услугами переводчика, позвоните нам по телефону 1-877-320-1235 (TTY: 711). Вам окажет помощь сотрудник, который говорит по-русски. Данная услуга бесплатная.

**Arabic:** إننا نقدم خدمات المترجم الفوري المجانية للإجابة عن أي أسئلة تتعلق بخططنا الصحية أو خطة الأدوية الموصوفة لدينا. للحصول على مترجم فوري، ليس عليك سوى الاتصال بنا على 1-877-320-1235 (TTY: 711). سيقوم شخص ما يتحدث العربية بمساعدتك. هذه خدمة مجانية.

**Hindi:** हमारे स्वास्थ्य या दवा की योजना के बारे में आपके किसी भी प्रश्न के जवाब देने के लिए हमारे पास मुफ्त दुभाषिया सेवाएँ उपलब्ध हैं. एक दुभाषिया प्राप्त करने के लिए, बस हमें 1-877-320-1235 (TTY: 711) पर फोन करें. कोई व्यक्ति जो हिन्दी बोलता है आपकी मदद कर सकता है. यह एक मुफ्त सेवा है.

**Italian:** È disponibile un servizio di interpretariato gratuito per rispondere a eventuali domande sul nostro piano sanitario e farmaceutico. Per un interprete, contattare il numero 1-877-320-1235 (TTY: 711). Un nostro incaricato che parla Italianovi fornirà l'assistenza necessaria. È un servizio gratuito.

**Portuguese:** Dispomos de serviços de interpretação gratuitos para responder a qualquer questão que tenha acerca do nosso plano de saúde ou de medicação. Para obter um intérprete, contacte-nos através do número 1-877-320-1235 (TTY: 711). Irá encontrar alguém que fale o idioma Português para o ajudar. Este serviço é gratuito.

**French Creole:** Nou genyen sèvis entèprèt gratis pou reponn tout kesyon ou ta genyen konsènan plan medikal oswa dwòg nou an. Pou jwenn yon entèprèt, jis rele nou nan 1-877-320-1235 (TTY: 711). Yon moun ki pale Kreyòl kapab ede w. Sa a se yon sèvis ki gratis.

**Polish:** Umożliwiamy bezpłatne skorzystanie z usług tłumacza ustnego, który pomoże w uzyskaniu odpowiedzi na temat planu zdrowotnego lub dawkowania leków. Aby skorzystać z pomocy tłumacza znającego język polski, należy zadzwonić pod numer 1-877-320-1235 (TTY: 711). Ta usługa jest bezpłatna.

**Japanese:** 当社の健康保険と処方薬プランに関するご質問にお答えするために、無料の通訳サービスをご用意しています。通訳をご用命になるには、1-877-320-1235 (TTY:711) にお電話ください。日本語を話す者が支援いたします。これは無料のサービスです。









This formulary was updated on 05/01/2024. For more recent information or other questions, please contact the NC State Health Plan Humana Customer Care Team with any questions at 1-888-700-2263 or, for TTY users, 711, or visit [your.humana.com/ncshp](https://your.humana.com/ncshp). Monday through Friday, from 8 a.m. - 9 p.m., Eastern time. Our automated phone system is available after hours, weekends, and holidays. Our website is also available 24 hours a day, 7 days a week, by visiting [our.humana.com/ncshp](https://our.humana.com/ncshp).

GRP042PDG2480024C\_v1

